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This Annual Report summarises information about the situation in the field of drug use and its consequences, in the 
fields of legislation, strategies, and drug policy coordination, and about interventions, especially in the areas of drug 
demand reduction, drug crime, and drug markets in the Czech Republic in 2008, as well as trends in the above-
mentioned fields. When the latest data are available, it also refers to the current period in 2009. In the parts where 
the latest up-to-date or more detailed data were published in recent years, references have been made to the Annual 
Reports on the Drug Situation for the years 2002-2007 (Mravčík et al.  2003; Mravčík et al.  2004; Mravčík et al.  
2005a; Mravčík et al.  2006; Mravčík et al.  2007; Mravčík et al.  2008). 
Many thanks are due to all of the collaborators, members of working groups, organisations, institutions, and bodies 
that provided the necessary data and contributed to the interpretation of the data for their help and collaboration 
during the preparation of this annual report. Their names can be found in the reference list or in the text of the report.
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SUMMARY 
The preparation and enforcement of the national drug policy is the responsibility of the Government of the Czech 
Republic. Its main counselling body for drug-related issues is the Government Council for Drug Policy Coordination, 
which met four times in 2008. The National Drug Policy Strategy for the Period 2005 to 2009 and the Action Plan for 
the Implementation of the National Drug Policy Strategy for the Period 2007 to 2009 are in force. All regions drew up 
their documents on regional drug policy strategies in 2008. In the first half of 2009, the Czech Republic held the 
presidency of the Council of the European Union. In relation to that, the Government Council for Drug Policy 
Coordination considered a number of documents pertaining to the preparation and the course of the presidency and 
its Secretariat was responsible for the leadership of the Horizontal Drugs Group, a working group of the EU Council. 
In early 2009, Act No. 40/2009, Coll. Penal Code, effective from 1 January 2010, was adopted and included in the 
Collection of Laws. The new Penal Code includes significant changes in how to address illegal drugs. In comparison 
to the previous sentencing guidelines, a lower punishment range will apply to people who possess cannabis in a 
quantity greater than small. A significant change was also introduced by the new provision concerning the illegal 
cultivation of plants containing a narcotic or psychotropic substance: the growing of designated plants or mushrooms 
for personal use will be covered by less strict sentencing guidelines than was the case under the previous legal 
regulations and the cultivation of a small quantity of plants or mushrooms for personal use will be punished under the 
Misdemeanour Act rather than the criminal law. In relation to the act on pharmaceuticals, restrictions on the over-the-
counter supply of medicinal products containing up to 30 mg of pseudoephedrine per tablet were imposed. This 
measure involves a ban on mail order sales, the setting of a maximum monthly dose of 1,800 mg of 
pseudoephedrine (i.e. 60 tablets of 30 mg) per person, and the control of supply by means of the central database of 
electronic prescriptions. 
Labelled public expenditure on drug policy reached a level of CZK 597.3 million (€ 23,947 thousand) in 2008. 
This amount included CZK 371.9 million (€ 14,912 thousand) provided from the state budget, and the 
regions and municipalities contributed amounts of CZK 162.9 million (€ 6,530 thousand) and CZK 62.5 
million (€ 2,505 thousand), respectively. In comparison to 2007, total expenses showed a nominal increase 
on all three levels by 7%; on the central level, there was a decrease in expenditure on the part of all the 
ministries and central agencies under scrutiny, with the exception of the Ministries of Defence and of Labour 
and Social Affairs and the National Drug Headquarters of the Police of the Czech Republic. On the regional 
level, there was a nominal increase in aggregate year-on-year expenditure of approximately one third. An 
increase was recorded in almost all the regions; only the Zlín and Vysočina regions reported a year-on-year 
decline. Approximately one third of labelled regional expenditures was earmarked to finance sobering-up 
stations and the treatment of people intoxicated with alcohol or other drugs. The aggregate of funds 
expended by municipalities remained almost on the same levels as in 2007. Out of a total of CZK 597.3 
million (€ 23,947 thousand), CZK 152.1 million (€ 6,100 thousand; 25.5%) was spent on law enforcement, 
CZK 184.5 million (€ 7,399 thousand; 30.9%) on treatment, CZK 159.4 million (€ 6,389 thousand; 26.7%) on 
harm reduction, CZK 58.4 million (€ 2,340 thousand; 9.8%) on primary prevention, and CZK 24.9 million 
(€ 999 thousand; 4.2%) on aftercare. 
 
Two surveys covering the adult population were carried out in the Czech Republic in 2008: a general population 
survey specifically addressing the use of illicit drugs and a survey focusing on the health of the population in general. 
Both studies differed significantly in the methodology used and also provided different results. The former study 
(using a sample of respondents aged 15-64) showed that 37% of the population have had at least one experience 
with any of the illicit drugs under study; 34% have used cannabis and 17% of the population has had experience with 
a drug other than cannabis. In the past year and the past month, cannabis had been used by 15% and 9% of the 
respondents respectively. According to the latter study (working with a sample of respondents over 15 years of age), 
15% had used an illicit drug at least once; cannabis had also been used by 15%, while any other drug than cannabis 
had been used by 4% of the respondents. Despite the above-mentioned differences, the results of both studies 
indicate that the proportion of people in the population who have experience of addictive substances is on the rise, 
with cannabis use showing the greatest increase. While in 2002 and 2004 at least one experience with cannabis 
was reported by one fifth of adult respondents, the 2008 study on illicit drug use recorded positive answers to this 
question from one third of the respondents. An increase over time has also been recorded in the surveys studying 
the population’s health in general, although the prevalence rates reported by them are lower. 
Out of the respondents included in the survey on the use of illicit drugs who reported having used cannabis in the 
past month, 9% used cannabis daily or almost daily. After extrapolation to the Czech population in the 15-64 age 
group, the number of daily, or almost daily, cannabis users may be estimated to amount to approximately 57 
thousand (0.8% of the population aged 15-64). The survey also sought to identify the level of risky cannabis use. The 
use of cannabis poses a moderate risk for 26% and a high risk for 12% of the respondents who had used the drug in 
the past year. Men and people aged 25-34 comprise the most vulnerable group. After extrapolation to the Czech 
population in its entirety, the number of cannabis users at significant risk of dependency may be estimated to amount 
to 150 thousand, with people in the 15-29 age group accounting for approximately two thirds of them. 
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The international comparison of the results of the ESPAD school survey indicates that, within the European context, 
the Czech Republic ranks among the countries with the highest prevalence rates concerning the use of most of the 
drugs under study, with the exception of inhalants. As far as cannabis use is concerned, the Czech Republic’s 
prevalence rates are by far the highest in Europe; at least one experience with cannabis use has been reported by 
45% of 16-year-old Czechs. 
Cannabis and ecstasy remain the most popular non-alcohol drugs in the nightlife setting, although experience with 
pervitin and cocaine has shown a rising trend recently. 
In 2008 the estimated number of problem drug users rose to approximately 32.5 thousand, including approximately 
21.2 thousand pervitin users and approximately 11.3 thousand opiate users. Approximately 31.2 thousand people, 
i.e. most of the users of opiates and pervitin, use drugs by injecting. In comparison to 2007, the number of problem 
users of all types of drugs increased in 2008. It is estimated that the highest numbers of problem drug users are in 
Prague (11.5 thousand) and in the Ústí nad Labem region (4.2 thousand); these regions also show the highest 
estimates of problem opiate users. 
The relatively favourable situation concerning the occurrence of infections among (injecting) drug users continued in 
2008; HIV seroprevalence remains far below 1%. The prevalence of hepatitis C virus among clients tested in low-
threshold programmes was approximately 12%. However, such a low level of HCV seroprevalence may result from 
the fact that the testing is mostly sought by young users with a shorter history of injecting drugs. In 2008 HIV was 
newly diagnosed in 13 people, who may have contracted it through injecting drug use. While it is less than in 2007, it 
is a relatively high number when compared to the period prior to 2006. An HAV epidemic developed in the Czech 
Republic in 2008. In Prague, particularly at the beginning, it was associated with injecting drug users. 
The number of overdoses on street drugs (illicit drugs and inhalants) remained very low in 2008; a total of 44 cases 
(15, 19, and 10 fatal overdoses on opiates, pervitin, and inhalants, respectively) were reported, which is 4 more than 
in 2007. There was a slight increase in opiates, pervitin overdoses recorded a significant increase, and the number 
of fatal overdoses caused by inhalants declined. No deaths by overdose on cocaine, ecstasy, hallucinogens, or THC 
were registered. One fatal overdose with the presence of methadone occurred in 2008, but none with the presence 
of buprenorphine. As regards causes of death other than fatal overdoses (especially accidents/injuries and suicides), 
the involvement of pervitin and THC has been detected with a rising frequency since 2004; 49 and 37 cases, 
respectively, were reported in 2008. Opiates/opioids accounted for 12 cases, including 5 cases of an active 
substance from a substitution product being detected. In addition, there was a significant year-on-year increase in 
the rate of positive findings for pervitin and cannabis in people who died in traffic accidents, or in consequence 
thereof, and were subjected to an autopsy at forensic medicine departments; 9.2% and 6.2% respectively of the 
drivers killed in accidents tested positive for these substances. However, the police have only registered sporadic 
cases. The increase concerning pervitin-related cases is also apparent in admissions to hospital for non-fatal 
overdoses. On the other hand, the number of non-fatal overdoses on heroin shows a declining tendency.  
In the Czech Republic, drug users and addicts may seek help from a variety of easy-to-access services providing a 
wide range of interventions. The network of helping organisations experienced no major changes in 2008. The 
profession of an addictologist (addiction specialist) was incorporated in the law on non-medical health professions 
and the professional competencies required for the performance of this profession were defined. 
Men outnumber women in all the types of treatment facilities; they account for approximately two thirds of the clients. 
The proportion of women tends to be higher in younger age groups. The average age of drug users in treatment 
continues to rise in the long term; this tendency is apparent across various sources of data. In the Czech Republic, 
the largest group of drug users in treatment comprises pervitin (methamphetamine) users, followed by the users of 
opiates/opioids (heroin and Subutex®) and cannabis. Polydrug use (the concurrent use of more than one drug) is 
commonplace. Injecting is the most frequent route of pervitin and opiate administration among users in treatment. 
The regions with the highest numbers of drug users in treatment include the Capital City, Prague, and the Ústí nad 
Labem region, where, as in the other regions of the Bohemian part of the country, high numbers and rates of opiate 
users are reported. 
There has been a long-term decline in the number of psychiatric outpatient facilities reporting the provision of care for 
drug users; the number of their patients in 2008 remained approximately the same as in 2007. The numbers and 
regional availability of AT clinics, i.e. outpatient healthcare facilities specialising in addiction treatment, and their 
utilisation by drug users are not known accurately; 124 outpatient facilities have declared that they provide 
specialised addiction treatment services. In 2008 there was a decline in the number of individuals in inpatient 
psychiatric facilities, which especially resulted from a drop in the number of admissions to the psychiatric 
departments of hospitals. On the contrary, the number of admissions to psychiatric hospitals rose slightly. The 
number of patients registered for substitution treatment has increased. This applies to both specialised centres and 
individual physicians who prescribe products containing buprenorphine (Subutex® and Suboxone®). Nevertheless, 
treatment with buprenorphine has not been fully included in the substitution register. 
Drug-related harm reduction activities in the Czech Republic are pursued by the dense network of low-threshold 
programmes, which have undergone no major changes in recent years. The number of needles and syringes 
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distributed as part of exchange programmes saw a slight increase again (from 4.5 million in 2007 to 4.6 million in 
2008). In 2008, for the first time after a long period, the number of tests for HIV and HCV performed on drug users in 
low-threshold facilities almost doubled. 
The number of people arrested or prosecuted for drug-related offences has remained relatively stable in recent 
years; in 2008 it ranged from 2,296 to 2,322 people, depending on the source. 2,100 people were charged with drug 
offences, which represents a slight year-on-year increase. Final sentences were passed on 1,360 individuals 
convicted of drug offences. Traditionally, the highest numbers of people prosecuted for drug-related criminal 
offences have been reported in the Ústí nad Labem region, followed by the Capital City, Prague, the Moravian-
Silesian region, and the South Moravia region. As in the previous years, most of the drug offences were committed 
in relation to pervitin. The structure of the sentences for drug offences has not changed significantly in the past four 
years: a suspended prison sentence has been the type most frequently imposed.  
Cannabis is the most widely available illegal drug in the Czech Republic. The availability of pervitin is also high in the 
long term. Traditionally, the highest numbers of seizures were associated with both of these drugs. The domestic 
production of marijuana with a higher THC content has been on the rise. It is grown in artificial conditions and, with 
increasing frequency, on a large scale. The volume of the marijuana seized more than tripled in comparison to the 
previous years, and there was also a significant increase in the number of growing sites detected and cannabis 
plants seized. The amount of pervitin seized was lower than in the previous years, but the number of pervitin-cooking 
laboratories detected was the highest in the past six years and the seizures of precursors used to manufacture 
pervitin also increased in quantity. Since May 2009 restrictions have been imposed on the sale of medicines 
containing pseudoephedrine by pharmacies. In relation to this measure, an increase in individual imports of these 
pharmaceutical products from the neighbouring countries has been observed recently. The prices of most drugs 
continue to be stable, according to the available data. There was a year-on-year increase in the average potency of 
the cannabis seized and the average purity of the heroin seized. 
The Report concludes with three chapters on selected issues, including Cannabis Markets and Production, page 96, 
Problem Amphetamine and Methamphetamine Use, Related Consequences and Responses, page 102, and 
Treatment and Care for Older Drug Users, page 115. 
In the Czech Republic, as in the rest of the world, cannabis is the most common illicit drug used. In the second half of 
the 20th century, cannabis was mostly grown and used among closed groups of people in the Czech Republic. A 
commercial market in cannabis (marijuana and hashish) opened up in the 1990s. At present, the Czech Republic 
ranks among the European countries with the highest prevalence of cannabis use. According to the majority of the 
adult population, it is difficult to obtain cannabis, but three quarters of respondents in the 15-24 age group find it 
easy. The places where cannabis is most frequently obtained in the Czech Republic include bars, restaurants, and 
clubs. Almost three quarters of the respondents reported that they had last obtained cannabis free of charge. 
Cannabis was most likely to be obtained from a friend, a relative, or a partner. The dealers tend to consume it 
themselves and do not usually sell any other drugs. The retail prices of marijuana and hashish remain stable; they 
are sold at approximately CZK 200 (€ 8) and CZK 250 (€ 10) per gram, respectively. On the occasion of their last 
sales transaction, three out of four respondents had bought cannabis in a quantity up to 2 grams. The average 
potency of marijuana shows a slight increase, while that of hashish is in decline. In the Czech Republic, the greatest 
proportion of cannabis, including that found on the commercial market, comprises indoor-grown marijuana, followed 
by outdoor-grown marijuana. Most of the cannabis users identified the Czech Republic as the country of origin of the 
marijuana they had last obtained. In the Czech Republic there are several “grow shops” selling equipment needed 
for the cultivation of marijuana; seeds for the growing of cannabis plants may be obtained through social networks or 
via the internet, both from within the country and abroad. The annual number of marijuana seizures ranges from 550 
to 600 and there has been an increase in the overall amount of marijuana seized; in 2008 the number of cannabis 
plants seized rose fourfold on a year-on-year basis. In the past three years, approximately 5% of marijuana seizures 
and only one hashish seizure involved an amount exceeding 1 kg. Since 2005 the number of large-scale indoor 
growing sites detected has increased; 79 such facilities were detected in the Czech Republic in 2008. 
The objective of the second chapter on a selected issue is to describe the situation concerning the use of 
amphetamines, i.e. amphetamine and methamphetamine, and the related measures. In the past thirty years, 
methamphetamine has had a dominant position among problem drug users in the Czech Republic, which makes the 
Czech situation exceptional within the European context. Therefore, this chapter deals almost exclusively with 
methamphetamine, which has been traditionally referred to as pervitin in the Czech Republic. It is estimated that 
there are approximately 20 thousand problem pervitin users in the Czech Republic, which amounts to two thirds of 
all the problem drug users in this country; 80-90% of those are injecting users. The level of pervitin use in the general 
population has remained very low over the years, although it has a rising tendency in nightlife settings. Pervitin users 
comprise the largest group of all the drug users in treatment; from the long-term perspective, they account for 
approximately 60% of all the cases. Pervitin is often used in combination with other drugs, mostly cannabis, opiates, 
and alcohol. Long-term pervitin use is associated with psychiatric co-morbidity, involving toxic psychoses especially. 
The incidence of infections is mainly related to pervitin use by injecting. However, it does not seem to differ 
significantly from that in (injecting) opiate users, as far as the level of risk is concerned. In the Czech Republic, there 
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are approximately 10-20 cases of fatal pervitin overdoses annually, which accounts for about one third of fatal 
overdoses on street drugs (i.e. illicit drugs and inhalants). Pervitin use treatment has long been integrated into the 
system of drug services. With few exceptions, no pervitin use-specific programmes are provided. There are 
differences in the provision of certain services: harm reduction organisations have recently conducted programmes 
featuring the distribution of gelatine capsules intended almost exclusively for pervitin users and, as far as treatment is 
concerned, variations can be found in its pharmacotherapy. These are determined by a different course of 
withdrawal and detoxification, different psychological complications, and, in particular, the development of psychotic 
symptomatology and toxic psychosis. There is sporadic, although long-term, experience with the substitution therapy 
of pervitin addicts using various psychostimulants, presently mainly methylphenidate. Pervitin is manufactured using 
ephedrine, pseudoephedrine in particular, which is extracted from over-the-counter medicines. The availability of 
these medicinal products from pharmacies has been reduced significantly since May 2009 as a result of legal and 
administrative measures. The number of illegal pervitin manufacturing sites detected by the police rose from 188 in 
2003 to 434 in 2008. The estimated annual pervitin consumption in the Czech Republic has maintained a level of 
about 4 tonnes in recent years; every year, law enforcement agencies seize approximately 5 kg of pervitin in total. 
The price of pervitin remains stable at CZK 1,000 (€ 40) per 1 g and its purity has been approximately 60% for a long 
time.  
The third selected issue concerns older drug users (for the purpose of this selected issue, an older drug user means 
any user over 40 years old), both in treatment and outside it, as well as specific services designed for older users. 
The prognosis announced by the Czech Statistical Office indicates that in 2050 people aged 65 and above will 
account for 31% of the Czech population. The demographic aging of the population results from the declining birth 
rate and the rising life expectancy, which are associated with better health care and a higher quality of life. The 
available data show that the population of drug users is also aging in the Czech Republic. There has been an 
increase in the average age of people in contact with low-threshold facilities for drug users and the number of older 
drug users in treatment is also on the rise, although their proportion is still low. In comparison to those of a younger 
age, drug users aged 40 and above are more likely to be unemployed and homeless, and they also include more 
individuals with higher education. Nevertheless, the Czech drug policy seems neither to articulate specific measures 
nor implement them in order to address the issue of the aging of the population of drug users. In the Czech Republic 
there is only one establishment specialising in services for older users of non-alcohol drugs. The vast majority of the 
existing programmes deals with older clients’ specific problems, encountered in treatment or during the provision of 
low-threshold or outreach services, on the basis of individual demands and needs. 
strana 5 
PART A: NEW DEVELOPMENTS AND TRENDS 
1 Drug Policy: legislation, strategies, and economic analysis 
In 2008 the Chamber of Deputies of the Czech Parliament passed the bill for a new Penal Code. In early 2009 the 
bill was adopted by the Senate and included in the Collection of Laws as Act No. 40/2009, Coll. Penal Code, 
effective from 1 January 2010. The new Penal Code includes significant changes in how to address illegal drugs. In 
particular, the changes concern the stipulation providing for drug possession for personal use, which is to distinguish 
drugs according to their social and health risks. In comparison to the previous sentencing guidelines, a lower 
punishment range will apply to people who possess cannabis in a quantity greater than small; other types of drugs 
will be covered by stricter sentences. A significant change was also introduced by the new provision concerning the 
illegal cultivation of plants containing a narcotic or psychotropic substance. The growing of designated plants or 
mushrooms for personal use will be covered by less strict sentencing guidelines than was the case under the 
previous legal regulations. In addition, the cultivation of a small quantity of plants or mushrooms for personal use will 
not be governed by criminal statutes but will be punished under the Misdemeanour Act. 
In relation to the act on pharmaceuticals, the National Institute for Drug Control has imposed restrictions on the 
supply of medicinal products containing up to 30 mg of pseudoephedrine per tablet. This measure involves a ban on 
mail order sales, the setting of a maximum monthly dose of 60 tablets per patient, and the control of supply by 
means of the central database of electronic prescriptions. 
In 2008, the profession of an addictologist (addiction specialist) was incorporated in the law on non-medical health 
professions and the professional competencies required for the performance of this profession were defined. 
The preparation and enforcement of the national drug policy is the responsibility of the Government of the Czech 
Republic. Its main initiating, counselling, and coordinating body for drug-related issues is the Government Council for 
Drug Policy Coordination; the activities of the Council are managed by the Secretariat, an organisational unit of the 
Office of the Government of the Czech Republic. The Council met four times in 2008. 
The National Drug Policy Strategy for the Period 2005 to 2009 and the Action Plan for the Implementation of the 
National Drug Policy Strategy for the Period 2007 to 2009 are in force.  
A draft of the Vision of Outpatient Drug Services was developed and submitted to the professional community for 
discussion in 2008. The document proposes structural changes in the network of facilities providing outpatient 
services for substance users. 
In 2008, there were regional drug coordinators working in 13 regions (the Moravian-Silesian Region has not 
established this office). They make use of a network of drug coordinators in individual municipalities with extended 
competencies in their region. With the exception of the Pilsen region, all regions had drawn up their regional drug 
policy strategies. 
Public expenditure on drug policy reached a level of CZK 597.3 million (€ 23,947 thousand) in 2008. This amount 
included CZK 371.9 million (€ 14,912 thousand) provided from the state budget, and the regions and municipalities 
contributed amounts of CZK 162.9 million (€ 6,530 thousand) and CZK 62.5 million (€ 2,505 thusand), respectively. 
In comparison to 2007, total expenses increased on all three levels by 7%; on the central level, there was a decrease 
in expenditure on the part of all the ministries and central agencies under scrutiny, with the exception of the Ministries 
of Defence and of Labour and Social Affairs and the National Drug Headquarters of the Police of the Czech 
Republic. On the regional level, there was an aggregate year-on-year expenditure increase of approximately one 
third. An increase was recorded in almost all the regions; only the Zlín and Vysočina regions reported a year-on-year 
decline. Approximately one third of regional expenditures was used to finance sobering-up stations and the 
treatment of intoxicated people. The aggregate of funds expended by municipalities was almost the same as in 
2007. Out of a total of CZK 597.3 million (€ 23,947 thousand), CZK 152.1 million (€ 6,100 thousand; 25.5%) was 
spent on law enforcement, CZK 184.5 million (€ 7,399 thousand; 30.9%) on treatment, CZK 159.4 million (€ 6,389 
thousand; 26.7%) on harm reduction, CZK 58.4 million (€ 2,340 thousand; 9.8%) on primary prevention, and CZK 
24.9 million (€ 999 thousand; 4.2%) on aftercare. 
1.1 Legal Framework 
1.1.1 Laws, Regulations, Directives, or Guidelines in the Field of Drug Issues 
1.1.1.1 Penal Code 
Following a protracted procedure1, a new Penal Code was adopted in 2008. On 11 November 2008, the bill for a 
new Penal Code was approved by the Chamber of Deputies of the Czech Parliament2. Subsequently, it was 
                                                          
1 The bill for a new penal code was (after spending many years in preparation and being subjected to parliamentary debate for almost 
two years) rejected by the Parliament of the Czech Republic in February 2006. In December 2007, after being reconsidered by the 
Government, it was presented to the Parliament again, almost unaltered.  
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debated and passed, on 8 January 2009, by the Senate3. The new Penal Code was included in the Collection of 
Laws, under Title 11, on 9 February 2009 as Act. No. 40/2009, Coll., Penal Code. It becomes effective on 1 January 
2010. 
The drug-related criminal offences, currently provided for by the stipulations of Sections 187 to 188a of Act No. 
140/1961 Coll., the Penal Code, as amended, are newly covered by Sections 283 to 287 of the new Penal Code. 
Definitions of the relevant offences fall under a heading of their own now: Section 283 – Unauthorised production 
and other handling of narcotic and psychotropic substances and poisons; Section 284 – Possession of a narcotic 
and psychotropic substance or poison; Section 285 – Unauthorised cultivation of plants containing a narcotic or 
psychotropic substance; Section 286 – Manufacturing and possession of equipment for the unauthorised production 
of a narcotic and psychotropic substance or poison, and Section 287 – Promotion of drug use. There is an 
innovation, the introduction of the definition of an offence under Section 285 – Unauthorised cultivation of plants 
containing a narcotic or psychotropic substance – which encompasses cannabis, as well as psychotropic 
mushrooms and other plants, as applicable. 
The growing of designated plants or mushrooms for personal use will be covered by less strict sentencing guidelines 
than was the case under the previous legal regulations. In addition, the cultivation of a small quantity of plants or 
mushrooms for personal use will not be governed by criminal statutes but will be punished under the Misdemeanour 
Act. Criminal sanctions for the possession of cannabis for personal use were also mitigated. Furthermore, other 
drug-related offences are specified in more detail or redefined in the new Penal Code (for more details refer to the 
2007 Annual Report4). 
The stipulations of Section 290 (2) and (3) of the new Penal Code authorise the Government to issue a regulation 
specifying (1) what substances should be considered poisons in terms of Sections 283, 284, and 286 and what 
quantities are to be considered greater than small as regards narcotics, psychotropic substances, including products 
containing them, and poisons, as well as to issue a regulation setting out (2) what plants and mushrooms contain a 
narcotic or psychotropic substance according to Section 285 and what quantities thereof are to be considered 
greater than small pursuant to Section 285. As of the closing date of this annual report, drafts of both regulations had 
been submitted by the Ministry of Justice and included in the Government’s agenda. At the moment they are at the 
stage of an amendment procedure. 
1.1.1.2 Changes in the Handling of Medicinal Products Containing Pseudoephedrine  
In relation to the new law on pharmaceuticals, i.e. Act No. 378/2007, Coll., effective from 1 January 2008 (for more 
details see the 2007 Annual Report), changes were made in the handling of medicinal products containing 
pseudoephedrine. As of 1 May 2009 restrictions were imposed on the supply of medicines containing up to 30 mg of 
pseudoephedrine per tablet (the sale of which was completely unlimited until the above date). This measure was 
introduced on the basis of a decision rendered by the State Institute for Drug Control (SUKL) which, according to the 
stipulations of Section 39 (3) of the Act on Pharmaceuticals, made a change to the marketing authorisation for these 
medicines and introduced the following measures: (1) a ban on mail order sales; (2) the setting of a maximum 
monthly dose per patient available without prescription (1,800 mg, i.e. 60 tbl. of 30 mg), and (3) the registration of 
supplies in the central database of electronic prescriptions. In practice, this implies that, in consideration of the 
restrictions mentioned above, medicinal products containing pseudoephedrine can only be supplied by pharmacies 
connected to the central database of electronic prescriptions. If not connected to this database, a pharmacy is 
allowed to provide medicinal products containing pseudoephedrine on prescription only. 
Another change in the approach to pseudoephedrine took place in the first half of 2009. With effect from 1 June 
2009, Act No. 167/1998, Coll.,5 on addictive substances, was amended. The legal conditions for the handling of 
products containing ephedrine and pseudoephedrine were tightened up. The restrictive measures prescribed by the 
law on addictive substances now apply to all products containing pseudoephedrine, not only those containing 
pseudoephedrine in an amount exceeding 30 mg per drug form unit, as was the case before.  
The aforementioned changes are expected to ensure better control of the illicit handling of pseudoephedrine, which 
is used as a precursor in the production of pervitin in the Czech Republic; see also the chapter on Drug Markets 
(p. 92) and the chapter on a selected issue, Cannabis Markets and Production (p. 96). 
                                                                                                                                                                                                
2 For more details see the website of the Chamber of Deputies of the Czech Parliament, where you can follow the history of the 
discussion on Chamber Print No. 410/0 http://www.psp.cz/sqw/historie.sqw?o=5&T=410.  
3 For more details about the history of the discussion on Senate Print No. 11 refer to the website of the Senate of the Czech Republic 
http://www.senat.cz/xqw/xervlet/pssenat/historie?ke_dni=08.01.2009&O=7&action=detail&value=2401.  
4 In comparison to the original text, changes were made to the numbers identifying the drug-related offences in the newly adopted 
wording of the Penal Code – in the wording submitted to the Chamber of Deputies, they were numbered as Sections 281-285 and 
Section 289. The newly adopted Penal Code refers to the relevant stipulations as Sections 283-287 and Section 290. These changes 
had no impact on the content of the provisions under consideration. 
5 The amendment was implemented by virtue of Act No. 141/2009, Coll. 
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1.1.1.3 Incorporation of the Profession of an Addictologist in Legislation 
Act No. 96/2004, Coll., (the Act on Non-medical Health Professions) laying down the conditions for the acquisition 
and recognition of qualifications for the performance of non-medical health professions and the performance of 
activities associated with the provision of health care, and revising certain related laws, was amended in 2008. By 
virtue of an amendment, implemented by Act No. 189/2008, Coll., a stipulation under Section 21a, setting out the 
professional competences required for the performance of the profession of an addictologist, was added to the law 
on non-medical health professions, together with some other new provisions. According to the above-mentioned 
stipulation, an addictologist performs activities within the framework of prevention, treatment, and rehabilitation 
provided as part of the discipline of addictology, i.e. a field of study concerned with the prevention and treatment of 
drug dependency and other types of addiction. This change provided the legal basis for the profession of an 
addictologist in relation to the accreditation of a new bachelor’s study programme in addictology, which has been 
provided by the Centre for Addictology of the Psychiatric Clinic, 1st Faculty of Medicine, and General University 
Hospital, Charles University in Prague (the Centre for Addictology) since the academic year 2005/2006. 
1.1.1.4 Changes in Providing Evidence of People Being under the Influence of Alcohol  
Act No. 379/2005 Coll., on the measures for protection against harm caused by tobacco products, alcohol, and other 
addictive substances, was amended in 20086. With effect from 1 January 2009, the stipulations of Section 16 (2) of 
Act No. 379/2005, Coll., provides that no additional special medical examination (i.e. blood alcohol testing carried out 
as a standard procedure prior to the amendment) should be conducted after a screening test for alcohol using a 
breathalyser has been performed. The amended stipulation provides that a specialised medical examination should 
only be carried out if a person refuses to undergo a screening test (for more details about the current application of 
this provision see the following chapter Implementation of Laws. 
1.1.2 Implementation of Laws 
In relation to the amendment to the law governing the process of proving that a person is under the influence of 
alcohol (see above), judicial practice shows certain differences in the application of this regulation in cases when a 
person under the influence of alcohol commits a crime (mostly traffic-related offences in this respect). Information 
provided by the Czech News Agency suggests that many courts find evidence based on a screening test for alcohol 
insufficient for the purpose of criminal proceedings. (Criminal court proceedings follow the principle of discretionary 
consideration of evidence and are conducted in accordance with the criminal code and the criminal procedure rules. 
Thus, it is up to a specific judge to determine what degree of significance is attributed to the individual items of 
evidence for the purpose of their decision). In this respect, it is necessary to wait until judicial practice becomes 
consistent in relation to such cases, which could be facilitated by the Supreme Court’s analysis of this issue on the 
basis of cases that have already been decided. 
No case law decisions which would significantly change the respective judicial decision making have been made in 
relation to the issue of drug-related criminal offences. 
Criminal activities associated with drug use are covered in more detail in the chapter on Drug-related Crime, page 
81. 
1.2 National Action Plan, Strategy, Evaluation, and Coordination 
1.2.1 National Action Plan and/or Strategy 
The year 2008 was the fourth year of the implementation of the National Drug Policy Strategy for the Period 2005 to 
2009 (the 2005-2009 National Strategy). The implementation of the strategy is facilitated by two action plans 
developed for the periods 2005-2006 and 2007-2009; for more information see the 2004 and 2007 annual reports. 
1.2.2 Implementation and Evaluation of National Action Plan and/or Strategy 
At its meetings in 2008, the Government Council for Drug Policy Coordination (GCDPC) discussed, on two 
occasions (in April and June), the interim evaluation of the application of the Action Plan for the Implementation of 
the National Drug Policy Strategy for the Period 2007 to 2009 (the 2007-2009 Action Plan) in order to review the 
fulfilment of tasks. Out of the total number of 171 tasks, 15 (9%) were found to have been completed by the set 
deadline, 18 (11%) had been partly completed, 9 (5%) had not been accomplished, and 59 tasks (35%) were in 
process or still being worked on. No information was provided on the remaining 70 tasks (41%). 
In view of the fact that the effective period of the 2005-2009 National Strategy is to expire soon, at its meeting held in 
June 2009, the GCDPC approved a plan for the evaluation of the Strategy and the related 2007-2009 Action Plan 
(Resolution No. 03/0609). The evaluation should cover the following areas: 
 the interrelationship between the Action Plan and the Strategy and the Action Plan’s internal structure; 
 the implementation and fulfilment status of the activities set out in the action plans and outcomes resulting from 
their application; 
                                                          
6 The amendment was implemented by virtue of Act No. 274/2008, Coll. 
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 the implementation process and identification of the causes of both successes and shortcomings, as well as the 
factors limiting the implementation of the 2007-2009 Action Plan, and 
 the degree of accomplishment of the objectives set in the Strategy on the basis of the relationship between the 
Strategy and the drug situation, i.e. the assessment of trends shown by measurable indicators according to the 
individual objectives of the 2005-2009 National Strategy.  
The evaluation process will have been completed by the end of 2009. First and foremost, it will involve an internal 
evaluation which will be carried out by the entities responsible for the implementation of the Strategy and the Action 
Plans. The evaluation will also serve as the basis for the development of a new strategy for the period starting in 
2010.  
1.2.3 Other Drug Policy Developments  
An interim evaluation of the Drug Policy Action Plan of the Prison Service of the Czech Republic for the Period 2007-
2009 was carried out in 2008; see also the chapter on Responses to Drug-related Health Issues in Prisons, page 89. 
It features 26 main tasks which determine other sub-tasks. The sub-tasks include 57 tasks from the 2005-2006 and 
2007-2009 national action plans and an additional 45 tasks set out by the Prison Service. The evaluation concerned 
the 2008 tasks. Out of 102 sub-tasks, 32 were accomplished, 2 were completed in part, 3 were not completed, and 
65 tasks were in process or still being worked on (Vězeňská služba České republiky, 2009).  
A draft of the Vision of Outpatient Drug Services was developed and submitted to the professional community for 
discussion in 2008; for more details see the chapter Legislative Framework of Services for Drug Users, page 32, 
which also provides additional information on the scope of the treatment system. 
1.2.4 Coordination Arrangements 
1.2.4.1 Coordination at the National Level  
The Government Council for Drug Policy Coordination (GCDPC) is the main coordinating body of the Government 
for issues related to drug policy. The Council met four times in 2008.  
A working group on Drug Use Prevention and Harm Reduction at Dance Parties was established in January 2008; 
for more details see the 2007 Annual Report. 
In October 2008, by virtue of its Resolution No. 06/1008, the GCDPC approved the establishment of the 
Methamphetamine Working Group, an inter-agency multidisciplinary body which, building on the operation and 
outcomes of the working group concerned with a reduction in the availability of medicinal products used for the illicit 
production of methamphetamine, working from 2007 to 2008 under the Ministry of Health, will address the issue of 
methamphetamine in the Czech Republic comprehensively and on a long-term basis. The working group’s major 
areas of interest will include the availability of precursors for the production of pervitin, the assessment of the impact 
and efficiency of measures adopted so as to reduce access to precursors for the illicit production of pervitin (see also 
the chapter on Legal Framework, p. 5), the monitoring of trends in the availability of medicinal products containing 
pseudoephedrine, the monitoring of the availability of other precursors of drugs and substances used for the illicit 
production of pervitin (such as ephedrine, toluene, iodine, red phosphorus, phosphoric acid, and hydroiodic acid), the 
study of the effectiveness of harm reduction and treatment interventions of various types in relation to pervitin users, 
and the assessment of the risks which the illegal production of pervitin may pose for the health of the people inside 
the houses where such activities are pursued and in terms of the contamination of the environment in general. 
As of June 2009, the GCDPC can use the expertise of a total of 5 committees and 4 working groups7 – see Table 
1-1.  
Table 1-1: GCDPC’s advisory bodies as of June 2009 
GCDPC’s committees GCDPC’s working groups 
GCDPC’s Committee of Departmental and 
Institutional Representatives  
Working Group on EU Collaboration – Ministerial 
Coordination Group 
Certification Committee GCDPC’s Working Group for Non-Substance Addiction 
GCDPC’s Funding Committee for the Provision of 
Special-Purpose Subsidies from the National 
Budget  
Working Group for Drug Use Prevention and Harm 
Reduction at Dance Parties 
Committee of Regional Representatives   
GCDPC Advisory Committee for Drug-related Data 
Collection  
Methamphetamine Working Group 
 
                                                          
7 In addition, the National Focal Point coordinates the activities of 7 working groups operating in various areas involving drug data 
collection. 
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1.2.4.2 Coordination at the Local Level  
As far as the coordination of drug policy at the local level is concerned, no major changes have occurred in 
comparison to the previous year. As in 2007, all 14 regions, with the exception of Moravia-Silesia, have established 
the office of regional drug coordinator and all the regions have developed strategic documents providing for their 
regional drug policies (including strategies, strategic plans, and action plans setting specific tasks and deadlines for 
their completion). Almost all the regions have established drug commissions, often as advisory bodies to the 
mayor/governor, or their deputies, or the regional council; in some regions, drug policy is in the remit of advisory 
bodies covering a wider range of issues (such as social and health affairs and negative social phenomena, including 
crime prevention). The commissions are complemented by a varying number of working groups in most of the 
regions; for more details see the 2007 Annual Report.  
The authorities of the municipalities with extended competencies provide drug policy coordination through local drug 
coordinators. They have been appointed in 196 out of a total of 205 municipalities with extended competencies and 
in all twenty-two Prague city districts. 
The list of regional and local coordinators, including contacts, can be accessed via the Help Map application at 
drogy-info.cz.  
1.2.4.3 Czech Presidency of the EU Council 
In the first half of 2009, the Czech Republic held the presidency of the European Union (EU). In relation to that, the 
GCDPC considered a number of documents pertaining to the preparation and the course of the presidency of the 
Horizontal Drugs Group (HDG), a working group of the Council of the European Union. In 2008, the GCDPC 
adopted the EU Council Presidency Drug Policy Framework Document (Resolution No. 06/0408) and the priorities of 
the presidency in terms of drug policy (Resolution No. 05/0408), including: 
 further development of the process of discussion, approval, and implementation of the EU Drugs Action Plan for 
2009-2012; 
 an integrated standpoint of the EU countries in the UN Commission on Narcotic Drugs, including a ministerial 
conference on the fulfilment of the conclusions of the 20th UN General Assembly Special Session (UNGASS) 
held in 1998; 
 the topic of migration, integration, and drugs; 
 the issue of methamphetamine production and use, and 
 the effective coordination of liaison with third countries. 
A session of the High-Level Segment of the UN Commission on Narcotic Drugs (CND) took place in Vienna in 
March 2009. The event adopted significant documents concerning the international coordination of drug policy, 
including the Political Declaration and the Plan of Action on International Cooperation towards an Integrated and 
Balanced Strategy to Counter the World Drug Problem. A 10-year review of the conclusions of the 1998 UNGASS 
was also on the agenda. The EU’s standpoint and the standpoints of the individual member states were coordinated 
by the Czech Republic as the presiding country. 
Another significant outcome of the Czech presidency was a proposal made for the Council Conclusions concerning 
illicit drug supply reduction indicators, which was approved by the Justice and Home Affairs Council of the EU in 
June 2009. 
1.3 Economic Analysis  
1.3.1 Public Expenditures 
In 2008, drug policy was funded in a method similar to that used in the previous years. This chapter summarises 
data on special-purpose, labelled, expenditures from the state and local (regional and municipal) budgets which 
were earmarked for the funding of drug policy (i.e. the direct cost of drug policy incurred by the state and local 
budgets). These are actual 2008 expenditures, stripped of transfers to the reserve fund and the amounts which were 
not utilised but returned by service providers to public budgets. The capital (investment) expenditures are indicated 
separately. 
On the central level, the data were obtained from the national final accounts of selected ministries whose budgets 
include a drug policy programme. Additional information was obtained directly from the representatives or contact 
persons of individual ministries and public institutions, as well as from regional drug coordinators. 
2008 expenditures from the state budget amounted to a total of CZK 371.9 million (€ 14,912 thousand)8; the trends 
of ministries and institutions from 2002 to 2008 are summarised in Table 1-2. 
The subsidies approved by the GCDPC are provided by the Office of the Government of the Czech Republic. In 
2008 such subsidies were used to support 154 projects to the tune of a total amount of CZK 95.3 million (€ 3,821 
                                                          
8 2008 average exchange rate was used (1€ = CZK 24.942).  
strana 10 
thousand). The resources were utilised for projects delivering prevention, harm reduction, treatment, and aftercare. 
The expenditure designated for the activities developed by the Secretariat of the GCDPC, including the National 
Focal Point, amounted to CZK 4.7 million (€ 188 thousand) and was predominantly allocated to monitoring and 
research, publication and information activities, the administration of the GCDPC’s subsidy proceedings, and the 
implementation of the system of the certification of the professional competence of drug services. 
According to the final national accounts, the Ministry of Education, Youth, and Physical Education (the Ministry of 
Education) spent a total of CZK 12.4 million (€ 499 thousand) on drug policy in 2008. The resources provided by the 
Ministry of Education concerned prevention. Subsidy proceedings involved three programmes: Programme I 
covered schools and educational facilities by means of subsidies to regions (CZK 7.4 million (€ 297 thousand) was 
distributed in this way in 2008), Programme II was intended for national and regional projects implemented mostly by 
NGOs, and Programme III addressed educational facilities for young people in institutional care and educational 
establishments for preventive care. 
The resources from the budget of the Ministry of Defence spent on drug policy in 2008 amounted to CZK 5.3 million 
(€ 212 thousand). This money was mainly used to purchase diagnostic equipment for the detection of drugs and 
professional literature and to organise lectures and seminars. 
Since 2007 the budget of the Ministry of Labour and Social Affairs has not included any expenses earmarked for the 
Drug Policy Programme. However, it provides financial support for social services for people at risk from drugs or 
dependent on them. In 2008 subsidies to the tune of CZK 79.5 million (€ 3,186 thousand) were spent on the 
operation of outreach centres (CZK 28.9 million; € 1,161 thousand)) and therapeutic communities (CZK 23.1 million; 
€ 926 thousand), the operation of streetwork programmes (CZK 16.2 million; € 648 thousand), social counselling 
(CZK 5.3 million; € 212 thousand), social rehabilitation (CZK 4.9 million; € 197 thousand), and other programmes9.  
In 2008 the Ministry of Health provided a total amount of CZK 18.9 million (€ 757 thousand) for drug policy, including 
capital expenditure of CZK 3.9 million (€ 155 thousand). Priority was given to the funding of projects ensuring both 
outpatient and inpatient addiction treatment, substitution treatment, detoxification, and the operation of outreach 
centres and streetwork programmes (in particular, to cover the cost of medical supplies). 
In 2008 the Ministry of Justice provided CZK 7.4 million (€ 296 thousand) for the drug policy. Subsidies amounting to 
a total of CZK 0.6 million (€ 24 thousand) were granted to NGOs working with drug users in prison. The Judicial 
Academy used CZK 0.2 million (€ 8 thousand) to host seminars and the Institute for Criminology spent CZK 49.9 
thousand (€ 2,000 thousand)  on participation in conferences. The largest sum (CZK 6.5 million; € 261 thousand) 
was earmarked for the Prison Service. These resources were used to train prison staff in dealing with drug-
dependent inmates, to detect and monitor drugs in prisons, and to operate prison-based counselling and treatment 
programmes. 
The budget of the General Customs Headquarters allows for the Drug Policy Programme. These funds, accounting 
for CZK 10.7 million (€ 427 thousand) in 2008, were primarily used for the refurbishment of stock (purchase of 
means of transport and special investigative equipment and technology). 
The budget of the Ministry of the Interior does not account for any expenditure on the Drug Policy Programme10. 
However, this ministry is responsible for the National Drug Headquarters of the Criminal Police and Investigation 
Service of the Police of the Czech Republic (National Drug Headquarters), whose expenses reached a total of CZK 
137.8 million (€ 5,527 thousand) in 2008, including (investment) capital expenditure of CZK 9.5 million (€ 380 
thousand).  
                                                          
9 The expenditures on the part of the Ministry of Labour and Social Affairs do not include subsidies for special-regimen homes providing 
services for older clients dependent on alcohol. 
10 The Ministry of the Interior coordinates and funds crime prevention activities which are not specifically targeted at drug issues; for 
more details see the chapter on Prevention of Drug-Related Crime, page 86. 
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Table 1-2: Drug policy expenditures from Czech state budget in 2002–2008 by ministries/departments (€ thousand) 
Allocation 2002 2003 2004 2005 2006 2007 2008 
GCDPC 2,886 3,261 3,153 3,547 3,838 3,762 4,008
Ministry of 
Education  299 293 316 315 381 452 499
Ministry of 
Defence  125 147 109 133 172 129 212
Ministry of 
Labour and 
Social Affairs  
1,104 1,391 1,323 1,546 1,753 2,054 3,186
Ministry of 
Health  808 692 829 1,124 635 801 757
Ministry of 
Justice 302 442 427 1,233 1,455 454 296
General 
Customs 
Headquarters  
863 708 292 487 829 963 427
National Drug 
Headquarters n.a. 3,022 2,711 3,189 3,757 4,601 5,527
Total 6,387 9,957 9,161 11,574 12,821 13,217 14,912
NB: Average exchange rates in respective years were used for re-calculation of expenses from CZK to €. 
In addition to the state budget, the drug policy in the Czech Republic is also funded by local budgets, i.e. those of 
regions and municipalities11. In 2008 regions and municipalities provided CZK 162.9 million (€ 6,530 thousand) and 
CZK 62.5 million (€ 2,505 thousand) respectively for this field. The funds provided by regions and municipalities in 
2008 and the trends since 2002 are indicated in Table 1-3 to Table 1-7.  
Table 1-3: Drug policy expenditures from Czech regional budgets in 2002-2008 (€ thousand) 
Regions 2002 2003 2004 2005 2006 2007 2008 
Prague 399 391 820 1,029 1,147 1,463 2,006
Central 
Bohemia 114 251 432 495 505 625 713
South 
Bohemia 95 88 181 175 212 223 408
Pilsen 0 31 47 113 82 65 256
Karlovy Vary 3 16 16 35 29 41 53
Ústí nad 
Labem 47 237 248 232 242 174 203
Liberec 0 86 181 271 285 233 459
Hradec 
Králové 24 30 63 69 102 244 277
Pardubice 49 47 56 185 58 198 224
Vysočina 0 57 129 233 109 285 157
South Moravia 97 63 157 249 300 306 341
Olomouc 3 10 41 67 72 90 334
Zlín 36 110 75 71 49 170 178
Moravia-
Silesia 74 94 112 147 157 505 921
Total 952 1,510 2,558 3,369 3,349 4,624 6,530
 
A summary of 2008 drug policy expenditures from the state, regional, and municipal budgets is provided in Table 
1-6; the data are divided into regions according to the locations where subsidies were utilised by the providers of the 
projects and programmes. The total sum of labelled expenditures in 2008 amounted to CZK 597.3 million (€ 23,947 
thousand), which is a 7% year-on-year increase12. The 2008 drug policy expenditures from the state and local 
budgets designated for use on regional levels are depicted by regions in Map 1-1. 
The developments in drug policy expenditure on drug demand reduction (i.e. prevention, harm reduction, treatment, 
aftercare, coordination, and research) and drug supply reduction (law enforcement) in the Czech Republic in 2002-
2008 are summarised in Table 1-4. Until 2006 the expenditure on demand reduction included resources expended 
by: the GCDPC; the Ministry of Education, Youth, and Physical Education; the Ministry of Defence; the Ministry of 
                                                          
11 The data on regional and municipal expenditure are based on the annual reports of drug policy implementation in regions and/or the 
specifying information requested from regional drug coordinators. 
12 All expenditures and its variations are indicated in nominal values. 
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Labour and Social Affairs, and the Ministry of Health, while expenditure on supply reduction included resources 
consumed by the Ministry of Justice, the General Customs Headquarters, and the National Drug Headquarters. 
Since 2007 the data have been more accurate, and the Ministry of Justice’s expenditures have been divided into the 
two areas to reflect their actual purpose. As a result, the consistency of the data over time is impaired. 
An overview of expenditures from state and local budgets in 2008 by service category is provided in Table 1-7. The 
first category is “primary prevention”. The “harm reduction” category includes outreach centres, low-threshold day 
centres, and streetwork programmes. The “treatment” category encompasses medical care (substitution 
programmes, detoxification, outpatient and inpatient alcohol/drug treatment services, and social services provided in 
institutional care), non-medical outpatient care (crisis intervention, social counselling, and outpatient treatment 
provided by NGOs), and therapeutic communities, and a new separate category has been created for sobering-up 
stations. Other categories include “aftercare”, “law enforcement”, “coordination” (covering coordination, as well as 
monitoring and research, the evaluation of services, information, and training), and “others”. Out of labelled 2008 
drug policy expenditures amounting to a total of CZK 597.3 million (€ 23,947 thousand), CZK 184.5 million (€ 7,399 
thousand) was earmarked for treatment (20% more than in 2007, although one third of the sum was dedicated to the 
operation of sobering-up stations), CZK 152.1 million (€ 6,100 thousand) was reserved for law enforcement (5% less 
than in 2007), CZK 159.4 million (€ 6,389 thousand) was allocated to harm reduction services (13% more), CZK 58.4 
million (€ 2,340 thousand) to primary prevention (20% more), and CZK 24.9 million (€ 999 thousand) to aftercare (an 
increase by 21%). A comparison of expenditures from public budgets in 2007 and 2008, by service category, is 
provided in Table 1-5. 
Map 1-1: 2008 drug policy expenditures from state and local budgets in regions of the Czech Republic (€ per 100,000 
inhabitants) 
 
 
Table 1-4: Drug policy expenditures from state and local budgets in 2002-2008 (€ thousand) 
Demand reduction* Supply reduction ** 
Year State budget Regional budgets 
Municipal 
budgets Total State budget 
Total 
2002*** 5,397 952 n.a. 6,349 1,204 7,553
2003 5,785 1,510 n.a. 7,295 4,172 11,467
2004 5,731 2,558 1,972 10,261 3,430 13,691
2005 6,666 3,369 1,699 11,733 4,909 16,642
2006 6,780 3,349 1,699 11,828 6,041 17,869
2007 7,425 4,624 2,243 14,292 5,792 20,084
2008 8,812 6,530 2,505 17,847 6,100 23,947
NB: * Expenditures indicated for the period 2002-2006 are those of the GCDPC, the Ministry of Health, the Ministry of Labour and Social 
Affairs, the Ministry of Education, and the Ministry of Defence; since 2007 a part of the Ministry of Justice’s expenditures has also been 
included; ** The amounts indicated for the period 2002-2006 represent the expenditures for the operation of the National Drug 
Headquarters and the General Customs Headquarters and those from the budget of the Ministry of Justice; since 2007 the expenditures 
on the part of the Ministry of Justice have been divided into those intended for demand reduction and those intended for supply 
reduction in order to reflect their actual purposes; *** Expenditures of the National Drug Headquarters are not included. 
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Table 1-5: Comparison of expenditures provided from public budgets by service category in 2007 and 2008 
2007 2008 Category € thousand % € thousand % 
Primary prevention  1,753 8.7 2,340 9.8
Harm reduction 5,078 25.3 6,389 26.7
Treatment  5,496 27.4 7,399 30.9
Aftercare 739 3.7 999 4.2
Coordination, research, evaluation 605 3.0 504 2.1
Law enforcement 5,792 28.8 6,100 25.5
Others, unspecified 620 3.1 217 0.9
Total 20,084 100.0 23,947 100.0
 
The selected issue of Drug-Related Public Expenditures included in the 2006 Annual Report provided estimates of 
both labelled (specifically earmarked) and non-labelled expenditures spent on the reduction of both drug supply (law 
enforcement) and demand (prevention and treatment, including expenses incurred by health insurers). 
1.3.2 Social Costs 
The most recent data regarding the social costs of drug use (including indirect costs) in the Czech Republic 
(Zábranský et al., 2001) were published in the 2002 Annual Report. 
Supported by the internal grant agency of the Ministry of Health, in 2009 the Centre for Addictology began carrying 
out a study of the 2007 social costs of the use of alcohol, tobacco, and illicit drugs in the Czech Republic; the results 
will be available in 2012. 
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Table 1-6: 2008 drug policy expenditures from state and local budgets by location (region) of use (€ thousand) 
Regions GCDPC  Ministry of Education 
Ministry 
of 
Defence 
Ministry 
of 
Labour 
and 
Social 
Affairs  
Ministry 
of 
Health  
Ministry 
of 
Justice 
General 
Customs 
Head-
quarters  
National 
Drug 
Head-
quarters  
Total 
state 
budget 
Regions Munici-palities 
Total 
local 
budgets 
Total Total (%) 
Prague 929 72 – 316 260 – – – 1,577 2,006 557 2,563 4,140 17.3 
Central Bohemia 124 47 – 620 114 – – – 906 713 196 909 1,815 7.6 
South Bohemia 190 35 – 168 87 – – – 480 408 78 486 966 4.0 
Pilsen 177 16 – 65 6 – – – 264 256 310 566 830 3.5 
Karlovy Vary 102 19 – 37 14 – – – 171 53 57 110 282 1.2 
Ústí nad Labem 292 21 – 189 79 – – – 581 203 208 411 992 4.1 
Liberec 57 13 – 96 0 – – – 166 459 66 525 692 2.9 
Hradec Králové 85 16 – 144 62 – – – 307 277 42 320 626 2.6 
Pardubice 68 15 – 66 10 – – – 159 224 73 296 455 1.9 
Vysočina 103 16 – 231 13 – – – 363 157 26 183 546 2.3 
South Moravia 259 66 – 200 39 – – – 564 341 231 572 1,136 4.7 
Olomouc 263 36 – 245 20 – – – 563 334 98 433 996 4.2 
Zlín 103 19 – 104 6 – – – 232 178 179 356 589 2.5 
Moravia-Silesia 160 37 – 162 2 – – – 361 921 383 1,304 1,665 7.0 
Expenditure with 
regional 
designation 
2,911 428 – 2,643 712 – – – 6,695 6,530 2,505 9,035 15,730 65.7 
Expenditure with 
central 
designation 
1,097 71 212 543 45 296 427 5,527 8,217 – – – 8,217 34.3 
Total 4,008 499 212 3,186 757 296 427 5,527 14,912 6,530 2,505 9,035 23,947 100.0 
 – including 
investment 
expenditure  
0 0 0 0 155 0 427 380 962 0 0 0 962 4.0 
Total (%) 16.7 2.1 0.9 13.3 3.2 1.2 1.8 23.1 62.3 27.3 10.5 37.7 100.0 – 
NB: For explanation of acronyms used in the table refer to the Abbreviations section below. 
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Table 1-7: 2008 drug policy expenditures in the Czech Republic by service categories (€ thousand) 
Service category GCDPC Ministry of Education  
Ministry 
of 
Defence 
Ministry 
of 
Labour 
and 
Social 
Affairs 
Ministry 
of 
Health 
Ministry 
of 
Justice 
General 
Custom
s Head-
quarters
National 
Drug 
Head-
quarters 
Total 
state 
budget
Regions Munici-palities 
Total 
local 
budgets 
Total Total (%) 
Primary prevention 217 471 212 – – – – – 900 658 782 1,440 2,340 9.8 
Low-
threshold 
centres 
1,103 – – 1,161 106 – – – 2,370 859 564 1,423 3,793 15.8 
Outreach 
programmes 621 – – 648 53 – – – 1,322 564 378 941 2,263 9.5 
Unspecified* 228 – – – – – – – 228 69 36 105 333 1.4 
H
a
r
m
 
R
e
d
u
c
t
i
o
n
 
Total 1,952 – – 1,808 159 – – – 3,920 1,491 978 2,469 6,389 26.7 
Medical 
care** 81 – – 43 554 15 – – 693 482 177 658 1,352 5.6 
Non-medical 
outpatient 
care*** 
265 – – 212 – 72 – – 549 280 148 428 977 4.1 
Communities 865 – – 926 – – – – 1,791 555 215 770 2,561 10.7 
Sobering-up 
stations – – – – – – – – 0 2,509 0 2,509 2,509 10.5 
Unspecified – – – – – – – – 0 0 0 0 0 0.0 
T
r
e
a
t
m
e
n
t
 
 
Total 1,211 – – 1,181 554 87 – – 3,033 3,826 539 4,366 7,399 30.9 
Aftercare 374 – – 197 – – – – 571 308 120 428 999 4.2 
Coordination, 
research, 
evaluation 
253 – – – 22 63 – – 338 158 7 166 504 2.1 
Law enforcement – – – – – 146 427 5,527 6,100 0 0 0 6,100 25.5 
Others, 
unspecified – 28 – – 22 – – – 50 88 79 167 217 0.9 
Total 4,008 499 212 3,186 757 296 427 5,527 14,912 6,530 2,505 9,035 23,947 100.0 
NB: * These projects include the activities of both low-threshold facilities and outreach work (streetwork). ** i.e., for example, outpatient and inpatient drug treatment, including substitution therapy, detox, and 
social services provided as part of institutional health care. *** i.e., for example, outpatient and intensive outpatient non-medical programmes, crisis intervention, social counselling, social rehabilitation, and 
prison-based programmes delivered by NGOs.  
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2 Drug Use in the General Population and Specific Targeted Groups 
Two surveys covering the population over 15 years of age were conducted in the Czech Republic in 2008: a general 
population survey on psychotropic substance use and the European Core Health Interview Survey. Both studies 
show dramatic differences in the methodology used, as well as in the prevalence rates found. According to the 
survey focusing specifically on drugs (working with a sample of people aged 15-64), 37% of the population have had 
at least one experience with the use of any of the illicit drugs under study; 34% have used cannabis and 17% of the 
population has had experience with other drugs than cannabis. In the past year and the past month, cannabis had 
been used by 15% and 9% of the respondents respectively. The survey focusing on the health of the population 
(using a sample of people over 15 years of age) showed that 15% had used an illicit drug at least once; cannabis 
had also been used by 15%, while any other drug than cannabis had been used by 4% of the respondents. Both 
surveys suggest, however, that the proportion of people in the population who have experience of the use of illicit 
drugs is on the rise, with cannabis use showing the greatest increase. While in 2002 and 2004 at least one 
experience with cannabis was reported by one fifth of adult respondents, the 2008 study on illicit drug use recorded 
positive answers to this question from one third of the respondents. A rising trend in cannabis consumption is also 
supported by surveys studying the population’s health in general, although the prevalence rates reported by them 
are lower. 
The general population survey on the use of psychotropic substances focused on the degree of risky cannabis use. 
Out of the respondents who had used cannabis in the past year, 26% were identified as moderate-risk users and 
12% were assigned to the high-risk category. Men and people aged 25-34 comprise the most vulnerable group. 
After extrapolation to the Czech population in its entirety, the number of heavy cannabis users at significant risk may 
be estimated to amount to 150 thousand, with people in the 15-29 age group accounting for approximately two thirds 
of them. 
An international report from the ESPAD school survey was published in 2008. It indicates that, within the European 
context, the Czech Republic ranks among the countries with the highest prevalence of use of most of the drugs 
under scrutiny, excluding inhalants. As far as cannabis use is concerned, the Czech Republic’s prevalence rates are 
by far the highest in Europe; lifetime cannabis use has been reported by 45% of 16-year-old Czechs. 
Cannabis and ecstasy remain the most popular non-alcohol drugs in the nightlife setting. 
2.1 Drug Use in the General Population 
Two general population studies were carried out in 2008. A monothematic general population survey on the use of 
psychotropic substances in the Czech Republic (CS 2008) was conducted by the National Focal Point in association 
with INRES-SONES and the Centre for Addictology. A set of items concerning experience with alcohol, cigarettes, 
and illegal drugs was also included in the questionnaire used for the European Core Health Interview Survey, carried 
out by the Institute of Health Information and Statistics in the Czech Republic. 
2.1.1 General Population Survey on the Use of Psychotropic Substances 
The principal objective of the general population survey focusing on the use of psychotropic substances was to 
describe the current situation and trends in drug use and compare them to the data generated by the previous 
general population survey conducted in 2004. The questionnaire included a set of items from the European Model 
Questionnaire (EMQ) enquiring about the prevalence and frequency of illicit drug use within three time spans 
(lifetime, the past 12 months, and the past 30 days), the CAST (Cannabis Abuse Screening Test) module 
addressing heavy cannabis consumption, and modules measuring the availability of illicit drugs and involvement in 
the cannabis market. The data were collected in October 2008 using a representative sample of 4,200 respondents 
aged 15-64, enlarged with 300 individuals in the 15-29 age range. The data were weighted to account for the 
gender, age, and regional structure of the Czech Republic’s population. 
The results of the survey show that 37% (45% of men and 28% of women) of the population have had at least one 
experience with the use of any of the illegal drugs under study; see Table 2-1. Cannabis was represented to the 
greatest degree (34%), while other drugs had been used by 17% of the population over 15 years of age. One out of 
ten Czechs reported the lifetime use of ecstasy; magic mushrooms (psilocybin), LSD, pervitin, cocaine, and heroin 
had been used by 9%, 6%, 4%, 2%, and 1% of the population respectively. During the past year an illicit drug had 
been used by 17% of the respondents (15% accounted for by cannabis, 4% ecstasy). Cannabis was also the most 
frequently used drug within the past month; 9% of the respondents reported having used the drug. 
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Table 2-1: Prevalence of substance use among the population aged 15-64 (%) (Národní monitorovací středisko pro 
drogy a drogové závislosti, 2009d) 
Lifetime (%) 12 months (%) 30 days (%) Drug Males Females Total Males Females Total Males Females Total 
Any illicit drug 45.0 27.8 36.5 22.2 11.6 17.0 13.5 5.1 9.3
Any illicit drug other than 
cannabis 21.3 11.6 16.5 9.8 4.7 7.3 4.1 1.7 2.9
Cannabis (marijuana and 
hashish) 42.5 26.0 34.3 20.1 10.1 15.2 12.4 4.6 8.5
Ecstasy  11.9 7.3 9.6 4.8 2.6 3.6 1.5 0.9 1.2
Pervitin (or amphetamine) 5.7 3.0 4.3 2.3 1.0 1.7 0.9 0.5 0.7
Cocaine  2.8 1.2 2.0 1.2 0.3 0.7 0.6 0.1 0.4
Heroin 1.7 0.5 1.1 0.7 0.2 0.4 0.3 0.0 0.1
LSD 7.8 3.4 5.6 2.8 1.4 2.1 0.9 0.6 0.7
Magic mushrooms 12.4 5.0 8.7 4.4 1.7 3.1 1.8 0.4 1.1
 
The use of illicit drugs – with the exception of the use of pervitin, cocaine, and heroin - is the most common among 
the youngest age group, 15-24 years old. With increasing age, the proportion of people who had tried illicit drugs 
decreases; see Figure 2-1. In the age group up to 24 years, experience with cannabis, ecstasy, hallucinogenic 
mushrooms, LSD, and pervitin was reported by 59%, 21%, 15%, 11%, and 7% of the respondents respectively. The 
highest lifetime prevalence rates of cocaine, heroin, and pervitin were recorded among the 25-34 age group; 
experience with pervitin, cocaine, and heroin was reported by 9%, 4%, and 2% of the respondents respectively. 
Figure 2-1: Lifetime prevalence of use of selected illicit drugs by age groups (%) (Národní monitorovací středisko pro 
drogy a drogové závislosti, 2009d) 
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The level of risk cannabis use in the population was measured by means of the CAST scale, consisting of six items 
enquiring whether a respondent had ever: (1) used cannabis alone or (2) before midday; (3) had memory problems 
as a result of cannabis use; (4) been told by friends or family members to stop or reduce their consumption of 
cannabis; (5) tried to stop or reduce their cannabis use without success, and (6) had problems (at school, for 
example) because of their use of cannabis. When transformed and added up, all six variables constitute the CAST 
scale with values ranging from 0 to 6, where one point or none means a low risk, 2 to 3 points imply a moderate risk, 
and 4 or more points suggest high-risk cannabis use requiring professional intervention (Beck and Legleye, 2008). In 
the 2008 study, cannabis consumption posed a moderate risk for 26% and a high risk for 12% of the respondents 
who had used it in the past year. Males and people in the age range from 25 to 34 years old comprise a particularly 
vulnerable group in this sense; for more details see Table 2-2. The results for the 55+ age group may be affected by 
the very small number of users belonging to this category. 
It is estimated that 1.9% of people aged 15-64 are exposed to high-risk cannabis use. When extrapolated to the 
entire population of the Czech Republic, the number of “problematic” cannabis users may be estimated at 
approximately 150 thousand, with people in the 15-29 age group accounting for two thirds of this figure. 
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Table 2-2: CAST scale results, by gender and age, for people who had used cannabis during the past 12 months (%) 
Gender (%) Age (%) Level of risk Males Females 15-17 18-24 25-34 35-44 45-54 55-64 
Total 
(%)  
No or low risk 56.4 73.5 71.8 59.3 55.1 67.1 82.5 68.4 62.1
Moderate risk 30.0 17.1 24.4 27.3 30.6 19.7 12.5 10.5 25.7
High risk 13.6 9.5 3.8 13.4 14.4 13.2 5.0 21.1 12.2
 
The results of the previous studies indicate that the proportion of people in the population who have experience with 
addictive substances is growing, with cannabis use showing the greatest increase. In 2002 the Prague Psychiatric 
Centre conducted the GENACIS study, focusing on differences in the use of addictive substances between the 
genders. It employed a set of standard questions about people’s experience with drugs in their lifetime and during 
the past 12 months. In 2004 the Institute of Health Information and Statistics carried out a general population survey 
(CS 2004), using, for the first time in the Czech Republic, the European Model Questionnaire (EMQ) comprising 
standard questions about the use of, and attitudes to, drugs. While in 2002 and 2004 at least one experience with 
cannabis was reported by one fifth of adult respondents13, in 2008 lifetime cannabis users accounted for one third of 
the population. In addition, the 2002 prevalence rates of lifetime experience with ecstasy, pervitin, and LSD had 
doubled by 2008; see Figure 2-2. 
Figure 2-2: 2002-2008 drug use trends in the population aged 18-64: lifetime prevalence of selected drugs (%) (Národní 
monitorovací středisko pro drogy a drogové závislosti, 2009d; Ústav zdravotnických informací a statistiky, 2006; 
Psychiatrické centrum Praha, 2002) 
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2.1.2 European Health Interview Survey 
In 2008 the Institute of Health Information and Statistics collected data for the Czech segment of the European 
Health Interview Survey (EHIS). Coordinated on the international level by Eurostat, the survey follows up on a series 
of sample surveys of the health status of the Czech population (HIS) carried out by the Institute of Health Information 
and Statistics in 1993, 1996, 1999, and 2002. The survey employs a unified methodology throughout Europe. All EU 
member states should carry out the EHIS in the period 2007-2010. The main purpose of the study was to assess the 
health of the population. In relation to healthy lifestyles, the questionnaire includes items concerning smoking, alcohol 
consumption, and illicit drug use. Data from 1,955 respondents aged 15 and over were collected in the summer and 
autumn of 2008. 
For all the drugs and time periods under study, the EHIS results indicated significantly lower prevalence rates than 
those of CS 2008. Lifetime cannabis use was reported by 15% of the respondents, and 5% and 2% of the people 
had used cannabis during the past year and past month respectively. Ecstasy and magic mushrooms had been tried 
at some point by 2% of the population; see Table 2-3. 
                                                          
13 All three studies used subsamples of people aged 18-64 to allow comparisons. 
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Table 2-3: Prevalence of substance use among the population aged 15 and over (lifetime, past 12 months, and past 30 
days (%) (Ústav zdravotnických informací a statistiky , 2009a) 
Lifetime (%) 12 months (%) 30 days (%) Drug Males Females Total Males Females Total Males Females Total 
Any illicit drug 19.0 12.0 15.4 6.0 4.1 5.0 3.4 1.5 2.4
Any illicit drug other than 
cannabis 5.1 2.5 3.7 1.9 0.6 1.3 1.3 0.4 0.8
Cannabis (marijuana and 
hashish) 18.9 12.0 15.3 5.3 4.0 4.6 2.9 1.4 2.1
Ecstasy  2.9 1.3 2.1 0.9 0.6 0.7 0.3 0.3 0.3
Pervitin (or amphetamine) 1.4 1.3 1.3 0.7 0.3 0.6 0.4 0.1 0.3
Cocaine  1.5 0.8 1.1 0.9 0.8 0.5 0.2 0.2 0.5
Heroin 1.1 0.2 0.6 0.6 0.2 0.4 0.5 0.1 0.3
LSD 1.5 0.9 1.2 0.9 0.3 0.6 0.5 0.1 0.3
Magic mushrooms 3.2 1.4 2.2 1.4 0.5 0.9 0.7 0.1 0.4
 
Similarly to general population surveys on drug use, surveys on the population’s health status also suggest an 
increase in the use of drugs. In the 2002 HIS survey, at least one experience with cannabis was reported by 6.7% of 
respondents aged 18-64, while the last year’s EHIS survey recorded lifetime cannabis use among the same age 
group at a level of 17.7% (Ústav zdravotnických informací a statistiky, 2003; Ústav zdravotnických informací a 
statistiky , 2009a). 
The variations in prevalence levels found by both surveys conducted in 2008 (CS 2008 and EHIS) are likely to result 
mainly from their different methodologies; the questionnaires used differed in their content and the formulation of the 
questions and there were also differences in the data collection methods and the construction of the sample. Foreign 
experience shows that surveys working with questionnaires which start with items on health status and healthy 
lifestyles tend to show lower levels of illicit drug use than those focusing on illicit drugs only (Decorte et al.  2009). 
Furthermore, the data from both studies reflect different populations in terms of age: while the respondents included 
in the CS 2008 survey were 15-64 years old, the EHIS survey focused on a population of people over 15 years old, 
with no upper age limit. The reasons for the differences in drug use prevalence levels indicated by both surveys will 
be subjected to further thorough analysis. 
2.1.3 Attitudes to Substance Use 
As part of the Czech Society project, the Public Opinion Poll Centre conducts an annual survey of the attitudes and 
opinions of the population of the Czech Republic in relation to substance use and the level of tolerance towards the 
users of addictive substances. A survey project, Czechs and Toleration (Centrum pro výzkum veřejného mínění, 
2008), was carried out in March 2008. The investigators presented the respondents with a battery of questions 
pertaining to 12 groups of people, out of whom the respondents were asked to choose those they would not like to 
have as their neighbours. Of the participants, 89%, 83%, and 78% would not like to have drug users, heavy drinkers, 
and people with a criminal history, respectively, as their neighbours. In 2008 people showed the least tolerance 
towards drug addicts since 2003; see Figure 2-3. 
strana 20 
Figure 2-3: Year-to-year comparison of responses to the question “Who would you like not to have as your neighbours?” 
(%) (Centrum pro výzkum veřejného mínění, 2008) 
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In May 2009 the Public Opinion Poll Centre conducted a survey in which respondents were asked about their 
attitudes towards the consumption of selected addictive substances (Centrum pro výzkum veřejného mínění, 2009b) 
and opinions about drug addiction (Centrum pro výzkum veřejného mínění, 2009a). The questionnaire included 
items enquiring about the moral acceptability of drug use and the perceived level of health risks. The respondents 
had the fewest reservations about coffee, the use of which (on a regular or occasional basis) was acceptable for 
96% of those interviewed. Alcohol consumption is tolerated by 93% of the respondents, while cigarette smoking was 
found acceptable by no more than 72%. As far as illegal drugs are concerned, marijuana is the most acceptable 
substance (18%), followed by ecstasy (6%), pervitin (3%), and heroin (2%). Undoubtedly, these results were also 
influenced by the perceived degree of risk associated with the substances under consideration. Heroin was identified 
as the most dangerous drug by the respondents (74% of them find even its first use risky), followed by pervitin 
(63%), ecstasy (55%), and marijuana (31%). In terms of criminal prosecution, the respondents were the most critical 
about the sale of “hard drugs”; 96% of them support criminal sanctions. 91% of those interviewed agree to the 
prosecution of dealing in cannabis. In addition, most of the respondents would be in favour of the criminal 
prosecution of the use itself; this was stated by 83% and 65% of the respondents as regards “hard drugs” and 
cannabis respectively (Centrum pro výzkum veřejného mínění, 2009b). 
The five most common factors believed by the population of the Czech Republic to contribute to the development of 
addiction include friends (this factor was identified by 94% of the respondents), knowing people using drugs (83%), 
individual personality (83%), parenting (80%), and the community where a person lives (70%) (Centrum pro výzkum 
veřejného mínění, 2009a). Opinions on other aspects of the drug issue are summarised in Figure 2-4. 
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Figure 2-4: Opinions about selected aspects of the drug issue (%) (Centrum pro výzkum veřejného mínění, 2009a) 
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2.2 Drug Use in the School Population and among Young People 
2.2.1 ESPAD Study in the International Context 
An international report from the European School Survey on Alcohol and Other Drugs (ESPAD), which the Czech 
Republic participated in for the fourth time in 2007, was published in March 2009 (Hibell et al.  2009). The results for 
the Czech Republic were summarised in the 2007 Annual Report. The data on 3,901 Czech students born in 1991 
(i.e. mostly 16 years old) were included in the international comparison. A comparison of the Czech and European 
levels of the eight key indicators of the 2007 ESPAD is provided in Figure 2-5. 
Figure 2-5: Comparison of selected indicators for the Czech Republic with 2007 ESPAD European average (%) (Hibell et 
al.  2009)  
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The Czech Republic ranks among the countries which show the highest proportions of students having experience 
with most of the substances under study. As far as illicit drugs are concerned, in 2007 the respondents were most 
likely to report experience with cannabis use (45.1%). Further positions were taken by experience with sedatives 
(9.1%), the use of hallucinogenic mushrooms (7.4%), and the inhalation of solvents (7.0%). Experience with LSD 
(5.0%), ecstasy (4.6%), and amphetamines (3.5%) is less frequent, and experience with drugs such as heroin and 
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cocaine is only sporadic among the population of 16-year-olds (2.0% and 1.1% respectively). Within the European 
context, the Czech Republic scored the highest prevalence rates in relation to the consumption of alcohol, cigarettes, 
and cannabis. On the other hand, it showed the lowest prevalence of experience with inhalants. While cannabis use 
in the Czech Republic remained at the same level when compared to 2003, the proportion of people reporting 
experience with ecstasy declined. 
2.2.2 HBSC Survey in the International Context 
A summary international report from the 2006 Health Behaviour in School-aged Children (HBSC) survey was also 
published in 2008. The HBSC study primarily focuses on the healthy lifestyle of 15-year-old students (mostly ninth-
graders in the Czech Republic), but it also addresses the use of alcohol and illegal drugs. For a summary of the 
results for the Czech Republic, refer to the 2006 Annual Report. Out of the illicit drugs, the international report only 
covers cannabis use. In the Czech Republic, at least one experience with the use of cannabis was reported by 25% 
of students, while 19% of students stated that they had used cannabis in the past year. It is noteworthy that the 
global lifetime prevalence average was 18% (World Health Organization, Regional Office for Europe, 2008). 
2.2.3 Local School Surveys 
In the spring of 2008 a survey among basic school pupils in the Prague 14 District was carried out using the ESPAD 
questionnaire (Skalský, 2009). The study included six basic schools, and the questionnaire was completed by 303 
ninth-graders. The survey showed that 35% of those interviewed had lifetime experience with marijuana or hashish, 
and 28% and 15% of the respondents had used cannabis in the past year and the past month, respectively. 
2.3 Drug Use among Targeted Groups/Settings at National and Local Level 
The 2008 data about drug use in the nightlife setting (see below), as well as limited information on the issue of drug 
use among members of national and ethnic minorities, are available; for more information see the chapter on Drug 
Use among Socially Excluded Groups, page 77. 
2.3.1 Drug Use in the Nightlife Setting 
Evaluation of the 2008 Safer Party Tour project, implemented at eight music festivals with the intention of preventing 
substance abuse (see also the chapter on Selective Prevention, page 26), involved a questionnaire survey among 
clients of the services provided. The questionnaire was completed by 363 individuals from 15 to 63 years old; males 
comprised two thirds (67.2%), and the average ages of the male and female respondents were 23.1 and 21.4 years 
respectively. People with secondary education accounted for over half of the sample; the vast majority (93%) of the 
sample comprised either students or people in employment. 
The most frequently consumed substances included alcohol and cannabis, followed by ecstasy and magic 
mushrooms. Alcohol, cannabis, and ecstasy were also the most likely to be reported by the respondents as the 
drugs which they had used, or planned to use, at the festival where they completed the questionnaire; in the case of 
alcohol and ecstasy, the proportion of such people was even larger than that of the people who had used drugs in 
the past thirty days (Národní monitorovací středisko pro drogy a drogové závislosti, 2008a). As regards the drugs 
used the most frequently, the clients of the 2008 Safer Party Tour services represented a group of recreational users 
as described in the 2007 Dance and Drugs study (Národní monitorovací středisko pro drogy a drogové závislosti, 
2008d). A comparison of the degree of experience with drugs between both samples is provided in Figure 2-6. 
Table 2-4: Proportions of 2008 Safer Party Tour clients who reported experience with drugs in their lifetime, in the past 
12 months, and the past 30 days, and/or planned to use them at the event where they completed the questionnaire (%) 
(Národní monitorovací středisko pro drogy a drogové závislosti, 2008a) 
Drug Lifetime (%) 12 months (%) 30 days (%) This event (%) 
Alcohol 89.3 50.4 43.3 51.2
Cannabis 82.6 56.7 32.2 28.4
Magic mushrooms 43.3 23.4 4.4 1.9
Ecstasy 41.3 24.5 8.3 11.0
LSD 28.7 13.8 5.2 2.2
Pervitin/amphetamine 25.3 14.0 4.4 2.2
Poppers 21.8 9.6 0.8 0.8
Cocaine 17.6 9.9 3.9 1.4
Opiates/heroin 5.5 0.8 0.3 0
Ketamine 3.6 1.4 0.6 0
GHB 2.5 0.8 0.3 0
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Figure 2-6: Lifetime prevalence of use of selected drugs among 2008 Safer Party Tour clients and 2007 Dance and 
Drugs survey respondents (Národní monitorovací středisko pro drogy a drogové závislosti, 2008d; Národní monitorovací 
středisko pro drogy a drogové závislosti, 2008a) 
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The 2008 Safer Party Tour clients were also asked about any health problems ensuing from their presence at a 
dance party and drug use, if any. A total of 78.9% of the clients reported that they had sometimes experienced health 
problems at a party or festival. It is noteworthy that 57% of them stated that they had had multiple health problems. 
They were most likely to have suffered from nausea, vomiting, and headaches; approximately a quarter of the 
sample reported overheating and dehydration, inexplicable tiredness, and/or disorientation. The most frequently 
reported causes of such problems included the excessive consumption of drugs and/or alcohol. However, only 4.3% 
of the respondents had sought professional assistance (Národní monitorovací středisko pro drogy a drogové 
závislosti, 2008a). 
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3 Prevention 
Primary prevention, including the primary prevention of drug use, is co-ordinated by the Ministry of Education. The 
main goals and activities in the field of prevention are laid down in the Strategy for the Prevention of Risk Behaviour 
in Children and Young People in Education in the Period 2009-2012. In 2008 the Ministry of Education updated the 
standards and rules for the certification of professional competency for providers of primary prevention against the 
use of addictive substances; a total of 36 providers with 48 programmes had been certified by the end of 2008, 
mostly NGOs. In 2009, amendments were proposed to the methodological guidelines on the primary prevention of 
socially pathological phenomena in children, pupils, and students in schools and educational facilities. 
The minimum preventive programme is the fundamental tool for school-based primary prevention in the Czech 
Republic. The programme focuses on promoting healthy lifestyles and preventing all forms of risk behaviour and is 
implemented in all basic and secondary schools. 
Selective and indicated prevention programmes are provided by non-governmental organisations or specialist 
institutions; these programmes are primarily oriented at working with groups, individuals, and families at risk. The 
Safer Party Tour 2008, focused on drug use in night recreational settings, is an example of applied selective 
prevention.  
Besides the "Pay Attention or Pay the Price!" safe driving campaign, which was partly targeted at driving under the 
influence of drugs, no other national campaign focused on drug use was launched in 2008. A number of events 
labelled as anti-drug events were organised at the regional and local levels, but their effect often remained unproven. 
3.1 Drug Prevention System and Framework 
Primary prevention is coordinated by the Ministry of Education. The main policy document in this field is the Strategy 
for the Prevention of Risk Behaviour in Children and Young People in Education in the Period 2009–2012. The long-
term goals of this strategy, which also aims at preventing the use of drugs (tobacco, alcohol, and narcotic and 
psychotropic substances), include placing emphasis on specific universal, selective, indicated primary prevention, 
support for education, and evaluation of the certification process. The goals of the strategy will be detailed in the 
Ministry of Education's action plan (Ministerstvo školství, mládeže a tělovýchovy, 2009a). 
In January 2009, the Government Council for Drug Policy Coordination imposed on the Minister of Education the 
task of adjusting and amending the methodological guidelines on the primary prevention of socially pathological 
phenomena in children, pupils, and students in schools and school facilities (Ref. No. 20 006/2007-51). The updated 
guidelines should already be applicable in the 2009/2010 school year. The proposed amendments concern: 
 The implementation of prevention programmes in schools and school facilities – giving preference to 
certified external programmes is recommended; as regards indicated prevention activities, counselling 
interventions should be preferred over disciplinary, administrative, or criminal law measures. 
 The implementation of screening drug tests in school settings – it is recommended to emphasise that 
across-the-board or random drug testing is not an effective prevention method, and nor is the use of drug-
sniffing dogs to screen the surfaces of benches and other objects in schools for traces of drugs. If a 
school decides to conduct drug tests, it is recommended that it should have a list of sanctions in place, 
developed and published prior to the testing. Drug testing should only be conducted if there are 
reasonable grounds to believe that drugs have been used and only subject to informed consent. It is 
recommended that the term "reasonable grounds" be defined more accurately. 
 Terminological improvements – some obsolete terms, such as "socially pathological phenomenon", 
should be replaced by more modern ones. 
The Standards of Professional Competency for providers of primary prevention against the use of addictive 
substances were developed in 2005, to facilitate the evaluation of the quality of specific primary prevention measures 
(Ministerstvo školství, mládeže a tělovýchovy, 2005) and the certification system in the field of prevention 
was launched in 2006; for details see the 2006 and 2007 annual reports. In 2008 the primary prevention 
standards development working group, comprised of representatives of the ministries and institutions who have a 
professional stake in this field, met regularly; in December 2008 the Ministry of Education approved the updated 
version of the standards and the certification rules. In total, 40 facilities and 54 programmes applied for certification 
between December 2006 and the end of 2008. Out of this number, 36 facilities and 48 programmes complied with 
the certification requirements. 8 local audits in 9 programmes took place in 2008 (Agentura pro certifikace, 2009). 
Since 2007, the Prev-Centrum civic association, with the support of the GCDPC and the Prague Municipal Authority, 
has been developing the PrevData application to unify reporting in the field of specific primary prevention. 2008 saw 
the pilot testing of the application and training of its users – primary prevention providers; see also the chapter 
Systems for Collection of Data on Drug Users in Treatment (p. 42). 
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In the second half of 2008 preparations started for the launch of the Prague Centre for Primary Prevention, in 
collaboration with the Prague Municipal Authority and the Centre for Addictology. The purpose of the centre is to 
create and coordinate a comprehensive system of primary prevention of risk behaviour in Prague by 2013. 
3.2 Universal Prevention 
3.2.1 Preventive Programmes in Schools and School Facilities 
The Minimum Preventive Programme (MPP), which was defined by the Ministry of Education, is the basic tool for the 
implementation of prevention in schools; its implementation is binding and subject to supervision by the Czech 
Schools Inspectorate. The MPP focuses on promoting healthy lifestyles and the prevention of all forms of risk 
behaviour, including the prevention of the use of addictive substances. The school prevention worker 
(methodologist) is responsible for the implementation of the programme, together with other teachers at the school. 
The MPP also includes work with parents and teacher training. Schools implement the programme on their own or 
complement it with programmes arranged by external bodies, including NGOs. 
The types of programme implemented in the framework of the Minimum Preventive Programme are illustrated by the 
structure of projects supported in 2008 by the Ministry of Education as part of Subsidy Programme I14. In total, 234 
projects with over 500 programmes were supported. The most frequently supported types of programme were 
adaptation courses (48%), experiential programmes (10%), and one-off lectures, debates, and seminars (4%). 43% 
of them were programmes implemented as part of the curriculum, and 45% were those implemented outside the 
school curriculum; a total of 12,300 individuals were reached by the programmes, of whom 92% were students and 
8% adults, mostly teaching staff, school prevention workers, and school counsellors. Parents and the public also 
played a part in the programmes (Ministerstvo školství, mládeže a tělovýchovy, 2009b). 
School-based prevention programmes are often implemented or co-implemented by NGOs. Out of the 154 anti-drug 
projects to which the GCDPC provided a subsidy in 2008, 35 projects developed activities in the field of prevention; 
25 of them mentioned the outcomes achieved in their final reports. For the most part, preventive programmes were 
delivered by the so-called prevention centres (17 programmes). In 11 cases, low-threshold programmes, i.e. low-
threshold centres and outreach programmes, were involved in such activities. A total of 17,030 interventions (themed 
training segments, debates, interactive seminars, consultations, interventions, residential programmes etc.) were 
implemented and 120,673 persons were contacted within the framework of school curricula. As concerns 
extracurricular prevention within the framework of indicated prevention, educational activities, and the information 
service, a total of 9,755 interventions were carried out and 6,422 adults were reached (Národní monitorovací 
středisko pro drogy a drogové závislosti, 2009j). 
The Czech component of the EU-DAP 2 international project (EUropean Drug Addiction Prevention Trial) included 
the evaluation of the programme entitled "Unplugged", which is focused on preventing the use of addictive 
substances in selected basic schools through improving the psychosocial skills of 6th-grade pupils, i.e. children aged 
12–14 (for information on the implementation of EU-DAP in the Czech Republic see also the 2006 and 2007 annual 
reports). The research project is implemented in 70 schools (an experimental group of 966 pupils from 37 schools; a 
control group of 888 pupils from 33 schools). Preliminary results after 6 months following the implementation of the 
project indicate that the programme is effective; achievements included a statistically significant reduction of tobacco 
use, the occurrence of insobriety, and the prevalence of cannabis and inhalants. Further testing is planned for June 
2009 (Miovská et al.  2009; Jurystová et al.  2009). An analysis was also conducted in 2008, aimed at describing the 
framework of primary prevention activities in the schools involved in the project. The results indicate that the 
prevention activities most frequently implemented are one-off events – debates, which the schools or school 
prevention workers mostly organise themselves; only 20% of schools in the control group implemented a long-term 
programme comprising multiple sessions (Adámková et al.  2009). 
Following amendments and additions to the methodological guidelines on the primary prevention of socially 
pathological phenomena in children, pupils, and students in schools and school facilities, the National Focal Point, in 
collaboration with the Ministry of Education, conducted a national questionnaire survey in 2009 to collect information 
about testing for alcohol and other drugs in Czech basic and secondary schools in 2008. Complete results are not 
available as yet but there are preliminary results, which describe the state of affairs in five regions of the Czech 
Republic (Prague and the Central Bohemia, Hradec Králové, Liberec, and Ústí nad Labem regions), see Table 3-1 
(Národní monitorovací středisko pro drogy a drogové závislosti, 2009d). 
In 2008 a school questionnaire survey was conducted in the school population of Pilsen. Among other things, the 
survey monitored the procedures that schools apply or intend to apply if a pupil is caught with a cigarette or shows 
signs of insobriety in school for the first time. These mostly include a notification to parents (59%), a written 
reprimand (55%), and an oral warning (50%). Approximately one school in four (27%) sends a drunk student a 
                                                          
14 For more information about drug policy expenditure and subsidies in 2008 see also the chapter Economic Analysis, page 9. Subsidy 
Programme I is a funding instrument for preventive programmes implemented by schools themselves. The Ministry of Education 
provides funding in the form of subsidies to individual regions, which further distribute them to schools and school facilities; school-
based programmes may also be co-funded by regions and municipalities. 
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written reprimand and approximately one school in four reports sanctions such as a reprimand from the principal, a 
counselling session with the parents, a poorer grade for discipline in the school report, or referral to a physician; 
approximately one school in five makes an entry in the student's personal file (Vacek et al.  2009).  
Table 3-1: Programmes of testing for alcohol and other drugs in basic and secondary schools in 5 regions of the Czech 
Republic in 2008 (Národní monitorovací středisko pro drogy a drogové závislosti, 2009d) 
Indicator Basic school 
Secondary 
school Total 
Total number of schools in the sample 1,264 517 1,781 
Schools that implemented alcohol testing 50 68 118 
– positive alcohol test (number of cases)  136 125 261 
Schools that implemented non-alcohol drug tests 32 53 85 
– positive cannabis test (number of cases)  72 46 118 
– positive pervitin test (number of cases)  6 5 11 
– positive test for other drugs (number of cases) 16 14 30 
Pupils/students punished*  63 115 178 
Schools with serious drug problems** 52 39 91 
Pupils/students with serious drug problems** 104 129 233 
Schools where across-the-board drug tests were 
applied 3 0 3 
Schools where furniture surfaces were tested for 
traces of drugs 4 4 8 
Schools where screening was conducted using drug- 
sniffing dogs 7 3 10 
NB: * In connection with their positive testing for alcohol and/or other drugs, ** in connection with the use of alcohol and/or other drugs.  
3.3 Selective Prevention in At-risk Groups and Settings 
Selective prevention programmes focus on groups of children and young people who are reasonably likely to have 
an increased probability of risk behaviour. These may include children living in families that are socially 
disadvantaged or come from a different cultural background (e.g. members of ethnic minorities, children raised 
outside their own family, children living in the families of drug and alcohol users, or children with non-specific or 
specific behavioural disorders such as ADHD). Effective selective prevention programmes include programmes 
based on working with the family, counselling, psychotherapy, and social skills training; evidence shows that 
approaches based on offering positive alternatives (e.g. low-threshold youth clubs) or peer programmes are also 
effective (Černý and Lejčková, 2007). 
Examples of good practice in the field of selective (and indicated) prevention in the Czech Republic include the work 
of the Prev-Centrum civic association, which delivers a selective prevention early intervention programme for at-risk 
groups of basic school pupils in the 5th to 9th grades. This is a continuous targeted programme, which comprises 3–
5 sessions with the class at intervals of 2–3 weeks. The programme aims to contribute, in collaboration with the 
school, to the improvement of relations between pupils in the class, focusing on those who are at risk because of 
bullying, experimenting with addictive substances, and other forms of risk behaviour that occur in the class. In its 
early intervention programme for children and adolescents, the Prev-Centrum civic association offers a counselling 
service for children, parents, and teachers where there are cases of a child having a difficult position in the class, 
problematic peer relations, and behavioural disorders such as stealing, truancy, experimenting with addictive 
substances, lying etc. (o.s. Prev-Centrum, 2008). Fifty-two selective-prevention training segments were provided in 
2008, involving 19 classes; 6 experts made 1,120 contacts during them. Sixty-nine consultations with 19 class 
teachers and prevention workers at schools were conducted (Národní monitorovací středisko pro drogy a drogové 
závislosti, 2009j). 
Examples of selective prevention programme include the 2008 Safer Party Tour project, which was implemented by 
the Chilli.org civic association, in collaboration with other NGOs. The project focused on preventing drug use at 
dance events during the summer season. At the eight largest music festivals chill-out zones were established and 
1,529 individuals were reached and provided with alcohol tests, crisis interventions, and other examinations and 
treatments (e.g. blood pressure measurements). Clients received leaflets with information about drugs and the 
associated risks, ear plugs, condoms, and other medical material. The project also continued during the summer 
festivals in 2009 (Národní monitorovací středisko pro drogy a drogové závislosti, 2008a). Information about the 
project for the general public, as well as experts, is available at www.saferparty.cz. Other outreach programmes at 
dance events are discussed in the section on Low-Threshold Harm Reduction Programmes, page 68. 
Drug information and counselling is provided by a number of facilities on the internet or by phone; for more details 
see the Help Map application at drogy-info.cz. 
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3.4 Indicated Prevention 
Indicated primary prevention programmes are focused directly on at-risk individuals showing signs of risk behaviour 
in combination with the use of addictive substances. The purpose of indicated prevention is to reduce the frequency, 
risks, and consequences of drug use. Indicated prevention is implemented by specialist governmental and non-
governmental institutions; a list of them is provided in one of the chapters on selected issues included in the 2006 
Annual Report. Indicated primary prevention programmes focus primarily on working with individuals and their 
families. 
In 2008, the Prevent civic association monitored the situation and needs in the field of drug services designed for at-
risk children and young people under imminent threat of using addictive substances in the South Bohemia region 
(Pešek et al.  2008). The results indicate that the target group in question comprises relatively well-established 
clients of various counselling services. These people most frequently show drug problems associated with the use of 
cannabis and experimental or weekend use of pervitin. The relative distribution of outpatient counselling services in 
the various districts of this region is satisfactorily even and the quality of care and level of liaison between them is 
good. Key facilities primarily include low-threshold centres or specialised facilities, such as the Drug Counselling 
Service Prevent. The availability of inpatient treatment is relatively good, both within the South Bohemia region and 
outside it. The main challenges include inaccurate referrals of clients from "non-drug" facilities (e.g. from 
pedagogical-psychological counselling services or educational care centres) and the lack of availability of 
collaboration with psychologists and psychiatrists or its often problematic nature. At-risk schools and locations were 
mapped, including the occurrence of drug-related problems in the Roma population in some locations. The needs 
repeatedly mentioned by the informants recruited from amongst professionals included, among other things, the 
development of targeted training programmes for experts primarily from "non-drug" services (Pešek et al.  2008).  
3.5 National and Local Media Campaigns 
The 2008 Safer Party Tour project (see above) was accompanied by a media campaign with a limited scope, 
supported by xPublishing, www.techno.cz, and Radio 1. The campaign was endorsed by the Czech Minister of 
Education, Ondřej Liška, who personally participated in the Creamfields festival (ČT24.cz, 2008; Národní 
monitorovací středisko pro drogy a drogové závislosti, 2008b).  
A national safe driving campaign, “Pay Attention or Pay the Price!", was launched in October 2008. The campaign 
was commissioned by the Czech Ministry of Transport. It runs on the TV and radio, in cinemas, and on the internet 
(http://www.nemyslis-zaplatis.cz/); printed information leaflets are also available. The goals of the campaign, which is 
planned to run until 2010, include discouraging drivers from using alcohol and other addictive substances. The 
campaign, with total costs of some CZK 150 million (€ 6,014 thousand), is intended to reduce the traffic accident rate 
by 5–7%, saving approximately 60–75 lives a year (Aktuálně.cz, 2008; ČT24, 2009). 
Numerous short-term or one-off events labelled as anti-drug are held in the Czech Republic each year; these usually 
include various leisure-time activities with an unproven preventive effect. For instance, in the town of Vsetín in the 
Zlín region the Cyrillos civic association organised a twelve-hour volleyball match between supporters and 
opponents of the legalisation of cannabis, with an accompanying programme (films, debates, simulations of court 
hearings, and counselling). A month-long campaign entitled "Can you tell if your child is on drugs?" was held in the 
town of Chomutov. It featured posters making parents aware of the signs of potential drug use by their children 
(Sláma, 2008; Chomutovský deník, 2009). 
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4 Problem Drug Use 
The EMCDDA defines problem drug use as injecting drug use and/or long-term/regular use of opioids/opiates and/or 
amphetamine-type drugs and/or cocaine. Cocaine use in the Czech Republic is at a very low level and the 
prevalence of problem cocaine use has not been estimated. As a result, problem drug use in the Czech Republic is 
associated primarily with pervitin (methamphetamine) and opiates/opioids (heroin and Subutex®, with the seasonal 
use of opium). 
The estimated number of problem drug users grew in 2008 and reached approximately 32.5 thousand, of which 
number approximately 21.2 thousand are pervitin users and approximately 11.3 thousand are opiate users. It is 
estimated that approximately 31.2 thousand persons inject drugs, i.e. the majority of opiate and pervitin users. 
Compared to 2007, the estimated number of problem users of all types of drug increased in 2008; however, the 
increase is not statistically significant. The number of estimated problem drug users is highest in Prague (11.5 
thousand) and the Ústí nad Labem region (4.2 thousand); at the same time, these two regions also have the highest 
estimated number of problem users of opiates. 
 
4.1 Estimates of Prevalence and Incidence or Problem Drug Use 
As in the previous years, in 2008 too the estimate of the prevalence of problem drug users was made using the 
multiplication method, which relies on data from low-threshold facilities. The data on the number of problem drug 
users in contact with low-threshold services were extrapolated to the total number of all such facilities in the Czech 
Republic and multiplied by the proportion of problem drug users in contact with such facilities (in-treatment rate), 
which was last updated in 2008 (for details of this method see the 2007 Annual Report). 
 
The estimate of problem drug users in 2008 was again constructed as a sum of the estimates for individual regions. 
The national average multiplier without Prague was 68% (95% CI15: 66-72%), and the value of the multiplier for the 
capital city was 76% (95% CI: 63-90%). The total number of problem drug users in the Czech Republic was thus 
estimated at 32,500 (95% CI: 30,400-34,700), of which number 21,200 (20,700-21,800) were pervitin users, 6,400 
(5,800-7,000) were heroin users, and 4,900 (4,500-5,200) were Subutex® users. Opiate users therefore form a group 
of approximately 11,300 (10,600-12,000) persons. The number of injecting drug users (IDUs) was estimated at 
31,200 (30,000-32,400). 
 
The trend of mean values of the estimated number of problem drug users between 2002 and 2008 is shown in Table 
4-1. Compared to 2007, there was an increase in the total number of problem drug users; given the range of the 
confidence intervals, however, the differential is not statistically significant. The highest number of problem drug 
users was traditionally in the Capital City, Prague, and the Ústí nad Labem region. Prevalence estimates of problem 
drug use by region are shown in Table 4-2 and Map 4-1, and the trend of the estimated number of drug users in 
each region is provided in Table 4-2. 
The incidence of problem drug users in the Czech Republic has not been estimated as yet. 
Table 4-1: Mean values of prevalence estimates of problem drug use carried out using a multiplication method with the 
use of data from low-threshold programmes in 2002-2008 (Mravčík et al.  2008; Mravčík et al.  2007) 
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2002 35,100 4,89 n.a. n.a. 13,300 1,85 21,800 3,04 31,700 4,41
2003 29,000 4,02 n.a. n.a. 10,200 1,41 18,800 2,61 27,800 3,86
2004 30,000 4,14 n.a. n.a. 9,700 1,34 20,300 2,8 27,000 3,73
2005 31,800 4,37 n.a. n.a. 11,300 1,55 20,500 2,82 29,800 4,1
2006 30,200 4,13 6,200 4,300 10,500 1,44 19,700 2,69 29,000 3,97
2007 30,900 4,2 5,750 4,250 10,000 1,36 20,900 2,84 29,500 4,01
2008 32,500 4,39 6,400 4,900 11,300 1,52 21,200 2,87 31,200 4,21
 
                                                          
15 95% confidence interval – i.e. the interval in which the value occurs with a 95% probability. 
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Table 4-2: Prevalence estimates of problem drug users in the Czech Republic in 2008 by region (Mravčík et al.  2007) 
Opiate users 
Region 
Total number of 
problem drug 
users Heroin Subutex
® Total 
Pervitin 
users  IDUs 
Prague 11,500 3,250 3,950 7,200 4,300 11,400
Central Bohemia 1,750 200 300 500 1,250 1,700
South Bohemia 1,550 50 150 200 1,350 1,550
Pilsen 1,650 750 < 50 750 1,000 1,550
Karlovy Vary 1,000 50 < 50 50 950 1,000
Ústí nad Labem 4,150 1,000 300 1,300 2,850 4,000
Liberec 1,500 < 50 < 50 < 50 1,500 1,500
Hradec Králové 1,100 < 50 < 50 50 1,050 1,100
Pardubice 450 < 50 < 50 < 50 400 450
Vysočina 500 < 50 < 50 < 50 500 450
South Moravia 3,250 900 < 50 950 2,300 3,100
Olomouc 1,600 50 < 50 50 1,550 1,400
Zlín 1,350 < 50 < 50 < 50 1,350 1,100
Morava-Silesia 1,150 100 < 50 150 1,000 950
Total 32,500 6,400 4,900 11,300 21,200 31,200
Map 4-1: Number of problem drug users per 1,000 inhabitants aged 15-64 and the number of problem users of opiates 
and pervitin in regions of the Czech Republic in 2008 (Národní monitorovací středisko pro drogy a drogové závislosti, 
2009c) 
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Table 4-3: Prevalence estimates of problem drug users obtained by means of questionnaire surveys among general 
practitioners in 2005-2008 (Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 2009c) 
Region 2005 2006 2007 2008 
Prague 9,800 8,400 10,000 11,500
Central Bohemia 2,500 2,450 1,700 1,750
South Bohemia 1,700 1,750 1,500 1,550
Pilsen 1,450 1,350 1 300 1,650
Karlovy Vary 1,450 1,250 900 1,000
Ústí nad Labem 4,450 4,450 4,100 4,150
Liberec 750 500 500 1,500
Hradec Králové 1,150 1,050 1,750 1,100
Pardubice 600 350 450 450
Vysočina 600 350 700 500
South Moravia 2,800 3,150 3,400 3,250
Olomouc 1,900 2,350 1,650 1,600
Zlín 1,150 1,300 1,850 1,350
Morava-Silesia 1,500 1,450 1,100 1,150
Total 31,800 30,200 30,900 32,500
 
4.2 Data on Problem Drug Use from Non-treatment Sources 
Data were collected between September 2008 and January 2009 in a study entitled New Trends on the Drug Scene 
(Radimecký et al.  2009). Data were collected from three focus groups comprising the staff of low-threshold 
programmes (one with representatives of the services in Prague and Central Bohemia, a second with participants 
from the Ústí nad Labem, South Bohemia, Karlovy Vary, Hradec Králové, and Pilsen regions, and a third with the 
staff of the services from the Olomouc, South Moravia, and Moravia-Silesia regions). The study was commissioned 
by the National Focal Point and undertaken by the Centre for Addictology. Its outcomes include a description of the 
clients of the low-threshold programmes. 
According to the participants, the average age of the clients varies according to the region and type of facility. Older 
clients usually come to low-threshold centres, while outreach programmes report a lower average age. The age 
structure of the clients also depends on whether the facility has contacted a specific target group (e.g. recreational 
drug users, commercial sex workers, or the newly approached group of older, long-term drug users). The proportion 
of men to women among the clients of low-threshold facilities is estimated to be 2:1 in the long term. Survey 
participants from Prague report an increasing number of women, pregnant drug users, and whole families, including 
children, on the drug scene (Radimecký et al.  2009). 
As regards the type of drugs used, the number of heroin users is decreasing in all regions except Prague and the 
Ústí nad Labem region, according to the respondents. Most low-threshold programmes in the Czech Republic work 
with a clientele using primarily pervitin, usually in combination with other substances. Using only one type of drug is 
less frequent; most clients are those with polydrug use. The abuse of medicaments (primarily benzodiazepines) 
reportedly occurs often in clients using opiates (heroin or substitution substances), to potentiate the effects of the 
drug. Clients using pervitin use benzodiazepines concurrently to dampen the unpleasant mental states associated 
with the use of stimulants. Among the reasons for abusing medicaments that were cited by the respondents was 
self-medication in clients with a dual psychiatric diagnosis. An increased use of pervitin was reported at dance events 
(Radimecký et al.  2009). 
As regards the abuse of Subutex® , the situation is specific. Suboxone®, a composite preparation that is not abused 
by injecting, has been on the Czech market since February 2008. If Suboxone® only, not Subutex®, is offered in 
substitution treatment, the demand for substitution treatment decreases16. Suboxone® is not sought on the black 
market and the occurrence of Subutex® on the black market also diminishes. In the opinion of low-threshold 
programmes, this makes some users turn (again) to heroin (Radimecký et al.  2009). 
The respondents’ experience suggests that the use of toluene and other inhalants shows a decreasing tendency and 
does not occur widely in (young) people from ethnic minorities either. Cocaine users are not among the clients of 
low-threshold centres at all or very rarely; there are no long-term and regular users, and the use of cocaine is 
primarily occasional. In the summer, the use of raw opium in poppy fields occurs as a seasonal phenomenon. The 
use of opium is associated with the occurrence of more serious health problems (Radimecký et al.  2009). 
Most clients of low-threshold services use drugs by injecting. The risky use of injecting occurs primarily in older, long-
term drug users, who are more difficult to persuade by messages concerning safer application. There is a demand 
for new equipment for drug administration and preparation among the clients (capsules and spoons for drug 
                                                          
16 The price of Suboxone® is higher than that of Subutex® and neither product is covered by public health insurance. 
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preparation17). Younger clients, particularly pervitin users, often also take the drug by sniffing it. This target group did 
not use to be much in contact with outreach programmes because it did not use their main service – the needle 
exchange programme. Since 2008 some outreach programmes have started to distribute gelatine capsules for oral 
drug application, which may be part of the outreach strategy towards non-injectors. Capsules are also used by older 
clients who experience trouble with injecting drugs because of damaged veins. The respondents also mention the 
distribution of aluminium foil as a method to reduce the injecting of heroin (Radimecký et al.  2009). 
In 2008, a survey was conducted among the clients of all the Prague-based low-threshold programmes for drug 
users (Šejvl, 2008). The participants were 783 clients from 7 facilities (the SANANIM civic association’s low-threshold 
centre and outreach programmes; the low-threshold centre and outreach programme run by DROP IN o.p.s.; the 
ESET HELP outreach programme, and the low-threshold centre and outreach programme run by the Progressive 
civic association). 79 clients refused to fill in the questionnaire (response rate 89.9%). The proportion of men to all 
clients was 70%, and the average age of the clients was 28.7. The clients’ drug of choice was pervitin (34%), 
followed by Subutex® (24%), heroin (20%), marijuana (5%), Suboxone® (3%), psychotropic medications (5%), and 
alcohol (3%). 
Information from both surveys concerning the clients’ attitudes towards using low-threshold services, information 
about the prevention of infectious diseases, including testing, and information about collaboration with other services 
is mentioned in the chapter on Responses to Health Correlates and Consequences, page 67, data concerning work 
with clients from ethnic minorities are provided in the chapter on Social Correlates and Social Reintegration, page 76, 
and data about the clients’ criminal activity in the chapter on Drug-related Crime, Prevention of Drug-related Crime, 
and Prison, page 81. 
In the spring of 2007, a survey was conducted among the clients of the low-threshold centre and outreach 
programmes of the SANANIM civic association in Prague, with the participation of 400 clients. The purpose of the 
survey was to compare the clients of the two low-threshold services (Větrovec and Porubský, 2008). At the turn of 
2007 and 2008, a qualitative survey focused on opium use was undertaken among the clients of the SANANIM low-
threshold centre in Prague (Zeithammerová, 2008); for more details see the 2007 Annual Report. 
More information about the characteristics and numbers of problem drug users who are in contact with various 
helping programmes is given in the chapters on Drug-related Treatment: treatment demand and treatment 
availability, page 32, Responses to Health Correlates and Consequences, page 67, and Social Correlates and 
Social Reintegration, page 76, and in the special chapter on Cannabis Markets and Production, page 96. 
4.3 Intensive, Frequent, Long-Term, and Other Problematic Forms of Use 
No study has been conducted in the Czech Republic so far that focused specifically on intensive or problematic 
forms of drug use which do not fall under the definition of problem use according to the EMCDDA. The studies in the 
general population and other sources of data (e.g. data about the treatment of drug users – see the chapter on Drug-
related Treatment: treatment demand and treatment availability on page 32 – or data about drug crime – see the 
chapter on Drug-related Crime, Prevention of Drug-related Crime, and Prison on page 81) indicate that the relatively 
high prevalence of health or social problems in the Czech Republic is primarily associated with the use of 
psychoactive medications or cannabis, besides being associated with the problem use of opiates/opioids and 
pervitin. For detailed data about the risk consumption of cannabis see the section on General Population Survey on 
the Use of Psychotropic Substances, page 16 and the selected issue on Cannabis Markets and Production, page 
96. 
The heavy use of cannabis and how cannabis users end their drug career were the topics of a diploma thesis by T. 
Nechutný in 2008 (Nechutný, 2009). Using the grounded theory method, the author analysed 17 former heavy 
cannabis smokers, focusing primarily on what in their biographies preceded or inspired the decision to quit 
consumption. According to the author, cannabis careers are typically characterised by a loss of the entertaining 
character of intoxication in the long term and an increasing number of experiences felt by the respondents as 
unpleasant. The way users quit smoking cannabis is different in so-called passive users of cannabis, i.e. users who 
in the past did not seek the drug and whose consumption depended primarily on whether cannabis was available in 
their social environment, as opposed to the cannabis smokers that are considered by the author to be active. The 
results of the study indicate that passive users quit their cannabis career at a moment when the opportunity has 
disappeared or their social networks have disintegrated. By contrast, active users make more conscious decisions 
and the end of their cannabis career results from: (a) longer-term considerations; (b) some unpleasant breakthrough 
experience, e.g. a paranoid-hallucinatory state or a flashback, or (c) a potentially breakthrough event, which in the 
current context makes the user decide to quit using cannabis (e.g. sickness). The end of a cannabis career, 
however, can also be motivated by breakthrough events and experiences that are not directly related to intoxication 
(e.g. miscarriage). The author also demonstrates that the end of a cannabis career often does not mean complete 
abstinence but a transition to the controlled use of cannabis, which is rather limited in terms of frequency and 
intensity. 
                                                          
17 The pilot distribution of spoons only took place in research projects. They are not made in the Czech Republic and their import and 
distribution would be rather expensive. 
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5 Drug-related Treatment: treatment demand and treatment availability 
The treatment of drug users and addicts in the Czech Republic takes the form of a network of various services with a 
relatively broad spectrum and generally good availability. In terms of the legislation, the treatment of drug users is 
regulated both by social and health care laws. The goals and measures in the area of treatment are laid out in 
national drug strategies; the first such strategy was adopted in 1993 and at present the 2005-2009 National Strategy 
and the related action plans are being implemented. A system of certification of the professional competency of 
services for drug users was implemented in 2005. 
The year 2008 saw a decline in the number of outpatient health care facilities providing treatment to drug users, and 
of the number of live cases registered in the databases of outpatient facilities in connection with drug use disorders; 
the number of opiate and stimulant users, however, rose slightly. 
In 2008, the number of patients hospitalised in inpatient psychiatric facilities declined for the first time in five years as 
a result of a drop in the number of admissions to psychiatric departments in hospitals, whereas the number of 
hospitalisations in psychiatric hospitals increased. Psychiatric hospitals recorded an increase in the three strongest 
patient groups (opiate/opioid, stimulant/pervitin, and polydrug users); the increase is most evident among patients 
hospitalised with disorders caused by polydrug use. 
The number of patients in substitution treatment continues to rise both in specialised centres and, evidently, in 
medical practices prescribing buprenorphine preparations (Subutex® and Suboxone®). Note that treatment using 
these preparations is not captured in the substitution register in its full scope. 
Men predominate over women in all types of treatment facilities, accounting for approximately two thirds of their 
clients. The proportion of women is higher in younger age groups. The average age of drug users in treatment 
continues to rise and the trend is evident across the various data sources. Pervitin (methamphetamine) is the drug 
most frequently connected with the treatment of drug users in the Czech Republic, followed by opiates/opioids 
(heroin and Subutex®) and cannabis. Polydrug use (the concurrent use of more than one drug) is commonplace. 
The Capital City, Prague, and the Ústí nad Labem region rank the highest in terms of the number of users in 
treatment, with a high number and proportion of opiate users in treatment, which is common to all Bohemian regions. 
5.1 Strategy/Policy 
The treatment of drug users and addicts in the Czech Republic takes the form of a network of various services with a 
relatively broad spectrum and generally good availability. Its present structure, including the legislative framework 
and current treatment strategies and policies, has a particular foundation in theory and historical developments 
(Skála, 2003; Kalina, 2007). The bio-psycho-socio-spiritual model of addiction and its treatment is presently the 
dominant concept in the Czech Republic (Kalina, 2003a; Kudrle, 2003b; Kudrle, 2003a); it is a model which assumes 
a multidisciplinary approach to drug users, integrating various biomedical and psychosocial interventions (Miovský, 
2003). 
Until 1989, the treatment of addictions and its legal basis were understood to be medical and health care issues. 
Since the first half of the 1990s there has been a boom in psychosocial services targeting drug users and existing 
outside the health care sector; the boom was driven, among other things, by the support given to these structures 
and by their integration into the official national drug strategies and policies of the Czech Republic as early as in 1993 
(Bém, 2003). In recent years we have been seeing the increasingly tight regulation of the area of the treatment of 
and care for drug users on the part of policy and legislation in the area of social welfare and services. 
5.1.1 Legislative Framework of Services for Drug Users 
In terms of the legislation, the treatment of addictions is framed by a number of laws and by-laws in the department 
of health care. The pivotal law in this context is Act No. 20/1966 Coll. on public health care, which was adopted in the 
period of socialism, survived without change until 1990, and was subsequently amended on numerous occasions; its 
replacement by another health care law has failed, as the bill did not pass the legislative process. Health care 
legislation comprises a great number of other norms providing, among other things, for health insurance, medical 
professions, non-public health care facilities, the control of infectious diseases and public health protection, etc. 
In terms of drug treatment, Act No. 379/2005 Coll. on the measures for protection from harm caused by tobacco 
products, alcohol, and other addictive substances, is the essential legal regulation. The law codifies key tenets and 
principles which were incorporated into all national drug strategies from the 1990s to date. The law recognises the 
term “drug policy” as one covering not only illegal drugs, but also tobacco products and alcohol. For the first time in 
the history of the Czech Republic, Section 20 of this law defined the types of services intended for drug users as 
follows:  
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 acute inpatient treatment, consisting of diagnosis and treatment, provided to patients who have, through the 
ingestion of alcohol or other addictive substances, induced themselves into a condition which presents a risk for 
their health, themselves, or their environment18; 
 detoxification, which is treatment provided by outpatient and institutional health care facilities in the event of a 
withdrawal syndrome; 
 outreach programmes, which are programmes of social services and health promotion, targeting users of 
addictive substances and addicted persons; 
 low-threshold and counselling services; 
 outpatient treatment of dependency on tobacco products, alcohol, and other addictive substances; 
 day care programmes offering outpatient day care to problem users dependent on alcohol and other addictive 
substances, whose condition requires regular care without the need to extract them from their environment; 
 short- and medium-term institutional (inpatient) treatment of problem users addicted to alcohol and other 
substances in inpatient health care facilities, with the usual duration being from 5 to 14 weeks;  
 inpatient treatment in therapeutic communities, which takes the form of a treatment and social rehabilitation 
programme in inpatient health care facilities and in non-health care facilities, with the usual duration being from 6 
to 15 months;  
 after-care programmes provided by health care and other facilities; these programmes comprise a host of 
services provided after the basic treatment is concluded which are aimed at creating conditions for sustained 
abstinence;  
 substitution treatment, which is a short- or long-term addiction treatment consisting of the administration or 
prescription of substances which act as substitutes for the original addictive substance and is provided in 
outpatient health care facilities under the supervision of a physician. 
In 2006, the Act No. 108/2006 Coll. on social services, which had been in preparation since the early 1990s19, was 
adopted. The law defines the various types of social services and the system for their financing, provision, 
availability, and quality. Social services are defined as residential, outpatient, or field services. The law recognises 31 
types of social services, which it divides into (1) social welfare services, (2) social prevention services, and (3) social 
counselling, which is the basic activity in the provision of all types of social services. Drug users are recognised by 
the law as a target group for some social prevention services; the following types of social services in particular are 
relevant in terms of the treatment of and care for drug users: 
 outreach programmes; 
 low-threshold/contact centres; 
 low-threshold facilities for children and adolescents; 
 social counselling and telephone intervention helplines; 
 social rehabilitation; 
 therapeutic communities; 
 after-care services and sheltered housing; 
 homes with a special regime (including, in particular, residential treatment for older clients dependent on alcohol). 
The above lists of types of services defined by the law show overlaps between health care and social services for 
drug users, and the resulting conflict which often materialises in the practice of providing these services. 
5.1.2 Treatment Strategies 
The goals and actions in the area of treatment are laid out in national drug strategies; the first such strategy was 
adopted in 1993 and the present government drug policy is the fourth in the line: the 2005-2009 National Strategy 
and the related action plans (Bém et al.  2003; Kiššová, 2009). The 2007-2009 Action Plan defines 25 tasks in the 
area of treatment; the previous 2005-2006 Action Plan defined 27 tasks in the same area, of which – according to 
the Evaluation Report approved by the Government Resolution No. 442/2007 – 12 tasks (44.4%) were fulfilled, 3 
were partially fulfilled (11.1%), and 12 tasks (44.4%) remained outstanding; see the 2006 and 2007 annual reports. 
A Vision of Outpatient Drug Services was presented to the professional community for discussion in 2008. The 
document proposes systematic changes with a view to optimising and strengthening the existing network of 
outpatient facilities providing services to drug users, and to change the ways in which it is funded. The final version of 
the paper had not been published when this Report was prepared (Radimecký et al.  2008). 
5.1.3 Professional Competency of Staff in the Area of Drug Services  
A medical specialisation of “treatment of alcoholism and other addictions” has existed since 1980. According to 
Decree No. 185/2009 Coll., on specialisation areas in the education of physicians, dentists, and pharmacists, and on 
the study areas of certified courses, it currently takes the form of an extension specialisation course of “addiction 
                                                          
18 This provision principally relates to sobering-up stations – see further below. 
19 The social services legislation to date has been wholly insufficient – only institutional care and nursing care had an adequate basis in 
the law; the other services were neglected. 
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disorders” that a physician may attend only if they have passed an examination in the basic specialisation course in 
psychiatry (this system of medical specialisations has also been referred to as “attestation”). An attestation 
specialisation may be conditional on professional competency for the provision of a certain type of treatment (e.g. 
pharmacotherapy), for instance, or the execution of a contract with a health insurer regarding reimbursement for 
medical interventions from public health insurance funds. Today, there are only two types of intervention defined in 
the area of addictology, which are tied in with the specialisation in the field of “addiction disorders”; they do not, 
however, relate to the treatment of non-alcohol drug users. The two types are an alcohol test diagnosis and a 
disulfiram (Antabus/e) reaction performed on a patient addicted to alcohol upon the commencement of 
desensitisation treatment; other interventions reimbursed from the system of public health insurance are either tied in 
with a specialisation in psychiatry or they are universal, across-the-board interventions for different medical 
specialists. The administration of a substitution preparation in treatment with opioid agonists, for instance, is not 
defined as an intervention reimbursed from the public health insurance system, and the prescription of substitution 
preparations is not tied in with the medical specialisation in addictology. These factors negatively affect the 
motivation and necessity to acquire the extension specialisation. In 2007 (the year of the last available statistics), the 
Institute of Health Information and Statistics of the Czech Republic kept a record of 1,411 psychiatrists (of these, 32 
had the extension specialisation in “addiction disorders”) out of the total of 36,815 practitioners of medicine in the 
Czech Republic (Ústav zdravotnických informací a statistiky, 2008). 
In 2005, the Centre for Addictology20 was founded as a multidisciplinary research and training facility in the field of 
addiction treatment. Its foundation also marked the formal recognition of the discipline of addictology as an 
interdisciplinary field of study. A bachelor’s academic programme in addictology was introduced; the first 15 
bachelors in addictology graduated in 2008. At the beginning of the 2008-2009 academic year, the three years of full-
time study had enrolled 75 students, 53 students were in their first year of the combined form of study. A master’s 
degree programme is currently being developed. The profession of an addictologist was established in 2008 (along 
with the professions such as a general nurse or midwife) in connection with these study programmes; it was made 
possible by the amendment to Act No. 96/2004 Coll. on non-medical health professions, as subsequently 
amended21. In addition, the professional competencies required for the performance of this profession were defined 
(see also the chapter on Legal Framework on page 5). 
At the time of publication of this Annual Report, the curriculum of an accredited qualification course, entitled 
Addictologist (with over 900 hours of instruction), was in the final stage of the approval process. The course is 
intended to train participants for the work of health professionals who will provide preventive, treatment and 
rehabilitation care in the field of addictology without professional supervision. The training course covers theoretical 
knowledge (about two thirds of the sessions) as well as practical skills in addictology services through practice-
oriented subjects and internships (about one third of the sessions). 
The professional competency of staff in the area of social services is defined in the Act No. 108/2006 Coll. on social 
services (see above), and, in principle, makes a higher vocational education or, if required, also an academic degree 
in study programmes such as social work, social policy, social pedagogy, social care, social pathology, law, or 
special pedagogy a prerequisite for the practice of the profession of a social worker; in all other cases, the practice 
requires completion of an accredited course of at least 200 hours and 5-10 years of experience in the field.  
The majority of professionals working in the area of services for drug users provided outside health care facilities 
hold the status of a social worker. In addition to the statutory qualification requirements, other competency criteria for 
working with drug users are also set out in the Standards of Professional Competences for Drug Services (Kalina, 
2003b), regulations and standards issued by professional bodies, for instance the Czech Psychotherapy Society22 or 
the Czech Medical Association of Jan Evangelista Purkyně (ČLS JEP), or in the methodological publication List and 
Definitions of Interventions of Drug Services (Národní monitorovací středisko pro drogy a drogové závislosti, 2006b). 
5.1.4 Professional Competency of Services and Quality Assurance 
In 2005, Government Resolution No. 300/2005, dated 16 March 2005, approved the system for the certification of 
the professional competency of drug services, which is an instrument of quality assurance for harm reduction, 
treatment, and after-care services. The certification system was implemented in 2006 and certification has been 
compulsory for NGOs applying for subsidies from the state budget since 2007; this requirement does not extend to 
new projects. Nine types of services are defined, and their quality is assured using the Standards of Professional 
Competency of Drug Services, which have a general part and a special part for each type of service (Kalina, 2003b); 
the certificate is good for a maximum of 3 years. 177 programmes were certified as of 30 June 2009; see Table 5-1.  
                                                          
20 The full name of the Centre for Addictology is the Centre for Addictology at the Psychiatric Clinic of the 1st Medical Faculty and 
General Teaching Hospital in Prague. 
21 The changes to the law were implemented by Act No. 125/2005 Coll., Act No. 11/2007 Coll., Act No. 124/2008 Coll. And Act No. 189/2008 Coll. 
The aforementioned amendment was implemented by the Act No. 339/2008 Coll. 
22 See http://www.psychoterapeuti.cz/.  
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Table 5-1: Overview of certified programmes by type as of 30 June 2009 (Národní monitorovací středisko pro drogy a 
drogové závislosti, 2009a) 
Type of service Number of programmes 
Detoxification 4 
Outreach programmes 58 
Low-threshold and counselling programmes 59 
Outpatient treatment 16 
Day care programmes 1 
Short- and medium-term residential treatment 3 
Inpatient treatment in therapeutic communities 12 
Outpatient after-care programmes 17 
Substitution treatment 7 
Total 177 
 
The above overview clearly indicates that the requirement of professional competence for the financing of services 
from the state budget is now the primary motive for applying for a review of professional competence; it is an option 
used mainly by NGOs. Health care facilities, on the other hand, were not bound by this requirement in 2008 as they 
are financed largely from the public health insurance system,– only three programmes are certified for residential 
treatment, four for detoxification, and seven programmes for substitution treatment. 
The Act No. 108/2006 Coll. on social services (see above) introduced the requirement of the registration of social 
services; the relevant regional authority approves registration applications submitted in writing by service providers 
(in the case of service providers operated by the regions themselves, the decision lies with the Ministry of Labour 
and Social Affairs). The regional authority, or the ministry, as the case may be, inspects the services for which 
registration is sought. The quality of social services is inspected on the basis of the quality standards for social 
services. 
The system of inspection of social services and the certification system of the Government Council for Drug Policy 
Coordination overlap in terms of their requirements for professional competency. In June 2008, the Government 
Council for Drug Policy Coordination discussed a report concluding a questionnaire campaign carried out as part of 
the evaluation study concerning the system and processes of the certification of professional competency of drug 
policy programmes. The report draws attention, among other things, to the conflict between the two processes of 
quality assurance, to duplication in the systems of quality inspection by government authorities, and to the fact that 
health care facilities do not need a certificate to be eligible for subsidies from the Ministry of Health. The Government 
Council for Drug Policy Coordination had already approved a plan to harmonise the different quality assurance 
systems in the area of drug treatment and services in December 2005, but the two systems had not been 
harmonised when this Report was prepared. 
A paper comparing the system of social services inspection and the certification system of the Government Council 
for Drug Policy Coordination was submitted to the professional community for discussion in May 2009 (Šedivá et al.  
2009). The paper explains the differences in the philosophy and focus between the two quality assurance systems, 
and the procedural differences between the process of inspection and of certification which arise from the legislation 
and the related methodologies; it also highlights specific issues of drug services’ practice as seen from the point of 
the Social Services Act, and it concludes with a glossary of terms, which codifies the interpretation of expressions 
used in both systems. The target audience is both drug service providers and social services inspectors. 
Procedures in the treatment of addictions are defined by the Psychiatric Society of the Czech Medical Association of 
Jan Evangelista Purkyně (ČLS JEP) (Raboch et al., 2006). The procedures include instructions for the treatment of 
withdrawal symptoms, psychotherapeutic and psychosocial methods for the treatment of addictions, and 
pharmacological procedures, including substitution treatment and harm reduction. The importance of psychiatric 
care, in particular when dealing with acute psychiatric conditions (intoxication and withdrawal, toxic psychosis) and 
psychiatric co-morbidities (e.g. depression, eating disorders, and pathological gambling) is underlined. 
5.2 Treatment System 
Treatment programmes for drug users and addicts and their capacity and occupancy in 2008, subject to the 
availability of data, are summarised in Table 5-2. 
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Table 5-2: Treatment programmes catering to drug users in 2008 
Type of programme Number
Capacity 
(persons, 
beds) 
Occupancy 
(number of 
persons) 
Outpatient health care facilities  357 n.a. 15,711* 
Outpatient (non-health care) facilities operated by NGOs 12 n.a. 1 923 
Day care centres 1 10 38 
Registered substitution centres 40 n.a. 1,375 
Sobering-up stations 15 n.a. n.a. 
Detoxification units 19 n.a. n.a. 
Psychiatric hospitals 16 9,240** 3 389 
Psychiatric departments in hospitals 32 1,396** 1,247 
Psychiatric hospitals for children 3 300** 25 
Therapeutic communities 15–20 138*** 427*** 
Specialised schooling facilities for children at risk of drug addiction  5 46 76 
After-care programmes 18 283**** 1,041 
Detoxification units in prisons 4 n.a. 208 
Substitution treatment in prisons 7 n.a. 76 
Departments for differentiated serving of sentence (voluntary 
treatment) 6 262 422 
Departments for serving of compulsory drug/alcohol treatment in 
prisons 3 120 206 
NB: * it involves the number of persons in the so-called live files, i.e. persons who have visited the facility at least once in that year, 
number of all psychiatric beds, *** data only from 10 communities, **** data involve the capacity of 15 intensive care programmes with 
sheltered housing. 
The services available in prisons are covered in the chapter on Responses to Drug-related Health Issues in Prisons, 
page 89; harm reduction services are described in detail in the chapter on Responses to Health Correlates and 
Consequences, page 67; after-care programmes are set out in the chapter on Social Correlates and Social 
Reintegration, page 76. 
The subsections below give more details on the outpatient and inpatient programmes of a health care and social 
nature. 
5.2.1 Outpatient Treatment 
Outpatient medical treatment is provided primarily through facilities in the field of psychiatry and other fields (in 
particular by general practitioners of adult medicine, also in connection with the more prevalent substitution 
treatment; see further below). The so-called AT clinics have historically played a special role in the treatment of 
addictions to alcohol and other drugs among psychiatric facilities. 
AT clinics are the successors to the alcohol addiction counselling services that have existed on the territory of what is 
today the Czech Republic since 1910. After 1956, alcohol addiction counselling services were made a part of 
psychiatric outpatient clinics, and in the sixties, their role also encompassed non-alcohol drugs (Skála, 2003); they 
existed under the name AT (“Alcohol – Toxicomania”) counselling centres since 1983 (Brožová and Šťastná, 2009). 
In the 1980s, there were approximately 180 AT counselling centres in the country (Brožová and Šťastná, 2009); the 
network was disbanded in 1989 and the formal role of AT counselling centres within the health care system has 
since been lacking. In the 1990s, the number of health care facilities which reported at least one user of illegal drugs 
grew to 350-400 in the latter years, but these were all outpatient psychiatric facilities that had drug users on record 
and that completed the A-013 psychiatry report sheet for AT facilities distributed by the Institute of Health Information 
and Statistics of the Czech Republic; they were not specialised AT counselling centres. 
Between July 2008 and April 2009, the National Focal Point carried out a questionnaire campaign aimed at 
treatment programmes available to drug users in the network of outpatient psychiatric facilities (Národní 
monitorovací středisko pro drogy a drogové závislosti, 2009f); its purpose was to map the outpatient psychiatric care 
provided to drug users (AT treatment). 274 facilities in total were invited to respond, and 161 (58.8%) actually did 
respond; of the total number of respondents, 124 stated they provided AT treatment (i.e. they treat people dependent 
on alcohol and/or non-alcohol drugs). Out of the total of 124 respondent centres, 53 were registered as AT outpatient 
clinics and 71 had a contract for AT treatment services with a health insurer (48 subscribed to both options); 42 were 
neither registered nor contracted to a health insurer; 6 centres did not respond to the questions related to registration 
and a contract with a health insurance company. 
In 2008, the provision of outpatient treatment of users of both legal and illegal drugs was claimed by 357 outpatient 
medical facilities in the field of psychiatry, which is down from 2007 by 4% (Ústav zdravotnických informací a 
statistiky, 2009c). Since 2005, there has been a decline in the number of outpatient clinics, as well as of their clients 
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in treatment, save for alcohol and tobacco users (in the so-called live cases records, i.e. clients in treatment in the 
given year); see Table 5-3. Outpatient clinics treating 1-10 patients per year – see Table 5-4 – comprised the largest 
group. The highest number of outpatient clinics and the highest number of patients have historically been reported by 
specialist clinics, i.e. largely private psychiatric/AT clinics; see Table 5-5. 
Table 5-3: Number of outpatient clinics providing services to drug users in 2000-2008 (Ústav zdravotnických informací a 
statistiky, 2009c) 
Year Number of clinics Number of drug-using patients in treatment 
2000 320 11,423 
2001 330 13,050 
2002 342 14,203 
2003 368 15,786 
2004 382 14,040 
2005 401 16,394 
2006 388 16,392 
2007 372 15,684 
2008 357 15,711 
 
Table 5-4: Number of outpatient facilities by number of drug users treated in 2003-2008 (Ústav zdravotnických informací 
a statistiky, 2009c) 
Number of facilities Number of patients 2003 2004 2005 2006 2007 2008 
1–10 139 144 156 161 140 122 
11–50 106 109 107 110 107 115 
51–100 27 32 37 31 28 25 
101–150 11 12 9 13 11 9 
151–200 7 7 9 4 7 7 
201–300 10 8 10 13 8 6 
301–400 5 3 4 2 6 6 
401 or more 8 7 8 9 6 10 
Total* 313 322 340 343 313 300 
NB: * The facilities are identified by their company identification number; one such identifier may represent several clinics. This is to 
explain why the number of facilities is lower than the number of clinics as shown in Table 5-3. 
Table 5-5: Number of drug users (including tobacco users) treated in outpatient medical facilities in 2003–2008 (Ústav 
zdravotnických informací a statistiky, 2009c) 
2004 2005 2006 2007 2008 
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Inpatient facilities 
with outpatient 
services 
49 3,896 49 4,131 51 5,130 45 4,918 42 4,118 
Integrated 
outpatient 
facilities 
23 1,458 26 1,877 25 2,760 23 2,794 21 3,280 
General practice 1 5 1 7 1 12 1 14 1 16 
Specialist 
practice 243 8,611 257 8,890 260 8,480 237 7,216 229 8,558 
Addiction 
treatment facility n.a. n.a. 6 2,584 5 1,495 5 1,513 5 1,322 
Other outpatient 
facilities 6 1,420 1 42 1 44 2 64 2 25 
Total  322 15,390 340 17,531 343 17,921 313 16,519 300 17,319 
NB.: * The “Drug addiction treatment facility” reporting category was introduced by the Institute of Health Information and Statistics of the 
Czech Republic in 2005. 
Outpatient treatment in the Czech Republic is also available through NGOs; some of these programmes are 
accredited as a medical facility, some also provide substitution treatment (these facilities and their clients may also 
be included in other reporting systems; see further below); the common denominator is that the NGOs apply for 
grants from the state budget to provide their services. The NGOs were founded after 1989, some of them by AT 
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treatment professionals, or they were transformed from state facilities that already existed23. In 2008, 12 outpatient 
programmes subsidised by the Government Council for Drug Policy Coordination were in existence and treating 
1,923 drug-using clients in total (Národní monitorovací středisko pro drogy a drogové závislosti, 2009j); see Table 
5-6. 
Table 5-6: Outpatient treatment facilities operated by NGOs and their clients in 2003-2008 (Národní monitorovací 
středisko pro drogy a drogové závislosti, 2009j) 
Year Number of subsidised facilities 
Number of drug 
users 
2003 19 1,590
2004 20 1,493
2005 18 1,743
2006 15 2,428
2007 13 1,642
2008 12 1,923
 
An intensive three-month outpatient programme in a day care centre is an option offered as a standard by only one 
facility in the Czech Republic: the Prague-based SANANIM civic association, in existence since 1996. The capacity 
of the programme is approximately 10 persons; in 2008, the service was provided to 38 clients. 
5.2.1.1 Opiate Substitution Treatment 
Three products for the substitution treatment of opiate/opioid addiction are available in the Czech Republic: (1) 
methadone, prepared from an imported generic substance (available in specialised substitution centres), (2) 
Subutex®, with buprenorphine as the active substance, available since 2000, and Suboxone®, a composite 
preparation containing buprenorphine and naloxone as the active ingredients, available since February 2008. 
Buprenorphine-based medication can be prescribed by any medical doctor, regardless of specialisation. Substitution 
preparations are only administered orally in treatment settings in the Czech Republic. Methadone in the form of 
syrup as a proprietary medical preparation has not yet been introduced in the Czech Republic. 
The methodology for substitution treatment is defined in the Standard of Substitution Treatment; the previous 
version, drafted in the late 1990s, was amended in 2008 (Ministerstvo zdravotnictví ČR, 2008). For more information 
about the standard see the 2007 Annual Report. 
All physicians administering a substitution preparation are obliged by law to report the patient data to the National 
Register of Users of Medically Indicated Substitution Substances (NRULISL) operated by the Institute of Health 
Information and Statistics of the Czech Republic. An electronic web-based application NRULISL24 was implemented 
in November 2007. Until 2007, the register was maintained as a simple database, and the reports were collated only 
from specialised substitution treatment centres accredited by the Ministry of Health and forwarded by way of paper 
forms and reports taken by telephone. With new substitution treatment facilities emerging outside the network of 
specialised centres, the number of reporting facilities has increased since 2008, as has the number of patients 
receiving treatment and the number of treatment episodes, which also complicates the monitoring of trend data 
provided by the NRULISL. 
Substitution treatment was introduced as a standard option in 2000, and the first substitution treatment centre was 
opened in the General University Hospital (“U Apolináře”)25 in Prague. In 2007, the Czech Republic had 15 
specialised (accredited by the Ministry of Health) centres registered (two of which were in prison facilities at Prague-
Pankrác and Příbram). In December 2008, the National Register of Users of Medically Indicated Substitution 
Substances kept a record of 40 facilities (Ústav zdravotnických informací a statistiky, 2009d), of which 21 reported 
patients to the NRULISL register in 2008 (of that number, 4 were prison medical facilities – in Brno, Kuřim, Opava, 
and Prague-Pankrác)26; see Table 5-7. 
In 2008, the NRULISL register received reports of 1,375 persons in substitution treatment (Ústav zdravotnických 
informací a statistiky, 2009e); the trend since 2000 is shown in Table 5-7. In 2008, a total of 887 persons were 
                                                          
23 Drop-In, for instance, was founded by the transformation of the Centre for Drug Addictions, which was established in 1971 at 
“U Apolináře”, as a project of the doyen of Czech alcohology and addictology, Prof. J. Skála (Kalina et al., 2008). As late as in 1993-
1994, there were only a few NGOs. In 1994 Kalina and Bém (Kalina and Bém, 1994) refer to only four NGOs active in the area of drug 
services (Drop-In, SANANIM, Domus, and Harmonie); of these, 2 are still among the largest providers of drug services in the Czech 
Republic today. In 2008, there are several dozen NGOs providing prevention, harm reduction, treatment, and after-care services in the 
Czech Republic, operating approximately 200 programmes which meet the standards of professional competency. 
24 See https://snzr.uzis.cz/nrulisl/.  
25 The first unofficial substitution treatment with ethylmorphine in the Czech Republic was started in 1987, also at “U Apolináře” (Kalina, 
2007), at the then existing Centre for Drug Addictions; a one-year experimental methadone programme was provided in 1992-1993 by 
Drop-In (the successor organisation to the “U Apolináře” Centre for Drug Addictions); from 1997, a pilot methadone programme was 
implemented at the Centre for the Treatment of Drug Addictions at “U Apolináře”, which was rolled out into a standard regime in 2000 
(Zábranský et al., 2002).  
26 In 2008 substitution treatment was available in 10 prison facilities in the Czech Republic; for more information see the chapter on 
Interventions in the Criminal Justice System, page 86. 
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admitted for substitution; the highest number (28%) was reported by the Prague-based Remedis, s.r.o., a facility 
newly registered in the National Register of Users of Medically Indicated Substitution Substances (Remedis is a 
specialist facility for the treatment of physical complications connected with drug use, viral hepatitis in particular), 
followed by Drop-In Prague (22%) and the substitution centre in Ústí nad Labem (18%). 
Methadone is used for treatment by 13 specialised centres – the so-called methadone centres; the Pilsen, Liberec, 
Pardubice, Zlín, and Vysočina regions do not have their own methadone centres. The Pilsen region announced that 
it would open a methadone centre in 2009 – to be operated by the civic association Ulice – Agentura sociální práce,; 
in August 2009, the centre was not yet operational27. 
Table 5-7: Number of registered facilities providing substitution treatment and the number of patients receiving 
substitution treatment in 2000-2008 (Mravčík et al.  2008; Ústav zdravotnických informací a statistiky, 2009e) 
Year Number of facilities registered in the NRULISL 
Number of 
clients 
2000 7 245
2001 8 483
2002 9 422
2003 9 657
2004 9 729
2005 10 716
2006 14 837
2007 15 959
2008 40 1,375
 
The number of patients using buprenorphine preparations has been rising since 2000 (until 2000, only methadone 
was available): in 2001, Subutex® was prescribed in 6% of cases, in 2004 already in 34% of cases, in 2007 in 42% 
of cases, and in 2008 Subutex® and Suboxone® were the treatment option for 52% of patients (i.e. 503 and 78, 581 
in total) reported to the NRULISL as of 31 December (Mravčík et al.  2008; Ústav zdravotnických informací a 
statistiky, 2009e).  
The NRULISL does not keep a record of all medical facilities prescribing buprenorphine products (Subutex® and 
Suboxone®); their total number, as well as the total number of patients using buprenorphine preparations, is not 
known. According to research among general practitioners of adult medicine who prescribed Subutex®, which was 
undertaken in 2007 (described in more detail in the 2007 Annual Report), their number was estimated at 150-240, 
and the number of patients receiving Subutex® was estimated at 4,300, of which number approximately 3,000 were 
the patients of psychiatrists, and approximately 1,400 were the patients of general practitioners (Národní 
monitorovací středisko pro drogy a drogové závislosti and Agentura INRES-SONES, 2008). The estimated number 
of patients treated with Subutex® in 2007 outside specialised centres was 3,500-3,800 (Mravčík et al.  2008). 
Between July 2008 and April 2009, the National Focal Point ran a questionnaire campaign focused on treatment 
programmes available to drug users in the network of outpatient psychiatric facilities (Národní monitorovací středisko 
pro drogy a drogové závislosti, 2009f); see also above. Out of the 161 facilities that responded, 42 (26.1%) stated 
they offered substitution treatment using buprenorphine preparations, and reported 1,109 patients receiving these 
preparations (the average was 32, the minimum was 0, the maximum was 275). Table 5-8 shows the number of 
facilities and persons receiving treatment by region. Ten facilities with 872 patients (78.6% of the whole data set of 
patients in substitution treatment) reported 20 or more patients; of this number, only 4 were physicians registered in 
the NRULISL, and together they treated 182 patients. The data only confirm the fact that there are still significant 
numbers (tens to hundreds) of medical practitioners and (hundreds to thousands) of patients outside the NRULISL 
reporting system. 
                                                          
27 Section “Services” on the website of the civil association Ulice – Agentura sociální práce, http://www.ulice-plzen.com, data from 6 
August 2009. 
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Table 5-8: Outpatient psychiatric facilities offering substitution treatment using buprenorphine preparations and the 
number of patients receiving substitution treatment in 2008 by region (Národní monitorovací středisko pro drogy a 
drogové závislosti, 2009f) 
Facilities prescribing 
substitution by 
buprenorphine 
Patients in 
substitution 
treatment Region 
Number of 
completed and 
returned 
questionnaires Number Share in % Number % 
Prague 16 10 62.5 686 61.9 
Central Bohemia 17 7 41.2 122 11.0 
South Bohemia 13 2 15.4 26 2.3 
Pilsen 11 3 27.3 18 1.6 
Karlovy Vary 6 3 50.0 32 2.9 
Ústí nad Labem 7 1 14.3 70 6.3 
Liberec 4 2 50.0 0 0.0 
Hradec Králové 7 2 28.6 90 8.1 
Pardubice 6 0 0.0  0 0.0 
Vysočina 19 2 10.5 2 0.2 
South Moravia 12 5 41.7 22 2.0 
Olomouc 9 1 11.1  0 0.0 
Zlín 22 2 9.1 1 0.1 
Moravia-Silesia 12 2 16.7 40 3.6 
Total 161 42 26.1 1,109 100.0 
 
In 2008, a quantity of Subutex® and Suboxone® equivalent to 3,595 g buprenorphine was distributed on the Czech 
market (Ministerstvo zdravotnictví ČR, IOPL, 2009), which is a slight increase on the years 2007 and 2006. The 
number of Subutex® users in 2008 is estimated – on the basis of the same premise as in the previous years (i.e. an 
average daily dose of 6 mg of buprenorphine and a bi-daily average frequency of administration28) – at 3,280 
persons; see Figure 5-1. 
Figure 5-1: Quantities of Subutex® and Suboxone® (in grams of buprenorphine) distributed and the estimated number of 
users of the preparations in 2000-2008 (Národní monitorovací středisko pro drogy a drogové závislosti, 2004; 
Ministerstvo zdravotnictví ČR, IOPL, 2009) 
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In 2008 and 2009, the outreach and counselling programmes for drug users which are operated by NGOs continued 
to cooperate with physicians prescribing buprenorphine in the area of the psycho-social component of substitution 
treatment; for more information see the 2007 Annual Report. 
The selected issue on Problem Amphetamine and Methamphetamine Use, Related Consequences and Responses 
(p. 102) recapitulates the experience with the oral substitution of pervitin (methamphetamine) by other stimulants. 
                                                          
28 The information on the average length of treatment (approximately 6 months) was obtained by way of a survey among outpatient 
psychiatrists in 2004 (Národní monitorovací středisko pro drogy a drogové závislosti, 2004), and was recalculated using the average of 
1 application in two days. 
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5.2.2 Inpatient Treatment 
The so-called sobering-up stations – special medical establishments for short-term stays (in the range of several 
hours) and for detoxification in the case of acute intoxication, of the alcohol kind in particular – are a special type of 
inpatient facility in the Czech Republic which is unique in Europe and in the wider world. The first facility of this type 
was opened in 1951 at “U Apolináře”, and in the mid-1970s there were already 50 sobering-up stations in the Czech 
Republic (Skála, 2003). At present, there are 15 sobering-up stations in existence in the country; they are 
established and operated by regions, and some regions which do not have such a facility of their own contribute 
towards the treatment of patients intoxicated by alcohol or other drugs in other health care facilities (e.g. the Liberec 
region). 
The detoxification units, of which there are presently 19 in the Czech Republic, are inpatient health care facilities 
(departments) affiliated to addiction treatment departments or to other departments of hospitals; they usually provide 
short-term (typically under 3 weeks in duration) inpatient treatment aimed mainly at managing the withdrawal 
syndrome in the early days of abstinence, prior to referral to another (typically also residential) treatment facility. 
Prague now has a Detoxification Centre for Children and Adolescents at the Hospital of Sisters of Mercy of St 
Charles Borromeo, which offers a comprehensive treatment package for children and adolescents under 18 years of 
age. The centre also has an outpatient psychiatric clinic and a related inpatient facility with 14 beds; in addition to 
detoxification, it also offers a psychotherapeutic motivational programme and after-care. The facility admits patients 
regardless of the region of their domicile. 
Psychiatric hospitals and the psychiatric departments of general hospitals provide inpatient medical treatment of 
addicted patients. Psychiatric hospitals in particular organise the treatment by departments specialising in various 
types of addiction. The first facility of this type was the men’s department for alcohol addiction treatment founded by 
J. Skála at the psychiatric clinic of the General University Hospital, “U Apolináře”, in Prague in 1948; gradually, over 
time, a whole range of services was developed, including an outpatient clinic, sobering-up station, therapeutic 
community, centre for children, adolescents, and family, self-help activities, regime activities, group psychotherapy, 
etc. (Skála, 2003; Kalina, 2007). This facility became the model for other departments and the whole system of 
inpatient and outpatient AT medical treatment of drug users in the Czech Republic as we know it today. 
In recent years, the network of psychiatric hospitals and departments has not undergone many changes, except for 
a general reduction in the number of beds (Ústav zdravotnických informací a statistiky, 2009c). 
The inpatient psychiatric facilities in 2008 admitted 14,228 patients for the treatment of disorders induced by the use 
of addictive substances, of which number 9,563 were disorders caused by alcohol dependency (there has been a 
marked decrease since 2005), and 4,665 were patients with disorders caused by the use of other psychoactive 
substances. 
Court-imposed compulsory treatment, including its institutional form, is described in the chapter on Interventions in 
the Criminal Justice System, page 87. 
Table 5-9: Number of inpatient psychiatric facilities, their total bed capacity, and occupancy by users of non-alcohol 
drugs (except tobacco) in 2000-2008 (Brožová and Šťastná, 2009; Ústav zdravotnických informací a statistiky, 2009c) 
Psychiatric hospitals for children Psychiatric hospitals for adults 
Psychiatric departments in 
hospitals 
Year 
Number Capacity Number of patients Number Capacity 
Number 
of 
patients 
Number Capacity 
Number 
of 
patients 
2000 4 358 28 17 9,717 3,181 32 1,534 1,868
2001 4 368 32 17 9,771 3,221 33 1,554 1,523
2002 4 368 13 17 9,677 2,494 33 1,546 1,200
2003 4 368 17 17 9,609 2,536 33 1,517 1,480
2004 4 368 27 17 9,583 2,880 33 1,501 1,762
2005 3 320 27 17 9,538 3,104 32 1,439 1,582
2006 3 320 29 17 9,442 3,200 31 1,420 1,629
2007 3 320 16 16 9,307 3,423 32 1,419 1,299
2008 3 300 25 16 9,240 3,389 32 1,396 1,247
 
A therapeutic community (TC) is another type of residential treatment programme. The first such programme 
developed on TC principles in the Czech Republic was the department at “U Apolináře” in 1948. After 1989, 
therapeutic community programmes were started mainly by NGOs. In the public sector, TCs are operated either as 
social services facilities or as separate departments of inpatient health care facilities – it is not common for a 
therapeutic community to be accredited as a health care facility itself. TCs provide medium-to-long-term treatment 
with a duration of 6-18 months. Enrolment in a TC is systemically preceded by detoxification and short-to-medium-
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term institutionalised treatment, and it is followed by after-care programmes (Kooyman et al.  2004; Nevšímal et al., 
2007).  
The TC Němčice (SANANIM civil association) founded in 1991 was the first therapeutic community in the Czech 
Republic. The following therapeutic communities for drug users have been gradually established and accredited: TC 
Mukařov (operated by White Light I.), TC Podcestný mlýn (Sdružení Podané ruce), TC Čeladná (Renarkon), TC 
Nová Ves (ADVAITA), TC Mníšek pod Brdy (Magdaléna), TC Karlov (SANANIM), TC Vršíček and TC Šluknov 
(Teen Challenge), TC o.s. Krok, TC Sejřek (Kolpingovo dílo CR). Some of the communities target specific groups 
(e.g. addicted mothers with children, adolescents, and clients with dual psychiatric diagnoses). The 11 programmes 
listed above and the Klíčov Rehabilitation Institute and Care Centre were fully accredited in 2008 for residential 
treatment in the form of a therapeutic community; 10 programmes drew grants from the Government Council for 
Drug Policy Coordination, which means they report the numbers of clients and services provided to them by means 
of project final reports; see Table 5-12 (p. 52). Therapeutic communities in the Czech Republic are associated in the 
section of therapeutic communities of the Association of Non-governmental Organisations (A.N.O.), which presently 
has 10 members (9 of the 12 programmes listed above and TC Fides at the Bílá Voda Psychiatric Hospital). In the 
Register of Social Services Providers maintained by the Ministry of Labour and Social Affairs29, there are 15 
programmes registered as therapeutic communities in the Czech Republic that target primarily people who are at 
risk of addiction or who are already addicted to substances; of this number, four are not accredited with the 
Government Council for Drug Policy Coordination and they are not members of the relevant professional section of 
A.N.O. 
In 2008, five educational establishments had departments specialising in the treatment of children at risk of drug 
addiction. The total capacity was 46 persons, and the average duration of the treatment was approximately 7 months 
(the longest treatment was 40 months in the case of one boy). Seventy-six children were placed into their care in 
200830. 
5.2.3 Systems for Collection of Data on Drug Users in Treatment 
Data on drug users using the services of low-threshold and treatment facilities are available from several data 
sources.  
Data about drug users who use the services of low-threshold and treatment facilities are available mainly thanks to 
the national system of reporting into the Register of Treatment Demands, which has existed since 1995 and is a 
database of the Public Health Service and is maintained by the Public Health Office in Prague. Drug users who – in 
any given year – sought treatment, counselling, or social services in designated facilities for drug users, either of the 
health care or non-health care type (e.g. therapeutic communities, low-threshold centres), are included in the 
database. A special record of first treatment demands is kept. The data set and its structure and the definitions in use 
comply with the treatment demands collection standard issued by the European Monitoring Centre for Drugs and 
Drug Addictions (EMCDDA). The register does not effectively cover the treatment provided through general 
practices, substitution treatment, and in-prison treatment. (Studničková, 2009c). 
Other sources of data about drug users in treatment include databases of health care facilities maintained by the 
Institute of Health Information and Statistics (IHIS). The data are obligatorily reported by inpatient and outpatient 
(psychiatric) facilities and the NRULISL database of substitution treatment (see above). A greater number of facilities 
report to the IHIS system, compared to the system of the Public Health Service; however, the system only accounts 
for health care facilities. 
The data on clients of and services provided by NGOs, or programmes delivered with financial support from the state 
budget, are mainly available from final reports of projects implemented as part of the subsidy proceedings 
administered by the Government Council for Drug Policy Coordination. This information is processed annually by the 
National Focal Point. In particular, the data cover low-threshold harm reduction, as well as other types of services 
provided by NGOs (outpatient treatment, after-care, and inpatient treatment in therapeutic communities)31. 
The above data collection systems have overlaps, which leads, for instance, to a situation in which an NGO-
operated outpatient health care facility providing substitution treatment and reporting to the Register of Treatment 
Demands completes datasheets for the Institute of Health Information and Statistics, reports data to the NRULISL 
register, and submits a report to the grant authority as part of the subsidy proceedings. Information originating from 
different sources therefore needs to be handled with knowledge of the overlaps. 
                                                          
29 See http://iregipagempsv.cz/.   
30 The information was disclosed by a representative of the Ministry of Education, Youth, and Sport at the meeting of the advisory 
committee for drug data collection of the Government Council for Drug Policy Coordination held on 22 September 2009. 
31 Since 2003 the NMC has operated FreeBase, a software application of the consolidated system for data collection in low-threshold 
facilities, and from 2008 also UniData, an application for all types of services. A similar application – PrevData – was implemented in the 
area of primary prevention in 2008. All these applications are principally intended for capturing data about clients and the services 
provided to them. They contain a number of other tools, for instance the processing of reports which are compatible with the Register of 
Treatment Demands and with the requirements from the running and final reports in the subsidy proceedings of the Government Council 
for Drug Policy Coordination. The applications can be downloaded for free from http://www.drogovesluzby.cz. 
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5.3 Characteristics of Clients in Treatment 
5.3.1 Treatment Demand Register 
In 2008, the Register of Treatment Demands received data from 223 centres (67 low-threshold centres, 104 
outpatient facilities, and 52 inpatient facilities). The most sought-after type of facility has traditionally been the low-
threshold centre; as in the previous years, the clients of these facilities accounted for more than a half of the 
treatment demands – 48.2% of first treatment demands and 51.8% of all treatment demands. Outpatient facilities 
were the most widely represented type among the centres; however, their share of the total volume of the reported 
incidence and of the prevalence of drug users in treatment was only 25.2% and 25.1%, respectively (Studničková 
and Petrášová, 2009). The proportions of different types of facilities and their clients in the register have been stable 
in recent years (Studničková, 2009c). 
A total of 8,279 drug users sought treatment services in facilities in 2008, i.e. 280 persons fewer than in 2007. Of 
these, 3,981 individuals sought treatment for the first time, i.e. 365 persons fewer than in 2007. Women made up 
approximately one third of treatment demands. The proportion of men was lowest in the 15-19 category 
(Studničková and Petrášová, 2009). 
The order of drugs which were the cause of all and first-time treatment demands continued to be the same as in 
2007. Users of stimulants32 were the most commonly represented among all treatment demands (61.3%) and even 
among first treatment demands (62.9%); this was especially the case for pervitin (61.0% and 62.6%, respectively), 
followed by opiate users among all treatment demands (24.9%) and cannabis users among first treatment demands 
(18.9%). Figure 5-2 and Figure 5-3 illustrate the development in the number of (first) treatment demands by drug 
type. 
The prevalence and incidence of treatment demands and the representation of treatment demands by drug type is 
different in each region. The highest relative prevalence and incidence was recorded in the Ústí nad Labem region 
and in Prague. Stimulant users predominated in 2008 in all regions (from 52.3% in Prague and in Moravia-Silesia to 
85% in South Bohemia). Opiate users were more significantly represented in Hradec Králové (37.6%), Prague 
(36.7%), Ústí nad Labem (29.9%), and South Moravia (29.9%); cannabis users sought treatment most frequently in 
the Vysočina (29.8%) and Moravia-Silesia (27.6%) regions; see Map 5-1. 
The average age of persons seeking treatment has been increasing33. The most commonly represented age group 
in 2008 among all treatment demands and among first treatment demands was 20-24-year-olds, who accounted for 
32.2% and 28.1%, respectively. The average age of first treatment demands and all treatment demands is 24.3 
years and 25.9 years, respectively (Studničková and Petrášová, 2009). 
Among all treatment demands in 2008, the oldest group represented were opiate and cocaine users (the average 
age of a cocaine user was 29.6 years and that of a heroin user 28.7 years). The average age of a pervitin user was 
25.4 years, of an inhalant user 25.7 years, and of a cannabis user 21.3 years. The order was also the same among 
first treatment demands; cocaine and heroin users were the oldest (29.5 and 27.3, respectively), followed by pervitin 
users (24), inhalant users (22.4), and cannabis users (20.5); see Figure 5-4 and Figure 5-5. 715 (18%) of first 
treatment demands and 1,290 (15.6%) of all the clients treated in 2008 began to use the primary drug before 
reaching 15 years of age; 70% of first treatment demands and 69% of all drug users treated began to use the 
primary drug before reaching 19 years of age. 
                                                          
32 The Public Health Service ranks amphetamine-type drugs, including MDMA, phenmetrazine, and ephedrine, as stimulants; cocaine is 
not included in this group. 
33 The number of cocaine users was very low. 
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Figure 5-2: First treatment demands by type of drug in 1997-2008 (Studničková and Petrášová, 2009) 
0
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2,000
2,500
3,000
Pervitin 1,510 2,177 2,042 1,880 1,969 2,389 2,281 2,685 2,605 2,528 2,749 2,492
Cannabis 512 631 648 912 747 1,070 981 994 893 755 778 755
Opiates 692 657 869 1,044 1,213 788 656 710 702 686 680 602
Inhalants 167 209 166 161 147 171 116 107 88 66 53 32
Ecstasy 12 7 10 23 50 193 24 27 16 7 5 10
Cocaine 12 7 7 10 5 3 15 13 5 5 13 15
LSD 25 29 31 30 17 13 6 11 9 2 5 5
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
 
Figure 5-3: All treatment demands by type of drug in 2002-2008 (Studničková and Petrášová, 2009) 
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Pervitin 4,589 4,490 4,790 4,855 4,889 5,177 4,925
Opiates 2,353 2,133 2,169 2,058 2,126 1,961 2,063
Cannabis 1,489 1,403 1,462 1,238 1,044 1,083 1,053
Inhalants 322 226 221 183 124 94 62
Ecstasy 218 50 37 23 12 11 14
Cocaine 13 22 18 15 12 22 24
LSD 34 15 19 10 4 7 6
2002 2003 2004 2005 2006 2007 2008
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Map 5-1: All treatment demands by type of drug in regions of the Czech Republic in 2008 per 1,000 inhabitants 
(Studničková and Petrášová, 2009) 
 
 
In 2008, the total of treatment demands involved 7,490 problem drug users (90.5%) and that of first treatment 
demands involved 3,428 problem drug users (86.1%)34. The intravenous application of drugs (including secondary 
ones) was noted in 5,986 (72.3%) of all treatment demands and in 3,981 (62.0%) of first treatment demands 
(Studničková and Petrášová, 2009). The trends of selected characteristics of treatment demands are shown in 
Figure 5-6 and Figure 5-7; additional information about the injecting use of drugs among treatment demands is given 
in the chapter on Risk Behaviour of Drug Users (p. 58). 
Figure 5-4: Average age of first treatment demands by selected drug type in 1997-2008 (Studničková and Petrášová, 
2009) 
17.0
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29.0
33.0
Heroin 21.0 21.9 21.5 21.5 22.1 23.4 24.6 25.1 25.5 25.7 27.2 27.3
Pervitin 20.2 20.4 21.0 21.4 21.6 22.3 22.2 23.1 23.4 22.7 23.7 24.0
Cannabis 18.7 18.4 18.6 18.5 18.3 18.7 18.9 19.5 19.3 19.0 20.1 20.5
Inhalants 19.0 18.1 17.5 18.6 18.3 18.4 19.6 20.0 20.4 20.0 21.2 22.4
Cocain+crack 21.7 23.4 27.2 32.0 27.8 26.0 29.5
All drugs 20.8 20.6 20.8 20.9 21.3 21.8 21.9 22.7 22.9 23.1 23.7 24.3
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
 
 
                                                          
34 i.e. injecting drug users and/or opiate users and/or amphetamine users and/or cocaine users. 
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Figure 5-5: Average age of all treatment demands by selected drug type in 2002-2008 (Studničková and Petrášová, 
2009) 
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Pervitin 23.7 23.6 24.2 24.5 23.7 25.0 25.4
Cannabis 19.4 19.6 20.1 20.0 20.3 21.0 21.3
Inhalants 21.1 21.2 22.0 22.7 22.0 23.7 25.7
Cocain+crack 25.2 25.7 26.9 29.1 28.3 26.8 29.6
All drugs 23.4 23.6 24.1 24.8 26.2 25.3 25.9
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Figure 5-6: Selected characteristics of first treatment demands in 1997-2008 (Studničková and Petrášová, 2009) 
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2,500
3,000
3,500
4,000
4,500
5,000
First treatment demands in total 3,132 3,858 3,891 4,148 4,233 4,719 4,158 4,600 4,372 4,119 4,346 3,981
Number of problem drug users 2,253 2,871 2,943 2,966 3,187 3,472 3,196 3,701 3,600 3,475 3,429 3,428
Number of injecting drug users 1,723 2,385 2,490 2,586 2,745 2,761 2,516 2,986 2,796 2,573 2,753 2,468
Number of persons aged under 19 1,694 2,023 1,914 1,970 1,860 2,000 1,808 1,656 1,506 1,327 1,335 1,186
Number of females 1,152 1,307 1,337 1,431 1,637 1,541 1,359 1,503 1,381 1,384 1,449 1,344
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
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Figure 5-7: Selected characteristics of all treatment demands in 2002-2008 (Studničková and Petrášová, 2009) 
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All treatment demands in total 9,237 8,522 8,845 8,534 8,366 8,487 8,279
Number of problem drug users 7,441 7,067 7,473 7,372 7,451 7,137 7,490
Number of injecting drug users 6,228 5,964 6,364 6,125 6,054 6,109 5,986
Number of persons aged under 19 2,773 2,541 2,322 2,064 1,811 1,792 1,625
Number of females 2,895 2,646 2,709 2,602 2,656 2,763 2,663
2002 2003 2004 2005 2006 2007 2008
 
 
In 2008, first treatment demands reported the daily use of drugs in 1,274 cases (32.0%); an additional 1,002 users 
(25.2%) used the drug 2-6 times per week. Among new treatment demands, heroin was the drug most frequently 
used on a daily basis (58.6% of heroin users); pervitin was the daily drug for 25.5% of its users. The most widely 
reported frequency of use of pervitin was 2-6 times per week. 
All treatment demands in 2008 reported the daily use of drugs in 2,772 cases (33.5%); an additional 1,888 users 
(22.8%) used the drug 2-6 times per week. Among all treatment demands, heroin was the drug most frequently used 
on a daily basis by a half of its users; pervitin was used daily in one quarter of cases, and among all treatment 
demands, pervitin was most frequently used 2-6 times per week (28.8%). Subutex® users also reported a relatively 
high frequency of use: 79.8% of Subutex® users used it on a daily basis (Studničková and Petrášová, 2009). 
The socioeconomic aspects of treatment demands’ characteristics have not changed since 2002. Out of the total of 
8,487 treatment demands in 2008, 11.1% were from homeless people, and another 6.8% were from people resident 
in institutions (e.g. in prisons, institutional care, hostels, or in sheltered housing); only 52.3% gave a permanent 
address of residence. Less than a half of both all and first treatment demands were from drug users who lived with 
their parents, and 20.6% of all clients in treatment stated they lived alone – men (21.8%) more frequently than 
women (12.6%); 18.2% of newly registered clients stated that they lived alone. A total of 522 clients (6.2%) receiving 
treatment indicated they lived in a household with children (Studničková and Petrášová, 2009). 
More than a half of treatment demands were from unemployed people or people in temporary jobs. 20.8% of first 
treatment demands and 22.2% of all treatment demands were from people who stated they were in regular 
employment. There was a higher proportion of unemployed or temporarily employed people among men. Almost 
50% of treatment demands were from people educated to elementary level. 6.0% of first treatment demands and 
4.1% of all treatment demands were from people who had not completed their basic education (Studničková and 
Petrášová, 2009). 
5.3.2 Clients in Outpatient Treatment 
In 2008, 17,319 users of various drugs with the exception of alcohol (dg. F11-F19) were treated in outpatient 
psychiatric facilities; of these, 15,711 were users of drugs with the exception of tobacco (dg. F11-F16, F18-F19). 
There were 10,707 men (68%), and 5,004 were women (32%). The 20-39 age group was the most numerous 
(71.4%), and 12.1% of the patients were in the under-20 age group. Table 5-3 and Table 5-4 show the trend in the 
total number of patients. Disorders caused by the use of opiates (F11), of stimulants (F15) and by polydrug use 
(F19) are traditionally the most frequent diagnoses of patients in treatment; see Figure 5-8. 
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Figure 5-8: Development in the number of drug users treated in outpatient health care facilities in 1993-2008 by 
diagnoses (group type) (Mravčík et al.  2008; Ústav zdravotnických informací a statistiky, 2009c) 
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Opiates/opioids 816 653 461 1,619 2,183 2,255 3,368 3,815 4,336 4,029 4,768 4,592 5,558 4,640 4,259 4,585
  of which heroin* 1,813 1,823 2,552 3,176 3,464 3,171 4,035 3,644 3,635 3,357 2,614 3,055
Cannabis 211 291 383 474 659 1,039 1,293 1,152 1,248 1,505 1,718 1,354 1,634 1,681 1,544 1,620
Sedatives/hypnotics 2,589 2,561 712 761 810 1,011 1,613 1,122 1,787 2,292 2,090 2,257 2,312 2,190 1,799 2,229
  of which benzodiazepines* 347 456 1,080 491 644 774 799 1,014 1,101 1,153 1,057 1,408
Stimulants 595 706 699 1,471 2,125 2,896 3,655 3,169 3,415 3,185 3,714 3,025 4,076 3,746 3,979 4,103
  of which pervitin* 979 2,436 3,211 2,695 2,718 2,719 3,162 2,579 2,662 3,055 3,272 3,330
Polydrug use 260 558 473 685 710 1,148 1,750 1,430 1,559 2,480 2,912 2,279 2,275 3,631 3,616 2,489
Other 763 842 610 931 1,027 1,083 817 735 705 712 584 533 539 504 487 685
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
 
NB: Separate statistics for heroin, benzodiazepines, and pervitin are not available prior to 1996. 
In 2008, outpatient treatment was also available from 12 NGOs funded by the Government Council for Drug Policy 
Coordination. Services were provided to a total of 1,923 users of illegal drugs (1,088 men and 835 women), and the 
average age of the clients was 28.9 years. 724 clients (37.6%) injected drugs, 456 (23.7%) used pervitin, 317 
(16.5%) heroin, 118 (6.1%) cannabis, and 186 (9.7%) other opiates, mainly buprenorphine obtained without 
prescription. Compared to 2007, there was a significant increase in the number of clients, in particular heroin users, 
and a slight decline in the number of pervitin users. Table 5-10 gives a comparison over the period 2003-2008 
(Národní monitorovací středisko pro drogy a drogové závislosti, 2009j). 
Table 5-10: Outpatient treatment facilities operated by NGOs and selected characteristics of their clients in 2003-2008 
(Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 2009j)  
Indicator 2003 2004 2005 2006 2007 2008 
Number of subsidised facilities 19 20 18 15 13 12 
Number of clients 2,820 2,506 3,127 4,301 3,044 3,278 
Number of drug users 1,590 1,493 1,743 2,428 1,642 1,923 
– injecting drug users 848 697 1,034 1,024 708 724 
– pervitin users 547 540 540 771 511 456 
– cannabis users 246 339 158 405 101 118 
– heroin users 310 223 391 240 256 317 
– Subutex® users n.a. n.a. 126 110 116 186 
Average age of drug user 23.6 25.9 26.8 29.6 26.3 28.9 
 
Only one facility in Prague, which is run by the SANANIM civic association, supplied intensive outpatient treatment in 
the form of a three-month course of treatment in a day care centre in 2008. The programme capacity was 10 
persons and services were provided to 38 clients (11 men, 27 women), whose average age was 26.5 years. 
Altogether, 24 clients (63%) were injecting drug users before the treatment; 6 (15.8%) were heroin users and 24 
(63%) used pervitin. 52.6% of the clients completed the treatment successfully. The average duration of the 
treatment per client was two months (Národní monitorovací středisko pro drogy a drogové závislosti, 2009j). 
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5.3.3 Clients in Substitution Treatment  
In 2008, the NRULISL register kept a record of 1,375 persons who underwent substitution treatment (Ústav 
zdravotnických informací a statistiky, 2009e); Figure 5-9 shows the trend from 2000. In 2008, a total of 887 persons 
were admitted for substitution treatment, of which number 422 were first-time substitution clients.35 
Clients from Prague, the Capital City, (45%), and the Ústí nad Labem region (20%) make up the largest groups 
among newly admitted substitution clients, whereas clients from the Pilsen, Liberec, Pardubice, Olomouc, Zlín, and 
Vysočina regions are relatively under-represented. With the exception of the Pilsen region, it is a reflection of the 
regional distribution of the problem use of opiates; for more information see chapter Problem Drug Use (p. 28). 
Figure 5-9: Number of patients in substitution treatment reported to the NRULISL database in 2000-2008 by gender 
(Mravčík et al.  2008; Ústav zdravotnických informací a statistiky, 2009e) 
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Total 245 483 422 657 729 716 837 959 1,375
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5.3.4 Clients in Inpatient Treatment 
The trend in the number of hospitalisations resulting from disorders caused by the use of alcohol and other 
psychoactive substances in inpatient psychiatric facilities since 1995 is shown in Figure 5-10 (Ústav zdravotnických 
informací a statistiky, 2009c), and the numbers of patients by primary diagnosis and type of psychiatric department 
are given in Table 5-11. 
Figure 5-10: Number of hospitalisations resulting from disorders caused by the use of alcohol and other psychoactive 
substances in inpatient psychiatric facilities for adults in 1995-2008 (Mravčík et al.  2008; Ústav zdravotnických informací 
a statistiky, 2009c) 
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35 It is not uncommon for a person to be admitted and re-admitted within a calendar year. Out of the persons who were admitted for 
treatment in 2008, 8.5% were attempting for the second time, 2.8% for the third time, and the maximum number of attempts for 
treatment by one person was six. The highest number of re-admissions was reported by the South Bohemia Substitution Centre in 
České Budějovice, Drop-In in Prague, and the substitution centre at the University Hospital in Ostrava. The re-admissions, or more 
specifically the terminations of the previous treatment episode, were most frequently caused by a violation of the treatment regime on 
the part of the patient; in the long term, repeated violation of the therapeutic agreement is the reason behind 70% of all treatment 
terminations (Ústav zdravotnických informací a statistiky, 2009e). 
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Table 5-11: Number of hospitalisations resulting from disorders caused by the use of alcohol and other psychoactive 
substances in inpatient psychiatric facilities in 2008 by type of health care facility, gender, and diagnosis (Ústav 
zdravotnických informací a statistiky, 2009c) 
Psychiatric hospitals 
for children 
Psychiatric hospitals for 
adults 
Psychiatric departments in 
hospitals Diagnosis 
Men Women Total Men Women Total Men Women Total 
F11-19 in total, 
excluding F17 23 2 25 2,389 1,000 3,389 793 454 1,247 
–  of which F11 
(opioids) 0 0 0 233 97 330 216 113 329 
– of which F12 
(cannabis) 5 0 5 69 14 83 41 5 46 
– of which F13 
(sedatives/hypnotics) 0 0 0 49 101 150 37 63 100 
– of which F14 
(cocaine) 0 0 0 2 0 2 1 0 1 
– of which F15 
(stimulants) 0 0 0 672 312 984 229 118 347 
– of which F16 
(hallucinogens) 0 0 0 7 0 7 5 0 5 
– of which F18 
(inhalants) 7 0 7 30 0 30 7 1 8 
– of which F19 
(polydrug use) 11 2 13 1,327 476 1,803 257 154 411 
F10 (alcohol) 0 0 0 5,317 2,263 7,580 1,301 682 1,983 
F17 (tobacco) 0 0 0 0 0 0 4 0 4 
Total F10-F19 23 2 25 7,706 3,263 10,969 2,098 1 136 3,234 
 
Polydrug use (dg. F19) was also the most common cause of the hospitalisation of users of illegal drugs in inpatient 
psychiatric facilities in 2008 (47.7% of admissions). Other causes included stimulant use (28.7%) and opioid use 
(14.2%). The most common cause of hospitalisation in inpatient facilities for children was polydrug use or the use of 
inhalants and cannabis. The 20-29 age group (53.8%) was the most numerous, followed by the 30-39 age group 
(21.9%). 12.3% of hospitalised drug users were under 19 years of age (Ústav zdravotnických informací a statistiky, 
2009c). 
The trend in the number of hospitalised patients by drug or by drug group varies. Since 2000, there has been a 
steady decline in the number of hospitalisations resulting from disorders caused by opiods (F11). In 2008, the 
number of hospitalisations resulting from disorders caused by polydrug use recorded a slight year-on-year increase, 
whereas the number of hospitalisations resulting from disorders caused by stimulant and opioid use declined 
marginally; see Figure 5-11. The number of hospitalisations resulting from disorders induced by other drugs is much 
lower by comparison; there was a slight decline in the number of hospitalisations resulting from disorders caused by 
inhalant use and an increase for cannabis and sedatives; see Figure 5-12. 
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Figure 5-11: Number of hospitalisations resulting from disorders caused by the use of opioids and stimulants and by 
polydrug use in inpatient psychiatric facilities in 2000-2008 (Mravčík et al.  2008; Ústav zdravotnických informací a 
statistiky, 2009c) 
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Figure 5-12: Number of hospitalisations resulting from disorders caused by the use of other drugs in inpatient psychiatric 
facilities in 2000-2008 (Mravčík et al.  2008; Ústav zdravotnických informací a statistiky, 2009c) 
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The data relating to the clients of therapeutic communities in 2008 were submitted by 10 therapeutic communities 
subsidised by the Government Council for Drug Policy Coordination. Their joint capacity was 138 beds (of these, 42 
were reserved for juveniles and 9 for mothers with children); a total of 427 drug users (of these, 20 were mothers 
with children), whose average age was 23.8 years, were enrolled in a programme. A total of 326 clients (76.3%) 
injected drugs prior to treatment, 283 (66.3%) used pervitin, and 73 (17.1%) used opiates (67 used heroin, 4 used 
illegally procured buprenorphine). 123 clients (28.8%) successfully completed a programme; the average duration of 
a successful (completed) treatment was 308 days (approximately 10 months). 153 clients (35.8%) dropped out, 12% 
within 3 months of the commencement of treatment. The average duration of the treatment of all patients was 188 
days (approximately 6 months). The trend in the period 2003-2008 is shown in Table 5-12 (Národní monitorovací 
středisko pro drogy a drogové závislosti, 2009j). 
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Table 5-12: Therapeutic communities and their clients in 2003-2008 (Národní monitorovací středisko pro drogy a 
drogové závislosti, 2009j) 
Indicator 2003 2004 2005 2006 2007 2008
Number of communities 17 14 12 12 11 10 
Capacity of the facility 238 218 183 185 169 138 
Number of clients 510 546 491 451 472 427 
– of which injecting drug users 428 429 400 375 347 326 
– of which pervitin users 270 306 287 281 291 283 
– of which heroin users 187 151 132 93 66 67 
Average age of client 23.4 24.2 24.9 25.1 24.2 23.8 
 
A study entitled Treatment Outcome Evaluation of Therapeutic Communities for Drug Users, covering five 
therapeutic communities associated in the Therapeutic Communities Section of the Association of NGOs, was 
commenced in early 2007. Its purpose is to monitor the clients of the five therapeutic communities for drug users in 
the period from beginning treatment until one year after the completion of treatment, with a view to establishing which 
changes occur in five key areas: (1) drug and alcohol use; (2) mental and physical health; (3) degree of socialisation; 
(4) criminal behaviour, and (5) quality of life. The recruitment of new clients from partner communities was completed 
in 2008. The study cohort comprises 214 clients who enrolled for treatment in a therapeutic community either in 2007 
or in 2008. The group represents 77.0% of all the clients who commenced treatment in the partner therapeutic 
communities in those years. The cohort comprises 137 men (64.0%) and 77 women (36.0%). The average age is 
25.5 years (age range: 16-45 years). 145 clients (67.8%) stated pervitin had been their drug of choice at the time of 
their enrolment in treatment; for 61 clients (27.4%) it was heroin or other opiates, and 196 clients (91.6%) were 
injecting drug users with an average history of intravenous application of 6.2 years. The cohort includes a sizeable 
group of clients who had already begun injecting drugs at the age of 11-15 years (46 clients, 21.4%). The cohort also 
includes a sizeable group of clients with a history of the intravenous application of drugs 10 or more years long (44 
clients, 20.5%). The number of clients who had shared needles and syringes in the 30 days preceding their 
treatment (47 clients, 29.5%) is also relatively high. In the area of physical health, 53 clients (24.8%) were infected 
with type C hepatitis. In the area of mental health, 72 clients (33.6%) reported severe symptoms of depression; the 
number of clients who reported serious anxiety symptoms is almost as high (78 clients, 36.4%). As for criminal 
behaviour, it was established that 55 clients (25.7%) had been detained or imprisoned. A total of 152 clients (71.0%) 
reported they had committed a crime in the period of 30 days prior to entering treatment (Šefránek, 2009). 
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6 Health Correlates and Consequences 
The state of affairs in terms of infections among (injecting) drug users remained relatively favourable in 2008 – the 
HIV infection rate was still far below 1% and the prevalence of HCV among clients examined in low-threshold 
programmes was approximately 12%. In 2008, 13 new HIV-positive persons were identified, who may have become 
infected through injecting drug use. This is less than in 2007; compared to 2006, however, the number is relatively 
high. There was an HAV epidemic in the Czech Republic in 2008. At its outset, it was spreading among injecting 
drug users in Prague. 
In the long term, the number of hospitalisations for non-fatal intoxication by pervitin appears to be growing. In 
contrast, the number of cases related to heroin appears to be declining.  
In 2008, the number of fatal overdoses on the main groups of street drugs traditionally reported in the Czech 
Republic has remained low. In total, 44 cases were reported (15 cases of fatal overdoses on opiates, 19 on pervitin, 
and 10 on inhalants), which means four cases more compared to 2007; there was a slight increase in the number of 
overdoses on opiates, a more pronounced increase in that of overdoses on pervitin, and fatal overdoses on inhalants 
decreased. No fatal overdose on cocaine, ecstasy, hallucinogens, or THC was reported. One death with the 
presence of methadone occurred in 2008, but none with the presence of buprenorphine. As regards causes of death 
other than overdoses (particularly accidents/injuries and suicides), the number of cases with pervitin and THC has 
been growing since 2004. In 2008, 49 and 37 cases were identified, respectively. In 12 cases an opiate/opioid was 
detected, of which number five cases involved substitution substances. 
As for deaths in traffic accidents or as a result of traffic accidents in 2008, the rate of positive findings increased for 
pervitin and cannabis – of the drivers killed in accidents, 9.2% and 6.2% respectively tested positive for these 
substances. However, the police records only contain one-digit numbers of these deaths. 
6.1 Drug-Related Infectious Diseases 
6.1.1 Reported Incidence of HIV/AIDS and Viral Hepatitis 
The number of new cases of HIV infection reported each year in the Czech Republic up to 2006 had long ranged 
between two and six cases among injecting drug users and another one or two cases in the mixed category of 
injecting drug users and homo-/bisexuals. In 2007, 16 cases were reported of HIV-positive persons who may have 
become infected through injecting drug use. A relatively high incidence of HIV-positive injecting drug users (IDUs) 
continued in 2008, with 13 new cases reported. Altogether, 1,190 HIV-positive persons with a permanent place of 
residence in the Czech Republic were registered as of December 31, 2008; 62 of them are injecting drug users and 
another 21 are in the mixed category of injecting drug users and homo-/bisexuals at the same time (Státní 
zdravotní ústav Praha, 2009); see Table 6-1. 
Table 6-1: Incidence of HIV in the Czech Republic in the period 1985-2008 by route of transmission (Státní zdravotní 
ústav Praha, 2009) 
Total Route of transmission 
(risk group) 1985-2003 2004 2005 2006 2007 2008 Number % 
Homo-/bisexual 
intercourse 356 30 52 54 72 88 652 54.8 
Heterosexual intercourse 208 31 29 27 30 44 369 31.0 
IDU 27 6 4 4 12 9 62 5.2 
IDU and homo-/bisexual 
intercourse 9 1 1 2 4 4 21 1.8 
Other 37 0 0 0 0 0 37 3.1 
Not ascertained 28 4 4 6 4 3 49 4.1 
Total 665 72 90 93 122 148 1,190 100 
 
The year 2008 saw a decrease in the number of newly reported cases of acute HBV in injecting drug users, which 
has been declining in the long term. The number of newly reported cases of HCV in IDUs also decreased (Beneš, 
2009); see Figure 6-1 and Figure 6-2. 
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Figure 6-1: Reported incidence of HBV among all patients and injecting drug users in the Czech Republic in 1996-2008 
(Beneš, 2009) 
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Figure 6-2: Reported incidence of acute and chronic HCV among all patients and injecting drug users in the Czech 
Republic in 1996-2008 (Beneš, 2009) 
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Since May 2008 there has been an epidemic of HAV in the Czech Republic, which in its initial period in May and 
June was associated with injecting drug use – IDUs accounted for two thirds of cases in this period. In the second 
half of 2008 the epidemic spread among other risk groups (homeless people, alcoholics, persons with risky sexual 
behaviour) and in the general population. Its proliferation through the alimentary route (water or food) was ruled out 
with a very high probability; direct contact or injecting were the likely routes of transmission among IDUs. Most cases 
were reported from Prague (54%), where the epidemic started, and from the Central Bohemia (13%) and Olomouc 
(9%) regions. Altogether, two persons died, of whom one case was an injecting drug user infected with HBV and 
HCV at the same time. One of the measures taken to counter the epidemic was the vaccination of drug users 
against HAV, which was introduced in Prague in July – in total, 2,002 drug users and homeless people were 
vaccinated in this campaign in 2008 (Beneš, 2009; Částková and Beneš, 2009). The trend of HAV incidence is 
shown in Figure 6-3. 
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Figure 6-3: Reported incidence of HAV among all patients and injecting drug users in the Czech Republic in 1996-2008 
(Beneš, 2009) 
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In early 2009, an increased incidence of syphilis was reported among the clients of the Prague contact centre of the 
SANANIM civic association, with 11 positive cases identified in the period March-April 2009. These cases were 
clients with promiscuous or commercial sexual behaviour (Národní monitorovací středisko pro drogy a drogové 
závislosti, 2009k). 
6.1.2 Prevalence of Infections Among Drug Users 
According to the National Reference Laboratory for AIDS at the National Institute of Public Health in Prague, a total 
of 887,443 laboratory tests were conducted in the Czech Republic in 2008, of which 147 were positive (0.17‰); 
1,363 tests were conducted among IDUs36, with one positive result (0.7‰); the number of tests carried out among 
IDUs decreased again in 2008, and reached its lowest value in the period in question (Vandasová and Malý, 2009); 
see Table 6-2. 
Table 6-2: Tests of injecting drug users for HIV antibodies in 1994-2008 (Vandasová and Malý, 2009) 
Blood tests Saliva tests Total 
Year Number of 
tests 
Number of 
positive 
results 
Number of 
tests 
Number of 
positive 
results 
Number of 
tests 
Number of 
positive 
results 
1994-1997 1,206 1 895 0 2,101 1 
1998 1,034 0 1,124 0 2,158 0 
1999 1,101 0 1,219 0 2,320 0 
2000 1,090 0 1,001 0 2,091 0 
2001 1,208 1 961 0 2,169 1 
2002 801 0 735 1 1,536 1 
2003 985 1 652 0 1,637 1 
2004 1,382 0 227 0 1,609 0 
2005 925 1 449 1 1,374 1* 
2006 994 1 412 0 1,406 1 
2007 845 1 531 1 1,376 2 
2008 886 1 477 0 1,363 1 
Total 12,457 7 8,683 3 19,734 9 
NB: * This involves one new case detected by a saliva test and subsequently confirmed by a blood test. 
The monitoring of testing for infections among IDUs has been ongoing since 2004 in low-threshold programmes; the 
2008 results were collected using an internet questionnaire at drogy-info.cz in the period January-February 2009. A 
total of 52 low-threshold programmes responded, of which 23 were low-threshold centres, 13 outreach programmes, 
and 16 were services concurrently operating a low-threshold and an outreach programme (Národní monitorovací 
středisko pro drogy a drogové závislosti, 2009i). The results are provided in Table 6-3. 
                                                          
36 These are cases when information about drug use is known prior to the test or is reported as the reason for testing. 
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Table 6-3: Results of testing among injecting drug users in low-threshold facilities in 2008 (Národní monitorovací 
středisko pro drogy a drogové závislosti, 2009i) 
Number of tests Number of persons 
Infection Type of test* 
Number 
of testing 
program-
mes 
Total Positive tests Total 
Positive 
tests 
Proportion 
of positive 
tests (%) 
Saliva test 12 241 0 155 0 0.0
Quick capillary blood test 15 311 1 281 1 0.4
Quick capillary blood serum 
test 5 65 0 52 0 0.0
Laboratory vein blood serum 
test 8 272 0 237 0 0.0
HIV 
Total 34 889 1 725 1 0.1
Quick capillary blood test 4 78 4 76 4 5.3
Quick capillary blood serum 
test 15 340 26 314 24 7.6
Laboratory vein blood serum 
test 11 269 52 232 45 19.4
HCV 
Total 26 687 82 622 73 11.7
HBV Laboratory vein blood serum test 8 263 4 227 2 0.9
Quick capillary blood test 3 162 0 119 0 0.0
Laboratory vein blood serum 
test 5 177 3 147 3 2.0Syphilis 
Total  8 339 3 266 3 1.1
NB: * The monitoring of infections in low-threshold programmes finds the results of tests for long-term antibodies against various 
infections. 
The prevalence of HCV determined on the basis of monitoring in low-threshold programmes is lower than that 
identified through the seroprevalence studies undertaken earlier (Trmal et al.  1999; Mravčík et al.  2000; Zábranský 
et al.  2006); one possible explanation is due to the fact that the opportunity for testing is used primarily by new 
clients with lower levels of infection and the results of monitoring are not available from all low-threshold 
programmes, particularly from localities with a higher prevalence of HCV (e.g. from Prague, where in 2008 low-
threshold programmes did not examine clients for HCV). The results acquired by quick tests indicate a lower 
prevalence than the results of laboratory tests of vein blood serum; however, this may also be influenced by regional 
differences in the application of the various tests – high prevalence levels of HCV were identified even if the quick 
tests were applied, e.g. in the Ústí nad Labem region (20%) and the Moravia-Silesia region (33%) (Národní 
monitorovací středisko pro drogy a drogové závislosti, 2009i). The results of the (sero)prevalence of HCV by region 
are given in Table 6-4. 
Table 6-4: Results of HCV testing among IDUs in low-threshold facilities in 2008 by region (Národní monitorovací 
středisko pro drogy a drogové závislosti, 2009i) 
Number of centres Number of persons tested 
Region Number of questionnaires 
returned 
Tested for 
HCV Total HCV+ HCV+ (%) 
Prague 5 0  –  –  – 
Central Bohemia 5 0  –  –  – 
South Bohemia 7 6 58 3 5.2 
Pilsen 2 2 113 3 2.7 
Karlovy Vary 1 1 25 6 24.0 
Ústí nad Labem 7 6 198 43 21.7 
Liberec 1 1 22 1 4.5 
Hradec Králové 3 1 41 1 2.4 
Pardubice 2 0  –  –  – 
Vysočina 2 1 25 1 4.0 
South Moravia 5 1 13 0 0.0 
Olomouc 5 3 36 5 13.9 
Zlín 2 2 50 2 4.0 
Moravia-Silesia 5 2 41 8 19.5 
Total 52 26 622 73 11.7 
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The dependence of HCV seroprevalence on the demographic and user characteristics of the clients of low-threshold 
facilities is shown in Figure 6-4. 
Figure 6-4: The results of HCV testing among IDUs in low-threshold facilities in 2008 by gender, age, primary drug, and a 
history of injecting use (Národní monitorovací středisko pro drogy a drogové závislosti, 2009i) 
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The trend in the number of low-threshold facilities performing tests for these infections and the numbers of tests 
conducted according to the information provided in the final reports of the projects supported in the GCDPC subsidy 
programme is given in Table 7-6 (p. 73) in the chapter on Prevention and Treatment of Drug-Related Infectious 
Diseases. 
The data about testing for infections and the results of the tests may also be retrieved from the Register of Treatment 
Demands maintained by the Public Health Service (Studničková and Petrášová, 2009; Studničková, 2009b). This 
information is provided by the clients themselves; only tests with known results are included; see Table 6-5. The 
data, although their information value is limited, indicate a stable prevalence of infections among drug users. As 
regards the prevalence of HCV, it is about 50% higher than the prevalence according to the monitoring of clients in 
low-threshold programmes, although dependability of the characteristics monitored is similar; see Figure 6-5. 
Table 6-5: The results of testing for HIV, HAV, HBV, and HCV among users demanding treatment, self-reported in 2003-
2008 (Studničková, 2009b) 
Infection 2003 2004 2005 2006 2007 2008 
Total tested 2,471 2,483 2,253 2,196 1,905 2,332 HIV Positive tests (%) 0.8 0.4 0.2 0.5 0.3 0.6 
Total tested 2,132 2,059 1,931 1,997 1,774 2,271 HAV Positive tests (%) 7.1 5.5 4.5 3.3 3.3 8.4 
Total tested 2,504 2,581 2,332 2,290 2,004 2,463 HBV Positive tests (%) 11.2 9.9 10.1 10.0 8.4 8.9 
Total tested 2,884 2,913 2,577 2,497 2,168 2,636 HCV Positive tests (%) 31.5 33.6 35.0 32.6 31.0 32.0 
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Figure 6-5 : The results of HCV testing among users demanding treatment in 2008 by gender, age, primary drug, and a 
history of injection use, self-reported (Studničková, 2009b) 
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The Centre for Addictology undertook a study of the seroprevalence of HIV, HBV, and HCV in 2007-2008; the study 
focused on injecting drug users from the countries of the former Soviet Union living in Prague. The results indicated a 
significantly higher prevalence of HIV and other blood-borne and sexually transmitted infections; for further details 
see the 2007 Annual Report. 
6.1.3 Risk Behaviour of Drug Users 
In 2008, the proportion of injecting drug users in first treatment demands in relation to heroin use increased again, 
and that of pervitin users decreased slightly; injecting is also the most frequent route of administration of Subutex® in 
treatment demands, as far as the use of this drug is concerned; the developments in the period from 1998 to 2008 
are shown in Figure 6-6. In the Czech Republic, cocaine is used almost exclusively by snorting (one out of the total 
of 23 treatment demands reported injecting); only one treatment demand in relation to the use of crack was 
registered in 2008 (Studničková and Petrášová, 2009). 
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Figure 6-6: Proportion of injecting drug use in first treatment demands and in all treatment demands in relation to the use 
of heroin, Subutex®, and pervitin (%) (Mravčík et al.  2008; Studničková and Petrášová, 2009) 
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The trend in the proportion of treatment demands among injecting drug users reporting having shared needles and 
syringes at any time in the past is given in Table 6-6. 
Table 6-6: Sharing of needles and syringes in the lifetime reported by IDUs demanding treatment in 2002-2008 
(Studničková, 2009b) 
Year Number of IDUs 
Number of those 
sharing Sharing (%)
2002 6,437 2,590 40.2
2003 5,901 2,356 39.9
2004 6,314 2,725 43.2
2005 5,769 2,421 42.0
2006 5,860 2,313 39.5
2007 5,338 2,139 40.1
2008 5,766 2,057 35.7
 
6.2 Other Drug-related Health Correlates and Consequences 
6.2.1 Non-Fatal Drug Intoxications 
The collection of data about non-fatal intoxications37 is based on the system operated by the Public Health Service 
and the data are collected centrally by the Public Health Office in Prague. There are still major differences between 
the regions in the system of collecting data generated by various health facilities, primarily emergency units. 1,146 
                                                          
37 This system reports cases of overdoses, as well as other health complications that require emergency hospitalisation.  
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cases of non-fatal intoxication by drugs were reported in 200838. The trend is shown in Table 6-7. In the long term, 
there appears to be an increase in the number of cases related to pervitin and, on the contrary, a decrease in the 
number of cases related to heroin and inhalants. 
Table 6-7: Non-fatal drug intoxications in the Czech Republic in 2001-2008 (Mravčík et al.  2008; Studničková and 
Petrášová, 2009) 
Drug 2001 2002 2003 2004 2005 2006 2007 2008 
Pervitin 163 191 149 180 222 231 343 364
Heroin 285 176 152 179 244 149 190 166
Methadone 2 6 3 2 10 7 2 1
Subutex®    2 12 14 18 32 7
Other opiates 16 23 22 20 19 21 40 17
Benzodiazepines 137 89 157 126 153 124 139 113
Other sedatives, 
hypnotics 195 137 82 103 88 107 125 135
Other drugs and pills 182 179 100 92 111 89 124 140
Cannabis 63 101 90 84 73 72 127 108
Inhalants 75 58 69 64 48 28 31 9
Psilocybin 15 7 4 10 6 5 10 9
Cocaine, crack 4 2 6 5 7 8 1 7
Datura stramonium 4 0 0 0 1 0 1 5
LSD 3 2 3 7 3 5 7 4
MDMA 15 4 8 3 8 12 12 3
Other, unknown 24 25 34 65 186 78 71 58
Total 1,183 1,000 881 952 1,193 954 1,255 1,146
6.2.2 Psychiatric and Somatic Comorbidity of Drug Users 
The results of a survey of psychiatric comorbidity of the clients of the CADAS outpatient psychiatric facility operated 
by the SANANIM civic association were published in the 2007 Annual Report. 
In the first half of 2008, a survey was carried out among the clients of seven low-threshold programmes in Prague, 
focused on an analysis of the sociodemographic and user characteristics of the clients and their use of services 
(Šejvl, 2008), see also the chapter on Data on Problem Drug Use from Non-treatment Sources, page 30. The survey 
included a question about health problems related to drug use. Out of 783 clients, 396 (50.6%) reported health 
problems; their structure is given in Table 6-8. The prevalence of viral hepatitis or overdoses is relatively low. 
Table 6-8: Health problems reported by clients of low-threshold programmes in Prague (Šejvl, 2008) 
Problems reported Number % 
Abscess at the injection site 266 34.0
Other inflammations around the 
injection site  49 6.3
HCV 34 4.3
HBV 15 1.9
Vein system disorders 14 1.8
Overdose 4 0.5
Other, unspecified 14 1.8
No problems 387 49.4
Total 783 100.0
 
Other information originally published in the 2005 Annual Report concerning somatic and psychiatric comorbidity and 
new information about the prevalence of toxic psychoses in a sample of hospitalised drug users in 2001-2005 are 
given in the special chapter on Problem Amphetamine and Methamphetamine Use, Related Consequences and 
Responses, page 102. 
6.2.3 Drugs and Road Accidents 
Since 2003, cases where ethanol and other drugs were detected39 have been analysed in the victims of traffic 
accidents autopsied in forensic medicine laboratories and forensic toxicology departments in the Czech Republic; for 
                                                          
38 The trends of the cases reported are also significantly influenced by changes in the network of the reporting facility – starting from 
2007, for instance, data are available from the emergency medical service of the Central Bohemia region, while there was no case 
reported from the South Moravia and Hradec Králové regions in 2007 and 2008. 
39 A test is considered to be positive for ethanol if the level of ethanol is higher than 0.2 g/kg (Společnost soudního lékařství a soudní 
toxikologie, 1999), positive for cannabis if THC or its active metabolite is proven (i.e. not THC-COOH, for instance), and positive for 
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details see the chapter on Drug-Related Deaths and Mortality of Drug Users (p. 63). The data set is divided into 4 
categories: pedestrians, cyclists, drivers of motor vehicles, and others. The category of other victims comprises 
mainly passengers in vehicles and the fatalities that could not be assigned to any of the three previous categories 
(i.e. victims of other than road accidents, e.g. aircraft accidents, construction site accidents, and public transport 
accidents). 
According to the date reported by forensic medicine departments, 1,040 persons died in traffic accidents or as a 
result of traffic accidents in 2008, of whom 582 (56%) were subject to toxicological examination40, which is a similar 
proportion as in the previous years. The highest proportion of positive tests was detected in the case of ethanol, 
where there was a year-on-year increase, particularly in drivers. As far as the three most common non-alcohol drugs 
are concerned, there was also an increase in the number of positive tests for pervitin and cannabis – 9.2% and 6.2% 
of drivers, respectively, tested positive for these substances; on the contrary, there was a decline in 
benzodiazepines; see Table 6-9. There were no cases where cocaine was detected in 2003-2008; cases with the 
presence of inhalants and opiates did not exceed 1% (Národní monitorovací středisko pro drogy a drogové závislosti 
and SSLST ČLS JEP, 2009). 
                                                                                                                                                                                                
inhalants if the autopsy detects substances which do not develop post mortem or are not indicated in some physiological or pathological 
conditions (e.g. acetone, acetaldehyde, n-propanol, n-butanol). 
40 i.e. tested for ethanol or any drug from the following groups: inhalants, opiates, stimulants, cannabis, cocaine, benzodiazepines, 
barbiturates. 
strana 62 
Table 6-9: Detection of ethanol and other drugs in the bodies of active road users who died in traffic accidents in 2003-
2008 (Národní monitorovací středisko pro drogy a drogové závislosti and SSLST ČLS JEP, 2009) 
Category of active road users who died in traffic accidents 
Pedestrians Cyclists Drivers Total 
Drug Year 
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2003 141 51.8 50 40.0 203 32.0 394 40.1 
2004 150 48.7 44 29.5 209 23.9 403 33.7 
2005 148 45.3 35 34.3 198 18.7 381 30.4 
2006 102 55.9 35 37.1 164 26.2 301 37.5 
2007 130 50.8 44 40.9 215 20.9 389 33.2 
Ethanol 
2008 139 51.8 40 37.5 202 29.2 381 38.3 
2003 91 1.1 27 0.0 152 3.3 270 2.2 
2004 109 1.8 23 0.0 170 1.8 302 1.7 
2005 103 1.9 17 0.0 148 0.7 268 1.1 
2006 79 1.3 15 0.0 125 7.2 219 4.6 
2007 107 0.9 27 0.0 223 5.8 357 3.9 
Stimulants (incl. 
pervitin and ecstasy) 
2008 121 3.3 21 0.0 195 9.2 337 6.5 
2003 70 2.9 21 0.0 101 4.0 192 3.1 
2004 44 2.3 14 0.0 100 0.0 158 0.6 
2005 54 1.9 11 0.0 94 3.2 159 2.5 
2006 53 11.3 8 12.5 91 4.4 152 7.2 
2007 61 3.3 11 0.0 154 4.5 226 4.0 
Cannabis (active 
metabolites of THC) 
2008 60 6.7 13 0.0 130 6.2 203 5.9 
2003 89 3.4 28 7.1 150 2.0 267 3.0 
2004 109 5.5 23 4.3 172 2.9 304 3.9 
2005 103 2.9 17 5.9 147 4.1 267 3.7 
2006 81 2.5 15 0.0 127 3.9 223 3.1 
2007 114 7.0 30 3.3 223 5.8 367 6.0 
Benzodiazepines 
2008 135 5.2 24 12.5 204 2.0 363 3.9 
2003 88 0.0 28 3.6 149 0.0 265 0.4 
2004 109 1.8 23 0.0 169 1.2 301 1.3 
2005 101 2.0 15 0.0 131 0.8 247 1.2 
2006 77 0.0 14 0.0 111 0.9 202 0.5 
2007 109 0.0 29 3.4 195 1.5 333 1.2 
Barbiturates 
2008 134 1.5 23 0.0 191 1.6 348 1.4 
2003 108 7.4 35 11.4 171 6.4 314 7.3 
2004 117 9.4 26 7.7 181 5.5 324 7.1 
2005 110 8.2 19 5.3 158 7.0 287 7.3 
2006 84 9.5 18 5.6 133 12.8 235 11.1 
2007 122 9.0 30 6.7 233 13.7 385 11.7 
Any drug besides 
ethanol 
2008 142 10.6 29 10.3 213 12.7 384 11.7 
 
Information about the influence of alcohol and other drugs on the rate of road traffic accidents registered by the 
police is given in Table 6-10. This information also indicates that in 2008 the number and proportion of accidents 
occurring under the influence of alcohol and other drugs and the number and proportion of those killed in the 
accidents occurring under the influence of alcohol increased; sporadic cases of accidents under the influence of 
drugs were registered by the police. 
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Table 6-10: Road traffic accident statistics in the Czech Republic in 2003-2008 – influence of alcohol and other drugs 
(Ředitelství služby dopravní policie Policejního prezidia ČR, 2009) 
Accidents Deaths 
Total 
Under the 
influence of 
alcohol 
Under the 
influence of 
medication and 
other drugs 
Total 
Under the 
influence of 
alcohol 
Under the 
influence of 
medication and 
other drugs 
Year 
Number Number % Number % Number Number % Number % 
2003 195,851 9,076 4.9 39 0.02 1,319 111 8.5 0 0.0 
2004 196,484 8,445 4.5 53 0.03 1,215 59 4.9 1 0.1 
2005 199,262 8,192 4.3 60 0.03 1,127 59 5.2 0 0.0 
2006 187,965 6,807 3.8 64 0.03 956 42 4.3 1 0.1 
2007 182,736 7,266  4.3 78 0.04 1,123 36 3.2  2 0.2 
2008 160,376 7,252 4.8 109 0.07 992 80 8.1 1 0.1 
 
Data about deaths due to other causes (including accidents and trauma in toto) under the influence of drugs are 
provided below in the chapter on Deaths with the Presence of Drugs (p. 65). 
6.3 Drug-Related Deaths and Mortality of Drug Users 
In the Czech Republic, a forensic surgeon carries out a mandatory autopsy in all cases of sudden death in which the 
examining practitioner could not determine the cause of death and in all cases of violent deaths. Since 1998 drug-
related deaths (fatal overdoses), and since 2003 also indirect fatalities (with the presence of drugs), have been 
monitored on a routine basis by means of a special register kept by all thirteen departments of forensic medicine and 
forensic toxicology departments, with close collaboration between the National Focal Point and the Professional 
Association of Forensic Medicine and Toxicology of the Czech Medical Association of J. E. Purkyně. Since 2007, 
aggregated reports have also been provided by three departments of pathology where irregular autopsies are 
carried out mandatorily under law by forensic surgeons (none of the three departments reported any drug-related 
deaths in 2008). 
6.3.1 Drug Overdoses 
238 fatal overdoses on illicit drugs, inhalants, and psychotropic medicaments were identified in 2008 (213 in 2007). 
Out of this number, 44 were overdoses on street drugs, i.e. illicit drugs and inhalants (40 in 2007), and 194 on 
psychotropic medicaments (173 in 2007). The substances which caused the fatal overdose were successfully 
identified in all the cases in 2008. 
In total, 15 cases were identified of fatal overdoses on (illicit) opiates (in 2007 there were 14 cases), primarily heroin 
(12 confirmed or very probable cases), out of which the opiate itself was identified in seven cases, in two cases in 
combination with pervitin, and in six cases in combination with ethanol or psychotropic medicaments (out of which 
one case involved methadone in combination with ethanol and barbiturates). Pervitin was the cause of the overdose 
in 19 cases (11 cases in 2007), out of which one case was in combination with THC and three cases in combination 
with psychotropic medicaments. Ten cases involved an overdose on inhalants (14 cases in 2007), out of which one 
case can be attributed to the inhalation of lighter gas. In 2008, as has been the case so far, no overdose with the 
presence of buprenorphine was identified (although a fatality due to other causes with the presence of 
buprenorphine has been reported for the first time ever) and there was no report of any overdoses on cocaine, 
MDMA, hallucinogens, or (as has been the case so far) THC or another cannabinoid (Národní monitorovací 
středisko pro drogy a drogové závislosti and SSLST ČLS JEP, 2009); see Table 6-11. 
Overdoses on psychotropic medicaments constitute a very heterogeneous category, which it would be difficult to 
evaluate accurately. This is because this category comprises suicidal overdoses, accidental overdoses, and 
overdoses without any established intention, both on medicaments prescribed lege artis and on diverted 
medicaments. In total, 194 cases of overdoses on psychotropic medicaments were identified in 200841 (173 cases in 
2007), out of which 77 cases involved overdoses on benzodiazepines (58 in 2007) and 37 involved overdoses on 
medicaments containing opiates (24 in 2007). 
In the past three years, the number of fatal overdoses on street drugs (inhalants and illegal narcotic and psychotropic 
substances) has been approximately 40 cases. The year 2008 saw a slight year-on-year increase in the number of 
cases related to opiates and a more pronounced increase in those related to pervitin (these are the highest numbers 
in the past 8 years), while there was a decrease in the number related to inhalants; the long-term trend is shown in 
Figure 6-7. 
                                                          
41 Most overdoses on medications are suicidal in nature, most often involving a combination of (several) medicaments with alcohol. 
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Table 6-11 Fatal drug overdoses in the Czech Republic in 2008 by groups of drugs, age groups, and gender (Národní 
monitorovací středisko pro drogy a drogové závislosti and SSLST ČLS JEP, 2009) 
Total 
Drug/Age group 
<1
5 
15
–1
9 
20
–2
4 
25
–2
9 
30
–3
4 
35
–3
9 
40
–4
4 
45
–4
9 
50
–5
4 
55
–5
9 
60
–6
4 
>6
4 
U
nk
no
w
n 
Men Women Total 
Only opiates/opioids  
(except methadone) 0 0 1 5 1 5 0 0 0 0 0 0 0 11 1 12
Only methadone 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
More substances, 
including 
opiates/opioids 
0 0 0 1 0 2 0 0 0 0 0 0 0 3 0 3
– of which methadone 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 1
Total opiates/opioids 0 0 1 6 1 7 0 0 0 0 0 0 0 14 1 15
One or more 
substances, 
excluding 
opiates/opioids 
0 3 5 6 5 5 2 2 0 1 0 0 0 22 7 29
– of which inhalants 0 1 1 1 2 4 0 0 0 1 0 0 0 8 2 10
– of which pervitin 0 2 4 5 3 1 2 2 0 0 0 0 0 14 5 19
– of which cocaine 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
– of which dance drugs 
 (e.g. MDMA) 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
– of which 
hallucinogens  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Psychotropic 
medicaments 1 4 6 10 20 16 25 21 28 22 9 32 0 102 92 194
– of which 
benzodiazepines 0 2 2 6 6 6 13 10 11 7 4 10 0 42 35 77
Unspecified/unknown 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Total excluding pills 0 3 6 12 6 12 2 2 0 1 0 0 0 36 8 44
Total 1 7 12 22 26 28 27 23 28 23 9 32 0 138 100 238
Figure 6-7: Fatal overdoses on selected drugs in 2001-2008 (Národní monitorovací středisko pro drogy a drogové 
závislosti and SSLST ČLS JEP, 2009) 
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Benzodiazepines 66 50 91 94 56 50 58 77
Inhalants 15 14 22 20 18 14 14 10
Opiates/opioids 56 21 21 19 24 10 14 15
Amphetamines (pervitin) 5 8 9 16 14 12 11 19
Cocaine 0 0 0 1 1 1 1 0
MDMA 0 0 1 0 2 0 0 0
Hallucinogens 0 0 0 0 0 0 0 0
Cannabis 0 0 0 0 0 0 0 0
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6.3.2 Deaths with the Presence of Drugs 
Altogether, 209 deaths with the presence of a drug were identified in 2008 (against 163 in 2007), of which eight 
cases involved an illness (one in 2007), 89 cases involved accidents (74 in 2007), 108 involved suicides (80 in 
2007), and four were cases of manslaughter or murder (six in 2006). A summary of the numbers and proportions of 
selected groups of drugs in the individual groups of deaths with the presence of drugs is given in Table 6-12, and the 
trend since 2004 is shown in Figure 6-8. In particular, the number of indirect drug-related deaths involving the 
detection of pervitin and THC is increasing in the long term (Národní monitorovací středisko pro drogy a drogové 
závislosti and SSLST ČLS JEP, 2009). 
As regards opiates, three cases involved heroin (one accident and two suicides), each time in combination with 
pervitin and in one case also with methadone. Substitution opioids were identified in five cases (two cases involved 
illness and three accidents) in various combinations (buprenorphine + methadone, methadone + morphine, 
buprenorphine + a metabolite of THC, buprenorphine + methadone + psilocybin, methadone + heroin + pervitin). 
Buprenorphine was identified in the special register of drug-related deaths for the very first time. 
Table 6-12: Deaths with the presence of drugs detected by forensic medicine departments in the Czech Republic in 2008 
by selected groups of drugs and causes of death (Národní monitorovací středisko pro drogy a drogové závislosti and 
SSLST ČLS JEP, 2009) 
Drug Illness(n = 8)
Accident 
(n = 89) 
Suicide 
 (n = 108)
Manslaughter/ 
murder (n = 4) 
Other 
(n = 0)
Total 
(n = 209) 
Proportion 
(%) 
Benzodiazepines 1 27 50 1 0 79 37.8 
Pervitin 2 24 21 2 0 49 23.4 
THC 1 19 15 2 0 37 17.7 
Opiates/opioids 2 4 6 0 0 12 5.7 
MDMA 0 0 0 0 0 0 0.0 
Inhalants 0 1 0 0 0 1 0.5 
Cocaine 0 0 0 0 0 0 0.0 
 
Figure 6-8: Deaths with the presence of selected drugs detected by forensic medicine departments in the Czech 
Republic, 2004-2008 (Národní monitorovací středisko pro drogy a drogové závislosti and SSLST ČLS JEP, 2009) 
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Pervitin 19 32 42 32 49
THC 10 18 18 25 37
Opiates/opioids 14 1 9 7 12
Inhalants 6 14 2 1 1
MDMA 3 3 1 2 0
Cocaine 1 0 1 1 0
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For information on the detection of drugs in the corpses of road accident victims see the chapter on Other Drug-
related Health Correlates and Consequences (p. 59). 
6.3.3 Mortality of Drug Users 
The results of a retrospective cohort study of the mortality of drug users in the Czech Republic in 1997-2002 
(Lejčková and Mravčík, 2005) were published in detail in the 2004 Annual Report. 
In 2008, a retrospective cohort study of the mortality of drug users in the Czech Republic was conducted as a follow 
up to the aforementioned study, on a combined cohort of people hospitalised for conditions related to drug use in the 
period 1997-2007 (primary or secondary diagnosis F11-F19 according to ICD-10) and persons in opiate substitution 
treatment in 2000-2007. The study evaluated overall mortality and its trends, structure, and population fractions of 
mortality attributable to drug use (Drug-Attributable Fraction, DAF). The preliminary results are available and are 
provided below (Zábranský et al.  2009). 
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An analysis was carried out on a subgroup comprising opiate users (dg. F11 in hospitalisation or participation in 
opiate substitution treatment), stimulants (dg. F15), and polydrug users (dg. F19 or a combination of diagnoses in 
repeated hospitalisations with the condition of dg. F11 or F15 in previous hospitalisations). This subgroup included 
15,799 subjects in total (of whom 10,581 were men), of whom 517 (of which number 420 were men), i.e. 3.3%, had 
died by the end of the period in question (as of 31 December 2007). In total, 92,390 man-days of monitoring were 
recorded. Overall mortality reached 5.6 (95% CI: 5.1-6.1) cases per 1,000 persons and year (6.8 in men; 3.2 in 
women; 6.5 in opiate users; 5.0 in users of stimulants). In contrast with a comparable cohort in the general 
population, mortality is approximately five times higher and the results show that drug use accounted for 
approximately 81% of the deaths in the group of problem drug users. The estimated number of problem drug users 
who died in the Czech Republic in the period under consideration was approximately 174 (95% CI: 160-190) and 
141 of these can be attributed to drug use (95% CI: 127-160), i.e. 81%. As regards the structure of the deaths 
attributable to drugs, 82% were due to external causes (17% involved intoxication, 26% accidents and/or injuries, 
27% suicide, and 2% assault), 18% were caused by illness (1% HCV, 2% endocarditis, 2% liver disease and liver 
carcinoma, 13% by other causes). Approximately 3% of the mortality (DAF) in the general population aged 15-45 
was attributable to drugs (Zábranský et al.  2009). 
Concurrently with the study mentioned above, another study was undertaken as part of a survey to determine the 
multiplier for estimates of problem drug use; the study focused on the structure of mortality in the clients of low-
threshold facilities in 2007; for details see the chapter on Problem Drug Use, page 28. Low-threshold facilities were 
surveyed as to the numbers and causes of deaths among their clients. The purpose of this part of the study was to 
examine whether a cross-section design can be used to determine the structure of the mortality of drug users and 
potentially to determine a multiplicator for the reported cases of drug overdoses on the basis of this structure. In total, 
92 low-threshold programmes were approached, of which 16 programmes from 9 regions reported at least one 
death among their clients. Overall, 41 deaths were reported, of which 37 were among problem drug users (of whom 
29, i.e. 78%, were men). As regards the structure of mortality, 54% of the deaths were due to external causes (16% 
involved intoxication, 24% accidents and trauma, 14% suicide), 19% were caused by illness (3% viral hepatitis, 8% 
sepsis, 3% liver failure, 5% by other causes), and in 27% of cases the cause of death was not reported. After 
multiplication of the number of drug overdoses reported from the special mortality register (see above), the number 
of deaths among problem drug users in the Czech Republic in 2007 can be estimated at 135-180 in total, which is 
virtually the same estimate as in the aforementioned cohort study (Mravčík et al.  2009). 
The outcomes of the cohort study of the health and social status and mortality of problem drug users who 
participated in the study entitled Young People and Addictive Substances (Zábranský et al.  2008) in 1994 are not 
available as yet; see also the 2007 Annual Report. 
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7 Responses to Health Correlates and Consequences 
The measures targeted at the reduction of drug-related health risks are implemented mainly by low-threshold 
facilities for drug users. Their availability is stable and the number of clients has been increasing in the past three 
years. Approximately 70% of problem drug users are estimated to be in contact with these facilities. A further 
increase in the number of needles and syringes distributed in exchange programmes in 2008 was observed, 
although the year-on-year increase was not as significant as in previous years. On the contrary, the availability of 
testing for infectious diseases can still be described as a weak point. Low-threshold facilities obtained the equipment 
to perform a certified blood serum test for HCV. HIV tests were available in 2008. Specifically, they were the capillary 
blood and saliva tests. However, the saliva tests which were formerly conducted in low-threshold facilities and 
evaluated by the National Institute of Public Health in Prague have not been available since the beginning of 2009. 
The Standard for the Treatment of Viral Hepatitis in Drug Users was published in the December issue of the Journal 
of the Czech Ministry of Health to establish the procedures for the prevention, diagnosis, and treatment of viral 
hepatitis in drug users. In connection with the HAV epidemic, drug users were vaccinated against HAV free of 
charge in co-operation with low-threshold facilities for drug users. 
 
In January 2008, the Government Council for Drug Policy Coordination appointed a working group on Drug Use 
Prevention and Harm Reduction at Dance Parties. The outcome of the group’s work was the Safer Party initiative 
and the implementation of a pilot project called Safer Party Tour 2008, which focused on the prevention and 
reduction of health risks and other consequences of drug use in the nightlife setting, and specifically at music 
festivals drawing large audiences. A number of low-threshold programmes were involved in the project. The project 
was evaluated in late 2008 and continues to run in 2009. 
A survey conducted in 2008 included, among other topics, the use of gelatine capsules in harm reduction, and its 
outcomes were followed up on in 2009 with a questionnaire study, a focus group involving representatives of the 
facilities, and a group interview with the clients of the outreach programmes of the SANANIM civic association in 
Prague. The analysis shows that capsules are currently distributed as harm reduction material by 17 facilities, and 
another 20 facilities are considering capsule distribution as an option. Capsules are a suitable alternative for injecting 
pervitin users, and the client demand for capsules is increasing. 
In May 2008, the PROGRESSIVE civic association launched the NON STOP 24 project concerning vending 
machines for harm reduction medical supplies. The project was suspended by the Prague 5 District Authority in 
October 2008, with the evaluation of the impact of the project on the city district being stated as the reason for the 
suspension. The project had not been resumed by August 2009 despite the fact that the evaluation had showed a 
continuous increase in the number of kits vended and positive feedback from the clients, and found that 
approximately one third of the clients had no contact with any other harm reduction programme, which means that 
the programme managed to address a group of injecting drug users in Prague who had not been previously 
contacted or were difficult to reach. Another harm reduction project running in Prague is the FIX POINT project 
conducted by the PROGRESSIVE civic association and involving the installation of special safe disposal containers 
for used injecting equipment. 
In 2007 and 2008 the Centre for Addictology conducted a two-year research study into the role of pharmacies in 
health care and counselling for (injecting) drug users in the Czech Republic. It was confirmed that pharmacies are a 
potential place for the systematic provision of harm reduction interventions for drug users. 
7.1 Prevention of Drug-Related Emergencies and Reduction of Drug-Related Deaths 
In the Czech Republic, the prevention of overdoses is conducted through drug user counselling and as part of the 
services provided by low-threshold and treatment facilities. For low-threshold programmes see below; treatment is 
discussed in the chapter on Drug-related Treatment: treatment demand and treatment availability, page 32. The 
main educational topics include first aid in the event of an overdose, the risks of polydrug use, and the principles of 
safer drug use. Most low-threshold facilities also provide anonymous counselling in this area via email and 
telephone. The facilities have prepared and have available a number of reference materials42, some of which are 
also in other language versions43. Sdružení Podané ruce, a civic association, has prepared a manual for safer 
(injecting) drug use44 and made it available on the internet. Low-threshold facility staff, and especially outreach 
programme staff, are trained to respond in case of a client overdose. 
                                                          
42 Research concerning the reference materials intended for the clients of low-threshold facilities was conducted in 2008. It evaluated 
the content and form of the information leaflets and brochures focused on the health consequences of drug use and published by the 
individual drug services and other institutions, and subsequently provided recommendations for the preparation of such materials 
(Svobodová, 2009). 
43 Mainly in the Roma and Russian languages. Dozens of Russian-speaking nationals of post-Soviet countries (mainly of Ukraine) can 
be found on the drug scene in Prague. The outreach programme of the SANANIM civic association therefore employs (native) Russian-
speaking streetworkers to approach such clients. Materials in English are also distributed, e.g. as part of the Safer Party Tour initiative; 
for details see the chapter Selective Prevention in At-risk Groups and Settings, page 26. 
44 http://www.extc.cz/  
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The Dekontaminace (Decontamination) magazine published by the SANANIM civic association is one of the sources 
of information for the clients of low-threshold programmes; for more information see the 2006 Annual Report. 
In the early warning system (EWS) for new psychoactive substances, all low-threshold facilities are notified if new 
drugs or dangerous drugs involving higher health and overdose risks are detected in the Czech Republic. For 
example, the facilities were notified in 2009 about the possible penetration of fentanyl45 into the Czech drug market 
and also received information regarding suspicious heroin-related deaths in Prague. 
No other specific activities are being pursued in the Czech Republic with a view to the prevention of overdoses (e.g. 
the preventive distribution of opiate antagonists to drug users or safe application rooms for injecting drug users). 
Information about counselling and other services provided to drug users upon their release from prison is included in 
the chapter on Post-Penitentiary Care, page 91. 
7.2 Prevention and Treatment of Drug-Related Infectious Diseases 
7.2.1 Low-Threshold Harm Reduction Programmes 
Activities in the field of the prevention of infection are among the basic services supplied by low-threshold facilities 
(dissemination of information, distribution of leaflets on the risks of infectious diseases and other health problems, 
education and motivation towards safer drug use and safe sex, exchange programmes for needles and syringes, the 
distribution of condoms, the provision of/referral to testing for infections and other medical care as needed). The 
target population of the low-threshold facilities includes problem drug users, experimenters, and their families and 
friends; some facilities deliver programmes aimed at drug users in the nightlife setting. The type and volume of the 
services vary from one low-threshold programme to another. 
The network of low-threshold facilities comprises low-threshold centres and outreach (streetwork) programmes. In 
2008, there were 100 of them in total; see Map 7-1. Information about the services provided in the low-threshold 
facilities and about the recipients of such services is mainly available from the final reports drawn up by the facilities 
for the purposes of the grant procedures of the Government Council for Drug Policy Coordination46. 
The number of drug users who receive the services of the facilities has been growing in the past three years; the 
ratio of male and female clients has been stable in the long term. However, there has been a noticeable increase in 
the number of problem drug users (injecting drug users, opiate and pervitin users), and a decline in the number of 
cannabis users since 2003. A decrease has also been observed in the number of inhalant users; however, that 
figure is of a lower order compared to the number of other drug users. In the long term, the average age of the users 
increased from 22.0 years in 2002 to 26.1 years in 2007, and reached 25.9 years of age in 2008; see Table 7-1. 
The number of visitors to low-threshold facilities and the volume of services provided have remained stable in the 
past three years; see Table 7-2. A year-on-year increase was again marked in the number of injection kits 
exchanged (see below). 
Similar to the previous year, the low-threshold programmes in Prague, followed by those in the Ústí nad Labem, 
South Moravia, and Olomouc regions, reported the highest numbers of contacts in 2008. The highest number of 
individual exchanges in exchange programmes was reported from Prague (app. 120,000), followed by the Ústí nad 
Labem (app. 31,000), South Moravia (app. 13,000), South Bohemia (app. 11,000), and Central Bohemia (app. 
9,000) regions. A detailed account of the services reported by the low-threshold programmes in 2008 by region is 
provided in Table 7-3. 
                                                          
45 Fentanyl is a high-potency opioid. It was first seized in Slovakia in 2009, which was the immediate reason for notifying the services. 
46 The number of programmes is influenced by the projects submitted by low-threshold facilities for their activities for grant procedures, 
and by the formal differentiation of the individual activities. A low-threshold centre or outreach programme may be both operated and 
conducted by a single entity within a single project and, in other cases or in other years, they can form two or more separate projects. 
Despite these influences, the offer and availability of low-threshold services in the Czech Republic have been stable in recent years. 
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Map 7-1: Low-threshold facilities in the Czech Republic in 2008 (Národní monitorovací středisko pro drogy a drogové 
závislosti, 2009j; Studničková and Petrášová, 2009) 
 
 
Table 7-1: Clients of Czech low-threshold facilities in the years 2002-2008, extrapolated to the total number of 
programmes (Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 2009j) 
Indicator 2002 2003 2004 2005 2006 2007 2008 
Number of low-threshold 
facilities/programmes 92 93 92 92 90 109 100
Number of drug users  n.a. 25,200 24,200 27,800 25,900 27,200 28,300
– injecting drug users 19,000 16,700 16,200 17,900 18,300 20,900 22,300
– pervitin users 12,900 11,300 12,200 12,300 12,100 14,600 14,900
– opiate users 8,000 6,100 6,000 6,800 6,900 7,300 8,300
   – Subutex® users among opiate 
users n.a. n.a. n.a. n.a. 2,900 3,200 3,700
– cannabis users 3,400 5,500 4,100 3,600 2,700 2,000 1,700
– inhalant users  n.a. 705 560 470 450 390 300
Average age of drug user (years) 22.0 23.2 23.4 25.0 25.3 26.1 25.9
Total contacts/visits 290,000 315,000 317,900 403,900 322,900 338,100 329,466
 
Table 7-2: Selected services of low-threshold facilities in the years 2004-2008, extrapolated to the total number of 
programmes (Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 2009j) 
Indicator 2004 2005 2006 2007 2008 
Number of exchanges in exchange 
programmes 139,800 249,000 191,000 215,800 217,200 
Food service 94,700 99,500 97,600 94,100 87,800 
Hygiene service 34,500 40,900 41,100 40,000 34,800 
Individual counselling 27,300 25,800 21,900 24,100 21,000 
Medical attendance 13,500 12,500 10,500 9,400 7,700 
Crisis intervention 3,000 2,500 1,800 1,600 1,100 
Group therapy 1,800 1,500 1,500 1,000 1,100 
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Table 7-3: Selected services provided by low-threshold facilities in the individual regions in 2008, extrapolated to the total 
number of programmes (Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 2009j) 
Region 
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Prague 137,594 347 119,551 16,054 3,489 3,057 2,612 1,382 214 212 
Central 
Bohemia 12,478 653 8,913 5,108 1,481 1,222 2,191 ,225 47 0 
South 
Bohemia 18,973 743 11,156 8,084 2,567 2,363 1,156 165 144 150 
Pilsen 10,636 776 5,324 3,053 1,594 1,925 1,801 472 87 43 
Karlovy Vary 8,055 315 5,069 3,963 2,567 ,342 1,113 3,149 34 67 
Ústí nad 
Labem 44,341 1,595 30,675 10,617 5,157 1,525 1,463 600 181 258 
Liberec 7,975 620 2,789 4,164 2,676 375 973 43 46 19 
Hradec 
Králové 6,102 247 2,955 ,526 425 256 120 54 17 0 
Pardubice 3,392 205 1,147 1,368 960 64 134 59 8 6 
Vysočina 6,561 152 1,303 3,726 1,815 774 707 130 26 0 
South 
Moravia 23,147 856 12,788 6,161 3,330 3,093 724 521 47 117 
Olomouc 20,683 851 5,444 10,521 3,109 3,705 1,018 575 108 23 
Zlín 10,663 435 2,857 3,141 1,568 684 1,497 221 43 82 
Moravia-
Silesia 18,865 325 7,250 11,313 4,094 1,574 328 139 144 109 
Total – 
Czech Rep. 329,466 8,120 217,221 87,799 34,831 20,960 15,838 7,735 1,147 1,086 
NB:* Referrals to a low-threshold centre or a treatment facility, including substitution treatment. 
Data on the clients of low-threshold facilities from other sources are also provided in the chapter on Data on Problem 
Drug Use from Non-treatment Sources, page 30. According to a survey conducted among the clients of all the low-
threshold programmes in Prague in May 2008 (Šejvl, 2008), the greatest proportion of the clients used the exchange 
programme (48%), followed by counselling and interviews (25%), the services of the contact room (12%), medical 
attendance, and the hygiene service (7%). 26% of the clients stated they used the services on a daily or almost-daily 
basis, 33% several times per week, 24% several times per month, 13% less often, and 4% of the clients did not state 
the frequency with which they used the services. As for HIV testing, 51% of the clients stated they had been tested in 
the past 12 months, 31% earlier, and 18% stated they had never been tested. Two thirds (66%) of the clients were 
tested for HIV in a low-threshold centre, 19% upon admission to custody or prison, and 15% upon commencing 
addiction treatment. As far as HCV is concerned, 53% of the clients had been tested in the past 12 months, 33% 
earlier than in the past 12 months, and 14% had never been tested. 53% of the clients were tested for HCV in a low-
threshold centre, 26% upon admission to custody or prison, and 17% upon commencing addiction treatment. 
The low-threshold programmes in Prague co-operated in 2008 in the examination and vaccination efforts undertaken 
as a part of the anti-epidemic measures taken in response to the increased incidence of HAV; for additional 
information see the chapter on Drug-Related Infectious Diseases, page 53. 
7.2.1.1 Needle and Syringe Exchange Programmes 
A needle and syringe exchange component was included in 98 out of 100 low-threshold programmes. A comparison 
of the number of programmes and the number of needles and syringes distributed in the individual years 1998-2008 
is provided in Table 7-4; the number of needles and syringes distributed in the individual regions is shown in  
Table 7-5. According to information obtained from the final reports, each injecting drug user who visited a low-
threshold facility made an average of 9.7 exchanges in 2008 (compared to 10.3 exchanges in 2007) and received a 
total of 208 sterile needles and syringes (214 in 2007). The number of injecting kits distributed in the individual 
regions corresponds with the relative number of injecting (problem) drug users; see Map 7-1 below and Map 4-1 
(page 29). 
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Table 7-4: Exchange programmes in the Czech Republic in 1998-2008 (Mravčík et al.  2008; Národní monitorovací 
středisko pro drogy a drogové závislosti, 2009j; Studničková and Petrášová, 2009) 
Year 
Number of 
exchange 
programmes  
Number of needles 
and syringes 
distributed 
1998 42 486,600 
1999 64 850,285 
2000 80 1,152,334 
2001 77 1,567,059 
2002 88 1,469,224 
2003 87 1,777,957 
2004 86 2,355,536 
2005 88 3,271,624 
2006 93 3,868,880 
2007 107 4,457,008 
2008 98 4,644,314 
 
Table 7-5: Number of needles and syringes distributed in the exchange programmes in 2002-2008, by region (Mravčík et 
al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 2009j; Studničková and Petrášová, 2009) 
Region/year 2002 2003 2004 2005 2006 2007 2008 
Prague 858,507 979,560 1,210,704 1,697,554 1,850,330 2,071,788 2,060,588 
Central Bohemia  12,561 31,682 66,600 110,325 168,220 215,640 309,590 
South Bohemia 14,883 69,004 102,621 124,454 141,825 212,791 228,872 
Pilsen 23,221 44,670 88,450 116,611 157,317 189,894 207,938 
Karlovy Vary 16,608 29,299 35,756 58,680 66,382 83,462 79,834 
Ústí nad Labem 256,071 262,418 351,561 479,383 612,259 655,882 637,887 
Liberec 12,273 21,108 33,467 32,800 47,756 63,967 129,903 
Hradec Králové 22,250 45,089 41,021 86,221 98,269 139,075 173,417 
Pardubice 23,622 23,330 36,081 38,725 48,144 29,908 52,690 
Vysočina 11,254 29,363 39,348 61,425 68,682 99,447 65,343 
South Moravia 134,285 122,137 165,846 173,090 227,833 269,236 264,872 
Olomouc 21,809 33,832 85,872 96,416 150,024 134,433 137,321 
Zlín 19,973 11,362 41,977 52,169 69,005 115,744 89,913 
Moravia-Silesia 41,907 75,103 56,232 143,771 162,834 175,741 206,146 
Total 1,469,224 1,777,957 2,355,536 3,271,624 3,868,880 4,457,008 4,644,314 
Map 7-1: Number of needles and syringes distributed in Czech regions in 2008 per 1,000 inhabitants (Národní 
monitorovací středisko pro drogy a drogové závislosti, 2009j; Studničková and Petrášová, 2009) 
 
Needle and syringe exchange programmes are complemented by the distribution of aluminium foil for smoking 
heroin and the distribution of gelatine capsules intended mainly for pervitin users. 
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7.2.1.2 Distribution of Gelatine Capsules as Harm Reduction Material 
The first information about the gelatine capsule distribution programmes as a service provided with a view to 
reducing injecting drug use is provided in the 2007 Annual Report. An online questionnaire survey was conducted in 
2009 in order to obtain a more detailed picture of capsule distribution. All the low-threshold facilities in the Czech 
Republic were approached. In addition, a focus group with the representatives of the facilities and a group interview 
with the clients of the Outreach Programmes of the SANANIM civic association in Prague were held. 
The online questionnaire was filled in by 52 low-threshold facilities. The questionnaires returned show that capsules 
as harm reduction material are currently distributed by 17 facilities, and another 20 facilities are considering capsule 
distribution as an option. The demand for capsules has been on the rise among drug users. According to the 
members of the focus groups, the primary target group consists of injecting pervitin users with damaged veins 
looking for an alternative to injecting drug use. Other target groups include mainly recreational pervitin users who 
have no injecting experience, and socially stabilised drug users who are afraid of using drugs by injecting under 
certain circumstances (e.g. at work). Opiate users were not specified as a target group, which is probably attributable 
to the lower metabolic availability of opiates from the digestive tract. Damaged veins and the motivation to reduce the 
frequency of injecting use are the main reasons specified for the use of the capsules. In comparison with simple oral 
application, the capsules help eliminate the typical bitter taste of the drug and do not prevent the onset of the effect of 
the drug. The advantage of the capsules is in the ease of preparation and safety of application that they offer. 
Nevertheless, the health risks associated with the oral use of pervitin were also mentioned, in particular those 
connected with damage to the mucous membranes in the gastro-intestinal tract. Capsule distribution appears to be a 
suitable and efficient approach to harm reduction, especially in the group of pervitin and/or amphetamine-type drug 
users. The potential risks and advantages of the use of capsules in harm reduction should be subject to further 
research (Škařupová et al.  2009).  
7.2.1.3 Syringe and Other Harm Reduction Material Vending Machines 
In May 2008, the PROGRESSIVE civic association launched the NON STOP 24 project concerning vending 
machines for harm reduction material. The objective of the project is to increase the availability of harm reduction 
supplies and address a specific group of injecting drug users. The pilot stage of the project commenced with the 
installation of two machines in the Prague 5 District. The vending machines provided non-stop access to clean 
injecting equipment, disinfectants, clean water, etc. One vending machine was provided with a safe disposal 
container for used needles and syringes. The project was suspended by the Prague 5 District Authority in October 
2008, with the evaluation of the impact of the project on the city district being stated as the reason for the 
suspension. The project had not been resumed by August 2009, despite the fact that the evaluation showed a 
continuous increase in the number of kits vended and positive feedback from the clients, and found that 
approximately one third of the clients had no contact with any other harm reduction programme, which means that 
the programme managed to address a group of injecting drug users in Prague who had not been previously 
contacted or were difficult to contact. 
7.2.1.4 Safe Disposal Containers 
Another harm reduction project is the FIX POINT project implemented by the PROGRESSIVE civic association. The 
project concerns the installation of special safe containers for the disposal of used injecting paraphernalia. The 
containers are placed in selected locations with a view to maximising their accessibility for injecting drug users. The 
objective of the FIX POINT project is to improve the opportunity to safely dispose of used injecting equipment in 
places exposed to a high level of injecting drug use. In preparation since 2008, the project was officially launched in 
June 2009. The containers are currently situated at 9 locations across the Prague 5 District (o.s. Progressive, 2009). 
7.2.1.5 Testing for Infectious Diseases 
Some low-threshold facilities conduct saliva HIV tests in co-operation with the National Reference Laboratory for 
AIDS, National Institute of Public Health, in Prague. However, HIV testing from saliva was suspended in late 2008 
because of an interruption to the deliveries of the laboratory materials by the manufacturer. The National Reference 
Laboratory for AIDS is currently making efforts to validate and introduce a new method of testing saliva for HIV 
antibodies. In 2006-2007, there was a persistent problem with the availability of HCV testing in low-threshold 
facilities, mainly as a result of the absence of a quick test for HCV antibodies from whole blood. In June 2008 a range 
of quick tests and the related equipment for HCV antibody tests from capillary blood serum were successfully 
obtained for selected low-threshold facilities, some of which started to conduct the tests during July and August 
2008. Seminars focused on using the tests were held for the staff of the low-threshold facilities in 2008 and 2009.  
The National Focal Point is informed about the extent of testing for infections in low-threshold facilities from the final 
reports concerning projects supported within the framework of the grant procedure of the Government Council for 
Drug Policy Coordination. The test results are available from the monitoring of the tests in low-threshold 
programmes; for detailed information see the chapter on Drug-Related Infectious Diseases, page 53. In 2008, 50 
facilities offered HIV testing, 40 HCV testing, and 18 HBV testing, and three low-threshold facilities offered syphilis 
testing. The number of tests conducted is still very low compared to the pre-2006 figures. Nevertheless, there was a 
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significant year-on-year increase in HIV and HCV tests (Národní monitorovací středisko pro drogy a drogové 
závislosti, 2009j). See Table 7-6.  
Table 7-6: Number of tests for infectious diseases and the number of low-threshold facilities providing tests in 2002-2008 
(Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 2009j) 
HIV  HBV HCV Syphilis Year Tests Facilities Tests Facilities Tests Facilities Tests Facilities 
2002 1,158 35 515 26 1,202 33 176 2 
2003 2,629 64 739 21 2,499 60 209 4 
2004 2,178 58 932 25 2,582 53 84 1 
2005 2,425 54 1,370 28 2,664 55 54 2 
2006 1,253 46 693 56 1,133 62 209 3 
2007 609 53 370 19 401 24 62 4 
2008 1,120 50 399 18 862 40 124 3 
 
In the past, a number of low-threshold and other providers of services to drug users co-operated with public health 
protection authorities in the field of prevention and testing for infections. Such authorities included regional public 
health offices or health institutes and, especially, the HIV counselling services of the health institutes. The monitoring 
of the tests for infectious diseases in low-threshold facilities in 2008 showed that only 4 out of 14 health institutes 
systematically co-operated with the drug services in the tests; to be specific, they were the health institutes in České 
Budějovice, Pilsen, Ústí nad Labem, and Pardubice (Národní monitorovací středisko pro drogy a drogové závislosti, 
2009i). 
7.2.1.6 Programmes Aimed at Drug Use in Nightlife Settings 
The 2008 final reports of the total of 6 outreach programmes (Drop-In Prague, the CPPT Pilsen outreach 
programme, the Dance8 outreach programme of CPPT Pilsen, the Olomouc outreach programme of Sdružení 
Podané ruce, the Jihočeský sreetwork programme of the Prevent České Budějovice civic association, and the 
outreach programme of the Kappa-Help Přerov civic association) specified harm reduction activities among drug 
users in dance party settings (Národní monitorovací středisko pro drogy a drogové závislosti, 2009j). The 
programmes reached a total of 1,839 clients, and 132 qualitative screening tests for synthetic drugs were performed. 
In comparison with 2007, this was the first year-on-year increase after a period of a decline in services provided in 
nightlife settings following 2004, when funding restrictions regarding the programmes significantly curbed these 
activities (in 2003 there were 18 active programmes in this area, reaching almost 5,000 clients); for additional 
information see the 2006 and 2007 annual reports and the issue of the “Zaostřeno na drogy” bulletin dedicated to 
this topic (Mravčík et al.  2008). 
2008 saw a revival of services focusing on the nightlife settings: the “Drug Use Prevention and Harm Reduction at 
Dance Parties” working group was established by the Government Council for Drug Policy Coordination, and the 
Safer Party project was launched (for additional information on the project see the chapter on Selective Prevention 
(page 26). Among other aspects, the project included the evaluation of the environment at the event with regard to 
factors with a potential impact on the visitors’ health and safety. The common negative factors included the absence 
of return transport from the festival, the mandatory disposal of non-alcoholic beverages prior to entry (even where the 
festival area offered no free drinking water), and the poor hygienic standard of the sanitary facilities. On the contrary, 
the positives included the presence of emergency medical services at all festivals and, for the most part, easy 
orientation around the festival area (Národní monitorovací středisko pro drogy a drogové závislosti, 2008a). 
7.2.2 Distribution of Needles and Syringes in Pharmacies 
In 2007 and 2008 the Centre for Addictology conducted a two-year research study into the role of pharmacies in 
health care and counselling for (injecting) drug users in the Czech Republic (see also the 2007 Annual Report). The 
study consisted of a quantitative and a qualitative part. In the quantitative part, 310 out of the 373 pharmacies 
contacted participated in a questionnaire survey (response rate of 83.1%), while the qualitative part consisted of a 
semi-structured in-depth interview with representatives of 40 out of the 58 pharmacies addressed. According to the 
questionnaire survey, drug users (or clients considered by the pharmacy staff as drug users) visit most of the 
respondent pharmacies (87.7%), with the estimated ratio of men and women being 2.5:1 and the 20-30 age 
category being the one most represented (54%). Almost one third (31%) of the pharmacies do not sell needles and 
syringes, and 24.6% of the pharmacies will not sell them to a drug user. The price of one kit consisting of a needle 
and syringe (intended for insulin application) does not exceed CZK 10.00 (€ 0,4). Only 38% of the pharmacies 
included in the sample collect used needles and syringes. 41.6% of the pharmacists in the group are in favour of 
more intensive forms of work with drug users in pharmacies. Only 17.1% of the pharmacies in the group work with 
low-threshold services in their region. Only 3.2% of the pharmacies offer printed materials on the prevention of 
infectious diseases (Gabrhelík et al.  2008a; Gabrhelík et al.  2008b). 
The qualitative study suggested that the pharmacy staff almost exclusively considered a drug user to be an injecting 
pervitin or opiate user. The most important distinctive way to identify a drug user was the goods requested (injection 
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supplies and medicinal products containing pseudoephedrine), followed by the person’s behaviour (with the typical 
signs including nervousness, agitation, and eagerness to close the transaction quickly) and other signs of drug use 
(neglected appearance, needle marks, and skin rash). The typical contact was no different from ordinary contact with 
any other customer. Despite problems with drug users being rare, pharmacists are afraid of losing non-user 
customers. Most pharmacies have no restrictions on the sale of needles and syringes and sell them to users in the 
quantities requested. Some pharmacies only sell multiple injecting kits. The drug-using customers often ask for 
larger quantities of preparations containing pseudoephedrine, in response to which the pharmacy staff apply various 
strategies to prevent the dispensation of larger quantities of such medicinal products. In turn, drug users use different 
strategies to gather the highest quantity of such preparations possible (multiple sources, multiple shoppers, shopping 
with multiple pharmacists in a single pharmacy)47. Conflicts, which were only rarely encountered in interacting with 
drug-using customers, mostly involved verbal aggression after the drug user’s request was declined. Physical 
aggression only occurs as an exception (about a quarter of the pharmacies reported experience with a physically 
aggressive client), while theft is more common and was described by the staff of nearly one half of the pharmacies, 
most usually in the form of the customer running away without payment). Issues seen by the pharmacists as 
problematic included the sale of medicines containing pseudoephedrine, the abuse of prescription substitution 
products, and dependency on prescription drugs (Vacek et al.  2008; Gabrhelík et al.  2008b). 
Proposals and recommendations were published in 2009 as part of the above-mentioned project in order to support 
the implementation of other services for injecting drug users in Czech pharmacies. Specifically, they included the 
potential involvement of the pharmacists in the prevention of drug use in terms of public health. In addition, the target 
groups for addictological interventions in pharmacies were identified, the potential of pharmacies in collecting drug 
user data was emphasised, etc. (Gabrhelík et al.  2008b; Gabrhelík and Miovský, 2009). 
Approximately 1.5 million injecting kits a year are sold to drug users in pharmacies; for additional information see the 
2007 Annual Report. 
7.2.3 Treatment of Drug-Related Infections 
There are 7 AIDS treatment centres in the Czech Republic, of which the AIDS Centre of the Na Bulovce University 
Hospital covers the area of Prague and the region of Central Bohemia and is the methodology and management 
centre for the other facilities. It is the only centre in the Czech Republic to provide obstetric care for HIV-positive 
mothers and paediatric care for newborn babies exposed to HIV. The treatment procedures include HAART (highly 
active antiretroviral therapy), which is also provided to indicated HIV-positive drug users. The treatment is funded 
partially from the health insurance budget and partially from government subsidies. 
The Standard for the Treatment of Viral Hepatitis in Drug Users was published in the December issue of the Journal 
of the Czech Ministry of Health (Issue 7/2008, ref. no. 28629/2008) to establish the procedures for the prevention, 
diagnosis, and treatment of viral hepatitis in drug users. Among other provisions, it specifies that, within the 
framework of the preventive measures, drug users should be included in the injecting equipment exchange 
programme and vaccinated against HAV and HBV. The standard emphasises that the therapeutic procedure for viral 
hepatitis C in addicted patients, including those with an active addiction to drugs and patients undergoing substitution 
therapy (i.e. stabilised patients), is identical to the recommended procedure for non-addicted patients but that the 
fundamental precondition for the commencement of the therapy is the patients‘ motivation and co-operation. The 
standard points out the need for a multidisciplinary approach to the patients. The treatment follows the 
recommended procedures of the Czech Hepatological Society and of the Society for Infectious Medicine of the 
Czech Medical Association of J.E. Purkyně48. 
The Czech Republic currently has 63 centres providing the treatment of chronic viral hepatitis and certified by the 
Czech Hepatological Society and the Society for Infectious Medicine. The centres operate in all the regions, thus 
ensuring a high level of treatment availability. Virtually all the certified centres treat patients with a history of drug use, 
patients actively using drugs with lower health and social risks, and co-operating and motivated patients undergoing 
substitution therapy. Active problem users of illicit drugs, especially of pervitin, remain an issue, as there is no 
substitution available for them, and there is usually a low level of stabilisation, co-operation, and motivation for 
treatment on the part of such patients. Another problem is the payment for the antivirals used in the therapy from the 
public health insurance budget49 (Urbánek et al.  2009).  
The Motol University Hospital in Prague operates a specialised centre for the treatment and prevention of infection-
related complications in drug users50. The network of services for drug users in Prague also includes an internal 
                                                          
47 The study was conducted prior to the restriction on the supply of medicines containing pseudoephedrine, which has been in effect 
since 1 May 2009; for additional information see the chapter on the Legal Framework, page 5. 
48 See also http://www.infekce.cz/ and http://www.ceska-hepatologie.cz/.  
49 Virostatic treatment is currently covered from fees whose amount is determined on the basis of prior reference periods, thus 
potentially failing to consider the current needs. The professional societies of the JEP Czech Medical Associations request that 
treatment be covered from health insurance on an individual basis in specific clients. 
50 See http://www.fnmotol.cz/infekce/.  
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medicine outpatient centre and the Remedis51 counselling centre for hepatic diseases, which specialises in the 
treatment of somatic diseases of drug users. 
Also employed in the Czech Republic are websites and free helplines aimed at counselling in the area of infections. 
For additional information see the 2007 Annual Report. 
7.3 Responses to Other Health Correlates Among Drug Users 
The treatment of drug users with dual diagnoses is carried out in an integrated manner, i.e. within the existing 
treatment system for drug users, and the specific needs of the patients are taken into consideration; see the chapter 
on Drug-related Treatment: treatment demand and treatment availability, page 32.  
Other somatic disorders of drug users in the Czech Republic are treated using the public medical and preventive 
care system. The potential problems on the part of the clients include unclear medical health insurance status (e.g. 
following the loss of their insurance card or, in the case of health insurance payments, that these are owed) or, in 
some cases, the total absence of health insurance (as regards foreigners, for example). 
                                                          
51 See http://www.remedis.cz/.  
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8 Social Correlates and Social Reintegration 
Social problems mainly accumulate among drug users who are members of ethnic minorities, among immigrants (in 
the Czech Republic, this mainly applies to Roma and people of Vietnamese descent and to users from the post-
Soviet states) and older drug users. 
Homelessness is likely to be associated with the use of mainly legal drugs (alcohol, tobacco). Nevertheless, the 
frequency of contact between illicit drug users among the homeless and the relevant institutions is lower. For that 
reason, their use of illicit drugs may be underestimated. 
It appears that the prevalence of drug use among Roma in the Czech Republic has been stable in recent years, 
involving mainly legal drugs such as alcohol and tobacco, with marijuana and pervitin representing the most 
widespread illicit drugs. The available data indicate a declining trend in the use of toluene among Roma. 
No major change in the number of aftercare facilities occurred in 2008. However, there was a significant increase in 
their capacity (which doubled in the case of sheltered housing, for example) and in the number of clients. 
A Narcotics Anonymous-type of self-help group was set up in Brno in May 2009, representing a unique initiative in 
the Czech Republic after a long period of time. 
8.1 Social Exclusion and Drug Use 
8.1.1 Social Exclusion among Drug Users 
The most significant social problems of drug users include family and work problems, unemployment, lower 
education, and poor housing, which sometimes even lead to homelessness. The specified problems mainly 
accumulate among drug users who are members of ethnic minorities and immigrants, as well as among older drug 
users, who show higher homelessness and unemployment figures (for more information see the chapter on 
Treatment and Care for Older Drug Users, page 115 . 
For information on the nature of housing and on the education and unemployment levels of the treatment demands 
seeDrug-related Treatment: treatment demand and treatment availability, page 32. 
In a survey conducted among 783 clients of Prague’s low-threshold programmes in May 2008 (Šejvl, 2008); see also 
the chapter on Data on Problem Drug Use from Non-treatment Sources, page 30 – 674 clients (86.1%) stated they 
were Czech, 59 (7.3%) were Roma, and 29 (3.7%) were Slovak. Clients from Ukraine (6 persons), Russia (4), and 
Georgia (4) and 5 clients from other countries were also represented in the sample. As for employment and source 
of income, 145 clients (20.1%) had a steady job with a proper employment contract, 93 (11.9%) had occasional legal 
work, 185 (18.5%) had occasional undeclared work, 140 (17.9%) were on welfare, and 182 (23.2%) reported having 
another source of income. These other sources of income included, in the first place, theft (42 persons), dealing 
drugs (8) and other criminal activities (8), prostitution (14), and begging (15), as well as support from the client’s 
parents, disability benefits, collecting scrap metal, and street performance. In terms of housing, 498 persons (63.6%) 
lived in a housing unit equipped with sanitary facilities (their own or a rented flat, living with parents or a partner), 165 
(21.1%) lived without sanitary facilities available (squat, cottage), and 120 (15.3%) were shelterless. 
The qualitative study into the new trends on the drug scene (for more information see the chapter on Data on 
Problem Drug Use from Non-treatment Sources, page 30) analysed responses from the staff of low-threshold 
programmes in the Czech Republic regarding their experience with clients who were members of ethnic minorities 
(Radimecký et al.  2009). The reported experience was mainly with Roma clients, who even represented the majority 
of the clients of the relevant programmes in certain areas (Pilsen, Ústí nad Labem, Brno, Ostrava, Uherský Brod, 
Teplice, Pečky). Other groups included clients from the post-Soviet states, Vietnamese, and Slovaks. The Roma 
clients are characterised by strong family bonds; whole families become clients, services are provided to family 
members with a different age profile, and drug procurement and use is under the strong influence of family rules. The 
Roma in certain areas participate in the trafficking of drugs, especially heroin, which is typically used by Roma. Some 
of the Roma clients consider pervitin a low-risk drug. The Russian-speaking clients are mainly concentrated in large 
cities (Prague, Brno) and only rarely appear elsewhere. They form a very tight group with little contact with the 
domestic drug scene. Both the language barrier and the clients’ fear of losing their anonymity hinder the contacts of 
outreach staff with these clients. The use of pervitin and Subutex® and a near-100% representation of men are 
typical of this group. According to the workers of low-threshold programmes, the current problems on the labour 
market in connection with the global economic crisis may result in an influx of unemployed migrant clients to the drug 
services. Vietnamese clients are the most difficult to access for the outreach workers. Because of its entirely different 
language and cultural background, this community is hard to contact. In some regions, people of Vietnamese 
descent are involved in drug production and trafficking (cannabis growing and marijuana sales, heroin sales). Some 
programmes also include clients from Slovakia – mainly blue-collar workers in the Czech Republic. 
For qualitative research into problem drug use among migrants in and around Brno, see the 2007 Annual Report. 
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8.1.2 Drug Use among Socially Excluded Groups 
8.1.2.1 The Homeless 
There is a close connection between addiction and/or mental disorders on the one hand and homelessness on the 
other hand; it is, however, often difficult to determine whether the addiction and/or a mental disorder is the cause or 
the consequence of the social status of the homeless. Combined with social and economic difficulties, a mental 
disorder may trigger homelessness, but, on the other hand, homelessness may result in mental problems, 
depression, and substance abuse (Šupková, 2008).  
The Institute for Criminology and Social Prevention conducted a study aimed at homelessness and the homeless in 
2006 (Štěchová et al.  2008). The research was conducted in 6 sheltered living homes in Prague (Salvation Army, 
Emauzy, Charita, Městské centrum, Naděje, and Dům Agapé). The social worker filled in an answer sheet about 
each client staying in the facility for over 14 days (or long enough to answer the questions regarding their behaviour 
in the sheltered living home). 157 answer sheets were completed. It was found that the clients of the shelters most 
typically smoked cigarettes and/or drank alcohol. Illicit drug use was not found. The explanation given by the authors 
of the study was that homeless illicit drug users have difficulty finding accommodation in the facilities and are 
therefore not their clients. 
8.1.2.2 Roma Communities 
In the Czech Republic, social exclusion also concerns certain Roma communities, where it is the product of the 
accumulation of social problems. The primary factors of the social exclusion of Roma include long-term 
unemployment, low incomes, and either the unavailability or poor quality of housing (Kancelář Rady vlády pro 
záležitosti romské komunity, 2007).  
Long-term monitoring and evaluation of the situation in Roma communities is provided by the Office of the 
Government Council for Roma Community Affairs as part of the Field Social Workers Support Programme. 
Altogether, 46 municipalities with 86 outreach workers were involved in the programme in 2008 (Kancelář Rady 
vlády pro záležitosti romské komunity, 2009). 
Field social workers supplied services to 13,144 clients in 2008 and made 59,687 contacts. Individual work (48%) 
and work with families (29%) were the most common approaches. The topics addressed most often included debt, 
housing, and unemployment. Drug use-related interventions were provided to 3% of the clients; see Table 8-1. The 
number and percentage of problems related to illicit drug use and gambling has been stable and relatively low in the 
long term (Kancelář Rady vlády pro záležitosti romské komunity, 2009). 
Table 8-1: Number of clients provided with the services of Roma field social workers in 2006-2008, by problem type 
(Kancelář Rady vlády pro záležitosti romské komunity, 2007; Kancelář Rady vlády pro záležitosti romské komunity, 2008; 
Kancelář Rady vlády pro záležitosti romské komunity, 2009) 
2006 2007 2008 Problem type Number % Number % Number % 
Debt 4,477 34.1 5,314 31.9 3,779 28.7 
Unemployment 2,672 20.4 2,916 17.5 2,598 19.8 
Housing quality 3,362 25.6 3,364 20.2 2,432 18.5 
Problematic tenant/landlord 
relations 1,847 14.1 1,522 9.1 1,285 9.8 
Insufficient sanitation 1,300 9.9 1,204 7.2 1,282 9.7 
Truancy 907 6.9 716 4.3 1,000 7.6 
Usury 277 2.1 320 1.9 696 5.3 
Crime 620 4.7 574 3.4 636 4.8 
Drug use 457 3.5 391 2.3 344 2.6 
Gambling 268 2.0 302 1.8 323 2.5 
Prostitution 63 0.5 39 0.2 51 0.4 
Total* 13,116 100.0 16,662 100.0 13,144 100.0 
NB: * The aggregate number of clients classified by problem type exceeds the total number of clients because of the accumulation of 
problems in individual clients. 
In 2007, the government established the Agency for the Elimination of Social Exclusion in Roma Localities. The 
Agency’s main objective is the transformation of Roma ghettos, with a view to an improvement in the quality of life in 
such problematic areas; for details see the 2007 Annual Report. In 2008, the Agency participated in the Long-term 
Monitoring of Roma Community Status – Locations in Moravia project (Kašparová et al.  2008). As a part of the 
project, ethnographic and anthropological research was conducted in the regions of Brno, Břeclav, Holešov, Jeseník, 
Přerov, and Silesian Ostrava in order to identify the context and dynamics of the social exclusion mechanisms. 
Among other factors, the research also focused on the health condition of the inhabitants of socially excluded 
communities, including drug use. All the sites reported tobacco and alcohol use and gambling. The most typical drug 
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in the past was toluene, whereas now pervitin users prevail. In addition, the use of cannabis (Břeclav, Holešov, 
Přerov), dance drugs (Břeclav), and opium (Holešov) was reported.  
The Agency also participated in the project of the World Bank and the Government Council for Roma Community 
Affairs named "Czech Republic: Improving the Employment Chances of the Roma”, and in the Roma Population and 
Health research conducted under the SASTIPEN project. The projects seek to describe the health and social status 
of Roma and their access to social and health resources. 
In the course of 2008 the staff of the Agency prepared a number of case studies concerning housing in locations 
inhabited predominantly by Roma in Brno, Kladno, Ostrava, Pardubice, and Prague. A situation analysis of the 
socially excluded areas in Litvínov was also prepared, focusing particularly on the Janov housing estate. Three areas 
were identified in Litvínov whose geographical location, social segregation, (un)availability of services, and the nature 
of the settlement, or a combination of these factors, corresponded with the characteristics of social exclusion. Next to 
marijuana, which is used by children from as early as 13 years of age, pervitin was the most commonly used illicit 
drug in those areas. Other drugs used include illegally procured Subutex®, magic mushrooms, and cocaine; the use 
of heroin is almost non-existent. As in other socially excluded communities in the Czech Republic, tobacco and 
alcohol use and gambling are widespread in those areas (Agentura pro sociální začleňování v romských lokalitách, 
2009). 
8.2 Social Reintegration 
Aftercare for drug users and their social inclusion in the Czech Republic are provided through outpatient aftercare 
programmes and structured intensive outpatient programmes, which may include sheltered housing programmes 
and sheltered work programmes (sheltered workshops, sheltered employment, supported employment). Their target 
population consists of abstaining people with a history of substance addiction and a recommended minimum 
abstinence period of three months. 
Aftercare was provided by 18 facilities using 27 programmes subsidised by the Government Council for Drug Policy 
Coordination in 2008; see Map 8-1. A total of 13 facilities offered sheltered housing and four also provided sheltered 
employment. 
Map 8-1: Aftercare facilities in the Czech Republic in 2008 (Národní monitorovací středisko pro drogy a drogové 
závislosti, 2009j) 
 
 
A total of 1,041 clients (65% of them male) used the aftercare services; 725 (70%) of them used to inject drugs 
before they entered treatment; 576 (55.3%) used to use pervitin and 176 (16.9%) heroin. The total capacity of the 
facilities offering sheltered housing was 126 places, and 25 clients worked in sheltered workshops (Národní 
monitorovací středisko pro drogy a drogové závislosti, 2009j); the comparison for 2005-2008 is provided by Table 
8-2. 
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Table 8-2: Aftercare programmes subsidised by the Government Council for Drug Policy Coordination in the period 2005-
2008 (Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 2009j) 
Indicator 2005 2006 2007 2008 
Number of facilities 20 18 18 18
Number of aftercare clients 865 904 883 1,041
Sheltered housing places 118 126 126 283
Number of clients in sheltered housing  244 235 261 298
Number of clients in sheltered workshops 59 40 44 25
 
Outpatient aftercare was offered by 12 facilities, whose services were used by 487 clients (335 of whom were men), 
which represents a marked increase compared to 2007. The average age of the clients has been rising in the long 
term and reached 30.3 years in 2008. A total of 306 clients (62.8%) had been injecting drug users prior to the 
treatment; 259 (53.2%) had used pervitin and 71 (14.6%) heroin or Subutex® (Národní monitorovací středisko pro 
drogy a drogové závislosti, 2009j). The comparison for the period 2003-2008 is provided in Table 8-3.  
Table 8-3: Outpatient aftercare programmes subsidised by the Government Council for Drug Policy Coordination, and 
their clients in the period 2003-2008 (Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 
2009j) 
Indicator 2003 2004 2005 2006 2007 2008 
Number of facilities 8 14 13 10 12 12
Number of clients 460 444 336 380 389 487
– injecting drug users 320 307 218 230 236 306
– pervitin users 210 187 182 216 209 259
– opiate users  120 115 58 78 69 71
Average age of clients 26.0 26.6 27.4 26.4 29.3 30.3
 
Fifteen facilities provided intensive aftercare (within a long-term structured programme, typically involving sheltered 
housing and employment); their total capacity of 283 beds was used by 554 clients (342 of whom were men). The 
average age of the clients was 28.7 years. A total of 422 clients (76.2%) had been injecting drug users prior to the 
treatment; 317 (57.2%) had used pervitin and 105 (18.9%) opiates (heroin or Subutex®). The average length of the 
programme per client was six months. 164 clients (29.6%) completed the programme, 121 (21.8%) dropped out, and 
61 (11%) were expelled (Národní monitorovací středisko pro drogy a drogové závislosti, 2009j); see Table 8-4. 
Table 8-4: Intensive aftercare programmes subsidised by the Government Council for Drug Policy Coordination, and their 
clients in the period 2003-2008 (Mravčík et al.  2008; Národní monitorovací středisko pro drogy a drogové závislosti, 
2009j) 
Indicator 2003 2004 2005 2006 2007 2008 
Number of facilities 14 14 15 16 15 15 
Capacity 321 342 385 365 325 283 
Number of clients 585 562 526 524 494 554 
– injecting drug users 463 404 399 364 360 422 
– pervitin users 245 260 276 304 284 317 
– opiate users  224 184 143 105 104 105 
Average age of clients 24.5 27.0 26.4 27.1 26.6 28.7 
 
In addition to the facilities specified above, aftercare services may be provided to drug users by other inpatient or 
outpatient facilities. Their use by drug users, however, is difficult to determine. Alcoholics Anonymous (AA) groups 
operate on a self-help basis. There are currently 36 AA groups in 25 towns and cities in the Czech Republic 
(Anonymní alkoholici - Česká republika, 2009). A Narcotics Anonymous (NA) group named “Fatima” started to 
operate in Brno in May 2009. According to available data, there is no other self-help group which focuses on non-
alcohol drugs in the Czech Republic. 
Four work and social agencies (run by the SANANIM civic association in Prague, the Christian Help Centre in Pilsen, 
the White Light I. civic association in Ústí nad Labem, and the PASÁŽ agency of Sdružení Podané ruce in Brno) 
focused on improving the situation of former drug users through assistance on the labour market in 2008. The clients 
of these agencies can make use of a wide portfolio of services, ranging from the provision of resources for working 
individually (e.g. internet access) to direct intermediation of employment. The Restart project of the Prev-Centrum 
civic association was launched in 2009 with a view to placing the clients of the substitution programme on the labour 
market. 
The Ministry of Labour and Social Affairs pursues a social protection and social inclusion policy, which specifies drug 
users as one of the target groups. The National Action Plan on Social Inclusion 2008-2010 currently applies. The 
National Report on Strategies for Social Protection and Social Inclusion 2008-2010 mentions drug addiction as a 
negative factor in the effort to reinforce social skills with a view to increasing employment and employability, and also 
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refers to the issue of drug addiction in the section dealing with projects in Roma communities (Ministerstvo práce a 
sociálních věcí ČR, 2008).  
The Ministry of Labour and Social Affairs also operates several databases that can help drug users or helping 
professionals obtain information about the social assistance available. The databases also provide statistical 
information about social services: 
 Information portal and database of social prevention services for persons facing social exclusion. As of the end of 
August 2009, the database included 113 out of 495 facilities (22.8%) for persons addicted to drugs; drug users 
were also the second-largest primary target group monitored in the database of social prevention services for 
people facing social exclusion52.  
 The Register of Social Service Providers in the Czech Republic – the register enables services to be sought 
according to the target group; as of late 2009, it included a total of 418 services for “persons facing or with a 
history of substance addiction“53.  
 Integrated portal of the Ministry of Labour and Social Affairs, which summarises all the information related to 
social issues and employment services54. 
                                                          
52 See https://www.sluzbyprevence.mpsv.cz/. 
53 See http://iregistr.mpsv.cz/.  
54 See http://portal.mpsv.cz/.  
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9 Drug-related Crime, Prevention of Drug-related Crime, and Prison 
The number of persons arrested, prosecuted, charged, and sentenced for drug-related offences has been stable in 
the Czech Republic in recent years. 70-80% of such individuals are arrested, prosecuted, charged, and sentenced 
for violating Section 187 (illicit drug production and trafficking) of the Penal Code, most often in connection with 
pervitin. 2,296-2,322 individuals were arrested or prosecuted for drug-related offences. The percentage of persons 
arrested or prosecuted for the possession of drugs for personal use according to Section 187a of the Penal Code, 
most typically in connection with cannabis and pervitin, remained stable (approximately 12%). The largest numbers 
of people prosecuted for drug-related offences were reported from the Ústí nad Labem region, both in absolute and 
in relative terms per 100,000 inhabitants. 2,100 persons were charged and 1,360 persons were sentenced. The 
number and composition of the sentences for drug-related offences has been stable in recent years; 450 
unsuspended and 688 suspended sentences were imposed in 2008. Institutional or outpatient compulsory 
(protective) treatment was imposed by the courts upon 162 persons; 91 of the cases involved the outpatient form 
and 71 the institutional form of treatment. 
According to expert estimates, drug users account for 29% of the property crimes and violent crime (mostly involving 
various types of theft) that were investigated, which represents approx. 110,000 offences detected, mostly those 
against property, in a period of 1.5 years. 
There were 35 prisons in the Czech Republic in 2008. In recent years, the daily headcount of prisoners in the Czech 
Republic has been around 19,000. However, an increase to 20,502 persons was reported at the end of 2008. A total 
of 9,390 inmates with a substance addiction, including individuals addicted to non-alcohol drugs, were reported in the 
prisons in 2008. Over 9,000 drug tests were performed in prisons, 13% of which returned a positive result, most 
frequently for pervitin. A total of 205 drug seizures, mostly involving cannabis, were reported in the prisons. 
The Drug Policy Action Plan of the Prison Service of the Czech Republic for the Period 2007-2009 is the main 
document governing the approach to drug users in prisons. Drug prevention counselling centres operated in all the 
prisons, and their services were used by 6,892 persons. Detoxification was carried out in the outpatient or inpatient 
form in four prisons and was used by 208 individuals. Thirty-three prisons have drug-free zones available, in which 
3,646 inmates served their sentences. Two types of dedicated departments aimed at drug users were made 
available to prisoners: voluntary treatment departments were operated in six prisons and three prisons had 
dedicated departments for court-ordered institutional treatment. Substitution therapy was pursued in seven prisons, 
in which methadone was distributed to 76 persons. Eleven NGOs complemented the services in the area of care for 
imprisoned drug users, operating in 27 prisons, making a total of 744 visits and contacting 3,389 inmates. 
9.1 Drug-related Crime 
There are several data sources available in the Czech Republic regarding the so-called "drug offences”, i.e. offences 
under the provisions of Sections 187, 187a, 188, and 188a of the Penal Code. They mainly include the statistics of 
the Police of the Czech Republic, especially the Criminal Statistics Record System and the statistics of the dedicated 
police unit – the National Drug Headquarters of the Criminal Investigation Service of the Police of the Czech 
Republic (the National Drug Headquarters) – as well as the statistics of the public prosecutors’ offices and court 
statistics prepared by the Ministry of Justice. Additional data in this area are collected by the Probation and Mediation 
Service (PMS) and the Prison Service of the Czech Republic.  
The data from the above-mentioned sources differ slightly. For example, persons arrested or prosecuted for drug-
related offences are recorded in the system of the National Drug Headquarters, which only focuses on drug-related 
crime, and in the police and Ministry of Justice systems, which cover general, i.e. not only drug-related, crime. The 
differences in certain details result from the different reporting practices and discipline, as well as from the 
methodological differences between the individual reporting systems. For example, such differences include the 
recording of offences and offenders at different stages of the criminal proceedings55, different definitions of the cases 
reported, and different statistical units (individuals, cases, or offences), duplications in the recorded data (e.g. if a 
single person has violated multiple drug-related sections of the Penal Code or in connection with multiple drug 
types). However, the non-existence of a uniform record-keeping system for all the institutions involved in the criminal 
proceedings (i.e. the police, PMS, public prosecutors' offices, and courts) is a major disadvantage in this context.  
9.1.1 Drug Law Offences 
The police data (Criminal Statistics Record System, National Drug Headquarters), as well as Ministry of Justice 
information regarding drug-related offences, confirm the relatively stable situation in recent years as far as the 
number of individuals arrested, prosecuted, charged, and sentenced is concerned, whether classified by drug-related 
Penal Code section, drug type, or region. 
                                                          
55 The police statistics (the National Drug Headquarters database and the Criminal Statistics Record System) register a case as early as 
when prosecution starts. The individual cases enter the statistics of the Ministry of Justice with a certan delay – after the preliminary 
stage of the criminal proceedings is concluded (following a decision to indict the offender, suspend the criminal proceedings, etc.). 
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2,322 and 2,296 persons were arrested in 2008 according to the National Drug Headquarters and the Criminal 
Statistics Record System, respectively, and 2,304 persons were prosecuted for drug-related offences according to 
the Ministry of Justice; see Table 9-1. The percentage of persons arrested or prosecuted for drug-related offences is 
shown in Table 9-2 to Table 9-4, broken down by Penal Code section and main drug type. The number of individuals 
prosecuted in connection with drug-related offences has been stable in recent years. However, the percentage of 
people charged under Section 187a has been rising since 2004, and so has the percentage of persons sentenced 
according to that Penal Code section; see Figure 9-1. 
Figure 9-1: Trends in the percentage of persons prosecuted, charged, and sentenced under Section 187a of the Penal 
Code in the period 2002-2008 (Ministerstvo spravedlnosti ČR, 2009b; Ministerstvo spravedlnosti ČR, 2009a; Mravčík et 
al.  2008) 
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According to the statistics of the National Drug Headquarters, 2,013 drug-related offenders (87%) were arrested for 
illicit drug production and trafficking (Section 187) and/or for possessing equipment for the unauthorised production 
of drugs (Section 188 of the Penal Code), most typically in connection with pervitin. 284 persons (12%) were 
arrested for the possession of drugs for personal use (Section 187a), mostly in connection with cannabis. Twenty-
five persons(1%) were arrested for promotion of drug use (Section 188a of the Penal Code); see Table 9-2 and 
Table 9-3. 
According to the Ministry of Justice statistics, 1,896 persons (83%) were prosecuted under Sections 187 and 188 of 
the Penal Code, mostly in relation to pervitin; 377 (16%) were prosecuted under Section 187a of the Penal Code, 
mostly in connection with pervitin and cannabis. The number of persons prosecuted under Section 188a of the Penal 
Code was 31 (1%) and the cases mostly involved cannabis; see Table 9-4. 
In terms of regions, the highest absolute numbers of people prosecuted for drug-related offences in 2006-2008 were 
reported from the Ústí nad Labem region (299 persons in 2008), the Capital City, Prague (226), Moravia-Silesia 
(242), and South Moravia (240). The lowest numbers were prosecuted in the regions of Pardubice (60) and Hradec 
Králové (60). The highest numbers of persons prosecuted in the last 3 years per 100,000 inhabitants were reported 
from the Ústí nad Labem (36.3 persons in 2008) and Karlovy Vary (33.2) regions, while the regions of Hradec 
Králové (10.9), Zlín (11.2), and Pardubice (11.8) posted the lowest relative figures. 
Table 9-1: Number of persons arrested and prosecuted for drug-related offences in 2003-2008 according to the individual 
information sources (Národní protidrogová centrála, 2009d; Ministerstvo vnitra ČR, 2009; Ministerstvo spravedlnosti ČR, 
2009b). 
Source 2003 2004 2005 2006 2007 2008 
National Drug Headquarters 2,357 2,157 2,168 2,198 2,031 2,322 
Police statistics 2,295 2,149 2,209 2,344 2,023 2,296 
Ministry of Justice 3,088 2,944 2,429 2,630 2,282 2,304 
 
Table 9-2: Number of persons arrested and prosecuted for drug-related offences in 2008, classified by Penal Code 
section (Národní protidrogová centrála, 2009d; Ministerstvo vnitra ČR, 2009; Ministerstvo spravedlnosti ČR, 2009b) 
Sections 
187+188 Section 187a Section 188a Total Source 
Number % Number % Number  % Number 
National Drug Headquarters 2,013 87 284 12 25 1 2,322 
Police statistics 1,990 87 278 12 28 1 2,296 
Ministry Of Justice 1,896 83 377 16 31 1 2,304 
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Table 9-3: Number of persons arrested in 2008, classified by main drug type and Penal Code section, according to the 
National Drug Headquarters (Národní protidrogová centrála, 2009d)  
Sections 
187+188 Section 187a Total  Drug type 
Number % Number % Number % 
Cannabis 608 30 138 49 746 32 
Pervitin 1,212 60 108 38 1,320 57 
Cocaine 20 1 3 1 23 1 
Heroin 124 6 27 10 151 7 
Other drugs 49 2 8 3 57 2 
Total number 
of people* 2,013 100 284 100 2,297 100 
NB: * The "total number of people” row does not include 25 individuals arrested under Section 188a because information about the drug 
type involved is missing. The total number of persons arrested in 2008 according to the National Drug Headquarters is thus 2,322. 
Table 9-4: Number of persons prosecuted in 2008, classified by main drug type and Penal Code section, according to the 
Ministry of Justice (Ministerstvo spravedlnosti ČR, 2009c) 
Section 187 Section 187a Section 188 Section 188a Total Drug type Number % Number % Number % Number % Number % 
Cannabis 460 28 158 42 20 8 17 55 655 28 
Pervitin 1,052 63 170 45 205 87 10 32 1,437 62 
Cocaine 43 3 11 3 0 0 0 0 54 2 
Heroin 108 7 34 9 1 0 0 0 143 6 
Other drugs 97 6 37 10 20 8 4 13 158 7 
Total number 
of people* 1,660 100 377 100 236 100 31 100 2,304 100 
NB: *The data provided in the “total number of people” row are not the aggregate number and percentage of drug-related offences by 
drug type because certain persons were prosecuted for the violation of multiple drug-related sections of the Penal Code or in connection 
with multiple drug types; a single person can therefore be included in the statistics several times. The Ministry of Justice provides two 
statistical reports, i.e. those by drug type and those by drug-related Penal Code section. 
In comparison with the previous years, the situation is also stable as far as the persons charged are concerned. 
According to the Ministry of Justice statistics (Ministerstvo spravedlnosti ČR, 2009b; Ministerstvo spravedlnosti ČR, 
2009c), 2,100 persons were charged with drug-related offences (compared to 2,042 in 2007), of whom 1,534 (73%) 
were charged under Section 187 (mostly in connection with pervitin), 318 (15%) under Section 187a (mostly in 
connection with pervitin), 221 (11%) under Section 188 (mostly in connection with pervitin), and 24 (1%) under 
Section 188a of the Penal Code in 2008 (mostly in connection with cannabis); see Table 9-5. 
Table 9-5: Number of persons charged in 2008, classified by main drug type and drug-related Penal Code section 
(Ministerstvo spravedlnosti ČR, 2009c) 
Section 187  Section 187a Section 188 Section 188a Total Drug type Number % Number % Number % Number % Number % 
Cannabis 375 24 121 38 17 8 11 46 524 25 
Pervitin 1,016 66 158 50 197 88 9 38 1,380 66 
Cocaine 43 3 9 3 0 0 0 0 52 2 
Heroin 107 7 33 10 1 0 0 0 141 7 
Other drugs 88 6 30 9 19 8 4 17 141 7 
Total number 
of people* 1,534 100 318 100 224 100 24 100 2,100 100 
NB: *The data provided in the “total number of people” row are not the aggregate number and percentage of offences by drug type 
because certain persons are charged under multiple drug-related sections of the Penal Code or in connection with multiple drug types; a 
single person can therefore be included in the statistics several times. The Ministry of Justice provides two statistical reports, i.e. those 
by drug type and those by drug-related Penal Code section. 
In comparison with the previous years, the situation also remains stable as far as the sentences are concerned. 
According to the Ministry of Justice statistics (Ministerstvo spravedlnosti ČR, 2009a; Ministerstvo spravedlnosti ČR, 
2009c), 1,360 persons were sentenced for drug-related offences (compared to 1,382 persons in 2007), of whom 
1,125 (83%) were sentenced under Section 187 (mostly in connection with pervitin – 572 persons), 150 (11%) under 
Section 187a (mostly in connection with cannabis – 44), 72 (5%) under Section 188 (mostly in connection with 
pervitin – 33), and 13 (1%) under Section 188a (mostly in connection with cannabis – 5 persons) in 2008; see Table 
9-6.  
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Table 9-6: Number of persons sentenced in 2008, classified by main drug type and drug-related Penal Code section 
(Ministerstvo spravedlnosti ČR, 2009c) 
Section 187  Section 187a Section 188 Section 188a Total Drug type Number % Number % Number % Number % Number % 
Cannabis 176 16 44 29 6 8 5 38 231 17 
Pervitin 572 51 31 21 33 46 1 8 637 47 
Cocaine 26 2 4 3 0 0 0 0 30 2 
Heroin 51 5 15 10 0 0 0 0 66 5 
Other drugs 174 15 23 15 21 29 4 31 222 16 
Total number 
of people* 1,125 100 150 100 72 100 13 100 1 360 100 
NB: *The data provided in the "total number of people" row are not the aggregate of the number and percentage of drug-related 
offences by drug type because the type of drug was apparently not determined for all the persons sentenced for drug-related offences. 
9.1.1.1 Sentences for Drug-Related Offences 
According to the Ministry of Justice statistics (Ministerstvo spravedlnosti ČR, 2009a; Ministerstvo spravedlnosti ČR, 
2009c), a total of 1,360 persons were sentenced for 1,607 drug-related offences in 2008 (compared to 1,382 
persons in 2007). A total of 450 unsuspended sentences (415 sentences in 2007) and 688 suspended sentences 
(734 in 2007) were imposed. The year 2008 saw an increase in the number and percentage of unsuspended prison 
sentences, with the courts imposing 335 unsuspended prison sentences ranging from one to five years – the highest 
number in the last 5 years. The composition of the sentences imposed in 2008 according to Sections 187 and 187a 
of the Penal Code is shown in Table 9-7 and Figure 9-2. 
Table 9-7: Number of sentences imposed for drug-related offences under selected Penal Code sections in 2008, by 
selected drug type (Ministerstvo spravedlnosti ČR, 2009a)  
Sentence type Section 187 Section 187a Cannabis  Pervitin Heroin 
Unsuspended sentences  410 19 26 247 29 
– up to 1 year’s imprisonment 41 12 3 29 5 
– imprisonment for 1-5 years 313 7 22 196 17 
– imprisonment for 5-15 years 56 0 0 22 7 
Suspended sentences  550 92 124 311 33 
Other sentences 165 39 81 79 4 
– community service 56 23 24 41 0 
– penal measure* 56 2 43 8 0 
– sentence waived 43 10 10 28 1 
– other sentences 10 4 4 2 3 
Total persons sentenced  1,125 150 231 637 66 
NB: * The penal measure is a summary term for various types of sentences imposed on juvenile offenders under Act No. 218/2003 Coll. 
on the judiciary in juvenile affairs. 
Figure 9-2: Composition of sentences imposed under selected Penal Code sections in 2008, by selected drug type 
(Ministerstvo spravedlnosti ČR, 2009a; Ministerstvo spravedlnosti ČR, 2009c) 
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9.1.2 Misdemeanours Involving Drug Possession for Personal Use 
An amendment56 to Act No. 200/1990 Coll. on misdemeanours changed the competence for the resolution of 
misdemeanours under Section 30(1)(j), i.e. the possession of a small quantity of a drug for personal use. Effective 
from 1 January 2009, the competence no longer rests with the Police of the Czech Republic but instead lies with the 
municipal authorities or special municipal bodies that have jurisdiction. 
A total of 970 misdemeanours involving drug possession for personal use were reported in 2006, and 966 
misdemeanours were reported in 2007. The incomplete data available for 200857 show 450 cases, which concerned 
473 persons, 90% of whom were men, 26% were underage, and 98% were Czech. A total of 3 kg of marijuana, 10.6 
g of hashish, 57.1 g of pervitin, 2 g of amphetamine, 1.5 g of cocaine, 10 g of heroin, 69 ecstasy tablets, and 28.3 g 
of magic mushrooms were seized in connection with all the cases reported above. Most cases (255) concerned 
marijuana (with 100 cases involving quantities of 1-5 g), 102 cases concerned pervitin (all under 1 g), 20 cases 
concerned heroin (with 17 cases involving less than 1 g), 3 cases were cocaine-related (all involving less than 1 g), 
and 5 were ecstasy-related (4 of which involved under 5 tablets). No misdemeanour was reported in connection with 
cannabis plants in 2008; however, the reports for 2008 are incomplete) (Národní protidrogová centrála, 2009c; 
Národní protidrogová centrála, 2009a). 
9.1.3 Secondary Drug-Related Crime 
In mid-2008, the National Drug Headquarters collected data to estimate the level of secondary drug-related crime for 
2007 and the first half of 2008 (i.e. for 18 months), using a similar methodology to that applied in 2007 (for details see 
the 2006 Annual Report). The study was conducted as an expert retrospective estimate made by the district police 
headquarters, which estimated the proportion of criminal offences committed by drug users (mainly for the purpose 
of acquiring the wherewithal for purchasing drugs for personal use) in the above-mentioned period of 18 months. 
This was done for each of the 42 selected58 offences defined in the Criminal Statistics Record System. The 
estimates were provided by 81 out of the total of 82 district police headquarters. In the course of the data processing, 
which was performed by the National Focal Point, the estimated percentages were weighted using the actual 
number of cleared-up criminal offences in the individual districts. 
In the 18-month period, a total of 374,248 selected criminal offences (see above) were committed, with drug users 
estimated to have participated in 109,038 of those offences (29.1%). The 10 most common criminal offences in 
which drug users participated mainly included various types of theft, burglary, unauthorised possession of a payment 
card, and illicit drug production and trafficking according to Section 187 of the Penal Code; see Table 9-8 (Národní 
protidrogová centrála a Národní monitorovací středisko pro drogy a drogové závislosti, 2009). 
Table 9-8: Estimated number of selected criminal offences committed by drug users, and their proportion in the total 
number of criminal offences, by type (Národní protidrogová centrála a Národní monitorovací středisko pro drogy a 
drogové závislosti, 2009). 
Criminal offence type Number Proportion (%) 
Vehicle burglary 46,838 62.7 
Theft - pickpocketing 9,500 34.2 
Other types of burglary 8,991 19.4 
Vehicle theft  6,323 21.9 
Theft on other premises 5,284 13.6 
Other types of theft 3,416 19.5 
Unauthorised possession of a payment 
card 3,227 27.4 
Production and trafficking of a narcotic 
and/or psychotropic substance 2,445 70.7 
Theft of bicycles 2,377 31.0 
Other theft committed against persons 2,319 17.0 
Others 18,318 17.7 
Total 109,038 29.1 
 
Criminal offences committed by drug users were also the topic of research conducted among the clients of all the 
low-threshold programmes for drug users in Prague in May 2008 (Šejvl, 2008); see also the chapters on Data on 
Problem Drug Use from Non-treatment Sources, page 30, and Social Correlates and Social Reintegration, page 76. 
As far as conflict with the law is concerned, the most common types of criminal activities mentioned by the clients 
included theft and the sale of drugs (with prostitution also being rather common). 73% of the clients stated that they 
                                                          
56 The amendment was implemented by virtue of Act No. 274/2008 Coll. revising certain acts in connection with the Police Force Act. 
57 On average, they include 60% of all the required monthly reports the relevant district police headquarters were able to provide to the 
National Drug Headquarters in 2008.  
58 They especially included crimes against property (e.g. theft, fraud), crime with violence (e.g. robbery, bodily harm, arbitrary 
interference with the home) and others (neglect of compulsory maintenance, extortion, etc.). The selection also included the criminal 
offences of illicit drug production and trafficking under Section 187 of the Penal Code. 
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had had final sentences imposed upon them in the past in relation to criminal activities they had committed in 
connection with drug use (21% of the clients had been sentenced to community service, and 21% received 
suspended and 31% unsuspended prison sentences). 
9.1.4 Clients of the Probation and Mediation Service 
Details from the Probation and Mediation Service of the Czech Republic (PMS) regarding its clients who are drug 
users are available again. In 2008, the PMS recorded a total of 25,465 persons, 659 (2.6%) of whom were the 
perpetrators of drug-related criminal offences (Probační a mediační služba ČR, 2009). According to the PMS, “drug-
related crime” includes both offences committed in connection with Sections 187, 187a, 188, and 188a of the Penal 
Code (i.e. primary drug-related crime) and property crimes committed for the purpose of acquiring the wherewithal 
for purchasing drugs (i.e. secondary drug-related crime). The proportion of all the drug-related cases59 in all the 
cases handled by the PMS was around 3.5% in 2006-2008 (see Table 9-9). The competent PMS workers consider 
this figure significantly underestimated. 
Table 9-9: Persons registered by the PMS in connection with drug-related crime in 2006-2008 (Probační a mediační 
služba ČR, 2009) 
2006 2007 2008 Cases registered by PMS Number % Number % Number % 
All cases  24,885 100.0 27,648 100.0 25,465 100.0
– primary drug-related crime  712 2.9 692 2.5 659 2.6
   – offences under Section 187 of the Penal 
Code 506 2.0 566 2.0 501 1.9
– offences under Section 247 of the Penal 
Code* 86 0.3 101 0.4 75 0.3
– others** 69 0.3 138 0.5 134 0.5
NB: * Theft committed by a drug user. ** Other criminal offences committed by a drug user. 
9.2 Prevention of Drug-Related Crime 
In the Czech Republic, crime prevention is in the remit of the Ministry of the Interior, which addresses the issue 
without distinguishing the prevention of drug-related crime from other types of criminal activities. The information is 
concentrated on the website of the Ministry of the Interior60. The issue also falls within the competence of the Ministry 
of Education, which is in charge of the prevention of risk behaviour among children and young people; for details see 
the chapter on Prevention, page 24. 
The Ministry of the Interior regularly prepares strategic documents on crime prevention and administers a grant 
programme to support crime prevention projects at the local level (e.g. the drawing-up of municipal crime prevention 
plans or lighting or camera systems in dangerous or risky locations in urban settings). The list of the projects 
supported is available on the website of the Ministry of the Interior61. The funds expended from the budget of the 
Ministry of the Interior on the crime prevention programme in the period 2008-2011 should reach a total amount of 
CZK 400 million (€ 16,038 thousand) (Government Resolution No. 1150 of 15 October 2007). 
The 2008-2011 crime prevention strategy mainly focuses on reducing acquisitive and violent crime and eliminating 
socially negative phenomena involving criminal risk (Ministerstvo vnitra ČR, 2007). The target groups include 
individuals dependent on alcohol and narcotic or psychotropic substances, at-risk children and young people, 
families with children showing behavioural disorders, and socially excluded individuals and groups, all as vulnerable 
individuals in the position of potential offenders or victims. Drug-related offences are present among the offences that 
are listed in terms of both acquisitive and violent crime. Crime prevention policies are also prepared at the regional 
level and are all published on the website of the Ministry of the Interior62. 
9.3 Interventions in the Criminal Justice System 
The instrument of (“protective”) compulsory treatment is mainly governed by Section 72 of the Penal Code, while 
Sections 351 et seq. of the Criminal Procedure Rules apply to its service; it is a protective measure rather than 
punishment. The compulsory treatment types include drug addiction, alcoholism, sexuological, psychiatric, and 
combined therapies. It is mostly the drug addiction form that applies to drug users but the compulsory treatment of 
alcohol use, psychiatric, or combined disorders may also be imposed. Treatment may be in either the institutional or 
outpatient form. Compulsory treatment may also be undergone as a part of serving a prison sentence. 
According to Section 72(2)(b) of the Penal Code, the court may also impose compulsory drug treatment on drug-
using offenders who committed an offence under the influence or in connection with the substances they misuse. 
                                                          
59 According to the reporting methodology employed by the Probation and Mediation Service, an unknown number of persons violated 
more than one provision of the Penal Code, i.e. a single person may have committed multiple offences. This implies that the total 
number of people may be lower than the quoted sum of the cases reported under the individual sections. 
60 See http://www.mvcr.cz/clanek/programy-prevence-kriminality.aspx  
61 See http://aplikace.mvcr.cz/archiv2008/prevence/ksp/dotace08.xls  
62 See http://www.mvcr.cz/clanek/programy-prevence-kriminality.aspx?q=Y2hudW09Nw%3d%3d  
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The court will not impose compulsory drug treatment if it is obvious that the purpose of such treatment cannot be 
achieved (e.g. in offenders with a negative attitude to treatment, in those who have a history of repeated 
unsuccessful treatment, etc.). The adequacy of compulsory drug treatment is assessed by a court-appointed expert; 
the court may, however, rule otherwise, in consideration of additional evidence (although it usually respects the 
recommendation of the expert). In cases which also involve another psychiatric disorder in addition to drug use, the 
court may impose multiple types of compulsory treatment at the same time. According to Section 72(6) of the Penal 
Code, compulsory drug addiction treatment lasts as long as warranted by its purpose, but no longer than two years. 
However, the court may, even repeatedly, extend the period of compulsory treatment by up to two additional years. 
The protective compulsory treatment of drug-using offenders may be terminated if it is found in the course of the 
treatment that the treatment cannot achieve the intended purpose. If there is a risk of the sentenced individual 
potentially committing another offence, the court may rule, in its decision on release from compulsory drug treatment, 
that the prisoner will be subject to supervision for a period of up to 5 years. This amendment was included in the 
Penal Code in connection with Act No. 129/2008 Coll. on security detention and amendments to certain related acts, 
effective from 1 January 2009. Before that date, there was no legal limit specifying the duration of court-ordered 
treatment (although it was common practice that the duration of institutional compulsory drug treatment was 
approximately 6 months). 
The decision on the release from compulsory drug treatment is made by the court, usually upon a proposal from the 
sentenced individual or the health care facility in charge of the relevant person’s treatment. If the offender does not 
start the compulsory drug treatment or violates the rules for its service, they may be liable to prosecution for 
obstructing justice (Section 171 of the Penal Code). 
Compulsory treatment may also be imposed by the court in addition to a sentence or when a sentence is waived. 
The waiver of a sentence together with court-ordered compulsory treatment is generally possible in the case of 
offenders who committed an offence while of impaired mental capacity, and the court is of the opinion that 
compulsory treatment is a better way of correcting the offender than a sentence would be. However, this option 
cannot be used in the case of patients whose impaired mental capacity was due to their having used an addictive 
substance (Section 25 of the Penal Code). 
If imposed together with an unsuspended prison sentence, institutional compulsory drug treatment can be served in 
the specialised departments in the Opava, Rýnovice, and Znojmo prisons or in the court-ordered compulsory 
treatment departments of psychiatric hospitals. In 2008, this concerned 10 psychiatric hospitals: Prague-Bohnice, 
Kosmonosy, Dobřany, Horní Beřkovice, Havlíčkův Brod, Brno-Černovice, Opava, Šternberk, Bílá Voda, and 
Červený Dvůr. The outpatient form of compulsory drug addiction treatment can be served in alcohol/drug treatment 
outpatient centres or in private psychiatric clinics, where the physician must be able to provide the expertise required 
for the field of addiction treatment. The court may change the form of compulsory treatment in the course of the 
therapy. 
Courts impose compulsory drug treatment on approximately 150 persons annually. Institutional or outpatient 
compulsory treatment was imposed by courts upon 162 persons; 91 of the cases involved the outpatient form and 
71 the institutional form of treatment in 2008; see Table 9-10. Out of the total number of 162 compulsory drug 
treatment orders, 53 concerned offenders sentenced for drug-related offences, 50 of whom violated Section 187 of 
the Penal Code. Another 37 persons were sentenced to compulsory drug addiction treatment for violating Section 
247 of the Penal Code (theft) (Ministerstvo spravedlnosti ČR, 2009a). The 2008 data provided by the Probation and 
Mediation Service indicate that the outpatient form of compulsory drug treatment was imposed on 33 of the 142 PMS 
clients referred to as persons addicted to non-alcohol substances, mostly (19 cases) in connection with offences 
under Section 187 of the Penal Code (Probační a mediační služba ČR, 2009). 
Table 9-10: Number of individuals ordered compulsory treatment by court in the period 2003-2008 (Ministerstvo 
spravedlnosti ČR, 2009a) 
Compulsory treatment type 2003 2004 2005 2006 2007 2008 
Drug use 143 161 141 164 139 162 
Alcohol use 195 190 193 220 232 217 
Others  222 199 239 221 221 201 
Total 560 550 573 605 592 580 
 
In addition to compulsory treatment, other options may also be applied in the case of drug users within the 
framework of procedural or criminal law diversions or alternative sentences. This mostly involves the imposition of 
the reasonable obligation to undergo treatment. For example, this may apply to decisions on suspended 
imprisonment with supervision (Section 60a of the Penal Code) or to cases of release on parole with supervision 
(Section 63 of the Penal Code). The key factor in these cases is the personal motivation to undergo treatment, which 
significantly affects the decision of the court or (in the course of preliminary proceedings) of the public prosecutor. 
Although this is not compulsory treatment, the failure to fulfil the obligation to undergo treatment or abstain from 
substance use may affect the decision of the court on meeting the conditions of the probationary period pertaining to 
a suspended sentence or release on parole. However, unlike in the case of compulsory treatment, the offender 
cannot face prosecution for obstructing justice. 
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9.4 Drug Use and Problem Drug Use in Prisons 
There were 35 prisons, ten of which were remand prisons and five combined the serving of prison sentences with 
the functions of a remand prison in the Czech Republic in 2008. In recent years, the daily headcount of prisoners in 
the country has been around 19,000. However, a total of 20,502 persons (with 18,100 individuals serving prison 
sentences and 2,402 in custody) were reported as of 31 December 2008. The average age of the persons awaiting 
trial was 33 years and that of the persons sentenced was 36 years. 95% of them were men. 6,334 persons were 
admitted to custody and 10,475 persons were admitted to prison from civil life (i.e. not from custody) in 2008, 
compared to 6,085 and 9,468 persons, respectively, in 2007 (Generální ředitelství Vězeňské služby ČR (Odbor 
zdravotní služby), 2009; Generální ředitelství Vězeňské služby ČR, 2009). 
As of 31 December 2008, a total of 1,662 prisoners were individuals sentenced or awaiting trial for drug-related 
offences according to Section 187-188a of the Penal Code; see Table 9-11 (Generální ředitelství Vězeňské služby 
ČR (Odbor zdravotní služby), 2009). 
The level of drug use among the inmates of Czech prisons can only be generally estimated on the basis of 
information from several information sources: 
 the data of the Health Service Department of the General Directorate of the Prison Service, which include 
persons addicted to habit-forming substances, including alcohol; 
 the results of the urine toxicology screening of prisoners awaiting trial and serving a prison sentence; 
 drug seizures in prisons.  
There are no results available from any representative (cross-section) studies conducted among prisoners which 
could be used as the basis for the qualified determination of drug use among prisoners. 
Table 9-11: Number of drug offenders sentenced to imprisonment under Sections 187-188 of the Penal Code, as of the 
end of the years 2007 and 2008 (Generální ředitelství Vězeňské služby ČR, 2008; Generální ředitelství Vězeňské služby 
ČR (Odbor zdravotní služby), 2009) 
Drug-related offences 31 Dec 2007 31 Dec 2008 
Section 187 1,314 1,257 
Section 187a 101 127 
Section 188 144 185 
Section 188a 69 93 
Total persons 1,628 1,662 
 
As part of the medical and preventive care of inmates awaiting trial or serving a prison sentence, the staff of the 
Health Service Department conducted 312,479 examinations or treatment interventions in 2008. In this context, 
9,390 persons dependent on habit-forming substances, including alcohol, were registered (compared to 8,338 in 
2007). 
Toxicology screening tests are conducted in Czech prisons on the grounds of a reasonable suspicion and randomly 
both upon admission to custody or prison and during the term of imprisonment, and as a part of substitution therapy 
(see below). A total of 9,165 tests capable of detecting multiple drug types at the same time were conducted in all the 
35 prisons in 2008 (compared to 10,257 tests in 2007). 1,177 tests (12.8%) were positive (21.4% in 2007). The most 
common drug detected was pervitin (approximately 50% of all the positive tests), followed by THC (approximately 
one in three tests), benzodiazepines63 (approximately one in three tests), and opiates (approximately one in ten 
tests). Scheduled and random searches using drug-sniffing dogs were performed in 24 prisons. They involved 
searches of the living quarters, common areas, and working places, and checks on correspondence, including 
packages etc. The dogs indicated 115 seizures (107 in 2007). In most (47) instances, it was a case of “positive 
indication without a find” (i.e. the dog reliably indicated the spot but a physical search was not able to reveal any 
drugs); marijuana was found in 21 cases, pervitin in 17 cases, and an unknown substance or syringe in 16 cases. 
Other seizures were made in various hiding places by the personnel of the Prison Service, who reported 90 seizures 
of various drug types with a total quantity of 143 g, mostly involving THC (39 seizures) and pervitin (25 cases) 
(Generální ředitelství Vězeňské služby ČR, 2009). 
9.5 Responses to Drug-related Health Issues in Prisons 
Information about counselling and therapeutic interventions for drug users in prisons is provided by the General 
Directorate of the Prison Service on an annual basis. Adopted in November 2007, Drug Policy Action Plan of the 
Prison Service of the Czech Republic for the Period 2007–2009 is the key document in this context. This plan, which 
is compatible with the Action Plan for the Implementation of the National Drug Policy Strategy for the Period 2007 to 
2009, focuses on the following seven basic areas: (1) primary prevention; (2) treatment and aftercare; (3) harm 
reduction; (4) supply reduction and law enforcement; (5) information, research, and evaluation; (6) coordination and 
funding, and (7) international co-operation.  
                                                          
63 Benzodiazepines may be a part of the medication prescribed by a physician. 
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9.5.1 Drug Prevention Counselling Centres 
Drug counselling centres exist in all the prisons and provide drug users with professional drug counselling and other 
types of care in order to minimise the medical and social risks arising from drug use and motivate drug users to 
undergo treatment while serving their prison sentence. 6,892 inmates used these services in 2008, with the highest 
number (1,295) reported from the Prague-Pankrác Remand Prison. Four prisons did not report the number of 
persons who used the services of the counselling centres (Generální ředitelství Vězeňské služby ČR, 2009).  
9.5.2 Detoxification 
Rather detailed data on drug user detoxification are available for 2008. It was conducted either in the outpatient form 
in the health centre of the relevant prison, utilising mostly psychiatric medication and letting the inmates remain in 
their cells, or (in the more serious cases and based on a physician’s decision), the persons were admitted to 
specialised departments (e.g. the Psychiatric Department of the Brno Remand Prison). If pharmacotherapy is 
applied in detoxification, the substances used mainly include opioids (e.g. buprenorphine), benzodiazepines, or 
neuroleptics (especially in the case of psychotic symptomatology). The detoxification period was between 5 and 10 
days. Detoxification was performed in four prisons in 2008 (the Prague-Pankrác, Prague-Ruzyně, Brno, and Ostrava 
prisons), three of which (all except the Prague-Ruzyně Prison) reported the number of persons who had used the 
detoxification programme – 208 in total. Of that number, 171 were men, 191 were injecting users, 151 were opiate 
users, and 82 were pervitin users (Generální ředitelství Vězeňské služby ČR, 2009).  
9.5.3 Drug-Free Zones 
Drug-free zones are available in prisons in order to restrict the contact of the prisoners with drugs and lead them to 
abstinence and a healthy style of living, both during and after imprisonment. Inmates are accepted in drug-free zones 
on the basis of the decision of the relevant attending physician or at their own request, reviewed by a committee of 
prison service professionals. Prisoners may be disqualified from the drug-free zone on the grounds of violating the 
set rules and monitoring measures (which include, for example, a higher intensity of specific anti-drug programmes 
and more frequent urine testing for drugs). On the contrary, adherence to the rules brings certain advantages to the 
prisoners. The structure of the individual drug-free zones follows the criteria of gender, age, and drug problem type. 
Drug-free zones were in operation in 33 remand prisons and prison facilities (a decrease by two drug-free zones 
compared to 2007), but the capacity increased by another 121 places in 2008 to reach a total of 1,998 (1,877 places 
in 2007); see Table 9-12. Prison sentences were served in drug-free zones by 3,646 inmates in 2008, i.e. 122 
prisoners more than in 2007 (Generální ředitelství Vězeňské služby ČR, 2009).  
9.5.4 Special Treatment Departments 
There were two types of special departments dealing with drug users in operation in prisons in 2008. The first type 
includes departments for prisoners with personality and behavioural disorders caused by the use of psychotropic 
substances; the treatment is voluntary and the prisoners enter the therapy at their own request, which is assessed by 
a committee of prison service professionals. Such departments operated in six prisons in 2008 (Bělušice, Nové 
Sedlo, Ostrov, Pilsen, Příbram, and Všehrdy), were all only intended for men, and offered a total capacity of 262 
places, with 422 men serving their prison sentences in these departments in 2008. 
The other special department type is used for serving court-ordered compulsory treatment sentences. They can be 
found in the Opava, Rýnovice, and Znojmo prisons. They employ group therapy-based regime activities with the 
features of a therapeutic community. The treatment programme is designed for 6-12 months, but the length of the 
stay is determined on an individual basis. The total capacity in 2008 was 120 places, which were used by 206 
persons; see Table 9-12 (Generální ředitelství Vězeňské služby ČR, 2009).  
Table 9-12: Number, capacity and use of drug-free zones and two types of specialised departments in Czech prisons in 
2006-2008 (Generální ředitelství Vězeňské služby ČR, 2009) 
Drug-free zones Voluntary treatment departments 
Departments for court-ordered 
treatment 
Year Number of 
departments/
prisons 
Capacity Persons 
Number of 
departments/
prisons 
Capacity Persons
Number of 
departments/
prisons 
Capacity Persons
2006 31 1,665 3,201 6 286 625 3 105 162 
2007 35 1,877 3,524 6 258 419 3 114 200 
2008 33 1,998 3,646 6 262 422 3 120 206 
 
9.5.5 Substitution Therapy 
Methadone substitution therapy was available in seven out of the ten prisons planned for substitution therapy in 
2008. Persons awaiting trial or serving a prison sentence may be included in substitution therapy at their own 
request (accompanied by a confirmation of the health facility in which the person underwent therapy prior to being 
admitted to the prison) or on the basis of a recommendation from the attending physician who performed the initial 
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medical examination of the inmate upon admission. Seventy-six persons were included in substitution therapy in 
prisons (compared to 12 prisoners in 2007); see Table 9-13. Six persons left the treatment early – two for breaching 
the therapy agreement, three at their own request, and one person for intolerance of the substitution substance 
administered (Generální ředitelství Vězeňské služby ČR, 2009).  
Table 9-13: Number of persons receiving substitution therapy in prisons with substitution therapy planned in 2008 
(Generální ředitelství Vězeňské služby ČR, 2009) 
Prison Programme implemented 
Total number of 
persons in 2008 
Number of 
persons as of 31 
December 2008 
Early 
termination 
Brno Yes 17 1 2 
Břeclav No 0 0 0 
Kuřim Yes 6 0 1 
Litoměřice No 0 0 0 
Opava Yes 3 3 0 
Ostrava No 0 0 0 
Prague-Pankrác Yes 34 9 2 
Prague-Ruzyně Yes 2 – – 
Příbram Yes 11 7 1 
Rýnovice Yes 3 1 0 
Total – 76 21 6 
 
9.5.6 Prevention and Treatment of Infectious Diseases 
As of 7 August 2009, the Health Service Department of the General Directorate of the Prison Service registered 
1,125 persons with chronic hepatitis type B, 874 (78%) of whom were drug users. As of the same date, five persons 
had received virostatic treatment with interferon. There were also 2,890 persons with hepatitis type C, 2,345 (81%) of 
whom were drug users. Virostatic treatment with interferon had been received by 51 persons as of the date indicated 
above. As of 20 August, Czech prisons had registered 17 HIV-positive inmates. Twelve of them had received 
antiretroviral therapy. The number of HIV-positive drug users serving their sentences in Czech prisons was unknown 
(Generální ředitelství Vězeňské služby ČR (Odbor zdravotní služby), 2009). 
9.5.7 Services Provided to Drug Users in Prisons by Non-Governmental Organisations 
Care for imprisoned drug users is complemented by the services provided by 11 NGOs. Six of the organisations are 
members of the Section for Drug Services in Prison of the Association of Non-Governmental Organisations (A.N.O.). 
These six NGOs provided various types of drug services, usually of a regular and comprehensive nature, in 15 
prisons in the Czech Republic in 2008. All the programmes paid particular attention to the pre-release stage in order 
to prepare the clients for their release from prison and living independently, and to establish the clients’ connection 
with other outpatient and residential treatment services in the community. These six programmes contacted 1,118 
persons, including those recently released from prison. The services were offered to 997 prisoners in custody or 
serving a prison sentence, predominantly pervitin drug users aged 29 on average; see Table 9-14 (Generální 
ředitelství Vězeňské služby ČR, 2009; Ženíšková, 2009). 
Table 9-14: Drug service providers associated in the A.N.O. Section for Drug Services in Prison, and prisons and remand 
centres in which their services were provided in 2008 (Generální ředitelství Vězeňské služby ČR, 2009) 
A.N.O. Section for Drug Services in 
Prison  Prisons and remand centres 
SANANIM Prague Prague-Pankrác, Prague-Ruzyně  
Semiramis Nymburk Jiřice 
Podané ruce Brno Brno, Břeclav, Kuřim 
Podané ruce Walhalla Olomouc Olomouc, Mírov 
Laxus – Hradec Králové Hradec Králové, Hradec Králové – Pouchov, Pardubice, Světlá nad Sázavou, Valdice, Odolov 
CPPT Pilsen Pilsen 
 
Other NGOs also offered various types of drug services. Their provision, however, was mostly irregular and non-
systematic and often only concerned single occasions and events (e.g. speeches and discussions on drugs). These 
NGOs included the White Light I. civic association (for the Bělušice and Litoměřice prison and remand centre), 
Renarkon, a public service company (Heřmanice, Ostrava, Karviná, Opava), the Rodiče civic association (Ostrov, 
Příbram), Magdaléna, a public service company (Příbram), and K centrum Karlovy Vary (Horní Slavkov). These 
NGOs operated in ten Czech prisons and remand centres, to which they made 22 visits and where they contacted 
251 clients (Generální ředitelství Vězeňské služby ČR, 2009). 
strana 91 
9.5.8 Post-Penitentiary Care 
Overdose prevention programmes are only pursued in the form of providing information to the relevant person being 
released from prison. Post-penitentiary care and the reintegration of drug users released from prison are a part of the 
services provided in the prisons by non-governmental organisations; see above. There were two programmes 
focusing specifically on post-release care in 2008 (those of SANANIM Prague and Podané ruce Brno). The problem 
in post-penitentiary care is the lack of services for drug users released from prison, especially in North and West 
Bohemia, and the generally insufficient co-operation between drug and non-drug social services (Ženíšková, 2009). 
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10 Drug Markets 
While marijuana is the most widely available drug in the Czech Republic, the availability of pervitin also remains high. 
Typically, these two drugs top the statistics for seizures. There is an increasing trend in the domestic production of 
cannabis with a higher THC content, which is grown in artificial conditions. The volume of marijuana seized more 
than tripled against the previous years, and the number of growing sites detected and cannabis plants seized also 
increased considerably. The number and volume of hashish seizures is stable. The volume of pervitin seized was 
lower than in previous years, but the number of pervitin cooking labs detected exceeded that reported in the previous 
years. There was also an increase in the quantity of the pervitin precursors seized. 
The decision restricting the availability of medicines containing pseudoephedrine in pharmacies has been in effect 
since May 2009. Increased individual imports of such medicines from Germany, Poland, and Slovakia are currently 
being observed. A lower amount of cocaine was seized in 2008. The street distribution of the drug is characterised 
by a decrease in price and quality. The availability of heroin, which predominantly comes to the country from 
Afghanistan via the so-called Balkan Route, has not changed; the volume of heroin seized showed an increase. First 
and foremost, ecstasy is commonly available in nightlife settings; the number of seizures of this drug was the lowest 
in the past 4 years. 
The prices of most drugs continue to be stable. There was an increase in the average purity of the marijuana and 
heroin seized. 
10.1 Availability and Supply 
Information provided by the National Drug Headquarters and the General Customs Headquarters represents the 
basic source of data regarding the availability, production, smuggling, and distribution of drugs on Czech territory 
(Národní protidrogová centrála, 2009b; Celní správa ČR, 2009). Especially according to these sources, drugs are 
available in all the larger towns and cities of the Czech Republic, and their availability in small towns and rural areas 
has been on the rise in recent years. Cannabis is the most widely available drug and an increasing trend has been 
noted in the availability of cannabis with a higher THC content. Pervitin is available in larger towns but its availability 
is also rather high in small towns and in rural areas. Cocaine and heroin are most widely available mainly in large 
cities, in particular in Prague. 
There has been an increase in the hydroponic growing of cannabis with a high THC content (up to 20%). Most of the 
large-scale plantations detected were run by offenders of Vietnamese descent, who have also been confirmed to be 
connected to Vietnamese groups in the Netherlands and in Canada. The production of cannabis from high-volume 
growing sites is intended both for the domestic market and for export to European countries (mainly to Germany, the 
Netherlands, Belgium, and Poland). Over 70 criminal cases related to indoor cannabis growing were instigated in 
2008, with most of the cases involving Vietnamese offenders. The imported hashish mostly originates in North Africa 
(Morocco) and is smuggled into the Czech Republic mainly from the Netherlands and Spain (for detailed information 
on the cannabis market see Cannabis Markets and Production on page 96. 
Pervitin is predominantly made by domestic producers (who are often also the users) using two precursors: 
ephedrine and the more widely available pseudoephedrine, which can be extracted from over-the-counter medicines 
such as Modafen®, Nurofen Stop Grip®, Paralen Plus®, and Panadol Plus Grip®. An improvement in the quality of the 
technologies used for the production of pervitin from medicines containing pseudoephedrine has been observed. 
Pervitin trafficking is also pursued by Roma, e.g. in the Central Bohemia, Hradec Králové, and Pardubice regions. An 
increase was noted in 2008 in the number of German nationals participating in the trafficking of pervitin to Germany. 
The shipments in question were mostly of small volumes of up to 200 grams. 
The decisions of the State Institute for Drug Control regarding the change in the marketing authorisation for 
medicines containing up to 30 mg of pseudoephedrine and used for pervitin production came into effect on 1 May 
2009. The decisions limit the dispensation of such medicines to a maximum pseudoephedrine content of 1,800 mg 
(i.e. 60 tablets containing 30 mg of pseudoephedrine) per person and month. In addition, these medicinal products 
must not be sold by mail order or via the internet. The pharmacist must verify the identity of the customer to ensure 
that the limit has not been exceeded, and enter the dispensation details in the central database of electronic 
prescriptions; see also the chapter on Laws, Regulations, Directives, or Guidelines in the Field of Drug Issues, page 
5. The sales of these products in pharmacies dropped by 75% in the second quarter compared with the first quarter 
(ČT1, 2009). In this context, an increase in the level of imports of medicines containing pseudoephedrine has been 
observed (mainly by the Customs Administration of the Czech Republic) since 2009. 
Information about pervitin production and the market in it has been obtained through focus groups with the staff of 
low-threshold programmes (Radimecký et al.  2009). The participants indicate that pervitin is mainly produced in 
small cooking labs situated in private homes or in squats. The cooking labs are frequently relocated in order to 
reduce the probability of detection. If a cooking lab is detected in a smaller town, the availability and quality of the 
pervitin on the market decrease for a temporary period of time, whereas the situation is more stable in larger towns in 
this regard. The produced drug is primarily intended to supply the local communities of pervitin users. One of the 
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ways for a user to obtain cheaper or free pervitin is to procure chemicals and medicines containing pseudoephedrine 
for the producer. In order to gain access to medicines containing pseudoephedrine, the producers and users also 
make use of persons with a credible appearance, such as young people and pensioners, and/or the homeless in 
order to obtain small quantities of these medicines in exchange for payment. Larger amounts of the drug that are 
produced may be intended for anonymous sale in larger towns. Pervitin is also exported abroad using postal 
consignments; pervitin cooks sometimes travel to other countries to produce pervitin in order to meet local demand. 
According to the National Drug Headquarters, lower price and quality were typical of the street distribution of cocaine 
in 2008. Its import and distribution are mainly pursued by West Africans (predominantly Nigerians), Albanian-
speaking groups, and both Polish and Czech nationals, who are often used as couriers to transport cocaine from 
South America. Cocaine is mostly hidden in specially modified luggage or smuggled by the so-called “swallowers” 
inside their body. 
Ethnic Albanians from Kosovo and Macedonia continue to participate in heroin importing and trafficking, mostly using 
the Balkan Route. At a lower level, Roma and Vietnamese groups are also involved in heroin trafficking, while the 
drug is also distributed by drug users in Prague in order for them to procure the wherewithal for drugs for their 
personal use (Radimecký et al.  2009). Heroin is most commonly transported in passenger vehicles in batches of 
under 10 kg. Trucks are mainly used by Turkish nationals for transporting heroin; the Czech Republic is usually only 
a transit country en route to Western Europe. 
Subutex® continues to be sold on the black market and competes with heroin. The estimated number of problem 
users of Subutex® in the Czech Republic was 4,900 in 2008. According to data from the National Drug 
Headquarters, the price of 8 mg of Subutex® on the black market ranged from CZK 300 (€ 12) to CZK 800 (€ 32). 
Subutex® prescriptions are also sold (Národní protidrogová centrála, 2009b). Another substitution preparation, 
Suboxone®, was introduced onto the Czech market in 2008. No interest was shown in the product on the black 
market. According to the staff of low-threshold programmes, the lower level of availability of Subutex® on the black 
market may result in some users (re)transitioning to heroin (Radimecký et al.  2009). 
Ecstasy is mainly imported from Poland and the Netherlands. Lower quantities of tablets are mostly imported on an 
individual basis, concealed in luggage transported in vehicles, most typically in buses. In 2008, 100 ecstasy tablets 
containing mCPP (1-(3-chlorophenyl)piperazine) were seized in the Czech Republic. 
10.2 Seizures 
The data on drug seizures represent seizures made by the Police of the Czech Republic and the Customs 
Administration of the Czech Republic, which also include cases treated as misdemeanours (possession of a small 
amount for personal use). Seizures which involved multiple types of drugs are always included separately in the 
individual drug types; the total number of seizures was therefore lower than the sum of all the seizures by drug type. 
Marijuana was the most commonly seized drug (602 seizures). In the last four years, the number of marijuana 
seizures remained in the range of 550-600 per year. The volume, however, more than tripled against previous years. 
Sixty-nine cannabis plant seizures were made in 2008. This represents a slight increase compared to previous years 
but the number of cannabis plants seized increased significantly and reached 25,223 in 2008, i.e. over fourteen 
times the number of plants seized in 2005. In this context, there is also a marked increase in the number of growing 
sites detected, from 17 in 2005 to 79 in 2008. The number of hashish seizures and the volume of the drug seized 
were relatively stable in 2006-2008. There are approximately 30-40 seizures per year, involving a total annual 
quantity of approximately 0.5 kg; see Table 10-2. 
With 405 seizures, pervitin is the second most commonly seized drug. 370-400 seizures annually were reported in 
the last three years. The volume of pervitin seized was lower compared with the previous years (with 3.8 kg in 2008) 
but the number of cooking labs detected was the highest in the last 6 years (434 sites). An increase is also apparent 
in the amount of medicines containing pseudoephedrine seized in 2006-2008; see Table 10-1. 
Table 10-1: Quantity of the precursors and medicines containing pseudoephedrine and intended for pervitin production 
seized, cooking labs detected, and pervitin seized in 2006-2008 (Národní protidrogová centrála, 2009b) 
Seizures 2006 2007 2008 
Ephedrine (g) 1,201 1,185 1,677 
Pseudoephedrine (g) 0.7 218 – 
Modafen® (tablets)  2,406 3,480 7,876 
Nurofen Stop Grip® 
(tablets) 4,631 11,948 21,785 
Panadol Plus Grip® 
(tablets) – 72 17,021 
Cooking labs 426 388 434 
Pervitin (g) 5,249 5,978 3,799 
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In comparison with 2007, there was a relatively significant decrease in the number of cocaine seizures (24) and in 
the amount of the drug seized (7.6 kg) in 2008. The number and quantity of ecstasy seizures also decreased, with 
18 seizures of 16,610 tablets in total. As far as heroin is concerned, the number of seizures remained rather stable 
(105) but there was an increase in the volume of heroin seized (from 20.3 kg in 2007 to 46.3 kg in 2008). The 
number of LSD doses seized reached 246, i.e. double the figure for 2007. No crack was seized in the Czech 
Republic in 2008. The other substances seized in 2008 included 20 tablets of Subutex® (310 in 2007) and 2 g of 
amphetamine (29 g in 2007); see Table 10-2. 
Table 10-2: Number and quantity of seizures of main drug types in 2005-2008 (Národní protidrogová centrála, 2009d) 
2005 2006 2007 2008 Drug/Year Number  Quantity Number Quantity Number Quantity Number Quantity 
Marijuana (g) 602 103,337 556 108,352 563 122,124 602 392,527
Pervitin (g) 316 5,310 406 5,249 374 5,978 405 3,799
Heroin (g) 107 36,340 86 27,877 96 20,332 105 46,302
Cannabis plants (pcs) 53 1,780 44 2,276 46 6,992 69 25,223
Hashish (g) 123 4,625 42 466 25 387 30 696
Ecstasy (tablets) 41 19,010 29 26,259 30 62,226 18 16,610
Cocaine (g) 16 10,169 11 4,708 38 37,587 24 7,631
LSD (doses) 5 3,067 7 1,748 5 117 5 246
 
The breakdown of the 2008 seizures by amount shows that almost two thirds of the marijuana seizures involved 
quantities of less than 20 g, and 6% of seizures concerned amounts of over 1 kg of the drug. In the case of cannabis 
plants, almost 60% of the seizures were of over 100 plants each. 75% of the pervitin seizures involved less than 5 g 
of the drug, 3% over 100 g, and no seizure of a quantity exceeding 1 kg was reported in 2008. As for cocaine, 63% 
of the seizures were of quantities up to 20 g, and one seizure of over 1 kg of the drug was noted. A quantity of 20 g 
of heroin was seized in 77% of the seizures, while approximately 8% of the seizures were of a quantity of over 1 kg. 
Less than 20 tablets were seized in two thirds of the ecstasy seizures; one seizure of over 1,000 tablets was 
reported. Forty-four seizures of marijuana, pervitin, cocaine or heroin involved a quantity exceeding 1 kg each, 
representing 4% of all the drug seizures by weight (Národní protidrogová centrála, 2009c). 
 
10.3 Price/Purity 
Information about the prices of the basic types of drugs in the Czech Republic is determined on an annual basis 
according to data and estimates provided by the district police headquarters (56 headquarters in 2008) to the 
National Drug Headquarters. The prices of the basic drugs in 2008 remain stable; see Table 10-3. Drug purity data 
are only available for a part of the drugs seized and are mostly obtained from regional forensic laboratories and from 
the Forensic Science Institute in Prague. In comparison with 2007, the average purity of the marijuana and heroin 
seized increased slightly in 2008. A reduced concentration was noted in hashish and cocaine (Národní protidrogová 
centrála, 2009f); see Table 10-4. 
Table 10-3: Average and most common (modus) prices of drugs in 2006-2008 (€) (Mravčík et al.  2008; Národní 
protidrogová centrála, 2009d) 
2006 2007 2008 Drug type Average Modus Average Modus Wholesale  Average Modus Wholesale  
Marijuana (g) 7.6 6.0 7.2 4.0 0.8-10.0 7.2 8.0 2.0-12.0
Hashish (g) 10.8 8.0 10.4 8.0 2.0-12.0 9.6 10.0 4.0-10.0
Ecstasy 
(tablets) 8.8 6.0 8.4 8.0 1.2-8.0 8.8 8.0 1.2-10.0
Pervitin (g) 42.5 40.1 45.3 40.1 20.0-60.1 45.3 40.1 16.0-60.1
Heroin (g) 43.7 32.1 44.1 40.1 16.0-60.1 43.3 40.1 16.0-42.1
Cocaine (g) 89.0 80.2 82.6 80.2 48.2-80.2 80.2 80.2 32.1-72.2
LSD (doses) 6.4 6.0 7.2 8.0 0.8-8.0 7.2 4.0 2.0-12.0
NB: Prices rounded to tenth of €. 
strana 95 
Table 10-4: Average drug purity percentage in 2005-2008 (Mravčík et al.  2008; Národní protidrogová centrála SKPV 
Policie ČR, 2008)  
2005 2006 2007 2008 
Drug type Number of 
samples 
Average 
purity (%) 
Number 
of 
samples
Average 
purity (%) 
Number 
of 
samples 
Average 
purity (%) 
Number 
of 
samples 
Average 
purity (%) 
Marijuana 108 3.8 151 4.5 177 4.7 404 5.5
Hashish 10 7.4 1 11.0 2 8.1 5 5.2
Ecstasy* 135 27.2 54 22.6 31 27.4 20 17.5
Pervitin 65 62.9 58 52.3 123 66.4 145 64.3
Heroin  19 41.5** 35 7.9 31 17.4 47 22.6
Cocaine 25 55.9 12 40.2 48 49.1 35 43.5
NB: * average MDMA content in a single tablet, given in milligrams; ** the high average purity of heroin resulted from the inclusion of 
several seizures of highly concentrated heroin. 
strana 96 
PART B: SELECTED ISSUES 
Selected issues are included in the Annual Report every year. The topics are set by the EMCDDA in co-operation 
with the focal points in the individual Reitox countries with regard to the topics’ relevance and the research needs. 
On the basis of the agreement between the EMCDDA and the focal points, a single issue (Sentencing Statistics) 
was selected for the 2007 Annual Report rather than three issues, as had been the case in previous years. From this 
year on, all the countries are to prepare chapters on two selected issues, one of which is mandatory (Cannabis 
Markets and Production this year) and one is selected by the focal point from two options offered. The Czech 
National Focal Point has chosen to cover both of the voluntary selected issues. 
11 Cannabis Markets and Production 
Cannabis is the most widely consumed illicit drug worldwide. While there is relatively enough information on issues 
relating to the use of and demand for cannabis, its production and market have not been described in satisfactory 
detail. The objective of this chapter is to present the available information about cannabis production and trafficking 
in the Czech Republic, the cannabis products market, the users’ practices on the market, and the prices and the 
factors that influence them. 
In the second half of the 20th century, cannabis was grown and used in the Czech Republic mostly within isolated 
groups. In commercial terms, the market in cannabis products (marijuana and hashish) opened up in the 1990s. The 
political approach to the growing and use of marijuana has been unsteady since the end of the last century. The use 
of cannabis is not illegal and its possession is classified as a misdemeanour or as an offence, depending on the 
quantity of the drug. The new penal code, which will come into effect in 2010, mitigates the punishment for 
individuals who possess or grow cannabis for their personal use. 
The Czech Republic ranks among the European countries with the highest prevalence of cannabis use; the lifetime 
prevalence among people aged 15-64 was 34% in 2008 (it was higher in men, and the highest levels were reported 
by the 15-24 age group).  
The seeds for growing cannabis can be procured within social networks or via the internet. In June 2009, there were 
several dozen “grow shops” supplying equipment for cannabis growing. Most of the respondents of the general 
population survey considered procuring cannabis difficult but the task was described as relatively easy for three-
quarters of the respondents aged 15-24. Cannabis can most commonly be obtained in the Czech Republic in bars, 
restaurants, or clubs. Almost three-quarters of the respondents stated that on the most recent occasion they had 
acquired cannabis it was free of charge. Cannabis can most usually be obtained from a friend, a relative, or a 
partner. The dealers are often also consumers and they usually do not sell other drugs. The retail prices of marijuana 
and hashish remain stable, they are sold at approximately CZK 200 (€ 8) and CZK 250 (€ 10) per gram, respectively. 
Three out of four respondents had purchased cannabis in a quantity of less than 2 grams in their most recent 
transaction. While the average potency of marijuana is increasing, that of hashish is dropping. Marijuana grown 
indoors accounts for the larger proportion of cannabis, including that on the commercial market, followed by 
marijuana grown outdoors. Most cannabis users identified the Czech Republic as the country of origin of the 
marijuana they had acquired most recently. The number of marijuana seizures is usually 550-600 per year; the total 
quantity of marijuana seized is increasing progressively. Approximately 5% of the marijuana seizures and only one 
seizure of hashish in the last 3 years involved a quantity of over 1 kg. Every second seizure of cannabis plants in 
2008 involved a quantity of over 100 plants. A growing number of large-scale indoor plantations detected has been 
observed since 2005; a total of 79 of them were detected in 2008. 
650-750 persons were arrested or prosecuted in connection with cannabis in 2008 (approximately 30% of all those 
arrested or prosecuted for drug-related offences), 524 persons were charged (25% of all those charged), and 231 
persons were sentenced (17% of all those sentenced) in 2008; there is a slight increase in the total number of people 
charged in relation to cannabis but the number of persons sentenced remains stable. In terms of sentencing, a slight 
increase can be noted in recent years in the proportion of unsuspended sentences and penal measures, with a 
falling proportion of suspended prison sentences. 
11.1 History of Cannabis Use in the Czech Republic 
Cannabis was traditionally grown on the territory of the former Czechoslovakia for industrial purposes until the 1980s. 
The use of marijuana for its psychotropic effects saw a significant increase in the Czech Republic especially in the 
1990s but marijuana had been home-grown before that. The use of cannabis before 1989 was characterised by a 
link between an individual user and a particular community or group with its own system of procuring the drug, most 
typically on a self-supply basis.64. The commercial market in cannabis, which opened up in the 1990s, managed to 
replace the self-supplying social network only partially. A significant commercialisation of the Czech cannabis market 
                                                          
64 During the socialist period in Czechoslovakia, marijuana was obtained and used within isolated groups. Two types of user groups 
have been described: (1) the so-called hard core of the drug scene, for whom marijuana was an additional drug in polydrug use, and (2) 
groups around and within the then dissident movement (Miovský et al., 2008). 
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occurred in the period 1997-2000. For example, the range of cannabis products supplied was extended, the prices 
between indoor and outdoor cannabis were differentiated, and more intensive links were established between the 
cannabis market and the market in other drugs. A number of users also moved to indoor growing in the same period, 
as this method also reduces the risk of seizure or theft, in addition to producing a drug with greater potency (Miovský 
et al.  2008). 
11.2 Legal Framework of Cannabis Use 
Since the beginning of a systematic drug policy in 1993, an ever-changing approach on the part of the Czech 
executive and legislative powers to the growing, possession, and use of cannabis can be observed. This is 
demonstrated in changes in the political attitudes to this issue, which range from an emphasis on a knowledge-
based, balanced, and rational approach on the one hand to an overpoliticised and populistic abuse of the topic by 
certain politicians or political parties (Miovský et al.  2008).  
Act No. 140/1961 Coll. (the Penal Code), as amended mainly in 1990 and 199865 as far as drug-related offences are 
concerned, is of particular importance in terms of the legislation concerning cannabis products in the post-1990 
history of the Czech Republic. Drug crime is currently defined by four provisions of the Penal Code: Sections 187, 
188, 188a (unauthorised production and other handling of drugs; manufacturing and possession of equipment for the 
production of drugs; promotion of drug use) and Section 187a, which, effective from 1 January 1999, introduced the 
illicit status of the possession of drugs for personal use in a quantity greater than small. The possession of a small 
quantity of drugs qualifies as a misdemeanour punishable through administrative proceedings according to Act No. 
200/1990 Coll. on misdemeanours. The relevant directives of the Police President and of the Supreme Prosecutor 
which define the “quantity greater than small” for the most common drugs, or the amount of the drugs which may be 
grounds for criminal prosecution, are used for practical policing and public prosecution purposes. Nevertheless, such 
directives are not binding for the decision making of the courts. 
Act No 40/2009 Coll. (the Penal Code), which will come into effect on 1 January 2010, will mitigate the penalties 
applicable to persons possessing cannabis (Section 284), as well as cannabis growers (Section 285). The greater-
than-small quantity of drugs which will be the grounds for criminal prosecution will be defined by a regulation adopted 
by the Government. For additional information, see the chapter on Legal Framework, page 5. 
11.3 Prevalence of Cannabis Use 
The 2008 general population survey on the use of psychotropic substances in the Czech Republic (CS 2008) 
revealed a lifetime prevalence of cannabis (marijuana, hashish) use of 34% among respondents aged 15-64 (the 
highest figure was reported in the 15-24 age group with 59%, an increase by 15 percentage points against 2004). 
The prevalence of use in the past year was 15.2% (topped by 37% in the 15-24 age group), and the prevalence of 
use in the past month was 8.5% (with the 15-24 age group leading the statistics with 22%). 57% of the respondents 
who had used cannabis in the previous month used it once a week and 9% of them used it on a daily or almost-daily 
basis. Extrapolated to the population of the Czech Republic aged 15-64, the number of daily or almost-daily users of 
cannabis can be estimated to 57,000. There are apparent differences between men and women in the frequency of 
use: men smoked marijuana statistically more significantly often than women (Národní monitorovací středisko pro 
drogy a drogové závislosti, 2009d). For details see the chapter on Drug Use in the General Population and Specific 
Targeted Groups, page 16.  
The respondents of the CS 2008 general population survey who stated that they had used marijuana in the past 12 
months were asked about other aspects of the cannabis market in the Czech Republic. These data, complemented 
with information from the National Drug Headquarters and information from an online search, are provided and 
interpreted below. 
11.4 Cannabis Market Organisation 
11.4.1  Sale of Cannabis Seeds and Cannabis-Growing Equipment  
The seeds of high-potency cannabis are not officially offered by any of the Czech “grow shops” (formally gardening 
supply shops, unofficially cannabis growing supply shops). Nevertheless, seeds for growing cannabis plants with a 
higher content of THC or scions of cannabis plants can be obtained via social networks or through internet 
discussion fora in the community of cannabis growers. Seeds can also be ordered commercially online, e.g. in 
Slovak “grow shops” or in other foreign online shops. 
As of June 2009, internet search identified over 25 brick-and-mortar “grow shops” in the regional capitals (except 
Olomouc, Zlín, and Karlovy Vary). The biggest number of grow shops (10) is found in Prague. A number of them 
also offer online sales. In addition, there are also exclusively online shops. The grow shops sell a full range of indoor 
growing equipment starting at approximately CZK 7,000 (€ 280). However, a number of growers also buy these 
supplies in ordinary gardening shops, where some of the items may be purchased at a lower price. 
                                                          
65 By Act No. 175/1990 Coll. and Act No. 112/1998 Coll. 
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11.4.2 Cannabis Retail Outlets  
Over one half (54%) of all the respondents in the CS 2008 survey found procuring cannabis rather difficult to 
impossible. On the contrary, 20% considered it very easy. However, cannabis is easy or very easy to obtain for three 
quarters of young people aged 15-24. The most common places for procuring cannabis in the Czech Republic in 
2008 were bars, restaurants, or clubs (36% of the most recently acquired cannabis among the respondents in the 
CS 2008 survey). It was there that the users obtained (i.e. purchased, were given, or shared) cannabis from friends 
or acquaintances. Even when they paid for it, the price was usually low. The second most common place for 
procuring cannabis was a private event or home (31%), where cannabis was usually given for free or shared. The 
third most common place for obtaining cannabis was a public space66 (20%), where 28% of the commercial 
transactions took place. They predominantly involved purchasing the drug, mostly indoor marijuana, from an 
unknown person for a relatively high price. In addition to the locations and circumstances mentioned above, a 
number of transactions took place in the dealer’s home (13%). One tenth of the respondents purchased their most 
recent batch of marijuana at school or at work (Národní monitorovací středisko pro drogy a drogové závislosti, 
2009d).  
11.4.3 Cannabis Transaction Types 
Almost three-quarters (72%) of the respondents stated that on the most recent occasion they had received 
marijuana it had been for free or by sharing it67, with sharing accounting for the higher proportion of the cases. 17% 
of the respondents purchased cannabis, and 8.5% stated their own cannabis growing as the source (11% of the 
cannabis most recently procured in men, 2.5% in women). In terms of the type of relationship between the user and 
the provider of the cannabis the user had obtained most recently, they were predominantly (61%) friends, relatives, 
or partners. 20% of the respondents received cannabis from an acquaintance and approximately 9.3% of the 
respondents from a dealer or an unknown person. In their most recent purchase, the users received cannabis from a 
friend, relative, or partner (35%) who has easier access to the drug; 32% received the cannabis from an 
acquaintance and 28% from a dealer. As far as cannabis product transactions are concerned, no statistically 
significant differences were found. They did, however, occur in the way the respondents handled the drug upon its 
acquisition; an average 70.5% of the users gave their last cannabis to others or shared it with them. However, over 
90% of the respondents in the Zlín, Karlovy Vary, and Ústí nad Labem shared it, compared to cannabis sharing by 
less than one-half of the respondents in the Pardubice region (Národní monitorovací středisko pro drogy a drogové 
závislosti, 2009d).  
In 2007, cannabis markets were the topic of a bachelor's thesis based on research conducted using a sample of 50 
marijuana consumers and dealers aged 15-30 in Prague and in Central Bohemia. The thesis divided the marijuana 
dealers into two categories: traffickers, who purchase the drug from a large-scale cultivator or home grower and sell 
exclusively indoor marijuana, and dealers who are at the same time growers, usually selling outdoor marijuana. The 
dealers are often also consumers and they usually do not sell other drugs together with marijuana. According to the 
thesis, the cannabis market is relatively relaxed, with a rather low risk of robbery or other kinds of violence. The 
dealers mostly expected activity on the part of the buyers (e.g. a telephone call) and there are no fixed locations or 
times for the sale. The dealers perform only a superficial assessment of the buyers’ risk level and often only judge 
them by their “coolness” and “friendliness”, appropriate language, appearance, etc. A specific phenomenon 
associated with this market is the fact that the price of marijuana and the growing socioeconomic independence of a 
number of the buyers result in them becoming growers and subsequently starting to offer the surplus of their own 
marijuana. This surplus is usually not sold but rather given for free or exchanged for other marijuana. The marijuana 
market is also characterised by a close relationship between the dealer and the buyer, which is often referred to as 
“friendly”. This relationship leads to the dealer giving various discounts and providing additional premium services 
such as home deliveries, purchase by phone, or purchase on credit. Open communities are established among 
marijuana consumers, in which dealers come not only to sell their goods but also to smoke and have fun. Solidarity, 
exchange, and assistance are present among the consumers, both horizontally (e.g. by lending or providing money 
and items, including marijuana, to each other) and vertically (with the socioeconomically more independent 
consumers supporting users, usually the younger ones, with a higher degree of social dependence) (Procházka, 
2008).  
11.4.4 Retail and Wholesale Prices and Amounts and the Macroeconomic Context 
According to the drug prices reported by the National Drug Headquarters on an annual basis, the retail prices of 
marijuana and hashish remained relatively steady in 2006-2008. However, the information about the prices obtained 
from the district police headquarters is not given in the context of the amount or type of marijuana (outdoor, indoor) 
and hashish. In the period 2006-2008, marijuana and hashish were sold for an average of CZK 180 (€ 7) and CZK 
250 (€ 10), per gram respectively (Národní protidrogová centrála, 2009d); see Table 10-3 (page 94) in the chapter 
on Drug Markets, page 92. 
                                                          
66 This may include cars or other environmnents providing more safety than the open street. 
67 In a number of indicators, the “shared“ and “free“ ways of procuring marijuana overlap and are not clearly distinguished by the users, 
which resulted in different responses to the question: “How did you procure the marijuana you used most recently?“ depending on which 
of the options “for free” and “shared” was offered to the respondent first. 
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A survey conducted in 2007 among marijuana consumers and dealers showed that the consumers usually 
differentiated between “grass”, i.e. marijuana with a lower THC content, and the more potent “skunk”. The price of 
“grass” was CZK 100-200 (€ 4-8) per gram, while that of “skunk” was most usually around CZK 250 (€ 10) per gram. 
According to most respondents, these prices had been stable for the last 9 years (Procházka, 2008). According to 
the CS 2008 survey, two thirds (65%) of the respondents who obtained their most recent batch of marijuana by 
purchasing it paid less than CZK 200 (€ 8) per gram, most commonly between CZK 100 and 150 (€ 4 and 6). The 
price under CZK 200  (€ 8) was also consistent with the replies from participants in internet discussions regarding the 
price of indoor-grown marijuana on the commercial market. The average price was CZK 134 (€ 5,4) for outdoor 
marijuana (median of CZK 150 (€ 6)), CZK 164 (€ 6,6)  for indoor marijuana (median of CZK 150 (€ 6)), and CZK 
225 / € 9 for hashish (median of CZK 175 (€ 7)) (Národní monitorovací středisko pro drogy a drogové závislosti, 
2009d).  
On the occasion of their last sales transaction, three out of four respondents purchased less than 2 grams of 
marijuana, with approximately two thirds of the respondents purchasing a quantity of one gram and less. Almost one 
half of the respondents (47%) who stated they had received marijuana for free most commonly reported receiving 
quantities of less than 1 gram (Národní monitorovací středisko pro drogy a drogové závislosti, 2009d). The 
participants in internet discussions mentioned that the amount of marijuana purchased often does not correspond to 
the agreed price or that the dealers sometimes moisten the drug to achieve a greater weight. 
The wholesale prices of cannabis products are difficult to determine with a higher degree of accuracy. This is mainly 
due to two facts. Firstly, most transactions involve lower quantities of marijuana. Secondly, the range of prices 
reported by the National Drug Headquarters in connection with “wholesale” is very wide. The data do not contain 
additional information about the amounts of the individual seizures from which the price was determined and about 
the quality of the cannabis products (indoor/outdoor, potency). Finally, the exact methodology for establishing the 
wholesale prices (e.g. by estimate, interrogation, interviews with producers and dealers, monitoring of 
communication by the police, etc.) is not known. See Table 10-3 (page 94) in the chapter on Drug Markets, page 92. 
 
On the basis of the CS 2008 general population survey, the size of the commercial marijuana market can be 
estimated at CZK 2.7 billion (€ 108,260 thousand), i.e. 0.07% of the GDP (according to the 2008 prices). The 
average amount spent on marijuana in the past year by its users was CZK 12,000 (€ 481) (one half of the 
respondents spent under CZK 4,200 (€ 168) per year, but up to CZK 73,000 (€ 2,927) per year was spent in 
individual cases). The financial value of the marijuana grown mainly for personal use and for non-commercial 
distribution within social networks corresponded to CZK 1.5 billion (€ 60,144 thousand) (0.04% of the GDP), which 
did not go through the black market because of the self-supply of users with cannabis.68 
11.5 Origin of Cannabis on the Domestic Market 
According to the CS 2008 survey, marijuana cultivated indoors accounted for the largest proportion of cannabis 
products in the Czech Republic in 2008 and was acquired69 by 37.1% of the respondents, including those who grew 
indoor marijuana themselves. Outdoor marijuana accounted for 26.8% and hashish for 2.7% of the cannabis 
products acquired most recently. A third of the respondents (33.3%) could not determine the type of cannabis they 
had last obtained. The results of an online poll conducted by the National Focal Point via its website starting in 
February 2009 (with 1,681 respondents as of 24 August 2009) concerning the type of cannabis most usually used in 
the past year were relatively consistent with the results of the CS 2008 general population survey: 35% of the 
respondents mainly used domestic indoor marijuana, 30% used domestic outdoor marijuana, 8% used imported 
indoor or outdoor marijuana, 6% used hashish, and 22% were uncertain of the origin of the drug. It is possible to 
draw a simplified conclusion from these results that approximately one third to a half of cannabis consumers use 
indoor marijuana, one third use outdoor marijuana, and the remaining one fifth to one third do not know the origin of 
the cannabis; hashish is used by an estimated 5-10% of cannabis users (Národní monitorovací středisko pro drogy a 
drogové závislosti, 2009d).  
The commercial market in cannabis products is dominated by indoor production, as almost half of the respondents 
had bought marijuana grown indoors in their most recent purchase (47.6% bought indoor and 18.3% outdoor 
marijuana, 4.6% bought hashish, and 29.4% bought cannabis of an unknown origin). 31% of the respondents who 
had shared or received their most recent batch of marijuana free of charge reported having obtained indoor 
marijuana, 23% outdoor marijuana, and almost half (45%) had no knowledge of the type. The respondents who 
grew marijuana themselves (8.5% of the respondents who had used marijuana in the past year) mainly reported 
outdoor cultivation (62%) but the validity of the information may be reduced by the fact that the survey was 
                                                          
68 The calculation based on the available data presumes several types of simplification: the most recent way of procuring marijuana, as 
stated by the respondents, is taken as their regular method of obtaining the drug; the overall calculation relies on average prices (CZK 
134 (€ 5,4) per gram for outdoor marijuana, CZK 164 (€ 6,6) per gram for indoor marijuana, and CZK 225 (€ 9) per gram for hashish); 
for each day on which marijuana was used in the past 12 months, the consumption of one gram of marijuana was presumed. The 
calculation also uses an estimate of the proportion of indoor and outdoor marijuana and hashish on the commercial market and data on 
the frequency of use collected from the respondents who purchased or grew marijuana. 
69 The data provided include all the methods of the most recent procurement of marijuana, including sharing and receiving the drug free 
of charge. 
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conducted in the respondents’ homes, which may have influenced their willingness to admit growing cannabis at 
home (indoors) (Národní monitorovací středisko pro drogy a drogové závislosti, 2009d).  
In the CS 2008 survey, most cannabis users (57%) identified the Czech Republic as the country of origin of the 
cannabis product most recently obtained, followed by the Netherlands (6.5%), other European countries (2%), and 
other non-European countries (0.3%). One third of the respondents could not determine the country of origin of the 
drug (Národní monitorovací středisko pro drogy a drogové závislosti, 2009d). Some Czech experts estimate that 
20% of the marijuana available on the domestic market is imported, with Holland accounting for approximately 60% 
of the imports (Národní monitorovací středisko pro drogy a drogové závislosti, 2009b). The imported hashish mainly 
originates in North Africa (Morocco). The National Drug Headquarters and the Customs Administration of the Czech 
Republic often report seizures of marijuana imported by post (mainly sent from the Netherlands)70. Hashish is mainly 
smuggled to the Czech Republic from the Netherlands or from Spain using postal consignments or couriers. The 
average weight of individual seizures was 12 g (see also the 2007 Annual Report). 
 
11.6 Potency 
Drug purity data are only available in the Czech Republic for a part of the drugs seized and are mostly obtained from 
regional forensic laboratories and from the Forensic Science Institute in Prague. A comparison of the data available 
from the period 2006-2008 shows a slight increase in the average potency of marijuana and a decrease in that of 
hashish; see Table 11-1 and also Table 10-4 (page 95) in the chapter on Drug Markets, page 92. 
Table 11-1: Potency of cannabis products in 2006-2008 (percentage) (Národní protidrogová centrála, 2009d) 
2006 2007 2008 Cannabis 
product Average Min.-max. Average Min.-max. Average Min.-max. 
Marijuana 4.5 0.37-32.0 4.7 0.2-26.9 5.5 0.3-21.1 
Hashish 11 – 8.1 4.7-11.5 5.2 3.0-15.6 
 
11.7 Seizures 
The usual number of marijuana seizures is 550-600 per year; the total quantity of marijuana seized is increasing 
progressively. In the past three years, approximately 5% of marijuana seizures and only one hashish seizure 
involved an amount exceeding 1 kg. Sixty-nine seizures of cannabis plants were reported in 2008, with 
approximately one in two seizures being of over 100 plants. The number of cannabis plants seized increased nearly 
fourfold on a year-on-year basis; see Table 11-2. The amount of hashish seized (700 g) in 2008 was almost double 
the 2006 or 2007 figures; see Table 11-3 (Národní protidrogová centrála, 2009d). 
A relatively recent trend in the Czech Republic can be seen in the increasing number of large-scale indoor 
plantations seized since 2005. Seventeen plantations were detected in 2005, 34 in 2007, and 79 in 2008. 
Vietnamese nationals are often involved in the organised large-scale growing of marijuana and have been confirmed 
to be connected to Vietnamese groups living in the Netherlands and in Canada. For example, over 70 criminal 
prosecutions related to indoor cannabis growing were instigated in 2008, with most of the cases involving 
Vietnamese offenders. The cannabis produced by the large-scale plantations is intended both for the domestic 
market and for export to European countries, mainly to Germany, the Netherlands, Belgium, and Poland (Národní 
protidrogová centrála, 2009b).  
Table 11-2: Cannabis plant seizures by amount and number of seizures in 2006-2008 (Národní protidrogová centrála, 
2009d) 
Number of cannabis plant seizures Year Total number of plants 1-50 pcs 51-100 pcs > 101 pcs Total 
2006 2,276 pcs 38 4 2 44 
2007 6,992 pcs 30 6 10 46 
2008 25,223 pcs 25 5 39 69 
 
                                                          
70 In 2007, the Customs Administration reported 11 seizures of imported marijuana, 8 of which were transported by air in postal 
consignments, mostly from the Netherlands (Celní správa ČR, 2008). 
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Table 11-3: Marijuana and hashish seizures by amount and number of seizures in 2006-2008 (Národní protidrogová 
centrála, 2009d) 
Number of seizures by amount Cannabis 
product Year 
Total number 
of seizures  0-100 g 101-1,000 g > 1 kg Total 
2006 108 kg 459 75 22 556 
2007 122 kg  464 69 30 563 Marijuana 
2008 393 kg 483 84 35 602 
2006 466 g 40 2 0 42 
2007 387 g 23 1 1 25 Hashish 
2008 700 g 28 2 0 30 
 
11.8 Offences 
Primary drug-related crime in the Czech Republic is defined by four sections of the Penal Code; see the chapter on 
Legal Framework, page 5. 
In the period 2006-2008, the total number of persons arrested or prosecuted for drug-related offences in the Czech 
Republic was between 2,023 and 2,630 per year, depending on the source (see also the chapter on Drug-related 
Crime, Prevention of Drug-related Crime, and Prison, page 81). 650-750 people were arrested or prosecuted in 
connection with cannabis in 2008 (approximately 30% of all those arrested or prosecuted for drug-related offences), 
524 persons were charged (25% of all those charged), and 231 persons were sentenced (17% of all those 
sentenced) in 2008. There is an increase in the total number of persons charged in connection with cannabis but the 
number of the persons sentenced remains stable; see Table 11-4. While a slight decrease can be observed in the 
last 3 years both in the total number and in the proportion of persons sentenced for producing and trafficking 
cannabis (Section 187), there is a slight increase in the total number and proportion of individuals sentenced for the 
possession of a greater than small quantity of cannabis for personal use (Section 187a); see Table 11-5. In terms of 
sentences for cannabis-related offences, a slightly increasing trend can be observed in recent years in the proportion 
of unsuspended sentences and penal measures, while the proportion of suspended sentences is decreasing; the 
proportion of community service sentences remains stable; see Table 11-6. 
Table 11-4: Persons prosecuted, charged, and sentenced in connection with cannabis in 2006-2008 (Ministerstvo 
spravedlnosti ČR, 2009b; Ministerstvo spravedlnosti ČR, 2009c) 
Prosecuted Charged Sentenced 
Year Number Proportion (%) Number 
Proportion 
(%) Number 
Proportion 
(%) 
2006 638 30 285 21 255 21 
2007 503 25 387 16 226 19 
2008 655 28 524 25 231 17 
 
Table 11-5: Persons sentenced according to Sections 187 and 187a of the Penal Code in connection with cannabis in 
2006-2008 (Ministerstvo spravedlnosti ČR, 2009a; Ministerstvo spravedlnosti ČR, 2009c) 
Section 187 Section 187a 
Year Number Proportion (%) Number 
Proportion 
(%) 
2006 215 84 28 11 
2007 184 81 28 12 
2008 176 76 44 19 
 
Table 11-6: Main types of sentences for drug-related offences committed in connection with cannabis in 2006-2008 
(Ministerstvo spravedlnosti ČR, 2009a; Ministerstvo spravedlnosti ČR, 2009c)  
Year Total sentences 
Unsuspended 
sentences (%) 
Suspended 
sentences (%) 
Community service 
sentences (%) 
Penal measures 
(%) 
2006 223 9 69 9 13 
2007 226 12 56 12 12 
2008 251 14 54 11 18 
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12 Problem Amphetamine and Methamphetamine Use, Related Consequences and Responses 
The objective of this chapter is to provide information about the situation concerning the use of amphetamines, i.e. 
amphetamine and methamphetamine, particularly the chronic or intensive (problem) use of such substances, and 
describe the health and social correlates and consequences of the use, production, and markets of amphetamines, 
as well as the preventive and treatment measures taken in the Czech Republic in relation to (meth)amphetamine 
use. 
In the past thirty years, methamphetamine (pervitin) has had a dominant position among problem drug users in the 
Czech Republic, which makes the Czech situation exceptional within the European context. Therefore, this chapter 
deals almost exclusively with methamphetamine – pervitin. 
In the Czech Republic, pervitin is the number one “hard drug”. It is estimated that there are approximately 20 
thousand problem pervitin users, which amounts to two thirds of all the problem drug users; 80-90% of those are 
injecting users. The level of pervitin use in the general population has remained very low over the years, although it 
has a rising tendency in nightlife settings. 
Pervitin users are the main group of users in contact with treatment and counselling services (from the long-term 
perspective, they account for approximately 60% of all the registered cases of drug-related treatment demands); this 
applies to services of all types, with outpatient medical facilities having the fewest clients from among pervitin users. 
Pervitin is often used in combination with other drugs, mostly cannabis, opiates, and alcohol.  
Long-term pervitin use is associated with psychiatric co-morbidity, involving toxic psychoses especially. Pervitin 
users show a higher suicide rate than opiate users. The incidence of infections among pervitin users is mainly 
related to injecting. However, it does not seem to differ significantly from that in (injecting) opiate users. In the Czech 
Republic, there are approximately 15-20 cases of pervitin overdoses annually, which accounts for about one third of 
overdoses on street drugs (illicit drugs plus inhalants). 
Pervitin use treatment has long been integrated into the system of general drug services. No pervitin use-specific 
programmes are provided; the treatment of pervitin use is not even set apart as requiring a different regimen and/or 
protocol. There are differences in the provision of certain services: harm reduction organisations have recently 
conducted programmes featuring the distribution of gelatine capsules intended almost exclusively for pervitin users, 
and, as far as treatment is concerned, variations can be found in its pharmacotherapy. These are determined by a 
different course of withdrawal and detoxification, different psychological complications and, in particular, the 
development of psychotic symptomatology and psychosis. There is rare, although long-term, experience with the 
substitution therapy of pervitin addicts using various psychostimulants, presently methylphenidate.  
12.1 Epidemiology of Amphetamine and Methamphetamine Use with Emphasis on Chronic/Intensive 
Use 
12.1.1 History of (Meth)amphetamine Use 
The history of the use of amphetamines, including the most common amphetamine in the Czech Republic – 
methamphetamine (pervitin) – needs to be perceived within the context of the history of stimulant and psychotropic 
substance use in general. 
As elsewhere in Europe in the 1920s and 1930s (e.g. France, Germany), cocaine use was widespread in 
Czechoslovakia, particularly among artists and intellectuals, as well as among criminals and people associated with 
the underworld, mainly in the environment which is now referred to as the nightlife setting (Urban, 1973; Janota, 
1941). As far as the Czech professional literature is concerned, cocaine dependency with psychotic bizarre 
hallucinatory symptomatology was probably described for the first time by Janota (Janota, 1924). In the late 1930s 
and 1940s, “psychotonism”, abuse of, and dependency on, benzedrine, a left-handed form of amphetamine 
(Psychoton®) – used for the treatment of somnolence – again featuring psychotic paranoid-hallucinatory 
symptomatology, was described within the territory of today’s Czech Republic (Janota, 1941)71; It is noteworthy that 
this work referred to benzedrine use as a new phenomenon among individuals on the verge of law-breaking, such as 
prostitutes using cocaine. As regards non-alcohol drugs, the post-World War II period, or the period following the 
1948 Communist coup d’etat, was marked by the misuse of psychotropic pills falling under the heading of stimulants, 
as well as narcotics, painkillers (including opiates), and sedatives, especially barbiturates and benzodiazepines 
(Zábranský, 2007). In the 1950s, the abuse of, and dependency on, l-amphetamine (benzedrine, Psychoton®), 
referred to as “psychotonism”, was seen as the most serious problem in terms of non-alcohol dependencies. These 
developments led to stricter controls on l-amphetamine prescription (Petráň). In parallel to the occurrences of 
amphetamine misuse, the late 1950s experienced reports on the misuse of Yastil, an asthma medication containing 
ephedrine, again associated with psychotic paranoid hallucinatory symptomatology, agitation, restlessness, and 
                                                          
71 The same work by Janota mentions German reports from the late 1930s describing the misuse of, and dependency on, a similar 
stimulant, Pervitin. 
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aggressiveness (Dvořák, 1956; Helcl, 1957); This form of dependency was referred to as “yastilism”; it should be 
noted that a combined, or subsequent, dependency on Psychoton® and Yastil® was described (Dvořák, 1956). The 
misuse of Yastil, “yastilism”, among prisoners was also documented, which later resulted in Yastil, previously an 
over-the-counter medicine, being included in medications available on prescription only (Urban, 1973). The 1960s 
saw another wave of the misuse of, and dependency on, psychostimulants, which was brought about by 
dexphenmetrazine and, in particular, phenmetrazine (Preludin®); phenmetrazine misuse was referred to as 
“phenmetrazinism”. While reports on their abuse had already appeared in the late 1950s, a major increase in the 
consumption of these substances occurred between 1959 and 1960 (Urban, 1973) and from 1963 to 1965 the 
individuals dependent on phenmetrazine accounted for approximately 40% of those dependent on non-alcohol 
drugs who were treated in inpatient psychiatric facilities; again, typical psychotic symptomatology resulting from 
chronic use was described (Vondráček et al.  1968). 
The use of methamphetamine (pervitin, as it is referred to in the Czech Republic, also within the professional 
community), manufactured on a home-made basis using ephedrine and ephedrine-containing medicines, emerged 
in the then socialist Czechoslovakia, particularly in today’s Czech Republic, in the 1970s72. By the 1980s, pervitin (in 
addition to pills and a home-made opiate drug, “braun”73) had taken a dominant position on the then drug scene 
(Zábranský, 2007; Kalina and Bém, 1994; Hampl, 1994). From the beginning, pervitin use in the Czech Republic has 
been associated with injecting (similar to the use of “braun”); during the era of socialism pervitin use was limited to 
closed groups of users (problem drug users, using the present-day terminology) around a drug producer. The period 
before 1989 is characterised by a lack of information on the extent of illicit drug use and the forms of such use, both 
in general terms and, specifically, as far as amphetamines and/or pervitin are concerned. Nevertheless, in the late 
1980s, the total number of people in the Czech Republic dependent on non-alcohol drugs was estimated to be 25-30 
thousand (Nožina, 1997), which is a figure corresponding to the current prevalence estimates, including pervitin and 
opiate users. 
After 1989 a pervitin black market emerged (see below) and the drug spread outside closed groups of users and 
producers to the whole of the Czech Republic (Zábranský, 2007). Heroin use became common in the Czech 
Republic in the mid-1990s74. While problem heroin use remained concentrated mainly in Prague, North Bohemia, 
and the Bohemian regions in general (in Moravia, only Brno shows significant levels of heroin use), problem pervitin 
use is widespread throughout the Czech Republic, including provincial areas. In the past decade pervitin also 
gradually spread from the subpopulation of problem users into the environment of dance and music events and 
nightlife settings in general (Mravčík et al.  2006). 
The use of other amphetamine-type drugs is almost non-existent and the incidence of cocaine use in the Czech 
Republic, however much it may be on the rise, continues to be low. Accordingly, pervitin is currently the predominant 
psychostimulant drug in the Czech Republic and a drug of choice among problem drug users75. 
Therefore, the following sections of this chapter deal almost exclusively with pervitin. In view of the fact that pervitin 
has played a key role in the drug problem in the Czech Republic for many decades and also constitutes an integral 
part of all the annual reports on the Czech drug situation, including this one, the following text will often refer to other 
chapters of this annual report, as well as the previous ones.  
12.1.2 Trends and Patterns of (Meth)amphetamine Use 
In the Czech Republic, the level of use of pervitin or amphetamine in the general population is relatively low, both in 
the adult population and among children and adolescents. 
According to the 2008 general population survey on the use of psychotropic substances in the Czech Republic (CS 
2008), employing a representative sample of 4,500 respondents aged 15-64, 4.3% of the population (5.7% of men, 
3.0% of women) had a lifetime experience of amphetamine, or pervitin, use, and the prevalence in the past year and 
the past month was 1.7% and 0.7% respectively. The highest lifetime prevalence, i.e. 8.5%, was reported for the 25-
34 age group; men in this age group reached a level of 10.6% (Národní monitorovací středisko pro drogy a drogové 
závislosti, 2009d). The results from the Czech part of the European Core Health Interview Survey for 2008 are also 
available (Ústav zdravotnických informací a statistiky , 2009a). They indicate that amphetamines, or pervitin, had 
been used by 1.4% of the adult population, and 0.6% and 0.3% had used the drugs in the past year and the past 
month, respectively. Possible reasons for the differences between both studies, as well as contextual information on 
the prevalence levels of other drugs and trends, are covered in more detail in the chapter on Drug Use in the 
General Population and Specific Targeted Groups, page 16. 
                                                          
72 Rather in the late 1970s – the early 1970s literature does not yet mention any methamphetamine (pervitin) abuse in Czechoslovakia 
(Vondráček, 1971; Urban, 1973). 
73 A typical opiate drug in socialist Czechoslovakia in the 1980s - a hydrocodone mix prepared on a homemade basis from medicines 
containing codeine. 
74 In 1994 Hampl still refers to the spread of heroin in the Czech Republic as a potential risk and indicates the number of the first 43 
heroin users treated in outpatient drug services in the Czech Republic (Hampl, 1994); in 1997, when the first official data from the 
Institute of Health Information and Statistics were available, 1,813 had been registered. 
75 Such a high level of methamphetamine use makes the Czech Republic exceptional even in the European context; only Slovakia 
shows levels of methamphetamine use similar to the Czech Republic (Griffiths et al., 2008). 
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The 2002 and 2004 levels of lifetime prevalence of amphetamine use in the adult population were 2.3% and 2.5% 
respectively; the levels of use in the past year reached 0.5% and 0.7% respectively (Psychiatrické centrum Praha, 
2002; Ústav zdravotnických informací a statistiky, 2006). As far as age is concerned, the highest lifetime prevalence 
of amphetamine use in 2004, i.e. 4.9%, was recorded for the 18-24 age category; the group of men aged 18-24 
reached a level of 6.2%. 
A decline in the prevalence of pervitin use among the school population has been observed since the late 1990s 
(Mravčík and Zábranský, 2001). Both the ESPAD survey among 16-year-olds and the HBSC study conducted with 
15-year-old pupils provided evidence of this trend. The results of the ESPAD study show that in 2007 3.5% of 16-
year-olds had lifetime experience with pervitin, while in 1999 it was 5.6% (Csémy et al.  2008). Equally, the HBSC 
survey among 15-year-old pupils of basic schools found a decline in lifetime prevalence, namely from 2.0% in 2002 
to 1.5% in 2006 (Csémy, 2007); for more details see the 2007 and 2006 annual reports. 
An increase in the use of pervitin in the nightlife setting, i.e. among those attending dance and music events, has 
been recorded since the beginning of the 21st century. Comparable results of three studies carried out among this 
population between 2000 and 2007 are available (in 2007, as in the previous years, 95% of the sample consisted of 
people aged 15-30 and two thirds of the sample comprised men); see Table 12-1. 
Table 12-1: Prevalence of pervitin use among dance partygoers in the Czech Republic between 2000 and 2007 (%) 
(Kubů et al.  2000; Kubů et al.  2006; Škařupová, 2007) 
Year Lifetime (%) 12 months (%) 30 days (%) 
2000 33.4 21.7 n.a. 
2003 44.6 24.9 13.8 
2007 47.6 28.0 15.8 
 
The common routes of pervitin administration among dance partygoers include snorting or oral use; injecting is 
exceptional. 
12.1.3 Prevalence Estimates of Problem (Meth)amphetamine Users 
The estimated number of problem pervitin users in the period 2002-2008 was approximately 20 to 22 thousand. In 
the long term, pervitin users account for about two thirds of the approximately 30 thousand estimated problem drug 
users in the Czech Republic; the majority of problem users inject drugs. For more information see the chapter on 
Problem Drug Use, page 28. 
In 1999, when a standard method was first used to estimate the prevalence of problem drug users in the Czech 
Republic, the estimated number of problem pervitin users was slightly higher – 22,500 individuals (95% CI: 18,000-
27,000), and so was the estimate of the total number of problem drug users, including opiate users – 37,500 
individuals (Mravčík and Zábranský, 2002; Mravčík et al.  2005b). 
12.1.4 Treatment Demand for (Meth)amphetamine Use 
In the long term, pervitin is the most common drug of choice among those people demanding drug treatment. 
According to the treatment demand register maintained by the Public Health Office, pervitin is the most common 
drug of choice in the Czech Republic; pervitin users accounted for about 60% of all the treatment demands in recent 
years (Studničková and Petrášová, 2009); The development of the absolute numbers of reported cases in the 1990s 
should be understood within the context of the growing network of drug services; see Table 12-2. 
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Table 12-2: Numbers and proportions of pervitin-related treatment demands in 1995-2008 (Mravčík et al.  2007; 
Mravčík et al.  2008; Studničková and Petrášová, 2009) 
First Treatment Demands All Treatment Demands  
Pervitin users Pervitin users  Year Total number Number % Total number Number % 
1995 2,905 1,005 34.6 n.a.  n.a. n.a. 
1996 3,252 1,390 42.7 n.a.  n.a. n.a. 
1997 3,132 1,510 48.2 n.a.  n.a. n.a. 
1998 3,858 2,177 56.4 n.a.  n.a. n.a. 
1999 3,891 2,042 52.5 n.a.  n.a. n.a. 
2000 4,148 1,880 45.3 n.a.  n.a. n.a. 
2001 4,232 1,969 46.5 n.a.  n.a. n.a. 
2002 4,719 2,389 50.6 9,237 4,589 49.7 
2003 4,158 2,281 54.9 8,522 4,490 52.7 
2004 4,600 2,685 58.4 8,845 4,790 54.2 
2005 4,372 2,605 59.6 8,534 4,855 56.9 
2006 4,199 2,528 60.2 8,366 4,889 58.4 
2007 4,346 2,749 63.3 8,487 5,177 61.0 
2008 3,981 2,492 62.6 8,279 4,925 59.5 
 
In the long term, the reported numbers of treatment demands in relation to amphetamine and other psychostimulants 
are sporadic; among all treatment demands in 2008, there were 3 amphetamine users, 10 phenmentrazine users, 
and one user of ephedrine. Additionally, 14 ecstasy users and 24 cocaine/crack users  were reported in 2008 
(Studničková and Petrášová, 2009). 
In the long term, pervitin-related treatment demands involve a higher proportion of women in comparison to other 
drugs; in 2008 women accounted for 37.3% of first demands and 35.7% of all treatment demands. As far as heroin 
users are concerned, these rates were 30.4% and 29.2% respectively, and 33.8% and 32.2% respectively among all 
treatment demands, regardless of the primary drug(Studničková and Petrášová, 2009). The proportion of women is 
generally higher among younger age groups, which especially applies to pervitin users: women consistently 
predominate over men in the lowest age group, up to 19 years old. In 2008 women comprised 57.5% of both first 
and all treatment demands, and, as regards the total number of treatment demands, irrespective of the primary drug, 
the rates were 47.1% and 47.9% respectively (Studničková and Petrášová, 2009). 
Pervitin users show a significantly lower average age (by more than three years) than heroin users and are also 
below the average age for all treatment demands. 26.4% of first treatment demands and 19.5% of all treatment 
demands related to pervitin are from people under 19 years of age, while the respective rates for heroin are reported 
to be 11.4% and 4.0%. In 2008 the average age of pervitin users was 24.0 years among first treatment demands 
and 25.4 years among all treatment demands. The respective figures for heroin users were 27.3 and 28.7 years, 
while for all treatment demands, irrespective of the primary drug, the average age was 24.3 and 25.9, respectively 
(Studničková and Petrášová, 2009). There has been a long-term increase in the pervitin users’ average age – in 
1996-1997 the average age of pervitin users demanding treatment for the first time in their lives was about 20 years; 
see Figure 5-4 and Figure 5-5 (p. 45). 
Pervitin use occurs in all the regions of the Czech Republic, although its extent varies. Pervitin users predominate in 
treatment facilities in all the regions. Nevertheless, Prague, the Capital City, and the regions of Hradec Králové, 
Central Bohemia, and Moravia-Silesia show the lowest rates of pervitin users among all the users in treatment; see 
Map 5-1 (p. 45). Until 2006, Prague, the Capital City, reported higher proportions of opiate users in treatment than of 
pervitin users (see the 2005 and 2006 annual reports); in Prague, this situation has not changed as regards 
prevalence estimates and clients of low-threshold centres (which provide information for prevalence estimates), in 
which opiate users are still predominant; see Map 4-1 (p. 29).  
Injecting is the most common route of pervitin administration among users in treatment. There is a higher proportion 
(by about 5 percentage points) of injecting users among all treatment demands. In the last five years the rate of 
injecting users has dropped from about 80-85% to 75-80%; see Figure 6-6 (p. 59). 
Polydrug use, i.e. the concurrent use of more than one drug, is a common phenomenon. After cannabis, pervitin is 
reported as the second most likely secondary (illicit) drug: apart from 4,925 users who reported it as their primary 
drug in 2008, pervitin was used as the secondary drug in 1,315 cases. In most cases (876), these were primary 
opiate users (including 686 heroin users and 137 Subutex® users); 382 cases involved cannabis users. 88% of 
people who use pervitin as their primary drug take another secondary drug; a chart of pervitin users’ secondary 
drugs is provided in Figure 12-1.  
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Figure 12-1: Proportions of secondary drugs among all treatment demands involving pervitin as the primary drug 
(Studničková and Petrášová, 2009) 
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Pervitin users include a significantly higher proportion of students than heroin users (13.3% versus 2.7%), while the 
rate of both unemployed people and those who report having regular jobs is lower among pervitin users, which is 
likely to be mainly associated with pervitin users’ younger age. Both pervitin and heroin users show a similar housing 
situation (Studničková, 2009a). 
In comparison to heroin users, pervitin users are less likely to seek treatment by themselves (51.8% and 61.6% 
respectively in 2008) or be referred by another agency (7.6% and 10.4% respectively), but are more likely to enter 
treatment as a result of pressure exerted on them by their family and friends (8.5% and 5.8% respectively) 
(Studničková, 2009a). 
Pervitin users also represent the largest, or one of the largest, groups in all of the other sources of data about the 
clients of treatment or low-threshold facilities. 
 In 2008 pervitin users accounted for 52.7% of clients of low-threshold facilities; for more information and trends 
refer to Table 7-1 (p. 69). 
 In 2008 pervitin users accounted for 21.2% of clients of outpatient psychiatric clinics; a higher representation was 
recorded for opiate users, and polydrug users and the users of sedatives and hypnotics also showed significant 
proportions among the patients of these facilities; for more data and trends see Figure 5-8 (p. 48). 
 Pervitin users also comprised 21.2% of those individuals admitted to inpatient psychiatric facilities in 2008; a 
higher representation was reported for polydrug users, and opiate users also accounted for significant rates; for 
more data and trends see Figure 5-11 (p. 51). 
 In addition, pervitin users account for the majority of clients of outpatient facilities operated by NGOs, therapeutic 
communities, and aftercare agencies; for more data and trends refer to Table 5-6 (p. 38), Table 5-12 (p. 52), and 
Table 8-2 (p. 79). 
More information about the clients of different types of services, including pervitin users, can be found in the chapters 
on Characteristics of Clients in Treatment (p. 43),Prevention and Treatment of Drug-Related Infectious Diseases, 
page 68) and Social Reintegration, page 78. 
 
12.1.5 Out-of-treatment Populations of (Meth)amphetamine Users 
More information on problem pervitin users can also be found in other chapters of this report, including Data on 
Problem Drug Use from Non-treatment Sources, page 30. 
Qualitative research conducted from September 2008 to January 2009 and involving three focus groups with the 
staff of low-threshold programmes showed that the majority of low-threshold programmes in the Czech Republic 
work with clients who mostly use pervitin, usually in combination with other substances, including opiates. The 
concurrent use of pervitin and benzodiazepines has also been recorded (Radimecký et al.  2009). 
strana 107 
The previous studies concerning drug users, especially those from among the clients of low-threshold facilities, 
support the data provided in this chapter. Pervitin users comprised the largest group in a study carried out in 2004-
2005; they accounted for 78% of the clients of low-threshold facilities (Petroš et al.  2005), and a significant 
proportion of the clients (16%) used pervitin in combination with opiates, mainly Subutex®. A high rate of polydrug 
users and, in particular, the concurrent use of pervitin and opiates (again, especially Subutex®) among the clients of 
Prague’s low-threshold facilities were also reported (Mravčík and Orlíková, 2007; Větrovec and Porubský, 2008). 
12.1.6 Production Sites and Laboratories, Origin of Products and Trafficking Routes, Seizures of 
Precursors 
The illicit production of pervitin in the Czech Republic dates back to the 1970s, when a simple procedure for reducing 
ephedrine to methamphetamine using readily available chemicals was rediscovered (Zábranský, 2007). Prior to 
1989, pervitin was manufactured from pure ephedrine or medicines containing ephedrine that were available at that 
time (typically, Solutan®, a cough medicine). The relatively easy availability of ephedrine probably played its role in 
the development of pervitin production and use. From 1971 pure ephedrine was manufactured by the VUAB 
(Research Institute of Antibiotics and Biotransformations) plant in Roztoky u Prahy, from where it was smuggled out. 
By the late 1990s VUAB had become a leading producer of ephedrine worldwide. Following a series of privatisation 
projects in the 1990s, the production of ephedrine was gradually reduced and, finally, came to an end in 2003-2004. 
It was known that ephedrine produced in the plant had been diverted to the black market. However, such cases were 
formally detected and reported only rarely and no estimates of the total amount of ephedrine smuggled out to the 
black market were ever made. 
Nowadays, pervitin is manufactured using both ephedrine (which is mostly smuggled into the Czech Republic from 
the Balkans) and, in particular, pseudoephedrine, which is easier to obtain, as it can be extracted from over-the-
counter medicines, such as Modafen®, Nurofen Stop Grip®, Paralen Plus®, and Panadol Plus Grip®. The massive 
misuse of medicines containing pseudoephedrine for the production of pervitin has been observed by the National 
Drug Headquarters since 2003–2004, and, at present, pseudoephedrine obtained from these pharmaceutical 
products is the main precursor used to manufacture pervitin. However, the National Institute for Drug Control has 
adopted a decision concerning a change in marketing authorisation for medicines containing pseudoephedrine in an 
amount of up to 30 mg, which has restricted their availability significantly. The measure became effective on 1 May 
2009. In this respect, since June 2009 the Customs Administration of the Czech Republic has recorded illegal 
imports of large quantities of these medicines from abroad; for more details see the chapters on Legal Framework, 
page 5 and Drug Markets, page 92. 
The medicines which were the most likely to be misused for the production of pervitin in 2008 were those containing 
a combination of pseudoephedrine and ibuprofen (Modafen® and Nurofen Stop Grip®). The Czech Chamber of 
Pharmacists assumes that up to 80% of the consumption of large packs of these medicinal products was used for 
illicit pervitin production, resulting in 1.2 tonnes of pure substance (Havlíček, 2008). The number of cooking labs 
detected by the police increased from 188 in 2003 to 434 in 2008 (which has been the highest annual rate thus far); 
for more details see Table 10-1 (p. 93) and the 2007 and 2006 annual reports. 
The post-1989 development experienced by the illicit drug market in general also applied to pervitin production and 
the market in it. Until 1989, its production, distribution, and use were limited to small groups hiding from the 
repressive policies of the Communist regime. Individual members of these groups were assigned specific roles in the 
manufacturing process (e.g. supplying precursors and chemicals, providing laboratory glassware and instruments, 
and ‘cooking’), and the final product was shared among them. Since the mid-1990s the pervitin market has become 
professionalised and partly merged with the heroin market (Miovský, 2007; Zábranský, 2007).  
The estimated pervitin consumption in the Czech Republic has maintained a level of about 4 tonnes in recent years. 
In 2003 (the latest data available) the estimate was 3.7 tonnes; 166 kg were used in the nightlife setting, and the 
remaining amount was consumed by problem drug users (Vopravil, 2005; Petroš et al.  2005). Every year, law 
enforcement agencies seize approximately 5 kg of pervitin on 300-400 occasions – see Table 10-2 (p. 94). The price 
of pervitin remains stable at CZK 1,000 (€ 40) per 1 g and its purity is approximately 60%; see Table 10-3 and Table 
10-4 (p. 94). 
In 2008, the Government Council for Drug Policy Coordination established the Methamphetamine Working Group, 
an inter-agency multidisciplinary body whose task is to address the issue of methamphetamine, including its 
manufacturing and the related health and environmental risks, comprehensively and on a long-term basis; for more 
details see the chapter on National Action Plan, Strategy, Evaluation, and Coordination, page 7. 
12.2 Health and Social Correlates of Chronic (Meth)amphetamine Use 
12.2.1 Physical Health Consequences 
In 2006 the National Focal Point carried out an analysis of comorbidity of drug users hospitalised in the period 2001-
2005; for more details see the 2005 Annual Report. The survey involved all hospitalisations of patients who had 
been admitted, at least once, for drug use disorders classified as either a primary or secondary diagnosis (i.e. F11-
F19, excluding F17). As far as stimulant (pervitin) users are concerned, the three most common diagnostic groups, 
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apart from dependency-related conditions, included mental and behavioural disorders (F00-F99, excluding F10-
F19), injury, poisoning, and other consequences of external causes (S00–T98), and infectious and parasitic diseases 
(A00–B99), found in 30.2%, 29.2%, and 19.8%, respectively, of the pervitin users admitted to hospital. In comparison 
to heroin users, the rate of external causes of morbidity is similar, while the frequency of infections is lower and that 
of mental disorders higher. The relatively high rate of infections seems to be associated with the frequent use of 
pervitin by injecting (as is the case among opiate users and polydrug users); see Table 12-3.  
Table 12-3: Diagnoses which occurred in combination with illicit drug use among selected patients hospitalised in 2001-
2005 (%) (Národní monitorovací středisko pro drogy a drogové závislosti, 2006a) 
Diagnoses F11 (%) n=5,723 
F12 (%) 
n=1,800 
F13 (%) 
n=2,545 
F14 (%) 
n=227 
F15 (%) 
n=4,688 
F16 (%)
n=438 
F18 (%) 
n=756 
F19 (%) 
n=8,075 
Total (%) 
N=19,795 
A00–B99 24.2 11.1 8.5 14.1 19.8 14.6 9.8 18.6 15.6
C00–D48 5.9 2.9 8.6 11.9 1.9 4.6 3.2 3.3 4.7
D50–D89 3.9 2.3 5.2 4.0 1.9 4.6 3.2 2.8 3.3
E00–E90 14.6 8.7 21.6 30.8 5.0 14.4 9.3 7.8 11.7
F00–F99 
(w/o F10–F19) 20.2 51.1 66.1 29.1 30.2 31.7 42.7 44.9 37.3
G00–G99 8.9 7.8 16.6 15.0 4.5 11.0 7.9 8.8 8.9
H00–H59 2.3 2.2 3.7 11.5 1.1 2.3 1.5 1.7 2.2
H60–H95 1.2 1.4 2.1 2.6 0.6 1.4 1.6 1.1 1.2
I00–I99 20.7 11.5 31.9 44.5 7.5 21.2 16.8 12.0 17.3
J00–J99 14.4 15.4 17.0 26.0 10.5 18.9 14.0 13.1 13.6
K00–K93 19.8 16.7 27.8 25.6 13.2 23.1 18.8 18.5 18.8
L00–L99 7.2 4.9 5.0 7.0 6.1 5.5 6.6 6.4 5.7
M00–M99 10.6 8.6 20.2 22.5 5.1 9.6 8.5 8.3 10.3
N00–N99 11.6 8.5 17.5 19.8 8.2 9.8 9.5 9.6 10.8
O00–O99 8.9 4.4 5.0 4.8 9.2 7.5 2.2 6.7 7.0
P00–P96 0.1 0.1 0.1 0.0 0.1 0.0 0.3 0.0 0.1
Q00–Q99 0.6 1.3 0.9 0.9 0.6 1.1 0.9 0.6 0.7
R00–R99 15.3 17.1 23.3 21.6 12.1 20.5 18.0 14.6 15.4
S00–T98 28.2 31.8 38.4 31.3 29.2 43.8 39.9 35.7 31.7
V01–Y98 0.4 6.1 9.1 5.3 4.1 8.7 5.8 6.1 5.3
Z00–Z99 17.1 18.8 20.0 19.4 14.2 18.9 16.4 16.2 15.9
NB: The three most common groups of diagnoses in users of individual drugs are in bold. 
A00–B99 – Certain infectious and parasitic diseases N00–N99 – Diseases of the genitourinary system  
C00–D48 – Neoplasms O00–O99 – Pregnancy, childbirth, and puerperium 
D50–D89 – Diseases of the blood and blood-forming organs and 
certain disorders involving the immune mechanism  
P00–P96 – Certain conditions originating in the perinatal period 
E00–E90 – Endocrine, nutritional, and metabolic diseases  Q00–Q99 – Congenital malformations, deformations, and 
chromosomal abnormalities 
F00–F99 – Mental and behavioural disorders  R00–R99 – Abnormal findings not classified elsewhere 
G00–G99 – Diseases of the nervous system  S00–T98 – Injury, poisoning, and other consequences of external 
causes  
H00–H59 – Diseases of the eye and adnexa V01–Y98 – External causes of morbidity and mortality  
H60–H95 – Diseases of the ear and mastoid process  Z00–Z99 – Factors influencing health status   
I00–I99 – Diseases of the circulatory system   
J00–J99 – Diseases of the respiratory system  
K00–K93 – Diseases of the digestive system  
L00–L99 – Diseases of the skin and subcutaneous tissue 
M00–M99 – Diseases of the musculoskeletal system and 
connective tissue 
Mental and behavioural disorders resulting from the use of opioids – 
F11, cannabinoids – F12, sedatives or hypnotics – F13, cocaine – F14, 
stimulants – F15, hallucinogens – F16, inhalants – F18, polydrug use 
and other psychoactive substances – F19. 
 
Data on non-fatal intoxications (emergency conditions accompanying acute drug intoxication which require 
hospitalisation) collected by the Public Health Service in the Czech Republic are available; for more information see 
the chapter on Other Drug-related Health Correlates and Consequences (p. 59). Pervitin was responsible for 
31.8% of all the cases of non-fatal intoxication reported in the Czech Republic in 2008, which reflects a long-term rise 
in the number and rate of non-fatal intoxications caused by pervitin; for more details see Table 6-7. 
12.2.2 Mental Health Consequences 
The prolonged use of pervitin induces psychological symptoms and complications such as agitation, tension, anxiety, 
fear, irritability, sleep disorders, panic, touchiness, depression, suspiciousness, pathological jealousy, confusion, 
memory and concentration disorders, hallucinations, and suicidal tendencies. Chronic and/or intensive use leads to 
the development of toxic psychosis with the appearance of a paranoid or paranoid-hallucinatory syndrome. The 
onset of psychosis is slow, beginning with sensitive self-reference and the loss of insight. The main features of 
developed toxic psychosis include paranoia, pronounced mood changes, and visual, auditory, and tactile 
hallucinations. In clinical terms, it may often be difficult to distinguish toxic psychosis from schizophrenia. People who 
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develop psychosis should be referred to inpatient treatment; their response to antipsychotics is very good (Minařík, 
2003). The historical summary at the beginning of this chapter suggests that the Czech professional community has 
long-term experience with the occurrence and treatment (see below) of psychiatric comorbidity and toxic psychoses 
among the users of stimulants, including pervitin. 
Groups of psychiatric diagnoses were also looked into as part of the analysis of comorbidity of drug users admitted 
to hospital in the period 2001-2005; for more information refer to the 2005 Annual Report. Stimulant users showed 
the highest rate of psychiatric diagnoses falling under the group of personality and behaviour disorders; see Table 
12-4. 
Table 12-4: Psychiatric diagnoses which occurred in combination with illicit drug use among selected patients in 2001-
2005 (%) (Národní monitorovací středisko pro drogy a drogové závislosti, 2006a) 
Diagnose
s 
F11 (%) 
n=5,723 
F12 (%) 
n=1,800 
F13 (%) 
n=2,545 
F14 (%) 
n=227 
F15 (%) 
n=4,688 
F16 (%) 
n=438 
F18 (%) 
n=756 
F19 (%) 
n=8,075 
Total (%) 
N=19,795 
F00–F09 2.9 1.8 11.1 3.1 1.2 1.8 3.6 3.6 3.8
F20–F29 3.4 13.7 7.9 4.4 7.1 9.4 7.0 11.5 7.9
F30–F39 4.6 6.0 25.5 6.2 3.9 5.7 3.4 8.1 7.9
F40–F49 7.6 18.4 38.3 14.5 9.8 11.2 11.1 16.8 15.2
F50–F59 0.9 1.2 3.4 3.1 1.4 1.1 0.8 1.6 1.4
F60–F69 7.7 22.4 24.4 15.0 16.2 14.4 16.1 22.5 15.8
F70–F79 1.0 2.0 1.1 0.9 0.8 2.3 7.1 2.1 1.6
F80–F89 0.0 0.6 0.2 0.4 0.1 0.2 1.3 0.2 0.2
F90–F99 1.6 11.3 3.3 5.3 3.8 4.1 12.8 4.6 3.9
NB: Three most common groups of psychiatric diagnoses in users of individual drugs are in bold. 
F00–F09 – Organic, including symptomatic, mental disorders  F70–F79 – Mental retardation 
F10–F19 – Disorders resulting from psychoactive substance use F80–F89 – Disorder of psychological development  
F20–F29 – Schizophrenia, schizotypal, and delusional disorders  F90–F99 – Behavioural disorders in children  
F30–F39 – Affective (mood) disorders 
F40–F49 – Neurotic, stress-related, and somatoform disorders  
F50–F59 – Behavioural syndromes associated with physiological 
disturbances and physical factors  
F60–F69 – Disorders of adult personality and behaviour  
 
Mental and behavioural disorders resulting from the 
use of opioids – F11, cannabinoids – F12, 
sedatives or hypnotics – F13, cocaine – F14, 
stimulants – F15, hallucinogens – F16, inhalants – 
F18, polydrug use and other psychoactive 
substances – F19. 
 
An analysis of the same sample, conducted by the National Focal Point for the purposes of this selected issue and 
intended to record the occurrence of toxic psychoses in users of different types of drugs referred to hospital (i.e. 
F1X.5, psychotic disorder, and F1X.7, residual and late-onset psychotic disorder), confirmed the high rate of 
psychoses among stimulant (pervitin) users; see Table 12-5. 
Table 12-5: Toxic psychoses among patients hospitalised with disorders induced by psychoactive substance use in 
2001-2005 by drug type (Národní monitorovací středisko pro drogy a drogové závislosti, 2009h) 
Psychotic disorder  Residual psychotic disorder  
Toxic psychoses in 
total 
Total 
number 
of people 
Diagnosis 
(Drug type) 
Number % Number % Number %  
F11 (opiates) 99 1.7 27 0.5 126 2.2 5,723
F12 (cannabis) 160 8.9 27 1.5 187 10.4 1,800
F13 (sedatives/hypnotics) 35 1.4 16 0.6 51 2.0 2,545
F14 (cocaine) 14 6.2 2 0.9 16 7.0 227
F15 (stimulants) 565 12.1 67 1.4 632 13.5 4,688
F16 (hallucinogens) 35 8.0 11 2.5 46 10.5 438
F17 (inhalants) 43 5.7 17 2.2 60 7.9 756
F19 (polydrug use) 691 8.6 166 2.1 857 10.6 8,075
Total 1,163 5.9 235 1.2 1,398 7.1 19,795
 
In addition, the majority of the psychiatrists/addiction specialists interviewed as part of a survey on pervitin use 
treatment conducted by the National Focal Point in 2009 reported that pervitin users who had experienced psychotic 
symptomatology or developed toxic psychosis required specific treatment procedures (see below). 
12.2.3 Infections – HIV, HCV, HBV 
Apart from blood-borne infections (HIV, HBV, HCV) occurring as a result of sharing equipment and paraphernalia 
when injecting drugs, drug users show an increased level of other diseases, such as infections of the skin and soft 
tissues around the site of injection, system infections (sepsis, endocarditis), and respiratory infections. 
In particular, infections among pervitin users result from their high rate of injecting drug use. General data on 
infections among (injecting) users are common, but specific figures pertaining to pervitin users are rare. 
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A high rate of abscesses and infections at injection sites was found by the analysis of a sample of drug users 
admitted to the centre for the treatment and prevention of infection-related complications in drug users at the Motol 
University Hospital in Prague; for more information see the 2006 Annual Report. Inflammations at injection sites were 
also one of the most frequently reported health complications among injecting drug users who sought the services of 
Prague’s low-threshold facilities in 2008 (approximately one third of the sample comprised pervitin users); they were 
reported by almost half of the respondents (Šejvl, 2008); see Table 6-8 (p. 60). 
Data on the reported incidence of HIV, HAV, HBV, and HCV are available for the group of injecting drug users 
(IDUs), but no information on the drugs used is available; for more details see the chapter Drug-Related Infectious 
Diseases, page 53. The number of reported cases of HIV among injecting drug users in the Czech Republic is very 
low. A total of 1,190 HIV-positive persons, including 83 injecting drug users (7%), had been recorded by 2008. 
Nevertheless, in the last two years there has been an increase in the number of cases among IDUs; see Table 6-1 
(p. 53). The prevalence of HIV is less than 1%; various studies and/or monitoring systems only refer to sporadic 
cases of HIV-positive IDUs; see Table 6-2 and Table 6-3 (p. 55). 
A national study of HCV seroprevalence among the clients of low-threshold centres revealed an HCV 
seroprevalence of 35% among IDUs; after adjustment to the period of injecting drug use, no statistically significant 
difference between pervitin and opiate users was identified as far as the incidence rate of HCV is concerned 
(Zábranský et al.  2006; Mravčík et al.  2009). 
Testing for infections has been carried out in low-threshold facilities. The process is monitored and the results show 
lower levels of HCV prevalence among IDUs (less than 20%), which, however, may be the effect of the higher 
representation of younger users (i.e. users with a shorter history of injecting) among the reported clients. The data 
generated by the process of the monitoring of infection tests performed in low-threshold facilities, as well as the data 
on the incidence of infections available from the register of treatment demands, suggest that pervitin users show a 
lower rate of HCV than heroin users (Figure 6-4 and Figure 6-5, p. 57). However, this difference may be caused by 
pervitin users’ younger age and a shorter history of injecting drug use. 
In comparison to the general population and opiate users, pervitin users show a higher rate of promiscuous sexual 
behaviour (Justinová and Weiss, 2009), which increases the risk of sexually transmitted infections.  
12.2.4 Deaths Related to (Meth)amphetamine 
Fatal overdoses (direct drug-related deaths) and other deaths with the presence of narcotic and psychotropic 
substances (indirect drug-related deaths) are covered by the chapter on Drug-Related Deaths and Mortality of Drug 
Users, page 63. Between 2007 and 2008 the number of fatal overdoses on pervitin rose from 11 to 19 cases; in the 
long term, fatal pervitin intoxications account for approximately one third of all the overdose deaths on street drugs 
(illicit drugs and inhalants) in the Czech Republic; see Table 6-11 and Figure 6-7 (p. 64). 
The rate of other pervitin-related deaths is higher. Forty-nine deaths with the presence of pervitin (often in 
combination with alcohol and/or other substances), mainly resulting from accidents and injuries (24 cases) or 
suicides other then by overdose (21 cases), were reported in 2008. Since 2004, when the data on indirect drug-
related deaths became available for the first time, their number has risen (in 2004, 19 cases involving pervitin were 
reported); for more details see Table 6-12 and Figure 6-8 (p. 65). In 2008, stimulants (especially pervitin) were 
detected in the bodies of 9.2% of the drivers who had been killed in traffic accidents; see Table 6-9 (p. 62). 
The results of a retrospective cohort study of the mortality of people hospitalised for substance use disorders in the 
period 1997-2002 have been published (Lejčková and Mravčík, 2007). The overall mortality rate of stimulant 
(pervitin) users was approximately half that of heroin users (4.9 cases per 1,000 persons and study year versus 8.6 
cases, respectively); after controlling for age, the rate was approximately three times lower. 
A study of a cohort of people hospitalised for substance use disorders and people undergoing opiate substitution 
treatment in the period 1997-2007 was conducted in 2008 (Zábranský et al.  2009); see also the chapter on Drug-
Related Deaths and Mortality of Drug Users (p. 63). The overall mortality rate among stimulant (pervitin) users 
reached a level of 5.0 cases (95% CI: 4.3-5.7) per 1,000 persons and year, while 6.5 cases were recorded as far as 
opiate users were concerned. However, pervitin and opiate users differ in their mortality structure – pervitin users 
appear to show a higher rate of deaths caused by external factors, especially suicides; see Table 12-6. 
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Table 12-6: Causes of deaths of pervitin and heroin users hospitalised or undergoing substitution treatment between 
1997 and 2007 (%) (Zábranský et al.  2009) 
Cause of death Stimulants (%) Opiates (%) 
HBV 0.0 0.3
HCV 0.5 0.7
HIV/AIDS 0.0 0.0
Tuberculosis 0.0 0.0
Septicaemia/viraemia 0.0 0.0
Endocarditis 0.5 2.4
Liver diseases/carcinoma  2.0 3.0
Other diseases  15.8 24.6
Diseases in total  18.8 31.0
Suicides 37.6 16.2
Road accidents 13.4 3.0
Other injuries/accidents 18.8 34.0
Assaults 1.0 2.0
Other external causes 10.4 13.8
External causes in total  81.2 69.0
Total 100.0 100.0
 
12.2.5 Social Problems 
Selected socio-economic characteristics of pervitin users in treatment compared to the users of other drugs 
(especially heroin) are indicated above in the section on Treatment Demand for (Meth)amphetamine Use, page 104. 
Pervitin has been involved in approximately 60-65% of the offences of the illicit production and trafficking of drugs 
and approximately 40-50% of the offences of possession of a drug (for personal use) in a quantity greater than small; 
for more details see the chapter on Drug-related Crime, page 81. No specific information on secondary (economic) 
crimes committed by pervitin users is available; this issue is addressed in general terms in the chapter on Drug-
related Crime, Prevention of Drug-related Crime, and Prison, page 81. 
12.3 Health and Social Responses to Chronic (Meth)amphetamine Use 
The analysis of pervitin use, data on pervitin users in treatment, and the findings about the consequences of pervitin 
use suggest that, historically, pervitin users comprise a significant, or major, group of illicit drug users in the Czech 
Republic. This makes them a “natural” part of the Czech drug scene and the preventive, treatment, harm reduction, 
and after-care programmes have also been designed to meet pervitin users’ needs. Each professional working in the 
field of drug treatment (particularly that involving illicit, non-alcohol substances) encounters pervitin users in their 
work on a day-to-day basis. In spite of this (or, maybe, because of this), no programmes (with a few exceptions – 
see below) intended specifically for pervitin users are provided in the Czech Republic. Pervitin users are one of the 
groups targeted by programmes designed for (problem) drug users in general; in the Czech Republic, treatment 
approaches specific to different substances are not monitored and covered on a systematic basis.  
No specific prevention programme addressing pervitin use is delivered in the Czech Republic. To a great extent, the 
same assertion can be made about harm reduction and/or treatment programmes. Nevertheless, certain specific 
needs of pervitin users are considered in treatment regimens or incorporated in individual treatment plans. A project 
developed by Sdružení Podané ruce, a civic association, that commenced in September 2009 is rather an isolated 
initiative. Its objective is to adapt the 12-Step programme, used in the United Kingdom for the treatment of cocaine 
and crack users, to the target group of (meth)amphetamine users.  
Certain specific aspects of the treatment of dependency on stimulants are referred to in the recommended 
procedures for psychiatric care in relation to the treatment of dependency on psychoactive substances. In view of the 
absence of severe physical withdrawal symptoms, withdrawal management does not require specific 
pharmacotherapy. Quiet, the treatment of the symptoms, and supporting psychotherapy are recommended. Therapy 
with antipsychotics is recommended in indicated cases. As in other forms of substance dependency, 
psychotherapeutic interventions such as psychodynamic psychotherapy, motivation building, family therapy, 
cognitive-behavioural therapy, therapeutic contract, and contingency management are recommended as part of the 
treatment of stimulant users. The utilisation of short-term inpatient treatment episodes is mentioned. It is also 
recommended that motivated patients should undergo residential treatment in a therapeutic community. It is 
emphasised that pharmacotherapy is not a method of first choice in the treatment of stimulant dependency. If the 
condition so requires, antidepressant drugs are considered suitable. However, it is necessary to take into account 
interactions with substances which the patient obtains by themselves. The use of antipsychotic drugs is 
recommended when patients experience feelings of threat or psychotic symptoms, or when psychotic 
decompensation is a concern (Popov and Nešpor, 2006). 
strana 112 
12.3.1 Harm Reduction Interventions 
The majority (80-90%) of pervitin users in contact with counselling and/or treatment facilities are injecting drug users. 
Thus, they make use of harm reduction interventions provided by low-threshold programmes and designed for 
injecting drug users in general (information, distribution of leaflets describing the risks of infectious diseases and 
other health problems, education about and motivation to safer routes of drug administration, needle and syringe 
exchange programmes, education about and motivation to safer sex, the distribution of condoms, the provision 
of/referral to testing for infections and other health care as needed, the newly introduced automated dispensing 
machines for harm reduction supplies, etc.); for more details refer to the chapter on Responses to Health Correlates 
and Consequences, page 67.  
The distribution of gelatine capsules as a safer alternative to injecting drug use is intended specifically for pervitin 
users76; for more information see the chapter on Responses to Health Correlates and Consequences, page 67. The 
latest information suggests that the capsules are distributed by approximately 20 low-threshold programmes and 
another 20 are planning to introduce the capsule distribution project. The information available indicates that the 
primary target group comprises injecting pervitin users who are seeking an alternative to the injection route of 
administration, particularly because of (momentarily) damaged veins. The reason why opiate users do not use the 
capsules may be the lower metabolic availability of opiates from the digestive tract. In comparison to regular oral use, 
the capsules eliminate the bitter taste of pervitin; the onset of the effect of the drug remains present. It is easy to 
prepare the drug for use in a capsule. Clients have shown increased interest in the capsules (Škařupová et al.  
2009). 
Prevention and harm reduction in relation to drug use in nightlife settings are an issue of interest for certain low-
threshold programmes. The Safer Party Tour project has also been in progress; for more details refer to the chapter 
on Selective Prevention, page 26 and Low-Threshold Harm Reduction Programmes, page 68. 
12.3.2 Treatment 
As part of the preparation for this selected issue, the National Focal Point conducted two surveys among counselling 
and treatment facilities. A questionnaire survey aimed at identifying specific aspects of services for pervitin users and 
drug users over 40 was conducted in May and June 2009 (see also the selected issue of Treatment and Care for 
Older Drug Users, page 120). The questionnaires were completed by 15 facilities: 10 outpatient programmes, 2 low-
threshold facilities, 2 methadone substitution centres, and a detox facility (Národní monitorovací středisko pro drogy 
a drogové závislosti, 2009e). A survey in outpatient psychiatric facilities/alcohol and drug treatment outpatient clinics 
and inpatient addiction treatment departments was carried out in August 2009; responses were collected from 13 
outpatient centres (8 completed the questionnaire; the remaining five do not treat pervitin users) and 5 inpatient 
facilities (Národní monitorovací středisko pro drogy a drogové závislosti, 2009g). The information is provided in 
aggregate form for both surveys. The only exception is the issue of pharmacotherapy, which was included in the 
second survey addressing healthcare facilities. 
As far as pervitin users’ specific needs are concerned, the professionals mentioned repeatedly that pervitin users’ 
behaviour is similar to that of other drug users; it shows signs of addictive behaviour in general and, also, the 
therapeutic relationship and process involving pervitin users do not differ significantly from those with other drug 
users. Nevertheless, certain specific features pertaining to pervitin users and addicts were identified. These need to 
be considered because of their impact on the process and outcomes of the treatment. 
On average, pervitin users are younger than opiate users and are more likely to be single and without children 
(which may increase the probability of them entering residential treatment). Generally, they show better (physical) 
health and better social circumstances (although the positive effect of substitution treatment on the social 
stabilisation of opiate users was repeatedly underlined). 
According to the therapists, complicating factors in contact and work with pervitin users include digressive thinking, 
nervousness, distrust, impulsivity, aggressiveness, low concentration, and a lack of consideration on the part of the 
clients. In comparison to opiates, pervitin use results in low physical dependency and only a moderate acute 
withdrawal syndrome, which hampers the user’s insight, causes the client to minimise their problems, and reduces 
the motivation to change. Conflicts in the family were mentioned very often, and work with the family is a common 
component of the therapeutic process. Pervitin users, too, are often urged by their family members to seek contact 
with a helping agency. 
The responses further suggested that pervitin users seem to be in a better financial situation – their debts tend to be 
lower – than opiate users. In comparison to opiate users, pervitin users are reported to have a lower record of 
acquisitive offences committed in order to purchase drugs (“for opiate users, to get their daily dose is the priority;” 
pervitin users are “often in connection with ‘cooks’ or can prepare the drug themselves”). Pervitin users are more 
likely to be involved in violent crime. 
                                                          
76 The distribution of aluminium foil to inhale heroin is specifically aimed at heroin users. 
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The combination of pervitin with other drugs was described. It was stressed repeatedly that this often happens after 
pervitin has been used for a certain period of time and marks a new stage in the use of pervitin which is more difficult 
to deal with in therapeutic terms. The combination of pervitin with opiates, alcohol, cannabis, and benzodiazepines 
was reported. In addition, the occurrence of pathological gambling among pervitin users (“getting hooked on slot 
machines”) was mentioned several times. 
Reported mental and behavioural disorders included higher psychological and emotional instability, depression and 
anxiety, suicidal thoughts, and aggressiveness. These need to be addressed as part of the treatment process 
involving pervitin users. Pervitin-related eating disorders in girls were mentioned repeatedly. Somatic disorders (and 
the health status in general) are similar to those experienced by opiate users, which is mainly associated with 
injecting drug use. Dental difficulties were mentioned repeatedly as problems specific to pervitin users. The 
development of toxic psychosis, with hallucinations, paranoia, and aggressiveness, is considered the most serious 
health complication of pervitin dependency and compromises the treatment prospects. 
As for treatment and treatment procedures and rules, it was consistently reported across all the types of the services 
that there are no specific rules, procedures, standards, or even special programmes designed for pervitin users and 
addicts. It was frequently stated that, in principle, the treatment of pervitin users does not differ from that of users of 
other addictive substances, with the exception of pharmacotherapy. It was pointed out that every client should be 
treated on an equal and individual basis, the client’s demands and needs should play a crucial role, individual 
objectives, plans, and treatment contracts should be developed, and a rapport between the client and the therapist 
should be established and maintained. 
On initial contact, communication with pervitin users is usually difficult. The first contact is often associated with a 
crisis and the provision of crisis intervention. A specific problem with pervitin users is their lack of insight into their 
problem and a lack of motivation to change. The success rate of treatment for both groups is perceived as 
comparable. However, some of the respondents suggested that the success rate of treatment in people dependent 
on pervitin is higher. The impact and significance of the stabilisation of opiate users in a substitution programme, 
which is not available for pervitin users, were often mentioned. It was also noted that pervitin users are more likely to 
leave treatment soon after admission and the first few appointments. If they remain in treatment, however, their 
success rate is high (“pervitin users tend to fail treatment at the very beginning, while heroin addicts are retained in 
treatment by substitution therapy”). 
The professionals did not find significant differences between opiate and pervitin users in terms of trust. Pervitin 
users tend to be less reliable in keeping appointments. As a result, the initial stage of treatment tends to involve a 
higher frequency of attendance and contacts with the client. The low-threshold centres’ staff expressed the opinion 
that clients using pervitin are less likely to enter individual motivational counselling and have fewer treatment 
referrals.  
Given pervitin users’ relatively low age, issues such as their relationships with their parents and other family 
members, as well as their separation from their original family, are often brought up during treatment. Therefore, 
when treating pervitin users, it is more common to work with the entire family as part of family therapy. Younger 
pervitin users often make contact with treatment facilities in response to the pressure exerted on them by their family 
members and, accordingly, their retention rate is low. The treatment process is then extended to the family as a 
whole. When they are older, pervitin users coming to drug services already have a perspective on their problems, 
but often also have a dependency on other substances. However, older pervitin users’ conditions are often 
complicated by psychotic symptomatology, which worsens the prognosis. On a standard basis, psychotic conditions 
are dealt with by pharmacotherapy in inpatient psychiatric/AT facilities. 
The detox department staff reported that pervitin users are very often referred to them involuntarily (for example, 
brought by the police) in a state of acute toxic psychosis, which is typically accompanied by aggressiveness towards 
both themselves and their environment. In view of their acute psychotic condition, patients often need to be 
restrained in movement, communication with them is difficult, and they usually reject any care.  
In the setting of inpatient psychiatric care provided in addiction treatment departments, pervitin users are not 
separated. They are assigned to the same treatment regimen and programme as the other patients, but, again, an 
individual approach to patients/clients is emphasised. The principles and procedures of the treatment, apart from the 
previously mentioned pharmacotherapy, are basically identical. The more problematic treatment of the withdrawal 
syndrome and detoxification was mentioned in relation to opiate users. Pervitin users show more difficulties in 
participating in a therapeutic group because of their interpersonal touchiness; more caution is exercised in building a 
therapeutic relationship. It was suggested that in recent years pervitin users have been more likely to seek inpatient 
treatment than opiate users (which may correlate with the higher availability of outpatient substitution treatment for 
opiate users). There seem to be no significant differences between drug users as far as the duration of their 
hospitalisation is concerned. 
Specific aspects of pharmacotherapy applied to people dependent on pervitin were noted, but, again, it has been 
underlined several times that the treatment of any psychiatric co-morbidity in users of various psychoactive 
substances is usually similar and an individual procedure needs to be followed, according to the condition of the 
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patient under consideration. As regards pervitin users, the administration of diazepam to respond to (fading) 
intoxication was mentioned repeatedly. Additionally, treatment with mood stabilisers (such as lamotrigine), 
antidepressants, and anxiolytics (including bupropion, trazodon, SSRIs, and SSREs) was often reported. Atypical 
antipsychotics (such as risperidon, olanzapin, and melperon) are administered in response to the development of 
psychotic symptomatology. In comparison, substitution preparations are regularly administered or prescribed to 
opiate users during detoxification or maintenance treatment. More frequent treatment using spasmolytics, 
anticonvulsants, hypnotics, and benzodiazepines (as a short-term alternative to substitution opioids) was mentioned 
with reference to opiates. 
The therapeutic approach known as contingency management has not been introduced in the Czech Republic (thus 
far). One of the questions included in the survey among psychiatrists/alcohol and drug specialists inquired about their 
opinions on this type of treatment and any motivational tools which could be utilised with pervitin users. It was often 
stated that drug users should not receive any material rewards for treatment. In fact, some respondents found the 
question about rewards absurd. The psychiatrists suggested repeatedly that good-quality treatment and the patient’s 
opportunity to improve their situation and grow personally should be viewed as rewards in themselves. Still, some 
psychiatrists referred to material rewards as a possible incentive; out of the given alternatives, goods vouchers or 
goods were mostly identified as appropriate tokens, but not money. Other suggested rewards included a certificate 
for the court indicating that the patient is in treatment or their admission to a social reintegration programme, even if 
they do not have enough financial resources of their own. None of the reported incentives seemed specific to pervitin 
only.  
12.3.2.1 Substitution Treatment of Methamphetamine Dependency 
A paper on the oral substitution of pervitin using an amphetamine derivate, methylphenidate (Ritalin®), was published 
in 2004. Ritalin® is used in the treatment of attention-deficit hyperactivity disorder (ADHD) in children, obesity, 
narcolepsy, and treatment-resistant depression. The author of the paper first used methylphenidate for pervitin 
substitution therapy in 1995. The article includes a case study of a man born in 1972. Prior to methylphenidate being 
administered, other stimulants had been prescribed for him, including phenmetrazine, dexphenmetrazine (no longer 
marketed in the Czech Republic), and phentermine (Adipex Retard®), an appetite suppressant, by the author of the 
article. Several lapses occurred during the treatment. The treatment with methylphenidate lasted almost half a year. 
Six weeks after its completion the client relapsed. At the time the article was published, the patient had abstained 
from pervitin for two years and become socially reintegrated, although he remained in aftercare for his high level of 
alcohol consumption. Safe treatment rules were defined: correct assessment, informed consent, a low dosage – 10-
20 mg daily, and comprehensive treatment, including psychotherapy, a treatment review, conditions for completion 
of the treatment, and aftercare. The paper concludes that the use of stimulant medication can lead to abstinence 
which may even be maintained after the completion of treatment (Hampl, 2004). 
The survey among psychiatrists/AT specialists revealed that substitution with methylphenidate is carried out, in 
indicated cases, by two physicians in the Czech Republic. It was emphasised that positive outcomes require the 
careful selection of patients. Methylphenidate is administered in daily doses of up to 60 mg. A one-off positive 
experience with follow-up treatment with bupropion after the discontinuation of methylphenidate was described 
(Národní monitorovací středisko pro drogy a drogové závislosti, 2009g). 
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13 Treatment and Care for Older Drug Users 
This chapter on a selected issue aims to describe the prevalence, trends, and characteristics of older drug users, 
both in treatment and outside it, and to describe the services designed specifically for older drug users. An older drug 
user in the context of this chapter is a drug user of 40 or more years of age. 
According to a median variant of the prognosis published by the Czech Statistical Office (Český statistický úřad , 
2004), persons over 65 years of age will make up 31% of the population in the Czech Republic in 2050. 
Demographic ageing of the population has been seen in all developed countries in the recent years, and comes as a 
result of the declining birth rate and growing mean life expectancy, which in turn stems from today’s improved health 
care and quality of life. Available statistics show that the drug user population in the Czech Republic is also ageing. 
The average age of persons in contact with low-threshold facilities is increasing, as is the number of older drug users 
in treatment; their proportion to the whole population of drug users is still, however, relatively small. Compared to 
younger drug users, there are more unemployed and homeless people in the 40-plus age group, which also has a 
greater proportion of drug users with a higher level of education. 
The rising average age of problem drug users cannot be explained only by the general ageing of the whole 
population. In this context, an important role is played by the system of services in the area of the prevention and 
treatment of addictions, infectious diseases, or overdoses in drug users. At present the Czech drug policy does not 
respond to the ageing of the drug user population – neither by formulating specific measures, nor by implementing 
them. There is only one facility in the Czech Republic that specialises in treating older users of non-alcohol drugs. 
The vast majority of existing programmes are coping with the specific difficulties involved in contact with older clients 
and the treatment of them on a case-by-case basis. In the Czech Republic there are four old people’s homes with a 
special regime for senior citizens dependent on alcohol. 
13.1 Ageing of Problem Drug Users 
13.1.1 Trends in Ageing of Drug Users in and outside Treatment 
The average age of drug users in contact with treatment services has been rising in the Czech Republic. According 
to data from the final reports of low-threshold facilities, in 2002, the average age of the clients of these facilities was 
22, and in 2007 and 2008 it was already 26 years; see also the chapter onLow-Threshold Harm Reduction 
Programmes, page 68. The average age of people seeking treatment in counselling and treatment centres has also 
been on the rise; see the chapter on Drug-related Treatment: treatment demand and treatment availability, page 32. 
The number of people in the 40-plus age group who are recorded in the Register of Treatment Demands77 has 
increased – in 2002, 240 persons sought the services of treatment facilities; six years later it had increased to 392. 
That said, the proportion in all treatment demands of drug users who are 40 years old or older has not exceeded 5% 
in any of the years for which data were collected; see Figure 13-1. 
                                                          
77 The Register of Treatment Demands is discussed in Chapter 5 of the Annual Report. Data on all 2008 tratment demands were used 
to illustrate the trends and characteristics pertaining to the 40+ users in treatment. 
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Figure 13-1: The numbers and proportion of treatment demands from the 40-or-older age category in relation to all 
treatment demands in 2002-2008 (%) (Studničková, 2009a) 
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The data available for drug users in outpatient treatment (Ústav zdravotnických informací a statistiky, 2009b) also 
show that there is a trend for the number of people in higher age groups to increase. Whereas in 1998 people in the 
40-plus age group made up 9% of the total, by 2008 almost one fifth of all outpatient clients were in this age group; 
see Figure 13-2; in the period between 2006 and 2008, however, the number and proportion of older clients 
receiving treatment declined again. 
Figure 13-2: The numbers and proportion of drug users in the 40-or-older age category in outpatient treatment in 1998-
2008 (Ústav zdravotnických informací a statistiky, 2009b) 
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Since 1998, the number of older drug users among patients admitted to inpatient psychiatric facilities (in psychiatric 
departments of hospitals and in psychiatric hospitals) has been growing; see Figure 13-3. 
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Figure 13-3: The numbers and proportion of drug users in the 40-or-older age category admitted to inpatient psychiatric 
facilities in 1998-2007 (Ústav zdravotnických informací a statistiky, 2009b) 
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The number of older patients receiving substitution treatment and recorded in the National Register of Users of 
Medically Indicated Substitution Substances (NRULISL Register) has also been rising since 2000; see Figure 13-4. It 
is, however, evident that the increase in the number of older drug users is related to the generally rising demand for 
substitution treatment; as concerns substitution treatment, in this area too the 40-plus age group comprises 
approximately 5% of all the persons treated. 
 
Figure 13-4: The number of patients treated in specialist substitution centres in 2000-2008 by gender, and the proportion 
of persons aged 40 or older to all patients in substitution treatment (%) (Ústav zdravotnických informací a statistiky, 
2009b) 
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In recent years low-threshold facilities have been collecting data on their clients; the data also provide an insight into 
the age structure of problem drug users; see Table 13-1. Although in neither study was the selection of participants 
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made by random sampling – the data were collected from available and willing respondents – the data can still be 
taken as an indicator of ageing in the drug user population. 
Table 13-1: The age of respondents in surveys among the clients of low-threshold facilities in the Czech Republic in 
2002-2008 (Mravčík et al.  2009; Větrovec and Porubský, 2008; Národní monitorovací středisko pro drogy a drogové 
závislosti, 2008c; Šejvl, 2008) 
Indicator 2002–2003 2007 2008 2008 
Average age 24.6 27.5–28.0 27.8 28.7
Proportion of people 
aged 40+ 4% n.a. 7% 8%
Number of persons in 
the study 757 583 677 730
Territorial coverage National Prague National Prague
 
Persons in the 40-plus category have traditionally accounted for 10-20% of all fatal overdoses caused by street 
drugs (illicit substances and inhalants), and for 70% of all fatal overdoses on prescription medications; see Table 
13-2. The average age of people who overdosed on street drugs was 30-33 years; men represent approximately 80-
90% of the total; for overdoses on prescription medication, the average age was 48-50 years and men accounted for 
50-60%; see also the 2007 Annual Report. 
Table 13-2: Fatal overdoses drugs in 2003-2008 – the proportion of persons aged 40 or older (Mravčík et al.  2008; 
Národní monitorovací středisko pro drogy a drogové závislosti and SSLST ČLS JEP, 2009) 
Substance 2003 2004 2005 2006 2007 2008 
Total number of cases 53 56 59 37 40 44Street 
drugs Proportion of people aged 40+ (%) 22.6 16.1 16.9 21.6 20.0 11.4
Total number of cases 167 171 156 170 173 194
Medicines Proportion of people 
aged 40+ (%) 74.3 71.3 68.6 72.9 68.2 70.6
13.1.2 Factors Related to Ageing and the Increasing Life Expectancy of Drug Users  
To date, no study has been undertaken in the Czech Republic which addressed the factors contributing to the 
ageing of the problem drug user population. However, several studies on the subject are in the pipeline. A qualitative 
study of long-term drug users is under way, with the working title Toxicomania – the 1970s and 1980s in the Czech 
Republic. The study will use semi-structured biographical interviews to map out the life stories of a generation of drug 
users from the 1970s until the mid-1990s. In addition to the contextual focus of problem drug use in Communist 
Czechoslovakia, the research will also focus on the progress of drug use and the factors that may play a role in 
sustaining abstinence or survival. 
A research study entitled Effective Behavioural Strategies to Prevent Blood-borne and Sexually Transmitted Viral 
Diseases in the Population of Chronic Injecting Drug Users, which is the Czech branch of the Staying Safe study 
(Friedman et al.  2008), was registered with the Ministry of Health’s Internal Grant Agency as a candidate for a grant 
in the 2009-2011 cycle. The study aims to establish how chronic drug users had managed to prevent infection or risk 
factors. The concept of Staying Safe was developed in New York, and the following countries are also presently 
preparing or implementing a local branch of the research: the United Kingdom, Spain, Australia, Canada, and 
Argentina. 
13.2 Drug Use, Health, and Social Characteristics of Older Drug Users 
A study to determine the multiplier of prevalence estimate in 2008 (Národní monitorovací středisko pro drogy a 
drogové závislosti, 2008c) monitored one or more primary drugs used by the clients of low-threshold facilities, and 
whether the client applies the drug(s) by injecting. Among persons in the 40-plus age group, a significantly higher 
number were users of pervitin (80% compared to 68% among younger drug users), and a significantly lower number 
reported the use of opiates/opiods (17% compared to 25% for heroin; 19% compared to 11% for Subutex®). Both 
client groups showed no difference in terms of the proportion of injecting drug users. 
People on stimulant drugs are much more prevalent among older users, as is attested by data from the Register of 
Treatment Demands of the Public Health Service (Studničková and Petrášová, 2009; Studničková, 2009a). Figure 
13-5 shows that the number of older people treated in connection with stimulants has been rising since 2000, 
whereas the number of treatment demands in connection with other drugs has remained stable. In 2008, 27% of the 
drug users in this age bracket sought treatment for opiate addiction (18% heroin and 3% substitution preparations – 
methadone or Subutex®); in connection with stimulants it was 56% of users; 6% sought treatment in treatment 
facilities in connection with cannabis. The majority of older drug users seeking treatment (70%) were injecting drug 
users. 
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Figure 13-5: The numbers of persons aged 40 or older in treatment by type of drug (Studničková, 2009a) 
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The Register of Treatment Demands also contains data concerning some other characteristics of drug users. A 
majority of older drug users are people who have sought treatment repeatedly – especially compared to treatment 
demands from the below-39 age group, where 49% were first treatment demands, while only 32% were first 
treatment demands among the older drug users. Persons in the 40-plus age group are also more likely to seek 
treatment themselves (61% compared to 52% in the younger age group). 
The vast majority (84%) of older drug users were men. More than one third (35%) of older treatment demands were 
from people living alone; a little under one fifth (17%) lived with a partner; 14% lived with friends, and 8% lived with 
their parents. This age group had a higher proportion of homeless people (26%) and a lower proportion of people 
with stable housing (33%). More than a half (56%) were unemployed. Older drug users tend to have a higher level of 
education: 33% of drug users in the 40-plus age group completed their elementary education, 47% had graduated 
from a secondary school or vocational college, and 5% were educated to a higher level. Figure 13-6 compares 
selected characteristics of older and younger drug users. 
The proportion of unemployed people over 40 years of age among patients admitted to psychiatric hospitals has 
been stable since 1998 at a relatively high 72-80% (Ústav zdravotnických informací a statistiky, 2009b). 
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Figure 13-6: Selected characteristics of users demanding treatment in 2008 by age (%) (Studničková, 2009a) 
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13.3 Treatment and Care for Older Drug Users 
13.3.1 Policies 
On 9 January 2008, the government adopted a resolution, effectively approving the National Programme of 
Preparation for Ageing for the period 2008-2012 (Quality of Life in Old Age), which provides a follow-up to a similar 
document for the period 2003-2007 and responds to the challenge of the demographic ageing of the population, 
outlines the principles for handling issues related to older citizens, and formulates a number of measures. The paper 
addresses drug policy issues only in terms of the prevention of social exclusion: “Mental health and the quality of 
social relationships improve the firmness of health, resistance, and adaptability of a human being. Depression 
increases the risk of alcohol or drug abuse and the risk of self-neglect, and makes coping with the changes brought 
on by old age more difficult – it is a risk factor of social exclusion.” 
The Czech drug policy is currently vested in the 2005-2009 National Strategy and in the 2007-2009 Action Plan. 
Neither of these documents presupposes the existence of a specific “higher age” group of drug users or formulates 
goals or tasks concerning older drug users specifically. 
13.3.2 Health and Social Responses 
Presently only one treatment facility specialises in the treatment of older drug users – it is the Němčice therapeutic 
community (SANANIM civic association). The average age of the new clients in 2008 was 32 years for men and 31 
years for women (SANANIM, o.s.  2009), while the average age of all treatment demands in the Czech Republic in 
2008 was 25.9 years (see Figure 5-5 on page 46), and the average age of the clients of therapeutic communities in 
the Czech Republic in 2008 was 23.8 years (see Table 5-12 on page 52). 
The Czech Republic has a special type of social care facility – old people’s homes with a special regime; 4 such 
facilities are reserved exclusively for senior citizens addicted to alcohol and they do not admit clients addicted to 
illegal drugs. The existing low-threshold, outpatient, and residential programmes for drug users do not, however, 
discriminate against potential clients on the basis of age, so they are also open to people over 40 years of age. 
Unlike other groups of drug users (e.g. women), for which specialised groups or programmes exist in some facilities, 
older clients are not worked with systematically. Older drug users tend to be treated in regular health care facilities – 
for their drug use as well as for any other problem stemming from their older age. 
In May and June 2009, the National Focal Point – as part of the work on selected issues for this Annual Report – 
carried out a questionnaire survey seeking to identify the specific features of the treatment of pervitin users and the 
users of other drugs over 40 years of age. The questionnaire was completed and returned by 15 facilities: 10 
outpatient programmes, 2 low-threshold facilities, 2 methadone substitution centres, and one detoxification facility 
(Národní monitorovací středisko pro drogy a drogové závislosti, 2009e). 
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The proportion of clients in the 40-plus age group in those programmes that completed the questionnaire ranged 
between 2 and 25%78, while some programmes reported a preponderance of pervitin users, other programmes a 
preponderance of opiate users. The responses indicate that no specific or non-standard services were supplied to 
the age group in question. Employees and physicians from outpatient facilities highlighted the point that the 
treatment was always adjusted to the individual situation of the client, and that the age was not the principal factor. 
The greater age of drug users does, however, imply certain specifics which were also mentioned in the 
questionnaires. Staff of low-threshold facilities are of the view, for instance, that older clients are less distrustful, they 
use the services more effectively, and that they violate the rules less frequently. As the older clients are often 
homeless or lacking in terms of social infrastructure, they tend to use mainly the food and hygiene services. Older 
clients are, on the other hand, less motivated to change – they frequently regard addiction as something immutable 
and untreatable. Older drug users often do not seek and enrol in treatment; typically, they have attempted treatment 
on a number of previous occasions. If they were in treatment prior to 1989, or if they were in compulsory treatment, 
they often do not trust such interventions (Národní monitorovací středisko pro drogy a drogové závislosti, 2009e). 
An argument exists that the success of treatment is indirectly proportional to the age of the drug user and the length 
of the time they have been using drugs: the longer their drug career, the more difficult it is for them to change their 
lifestyle, user habits, and routines, and the so-called addiction to the needle is more commonplace. The degree of 
somatic damage (related to the long-term intravenous application of drugs) and social handicaps also grow with age 
– many older users have served time in prison, which reduces their chances on the labour market; they are often in 
debt, and they lack hope. Older clients in substitution treatment with methadone more frequently rely on a lifelong 
course of substitution and they are less able or willing to abstain (Národní monitorovací středisko pro drogy a 
drogové závislosti, 2009e). 
13.3.3 Quality Assurance and Best Practice 
Services for drug users that are subsidised from the state budget are subject to certification for the professional 
competency of drug services, and they must also meet the criteria of the professional competency standard; for 
more see the chapter Drug Policy: legislation, strategies, and economic analysis, page 5. The general part of the 
standard stipulates, among other things, that in access to services, the client/patient must not be discriminated 
against on the basis of age. The standards are formulated without any reference to client characteristics and they do 
not address any particulars of caring for older users and senior citizens. 
                                                          
78 The A-Klub low-threshold centre was an exception, with 70% of its clients all battling alcohol addiction. The results from this facility 
were excluded from the survey summary. 
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SELECTED DRUG-RELATED WEB PAGES ON THE CZECH INTERNET 
The following list provides selected official websites of key institutions concerned with drug-related issues. An 
exhaustive list of helping organisations is provided in the Help Map application available at drogy-info.cz. 
Adiktologie – odborný časopis pro prevenci, léčbu 
a výzkum závislostí (Addictology – a professional 
journal for the prevention and treatment of and research 
into addiction): http://www.adiktologie.cz/Casopis-
Adiktologie.html  
A.N.O. – Asociace nestátních organizací zabývajících 
se prevencí a léčbou drogových závislostí (Association 
of NGOs Concerned with the Prevention and Treatment 
of Drug Addiction): http://www.asociace.org/  
An application used to register drug-related services 
and their clients: http://www.drogovesluzby.cz  
Celní správa ČR (Customs Administration of the Czech 
Republic): http://www.cs.mfcr.cz/  
Centrum adiktologie Psychiatrické kliniky 1. LF UK a 
VFN v Praze (Centre for Addictology, Psychiatric Clinic, 
1st Faculty of Medicine, Charles University, and General 
University Hospital, Prague): http://www.adiktologie.cz/  
Centrum pro výzkum veřejného mínění – Sociologický 
ústav AV ČR (Public Opinion Poll Centre – Institute of 
Sociology of the Academy of Science of the Czech 
Republic): http://www.cvvm.cas.cz/  
Česká asociace streetwork (Czech Outreach Work 
Association): http://www.streetwork.cz/  
Česká lékařská společnost JEP (Czech Medical 
Association of J. E. Purkyně): http://www.cls.cz/  
Česká neuropsychofarmakologická společnost (Czech 
Neuropsychopharmacological Society): 
http://www.cnps.cz/  
Český statistický úřad (Czech Statistical Office): 
http://www.czso.cz/  
Database of social prevention services:  
https://www.sluzbyprevence.mpsv.cz/  
Drug information server (administered by SANANIM, a 
civic association): http://www.drogy.net/  
Drug counselling service (administered by SANANIM, a 
civic association): http://www.drogovaporadna.cz/  
EXTC – web counselling – prevention of synthetic drug 
abuse: http://www.extc.cz/  
UN Information Centre in Prague: http://www.osn.cz/  
Primary prevention information portal (administered by 
SANANIM, a civic association): http://www.odrogach.cz/  
“Safer Party” initiative: http://www.saferparty.cz  
Institut pedagogicko-psychologického poradenství 
(Institute for Pedagogical and Psychological 
Counselling): http://www.ippp.cz/  
Institut pro kriminologii a sociální prevenci (Institute for 
Criminology and Social Prevention): 
http://www.ok.cz/iksp/  
Ministerstvo spravedlnosti (Ministry of Justice – portal of 
Czech judiciary): http://portal.justice.cz/  
Ministerstvo práce a sociálních věcí (Ministry of Labour 
and Social Affairs): http://www.mpsv.cz/  
Ministerstvo školství, mládeže a tělovýchovy (Ministry of 
Education, Youth, and Physical Education): 
http://www.msmt.cz/  
Ministerstvo vnitra (Ministry of the Interior): 
http://www.mvcr.cz/  
Ministerstvo zdravotnictví (Ministry of Health): 
http://www.mzcr.cz/  
Národní monitorovací středisko pro drogy a drogové 
závislosti (National Monitoring Centre for Drugs and 
Drug Addiction – National Focal Point): 
http://www.drogy-info.cz/  
Národní program řešení problematiky HIV/AIDS 
(National HIV/AIDS Programme): 
http://www.mzcr.cz/Verejne/Pages/133-narodni-
program-reseni-problematiky-hivaids.html; Národní 
program boje proti AIDS ČR (National Programme for 
Combating AIDS in the Czech Republic): 
http://www.aids-hiv.cz/  
Národní protidrogová centrála Služby kriminální policie 
a vyšetřování, Policie ČR (Police National Drug 
Headquarters):  
http://www.policie.cz/clanek/narodni-protidrogova-
centrala-skpv-prezentace-utvaru.aspx  
Poslanecká sněmovna Parlamentu ČR, Výbor pro 
zdravotnictví, Podvýbor pro problematiku civilizačních 
onemocnění a závislostí (Chamber of Deputies of the 
Parliament of the Czech Republic, Health Committee – 
Subcommittee for Drugs and Addiction Issues): 
http://www.psp.cz/sqw/snem.sqw?id=779  
Probační a mediační služba ČR (Probation and 
Mediation Service of the Czech Republic): 
http://www.pmscr.cz / 
Psychiatrické centrum Praha (Prague Psychiatric 
Centre): http://www.pcp.lf3.cuni.cz/pcpout/  
Rada vlády pro koordinaci protidrogové politiky 
(Government Council for Drug Policy Coordination): 
http://rvkpp.vlada.cz  
Register of social service providers: 
http://www.mpsv.cz/cs/3880  
Sekce terapeutických komunit A.N.O. (Therapeutic 
Communities Section, Association of NGOs): 
http://www.terapeutickekomunity.org/  
Státní zdravotní ústav (National Institute of Public 
Health): http://www.szu.cz/  
Ústav farmakologie 3. LF UK – 
neuropsychofarmakologie a prevence drogových 
závislostí (Institute of Pharmacology of the 3rd Medical 
Faculty of Charles University in Prague – 
Neuropsychopharmacology and Prevention of Drug 
Addiction: http://www.lf3.cuni.cz/drogy/  
Ústav zdravotnických informací a statistiky (Institute of 
Health Information and Statistics of the Czech 
Republic): http://www.uzis.cz/  
Vězeňská služba ČR (Prison Service of the Czech 
Republic): http://www.vscr.cz/  
Výzkumný ústav práce a sociálních věcí (Research 
Institute of Labour and Social Affairs): 
http://www.vupsv.cz/
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ABBREVIATIONS 
2005–2006 Action Plan – Action Plan for the 
Implementation of the National Drug Policy Strategy for 
the Period 2005 to 2006 
2007–2009 Action Plan – Action Plan for the 
Implementation of the National Drug Policy Strategy for 
the Period 2007 to 2009 
2005–2009 National Strategy – National Drug Policy 
Strategy for the Period 2005-2009 
ADHD – Attention Deficit Hyperactivity Disorder  
Annual Report – Annual Report: The Czech Republic – 
Drug Situation 
AT – Alcohol – Toxicomania (AT clinic – a name for an 
outpatient medical facility dealing with addiction 
treatment) 
Centre for Addictology - Centre for Addictology at the 
Psychiatric Clinic of the 1st Medical Faculty and General 
Teaching Hospital in Prague 
CS 2008 – General population survey on the use of 
psychotropic substances in the Czech Republic in 2008 
EMCDDA – European Monitoring Centre for Drugs and 
Drug Addiction 
ESPAD– European School Survey on Alcohol and 
Other Drugs 
EU – European Union 
GCDPC – Government Council for Drug Policy 
Coordination 
HAV – hepatitis A virus, viral hepatitis A 
HBV – hepatitis B virus, viral hepatitis B 
HCV – hepatitis C virus, viral hepatitis C 
ICD-10 – International Classification of Diseases, 10th 
Revision 
IDU(s) – injecting drug user(s) 
NFP – National Focal Point (Czech National Monitoring 
Centre for Drugs and Drug Addiction) 
NGO(s) – non-governmental organisation(s) 
PMS – Probation and Mediation Service of the Czech 
Republic 
WHO – World Health Organisation 
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